# ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood

slug: ara-290 · https://miscsubjects.com/a/ara-290 · tags: peptide, ara-290, cibinetide, neuropathy, disc · updated 2026-08-06T07:53:46.499Z

Six randomised, placebo-controlled trials have put this compound into people and measured what happened. Three hit the thing they set out to change. Three missed.

> **The number most people need first: the trials gave 4 mg a day. Public reports of self-use run 250 to 1,000 mcg a day — four to sixteen times less, and below the lowest arm of the only dose-ranging trial ever run, which itself missed at 1 mg. Whatever the trials showed, almost nobody is taking that dose.** Nothing else written up on this site has that record. This is the one compound here whose evidence starts in people rather than in rats.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
The compound is ARA-290, also written cibinetide. It is eleven amino acids in a row, copied off one face of a hormone your kidneys already make — erythropoietin, the hormone that tells bone marrow to build red blood cells. That hormone does a second job as well: it keeps injured cells from dying and helps damaged nerves grow back. The two jobs run through two different docking points on the cell. ARA-290 was cut out of the parent molecule to hit the repair one and miss the blood one. It does not raise your red cell count and it does not carry erythropoietin's clotting risk.

If you have burning feet, numb toes, electric jabs in the legs at night, or skin so sensitive that a bedsheet hurts, this is the compound in this library with the most human data behind it. What follows is what was given, to whom, at what dose, what moved and what did not, where the measurements stop, and the arithmetic that decides whether the dose you can actually buy is anywhere near the dose that was tested. That last answer is short: it is not. What people take sits four to sixteen times below anything a trial has ever given.

[[embed:source:s25]]

## Two jobs, one hormone, and a peptide cut to do only one of them

The reasoning that produced ARA-290 runs in five steps, and each step is a published result rather than a guess.

1. Erythropoietin tells bone marrow to make red blood cells. It does that by clamping two identical erythropoietin docking points together. This is the effect that makes the hormone a doping agent and a stroke risk.
2. Erythropoietin also keeps injured tissue alive and helps it rebuild. That was seen in stroke, in kidney damage, in heart damage and in nerve damage, decades before anyone knew why.
3. The two effects are not the same signal. Brines and Cerami showed that the repair effect runs through a different docking point entirely: one erythropoietin subunit joined to a second protein called CD131. They named the pair the innate repair receptor.

[[embed:source:s8]]

4. Because the two docking points are built differently, the two effects can be pulled apart by design. A molecule shaped to fit the repair pair, but too small to clamp the blood pair, would rebuild tissue without touching the marrow.
5. The part of erythropoietin that faces outward and does the repair binding is called the helix B surface. An eleven-residue peptide that reproduces that surface, with its front end looped shut so enzymes cannot chew it, is ARA-290 — also written pHBSP.

[[embed:source:s9]]

What that produces is not a weaker dose of erythropoietin. It is a different molecule that physically cannot reach the docking point erythropoietin uses to thicken your blood.

## What is dying back, and what would have to grow for it to stop hurting

Small-fibre nerve damage is a degeneration story with a specific shape, and the whole case for this compound is that it acts on one particular link in it.

**What is breaking down.** The nerve endings that carry pain, temperature and sweating signals are the thinnest fibres in the body — unmyelinated C fibres and thinly wrapped A-delta fibres. They end in your skin, in your cornea, in the lining of your gut. They are the furthest thing from the cell body that keeps them alive, so they are the first to die back when anything goes wrong upstream.

**What makes it break down faster.** Two drivers, and they are different diseases. In sarcoidosis, immune cells clump into granulomas and the inflammation eats the fibres. In diabetes, high blood sugar starves and poisons them from the inside. Both drivers keep working while the fibre is trying to survive, which is why removing the driver matters more than any repair signal.

**What the pain actually is.** As fibres die back, the ones left behind fire without being touched. That is why the pain is burning, electric and worse at night rather than sharp and located. The pain is not a measure of how much nerve you have left. It can rise while fibres are still dying and fall while fibres are still gone.

**What would have to grow.** New fibre, sprouting from the surviving stump outward, re-entering the skin. That is a slow, expensive process for a cell, and it is switched off by the same inflammation that caused the damage. Two things have to happen: the surviving cell has to not die, and it has to be given the signal to extend.

**What this compound does to that chain, and how strongly the evidence holds at each step.** It switches on a repair receptor that only assembles on damaged cells — shown directly in cells and animals, strong. Switching it on stops injured cells killing themselves and quiets the immune cells around them, dropping IL-6, IL-12 and TNF-alpha — shown in cells and animals, strong. Quieting that inflammation lets fibres regrow — shown in people, in two randomised trials, by counting fibres, moderate. Regrown fibres make the pain better — shown once, weakly, and missed twice. That last link is the weak one and it is the one you care about.

[[embed:source:s6]]

## The receptor only exists where there is damage

The repair docking point is not sitting on healthy cells waiting to be switched on. The erythropoietin subunit and the CD131 subunit sit apart until injury, inflammation or metabolic stress brings both to the cell surface at the same time. Only then does the pair exist. Only then is there anything for ARA-290 to bind.

Daniel Culver of the Cleveland Clinic, who ran the largest trial, described the assembly to a room of patients in plain terms: a subunit "comes out of the inside of the cell and comes up and joined its partner, joins the beta common receptor here on the surface the cell and it makes this dimer, this two-headed receptor."

[[embed:source:s28]]

Two things follow from that, and both are practical.

The drug does something where there is damage and nothing where there is not. That is the mechanical reason its safety record across the trials is as clean as it is — there is no receptor for it to act on in healthy tissue.

And the size of any effect is capped by how much damaged tissue is putting the receptor out. A person with nothing wrong should expect to feel nothing at all. That is not a disclaimer; it is what the trials found. Eleven of the diabetic subjects in the 2015 trial had normal corneal nerve counts at the start. They had nothing to repair, and their numbers did not move.

## Six trials in people: three hit, three missed

Every registered or published human study of ARA-290 and cibinetide, with the result stated the way the trial stated it.

| Trial | Registration | n | Who was enrolled | Dose and route | Length | What it set out to change | Result |
|---|---|---|---|---|---|---|---|
| Heij 2012 pilot, Leiden | Reported in Mol Med 2012; no NCT number | 22 (12 active / 10 placebo) | Sarcoidosis with small-fibre nerve symptoms | 2 mg into a vein, three times weekly | 4 weeks | Safety; change in the small-fibre symptom score | **Hit.** Symptom score −11.5 ± 3.04 against −2.9 ± 3.34 on placebo, p < 0.05. Pain and fatigue scores improved equally in both arms — no separation |
| Dahan 2013, Leiden | Investigator-run, single centre | 38 (21 active / 17 placebo) | Sarcoidosis with confirmed loss of small nerve fibres | 4 mg under the skin, daily | 28 days | Change in the number of nerve fibres in skin or cornea at day 28 | **Split.** Corneal fibre count rose significantly. Fibres in a lower-leg skin sample rose 0.38 ± 0.48 per mm, 7.2% above their own starting point, not significant. Symptoms, temperature sensing and 6-minute walk all improved |
| Culver 2017 Phase 2b, Cleveland Clinic and Leiden | NCT02039687 | 64, 16 per arm | Sarcoidosis with lost small nerve fibres and nerve pain | 1, 4 or 8 mg under the skin, daily | 28 days | Change in corneal nerve fibre area at day 28 | **Hit at one dose only.** Above placebo: 109 µm² at 1 mg (not significant), 697 µm² at 4 mg (p = 0.012), 431 µm² at 8 mg (not significant). Newly sprouting fibres in skin, tagged with GAP-43, rose in the 4 mg arm, p = 0.035. Pain in the moderate-to-severe subgroup: p = 0.157, missed |
| Brines 2015, Leiden / Karolinska / Manchester | NTR3858 | 49 enrolled, 48 analysed, 24 per arm | Type 2 diabetes with painful nerve damage in the feet and legs | 4 mg under the skin, daily, self-injected | 28 days dosing, 56 days follow-up | Side effects and blood work; change in HbA1c; change in symptom scores | **Hit.** HbA1c −0.16% at day 28 and −0.21% at day 56, against −0.01% and +0.21% on placebo, p = 0.002. The PainDetect score improved significantly. Corneal fibre count +2.6 ± 1.0 per mm² in the subgroup that started abnormal (n = 18, p = 0.02) against +0.7 on placebo |
| Cerit 2015, Leiden | NCT02070783 | 36 healthy volunteers | Healthy adults, in a task that predicts antidepressant action | 2 mg, single dose | One dose, read at one week | Brain response to fearful against happy faces; reading emotional expressions | **Missed.** Some shift in emotional processing, nothing in mood or symptoms. The authors wrote that the effects "do not unequivocally support an antidepressant-like profile" |
| Lois 2020, Queen's University Belfast | NCT06626971 / EudraCT 2015-001940-12 / ISRCTN16962255 | 9 recruited, 8 finished | Swelling at the back of the eye from diabetes, retinal thickness above 400 µm | 4 mg under the skin, daily, self-injected | 12 weeks | Change in best-corrected vision and retinal thickness at week 12 | **Missed, then stopped early.** Vision −2.9 ± 5.0 letters, retinal thickness +10 ± 94.6 µm, retinal sensitivity −0.53 ± 1.9 dB, tear production −0.13 ± 7.7 mm. The vision questionnaire score rose 2.7 ± 3.1 |

[[embed:source:s1]]

[[embed:source:s2]]

[[embed:source:s17]]

[[embed:source:s3]]

[[embed:source:s23]]

[[embed:source:s21]]

[[embed:source:s22]]

[[embed:source:s20]]

A seventh trial was registered and never reported: NCT01933529, a Karolinska study in prediabetes and type 2 diabetes, planned for 24 people, still listed as status unknown against a finish date of December 2015.

[[embed:source:s24]]

Across all six trials, about 132 people have received the real drug rather than placebo. The longest anyone has taken it under observation is 12 weeks, and that was the trial that failed.

## Three of the four wins came out of one disease

Three of the four positive results sit inside a single condition, which changes how far you can read them across to anything else.

In sarcoidosis, the small-fibre damage is driven by the immune system. Clumps of inflammatory cells damage the thin fibres that carry pain, temperature and sweating signals. Unlike diabetes, the damage is often not worst at the far end of the limb — it comes in patches rather than the glove-and-stocking pattern. About half of sarcoidosis patients with small-fibre damage carry the inflammatory protein signature of the far-end-worst form.

The people enrolled were not mild cases. In the Phase 2b, more than 80% were already on painkillers, about two-thirds were on nerve-pain drugs, most were taking around two drugs a day for it, and, in Culver's words, "usually not achieving very good benefits." Their skin fibre counts at the start were roughly half those of healthy people the same age and sex.

The diabetes trial is the one win outside sarcoidosis, and its nerve result was a subgroup result. Eleven of the diabetic subjects already had corneal nerve counts within one standard deviation of normal — they had nothing measurable to repair. The +2.6 fibres/mm² gain belongs to the 18 subjects who were genuinely abnormal to start with.

[[embed:source:s4]]

## They counted the nerves in a microscope instead of asking how it felt

What makes this data set unusually believable is not the pain scores. It is where they pointed the camera.

Your cornea has more nerve endings per square millimetre than anywhere else on your body, and they sit a few hundred microns under a clear window. A confocal microscope photographs that mesh in a conscious patient in a few minutes — no numbing, no cutting, no biopsy. Software then counts the fibres per square millimetre, the branch points, the total length, and the number the Phase 2b used: corneal nerve fibre area, meaning how much of the picture is nerve.

What that buys you, against the alternatives:

- **Against a pain questionnaire.** Pain scores moved in every arm of every trial. Culver's summary of the Phase 2b was that "every single group had improvements including the placebo." A photographed count of nerve fibres does not respond to hope.
- **Against a skin biopsy.** Counting fibres in a punch of skin is the reference method, but it needs holes cut in you at several time points, is read in a handful of specialist labs, and in this drug's own trials was the measure that failed to separate from placebo twice. The corneal picture picks up regrowth better.
- **Against a nerve conduction test.** Those read the big insulated fibres. Small-fibre disease is invisible to them, which is why so many people with burning feet are told their nerve test was normal.

[[embed:source:s19]]

The Phase 2b then did the thing that turns a stand-in measurement into a real one. It checked whether the eye moved with the rest of the body. Change in corneal nerve fibre area tracked change in newly sprouting GAP-43-tagged fibres in skin, ρ = 0.575, p = 0.025, and change in how far people could walk in six minutes, ρ = 0.645, p = 0.009. The eye, the skin and the legs moved together.

Culver stated the limit of that logic himself, and it is the honest caveat on the entire programme: "heaven forbid that you're measuring something that affects a surrogate endpoint but it doesn't have anything to do with the clinically meaningful endpoint, because then you might end up with a medication that is beneficial to something we measure but not beneficial to how you feel, function or survive."

He reported the durability problem just as plainly. Twenty-eight days of injections produced a measurable gain at day 28, and then: "By day 56 some of that goes back to the baseline... it looks like 28 days is probably not going to be enough to maintain a durable benefit."

[[embed:source:s28]]

## Where the trial record stops

If your problem is sciatica from a disc, you have a different injury from everyone in these trials. Here is exactly what carries across and what does not.

| Feature | Sarcoid small-fibre damage (trial population) | Diabetic nerve damage (trial population) | A nerve root squeezed by a disc |
|---|---|---|---|
| What started it | The immune system, clumping into granulomas | High blood sugar | Mechanical squeezing, plus chemical burn from the soft centre of the disc leaking onto the root |
| Which fibres | Thin unmyelinated C and A-delta | Thin fibres first, thick ones later | Thick insulated motor and sensory fibres of the root, plus thin ones |
| Where it is felt | Often patchy, not worst at the far end | Far-end-worst, glove and stocking | Along one or two nerve root bands |
| Inflammation in the picture | Central to the disease | Present | Present — disc material against a root sets off TNF-alpha, IL-1beta and immune cells in the spinal cord |
| Is something still physically pressing | No | No | Yes, and it stays there |
| ARA-290 evidence | Three trials, two positive main results | One positive trial, subgroup result on nerve counts | None |

The row that carries across is the inflammation row. Root pain is not purely a squeezing problem: contact between disc material and a nerve root sets off an inflammatory cascade in the spinal cord, and the immune cells there are a large part of what keeps the pain going. That is exactly the target ARA-290 was shown to hit in a mechanical nerve injury. In rats whose nerve was cut in the spared-nerve-injury model, ARA-290 at 3–60 µg/kg on days 1, 3, 6, 8 and 10 reduced pain from light touch and from cold out to 20 weeks, and the animals given 30 µg/kg showed no rise in spinal immune cell activity at all.

[[embed:source:s5]]

Spared nerve injury is a surgical, mechanical cut — closer to a squeezed root than either trial population is. That is the strongest bridge available, and it is a rat.

The row that does not carry across is the squeezing row, and it was put as a question by someone reading the same evidence:

[[embed:source:s31]]

Nothing in the ARA-290 record touches ongoing pressure. The peptide does not widen the gap the nerve is passing through, does not shrink a bulge, and does not change a joint. Every trial population had an injury with no mechanical cause left to remove. If something is still pressing on your root, you have a driver this drug cannot reach.

Searching the trial registry for the spine returns nothing. ClinicalTrials.gov holds four studies under "cibinetide" and four under "ARA-290", and they are the same four: sarcoidosis, type 2 diabetes, depression, swelling at the back of the eye. No sciatica trial. No disc trial. No trial in a pinched nerve root of any kind.

## The tested dose is about twelve vials a month, and almost nobody takes it

The number that governs everything practical about this compound is 4 mg a day.

It came out of a crossover study of how the body absorbs and clears it, run inside the Dahan 2013 trial. Blood levels above 1.3 ng/mL were treated as the working range, and the total exposure above that line was 65 ng/mL×min for 2 mg into a vein, 23 for 2 mg under the skin, 59 for 4 mg under the skin and 249 for 6 mg under the skin. Only the 6 mg dose was significantly different from the others. The 4 mg subcutaneous dose was picked because it reproduces the into-a-vein exposure that had already worked, in a form you can inject at home.

A separate run in healthy volunteers gives the shape of the curve. Four milligrams under the skin peaks at about 3 ng/mL in the blood — roughly 2.4 nmol/L — and is half gone in about 20 minutes. Injected into a vein, it is half gone in about 2 minutes.

[[embed:source:s35]]

A drug that clears in twenty minutes, injected once a day, looks like a contradiction. It is not. Binding the repair receptor starts a gene programme inside the cell, and that programme keeps running for days after the peptide itself is gone. Collino and colleagues titled their review of exactly this "flipping the molecular switch", and it is why effects in animals last weeks after five injections.

[[embed:source:s18]]

Then the arithmetic that decides whether any of this is within reach.

A 28-day course at 4 mg a day is 112 mg of peptide. Research-grade ARA-290 is sold in 5 mg and 10 mg vials. So one trial-equivalent month is eleven to twelve 10 mg vials, or twenty-three 5 mg vials.

Nobody buys that. The doses described in public reports run 250 to 1,000 mcg a day — a quarter of a milligram to one milligram, against the four milligrams every successful trial used. That is four to sixteen times less. Say it as bluntly as it deserves: the dose people take has never been tested in a person for anything, and it sits below the lowest arm of the only dose-ranging trial ever run, which itself missed at 1 mg.

## Mixing a vial, in numbers a syringe can read

The trials injected 4 mg in 0.5 mL. That is 8 mg per mL, and it is worth copying because it fills exactly half an insulin syringe.

The arithmetic, one step at a time:

1. Take a 10 mg vial. 10 mg is 10,000 mcg.
2. Add 1.25 mL of bacteriostatic water, slowly, running it down the inside wall of the vial. Do not shake. Swirl until it is clear.
3. Concentration = 10,000 mcg ÷ 1.25 mL = **8,000 mcg/mL**.
4. A U-100 insulin syringe holds 1 mL across 100 marks, so one mark is 0.01 mL.
5. Mcg per mark = 8,000 mcg/mL × 0.01 mL = **80 mcg per mark**.
6. The 4 mg trial dose = 4,000 mcg ÷ 80 = **50 marks = 0.5 mL**, the exact volume injected in the diabetes trial.

Other fills, same arithmetic:

| Vial | Bacteriostatic water | Concentration | Mcg per mark | Marks for 4 mg | Marks for 1 mg | Marks for 500 mcg | Marks for 250 mcg |
|---|---|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 1.0 mL | 5,000 mcg/mL | 50 | 80 | 20 | 10 | 5 |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 200, two injections | 50 | 25 | 12.5 |
| 10 mg (10,000 mcg) | 1.25 mL | 8,000 mcg/mL | 80 | 50 | 12.5 | 6.25 | 3.1 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 80 | 20 | 10 | 5 |
| 10 mg (10,000 mcg) | 2.5 mL | 4,000 mcg/mL | 40 | 100, a full syringe | 25 | 12.5 | 6.25 |

For sub-milligram doses, use the weaker fills. At 8,000 mcg/mL a 250 mcg dose is three marks on the barrel, and three marks is not a measurement, it is a guess.

The rest of the regimen, as the trials actually ran it:

- **Where it went.** Under the skin. Diabetes-trial subjects injected their own front thigh, moving the spot each day. The sarcoidosis trial used upper leg or lower belly and reported no stinging and no irritation at the site.
- **How often.** Once a day. The only human schedule that was not once a day was the 2 mg into-a-vein pilot at three times weekly, and it was dropped because you cannot run a vein line at home.
- **How long.** 28 days in five of the six trials, 12 weeks in the sixth. There is no human data on any schedule longer than 12 weeks.
- **How long until anything moved.** Symptom scores separated from placebo by week 4 in the pilot. Corneal nerve fibre area separated at day 28. Both drifted back toward the starting point by day 56 once the injections stopped.
- **What it was mixed in.** The trial formulation was 20 mmol/L sodium phosphate buffer at pH 6.5 with 1% sucrose and 4% D-mannitol — a buffered, sugar-stabilised solution, not plain water.

## Once water goes in you have four weeks

| State | Temperature | How long it is good for |
|---|---|---|
| Sealed dry vial | 2–8 °C, out of the light | Months, to the manufacturer's date; −20 °C for long holding |
| Mixed with bacteriostatic water | 2–8 °C | About four weeks, set by the 0.9% benzyl alcohol preservative |
| Mixed with plain sterile water | 2–8 °C | One session. No preservative, no second needle entry |
| Mixed, left on the counter | 20–25 °C | Treat it as spoiled |
| Mixed, then frozen | −20 °C | Do not. Freezing and thawing clumps short peptides |

At 4 mg a day a mixed 10 mg vial lasts two and a half days, so the four-week clock never bites at trial dosing. At 250–500 mcg a day the clock is the thing that decides how the vial gets split, and most of the vial will expire before you use it.

## One death, four serious events, and no change in the blood counts

The safety claim that matters here is narrow and specific: ARA-290 does not act on the blood-building docking point, so it should not raise red cell production. The trials tested that, and it held.

- **Dahan 2013, n = 38.** "No medically significant deviations were noted in the general blood chemistry or hematology assessments." No serious events during dosing or across 12 weeks of follow-up. No pain or irritation at the injection site. One person on ARA-290 had a moderate event: 14 kg of weight loss over several months. The placebo arm had three moderate events — diarrhoea, irritability, light-headedness.
- **Brines 2015, n = 48.** No meaningful drug-related change in red cells, platelets or white cells. Four serious events happened in the ARA-290 arm. Two were judged unlikely to be related. Two were judged possibly related: one subject on daily furosemide developed worsening borderline kidney failure and stopped at day 15, and one subject was hospitalised for poor blood supply to a leg two weeks after the last dose and then died of a heart attack, which the safety committee judged unrelated to treatment. Non-serious events ran 64 in the ARA-290 arm against 66 on placebo.
- **Culver 2017 Phase 2b, n = 64.** One person had a serious event that led to stopping the drug, judged "possibly related at all". No deaths. Culver's reading: "there's no clear-cut serious or even not very serious adverse effects that occur very frequently with the medication", qualified in the same breath by "we're analysing small numbers of patients here so we'll need a larger trial to really answer the question."
- **Lois 2020, n = 9.** "No serious adverse events/reactions or anti-cibinetide antibodies were seen" across 12 weeks, the longest human exposure on record.
- **Heij 2012, n = 22.** "No safety concerns were raised by clinical or laboratory assessments."

[[embed:source:s16]]

Whether the immune system reacts to it — meaning whether the body starts making antibodies against the injected peptide — was tested in the diabetes trial and in the eye trial. Neither found any. For an injected peptide that is a real question, and it has now been answered twice, at small numbers.

State the limits exactly. About 132 people have had the real drug. Nobody has taken it beyond 12 weeks under observation. The mechanism is switching on a survive-and-repair signal, which is a reason for caution if you have an active cancer, and no trial has looked at that. And the one death on record happened in a diabetic group averaging 63 years old, where a heart attack two weeks after the last injection is what the underlying disease produces anyway — which is why it was judged unrelated, and why 48 people can neither rule it in nor rule it out.

## Two regulators gave it orphan status, then the company shut

| Date | Authority | Action | Condition |
|---|---|---|---|
| 7 October 2013 | European Commission / EMA | Orphan designation EU/3/13/1191 | Treatment of sarcoidosis |
| 28 October 2014 | FDA | Fast Track designation | Small-fibre nerve damage in sarcoidosis |
| 5 July 2016 | FDA | Orphan Drug designation | Treatment of sarcoidosis |
| 29 August 2016 | European Commission / EMA | Orphan designation EU/3/16/1721 | Preventing graft loss in pancreatic islet transplant |
| May 2017 | Cleveland Clinic and Leiden | Phase 2b published; main result met at 4 mg | Small-fibre nerve damage in sarcoidosis |
| 2016–2017 | Belfast Health and Social Care Trust | Eye trial run, then stopped at n = 9 | Swelling at the back of the eye from diabetes |
| April 2019 | EMA | Orphan sponsorship moved to Araim Pharmaceuticals Europe Limited, Ireland | — |

[[embed:source:s14]]

[[embed:source:s27]]

[[embed:source:s26]]

Orphan designation and Fast Track are not approvals. Culver told the patient audience exactly what was still missing: "a phase 2b trial does not equal approval of a medication you must have a phase three trial and sometimes two phase three trials in order for the FDA to approve a medication for commercial distribution." He added, in the same breath, "I don't know if a phase three Cibinetide trial will happen."

It did not. No Phase 3 was ever started, in any condition. Araim Pharmaceuticals, of Tarrytown, New York, stopped operating, and the four registry entries now read completed, terminated or status unknown. Cibinetide is approved nowhere, for anything.

That leaves no pharmaceutical supply at all. What circulates is research-grade material, and an eleven-residue peptide with a looped front end is not the easiest thing to make correctly. A third-party purity run and a mass-spectrometry identity check on the specific batch is the only evidence that a vial holds what the label says.

[[embed:source:s30]]

## What the people taking it report, counted

Five public accounts of ARA-290 are catalogued on this page. Three are first-person reports from someone who took it. Two describe improvement. One is a person eight weeks into a course with no result yet. None report nothing happening. None report harm. The remaining two accounts are a sceptic asking a question and a reader quoting the trial numbers back.

Three is not a denominator. Say that plainly rather than dressing it up: for BPC-157 and KPV there are dozens of first-person reports and they can be counted into a rate. Here there are three, and a rate built on three people is noise. Everything below is labelled anecdotal and is here for one reason — it is the only record of what this compound does at doses and durations no trial ran.

**Reported improvement, 2 of 3.**

[[embed:source:s13]]

That account describes 500 mcg under the skin into the outer hip near the pain, about six hours of tiredness afterward, and then: "I went from 3 weeks of being unable to put on pants or get in the car without stabbing pain, to zero pain." The same writer settled on roughly 400 mcg a day across four months — a tenth of the trial dose, for four times the longest trial.

[[embed:source:s32]]

**Under way, no result yet, 1 of 3.**

[[embed:source:s33]]

**Not a personal report — a question, and a reading of the trial.**

[[embed:source:s31]]

[[embed:source:s34]]

The public accounts agree on one thing and are silent on another. They agree that burning, tingling and sensitivity in the feet and legs are what got better. They are silent on nerve root pain: nobody is reporting a resolved pinched root, and nobody is reporting any kind of controlled comparison.

One report belongs here because it came from inside a trial rather than off a forum. Culver, quoting a Phase 2b participant: "Hey I just went to the mall all afternoon and I haven't done that for many, many years. I'm able to do much more than I was ever able to do." That person's 6-minute walk distance was one of the numbers that moved with the corneal nerve count.

## Where it sits next to the other compounds here

BPC-157 and TB-500 have animal evidence in tendon, ligament and muscle, and no controlled human trial in any of those tissues. ARA-290 is the mirror image: almost nothing preclinical in muscle or tendon, and the only randomised, placebo-controlled human trials in this whole group, every one of them aimed at nerve.

So the division of labour in a disc protocol is clean. The others are aimed at the tissue around the nerve. This one is aimed at the nerve. The framework is laid out on the disc-stack, herniated-disc and degenerative-disc-disease pages.

[[embed:source:s29]]

## What is settled, what missed, and what nobody has measured

| Status | Statement |
|---|---|
| Settled | An eleven-amino-acid peptide reproducing one face of erythropoietin, which switches on the EPOR/CD131 repair receptor and not the blood-building one |
| Settled | In small-fibre nerve damage from sarcoidosis, 4 mg a day under the skin for 28 days raised corneal nerve fibre area 697 µm² above placebo, p = 0.012, in a randomised trial of 64 people |
| Settled | The same dose raised the count of newly sprouting GAP-43-tagged fibres in skin, p = 0.035, and those changes moved with 6-minute walk distance |
| Settled | In type 2 diabetes, 4 mg a day for 28 days improved HbA1c against placebo, p = 0.002, and improved the PainDetect symptom score significantly |
| Settled | No meaningful change in red cells, platelets or white cells in any trial that measured them |
| Settled | Half gone in about 20 minutes under the skin and about 2 minutes into a vein, with the biological effect lasting days |
| Settled | Orphan designation in the US and EU, Fast Track in the US, and no approval anywhere |
| Missed | The count of nerve fibres in a skin sample did not separate from placebo in either sarcoidosis trial that measured it |
| Missed | Pain in the moderate-to-severe subgroup of the Phase 2b, p = 0.157 |
| Missed | Swelling at the back of the eye from diabetes — no change in vision or retinal thickness at 12 weeks, trial stopped at n = 9 |
| Missed | Antidepressant activity in a healthy-volunteer model |
| Untested | Any effect on sciatica, root pain or a nerve compressed by a disc. No trial has been run |
| Untested | Whether gains hold after the injections stop — the day-56 numbers show they partly reverse |
| Untested | Whether sub-milligram doses, which is what circulates, do anything at all |
| Unknown | Safety past 12 weeks, in anyone |
| Unknown | What it does in an active cancer, given that the target is a survive-and-repair receptor |
| Unknown | Whether a research-grade vial holds correctly made peptide, without a purity and mass-spectrometry run on that batch |

*Cibinetide is not an approved drug in any country and has no pharmaceutical supply. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:wolverine-stack-ara-290]]

[[embed:herniated-disc]]

[[embed:degenerative-disc-disease]]

[[embed:what-are-peptides-herniated-disc]]


## Sources

1. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study — https://pubmed.ncbi.nlm.nih.gov/23168581/
2. Phase 2 Dose Ranging Study of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis — https://clinicaltrials.gov/study/NCT02039687
3. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain — https://research.manchester.ac.uk/en/publications/cibinetide-improves-corneal-nerve-fiber-abundance-in-patients-wit/
4. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — https://pubmed.ncbi.nlm.nih.gov/25387363/
5. ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response — https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/
6. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets — https://pubmed.ncbi.nlm.nih.gov/26683514/
7. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin — https://pubmed.ncbi.nlm.nih.gov/20660739/
8. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor — https://pubmed.ncbi.nlm.nih.gov/15456912/
9. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin — https://pubmed.ncbi.nlm.nih.gov/18676614/
10. ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor — https://superpower.com/guides/ara-290
11. Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients — https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/
12. ARA 290 for Nerve Pain & Regeneration (first-person account) — https://diaryofrecovery.com/ara/
13. Araim Pharmaceuticals Receives FDA Orphan Drug Designation for ARA 290 (sarcoidosis) — https://www.prnewswire.com/news-releases/araim-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ara-290-for-the-treatment-of-sarcoidosis-300293773.html
14. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Dahan 2013, Mol Med, PMID 24136731) — https://pubmed.ncbi.nlm.nih.gov/24136731/
15. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (Culver 2017, IOVS, PMID 28475703) — https://pubmed.ncbi.nlm.nih.gov/28475703/
16. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin (Collino 2015, Pharmacol Ther, PMID 25728128) — https://pubmed.ncbi.nlm.nih.gov/25728128/
17. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy (Brines 2018, Sci Rep, PMID 29549285) — https://pubmed.ncbi.nlm.nih.gov/29549285/
18. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action (Cerit 2015, Eur Neuropsychopharmacol, PMID 26431906) — https://pubmed.ncbi.nlm.nih.gov/26431906/
19. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (Lois 2020, J Clin Med, PMID 32674280) — https://pubmed.ncbi.nlm.nih.gov/32674280/
20. NCT06626971 - The Use of ARA290 for the Treatment of Diabetic Macular Oedema (TERMINATED, n=9) — https://clinicaltrials.gov/study/NCT06626971
21. NCT02070783 - Cognitive and Neural Effects of ARA290 (Leiden University Medical Center, n=36) — https://clinicaltrials.gov/study/NCT02070783
22. NCT01933529 - Effects of ARA 290 in Prediabetes and Type 2 Diabetes (Karolinska, status unknown) — https://clinicaltrials.gov/study/NCT01933529
23. EU/3/13/1191 - EMA orphan designation for cibinetide for the treatment of sarcoidosis — https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191
24. EU/3/16/1721 - EMA orphan designation for cibinetide for prevention of graft loss in pancreatic islet transplantation — https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721
25. Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy (28 October 2014) — https://www.prnewswire.com/news-releases/araim-pharmaceuticals-given-fda-fast-track-designation-to-ara-290-for-the-treatment-of-sarcoidosis-associated-small-fiber-neuropathy-280635872.html
26. Webinar transcript: Small Fiber Neuropathy and ARA-290 Results - Dr. Daniel Culver, Cleveland Clinic, 17 May 2017 (Foundation for Sarcoidosis Research) — https://www.stopsarcoidosis.org/wp-content/uploads/SFN-ARA290.pdf
27. ARA 290 for treatment of small fiber neuropathy in sarcoidosis (van Velzen 2014, Expert Opin Investig Drugs, PMID 24555851) — https://pubmed.ncbi.nlm.nih.gov/24555851/
28. Araim Pharmaceuticals: Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis (2017) — https://www.prnewswire.com/news-releases/araim-pharmaceuticals-cibinetide-ara-290-regenerates-small-nerve-fibers-and-improves-neuropathic-clinical-symptoms-in-the-orphan-disease-of-sarcoidosis-300452818.html
29. X - @vedichi_ (Steady State), 16 July 2026 - anecdotal, skeptical — https://x.com/vedichi_/status/2077787145238913472
30. X - @NewsDeskOne (Scratch Off), 17 July 2026 - anecdotal, positive — https://x.com/NewsDeskOne/status/2077929820760019113
31. X - @BarbaraPaden (Barbara Paden), 26 June 2025 - anecdotal, in progress — https://x.com/BarbaraPaden/status/1938281042944872509
32. X - @0xTrenbolone, 10 July 2026 - anecdotal, cites the trial record — https://x.com/0xTrenbolone/status/2075641254810198018
33. Brines 2015 full text: pharmacokinetics, injection volume and adverse events in the type 2 diabetes trial (PMC4365069) — https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/


---

# Tirzepatide: a dual GIP and GLP-1 receptor agonist

slug: tirzepatide · https://miscsubjects.com/a/tirzepatide · category: research · tags: peptide, tirzepatide, glp-1, gip, weight, obesity, sleep-apnoea · updated 2026-08-06T07:48:06.444Z

Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors at once, and it has the strongest randomised human evidence of any compound documented on this site. The same opening should carry what it costs and what it does not settle: gut side effects hit most people during dose escalation, under 5% of participants stopped for them in the diabetes trial, and when the drug is withdrawn the weight comes back — the maintenance trial measured that directly, which is why it is on this page rather than left to a reader to discover. Across 2,539 adults in a 72-week trial, the top dose took 20.9% of body weight off, against 3.1% on placebo, and 57% of people on that dose lost a fifth of their body weight or more. In a second trial in 938 people who also had type 2 diabetes it took 14.7% off. In two more trials in people with obstructive sleep apnoea it cut breathing interruptions by 25 to 29 events an hour.

It is an approved prescription medicine, which changes what the numbers on this page mean: they belong to a specific manufactured product at a specific dose, not to the compound in the abstract. The site you are reading this on is funded by a business that sells this compound. That is a commercial interest, and it is why the placebo arm is quoted next to every result below.

## The molecule pulls two levers where the older drugs pull one

Your gut releases hormones when you eat. Two of them matter here. GLP-1 slows the stomach, tells the pancreas to release insulin when glucose is high, and signals fullness to the brain. GIP does related work on insulin and on how fat tissue handles energy.

Semaglutide copies GLP-1. Tirzepatide copies both — one molecule that fits both docking points. That is the whole design difference, and in head-to-head weight numbers the two-lever version comes out ahead.

It is a once-weekly injection under the skin. Doses run 2.5 mg to 15 mg, escalated slowly over about 20 weeks, because the side effects are worst while the dose is climbing.

## Twenty-point-nine per cent, and the four numbers that matter more than the headline

SURMOUNT-1 randomised 2,539 adults with a body mass index of 30 or more — or 27 or more with a weight-related problem — excluding diabetes, to 5 mg, 10 mg, 15 mg or placebo for 72 weeks. Average starting weight was 104.8 kg.

Weight change at week 72:

- 5 mg: −15.0%
- 10 mg: −19.5%
- 15 mg: −20.9%
- placebo: −3.1%

Those are averages, and averages hide the thing a person actually wants to know, which is their odds. The trial reported those too. Losing 5% or more of body weight: 85%, 89% and 91% across the three doses, against 35% on placebo. Losing 20% or more: 50% at 10 mg and 57% at 15 mg, against 3% on placebo.

Read the last pair again. More than half the people on the higher doses lost a fifth of their body weight. On placebo, three in a hundred did. There is no other compound documented on this site with a result of that shape.

Side effects were mostly stomach and bowel — nausea, diarrhoea, vomiting — mostly mild to moderate, and concentrated in the dose-climbing phase.

## The diabetes trial got a smaller number, and that is the expected pattern

SURMOUNT-2 ran the same design in 938 adults who had obesity and type 2 diabetes, at 10 mg and 15 mg for 72 weeks. Starting weight 100.7 kg, average HbA1c 8.02%.

Weight change at week 72: −12.8% at 10 mg, −14.7% at 15 mg, against −3.2% on placebo. Between 79% and 83% lost at least 5%, against 32% on placebo. Serious adverse events occurred in 7%; fewer than 5% stopped because of side effects.

Less weight comes off in people with diabetes than in people without it, on the same drug at the same dose. That holds across this drug class and it is worth knowing before comparing your own result to a headline from the wrong trial.

## Sleep apnoea is the second thing it was proven to change, and the effect is large

Two 52-week randomised trials in adults with moderate-to-severe obstructive sleep apnoea and obesity: one in people not using a CPAP machine, one in people using one. Average starting severity was about 50 breathing interruptions per hour of sleep — severe.

Breathing interruptions per hour at week 52 fell by 25.3 in the first trial and 29.3 in the second, against 5.3 and 5.5 on placebo. Every pre-specified secondary measure improved as well: weight, the oxygen debt built up overnight, C-reactive protein (an inflammation marker), systolic blood pressure, and how people rated their own sleep.

That second list matters as much as the breathing number. A drug approved on an apnoea endpoint that also moves blood pressure and an inflammation marker in the same trial is doing more than one thing, and all of it was measured under placebo control.

A 2026 post-hoc analysis of those same sleep trials went further and sorted participants by how they described themselves at the start — fatigued or not, sleepy or not, snoring or not, sleeping well or badly — then tracked both the machine measurements and what people said about their own days. That is the analysis worth reading for anyone whose complaint is exhaustion rather than a number on a sleep report, because it asks whether the people who felt worst got the most back.

## Stop taking it and the weight comes back: the trial that tested exactly that

SURMOUNT-MAINTAIN is the most useful trial for anybody deciding whether to start. Its 441 participants first lost weight on the maximum tolerated dose for 60 weeks. Then 378 of them were randomly assigned to one of three arms for another 52 weeks: stay on that dose, drop to 5 mg, or switch to placebo.

Weight change from baseline at week 112:

- Stayed on the maximum tolerated dose: −21.9%
- Dropped to 5 mg: −16.6%
- Switched to placebo: −9.9%

The placebo arm had already lost the weight. They put more than half of it back over a year without the drug. A dose reduction cost about a third of the result; stopping cost more than half.

That is what "chronic treatment" means in practice, and it is the part that gets left out of the marketing. The comparison to make is not this drug against nothing, it is this drug against this drug plus the plan for what happens when you stop.

## What the first few weeks predict about the rest

A 2026 post-hoc analysis pooled SURMOUNT-1 and SURMOUNT-2 and sorted participants by how much weight they had lost early, then followed what happened to each group: total weight change, cardiometabolic markers, tolerability and low-blood-sugar events.

The reason to know this exists: it means early response carries information. Somebody four weeks in, seeing very little movement, is not reading noise — that early trajectory tracks with where they land. It also cuts the other way. The people who respond fastest are not the ones who suffer most for it; tolerability did not simply worsen with a bigger response.

## The inflammation markers moved, separately from the weight

A 2026 analysis in the *Journal of the American College of Cardiology* took SURMOUNT-1 and looked at cardiovascular risk markers over the long haul rather than weight: high-sensitivity C-reactive protein, interleukin-6, fibrinogen and white-cell counts — the standard readouts of low-grade, whole-body inflammation.

Fat tissue is not inert. It releases signalling molecules that keep low-grade inflammation running throughout the body, and those four markers are how that state is read in a blood test. A trial showing them fall alongside 20% of body weight is measuring something separate from the weight itself.

What it is not measuring is any symptom. These are intermediate markers, they moved in the right direction in thousands of people under placebo control, and that is the whole claim.

## The rescue rule inside the maintenance trial, which is the detail that makes it honest

The maintenance trial did something most withdrawal studies do not: it wrote in an escape hatch. From week 84 — 24 weeks after the switch — any participant whose regain passed 50% of what they had lost could be given tirzepatide again as rescue. Of the 378 randomised, 345 (91%) completed.

That design choice matters twice over. Ethically, it means nobody was held in a placebo arm watching all of their result reverse. Statistically, it means the placebo arm's final figure of −9.9% is if anything generous to stopping: the people regaining fastest were pulled out and re-treated, and the analysis assumed they gained no further benefit from their assigned arm. The real cost of stopping is at least as large as the number printed.

## What the dose climb actually involves

The trials did not start people at the dose that produced the headline result. SURMOUNT-1 included a 20-week escalation period inside its 72 weeks, meaning more than a quarter of the trial was spent getting to the top dose. Doses run 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.

Two consequences follow directly. The first is that the stomach and bowel side effects concentrate in that quarter of the timeline rather than spreading evenly, which is why the trials report them as mostly mild to moderate and mostly early. The second is that anyone comparing their own week-8 result to a 20.9% figure is comparing themselves to a 72-week endpoint reached at a dose they have not started yet.

## Population matters, and so does the setting

A 2026 systematic review and meta-analysis compared results in Asian against non-Asian adults with obesity and without diabetes across the phase 3 trials, because body composition and cardiometabolic risk differ between those groups at the same body mass index. The trials themselves were run across seven countries in the diabetes arm and included Chinese, Japanese, Russian, Brazilian and Argentine sites in the first — this is not a single-country evidence base.

There is also a five-year pragmatic trial running in UK primary care, SURMOUNT-REAL UK, enrolling roughly 3,000 adults with class I obesity, delivered as an addition to ordinary care and tracked through the health record rather than through clinic visits. That is the study that answers the question a trial never can: what happens when the drug is used by ordinary people in an ordinary practice, rather than by trial volunteers under supervision. It has not reported.

## The muscle question, which is real and unresolved

When people lose 20% of body weight, some of what leaves is muscle. That is true of dieting, of surgery, and of this drug class, and it is the one cost of a large weight loss that does not show up in the headline number.

The trials measured body weight, not body composition, as their main endpoint. Sub-studies using scans have reported that the proportion of loss coming from lean mass looks broadly similar to other weight-loss methods, which is reassurance rather than resolution.

What follows practically is not a hedge: resistance training and adequate protein during the loss phase are the standard countermeasures, and there is no version of this drug that removes the need for them.

## What is approved, what is compounded, and why the label on the vial matters

Tirzepatide is an FDA-approved medicine. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and for obstructive sleep apnoea with obesity, both from Eli Lilly, both prescription-only.

Everything else in circulation is a different legal object. Compounded tirzepatide, "research use only" vials, and grey-market powder are not the approved product, have not been through the approval process, and carry no guarantee that the contents match the label. The trials on this page were run with the manufacturer's molecule at a controlled dose. A vial from another source has no established link to those numbers, and the correct assumption is that dose, purity and sterility are unknown until somebody tests them.

That distinction is sharper for this compound than for the others on this site, precisely because an approved version exists. With BPC-157 there is no approved product to compare against. Here there is, and buying around it means giving up the one thing the evidence is attached to.

## How the side effects actually behave

Across the trials the pattern is consistent. Nausea, vomiting, diarrhoea and constipation dominate, they cluster during dose escalation, most are mild to moderate, and discontinuation for side effects ran under 5% in the diabetes trial.

Two further points that come from the trial designs rather than the results. The 20-week escalation exists because going up faster produces worse symptoms — the slow ramp is part of the drug, not a suggestion. And gallbladder problems and pancreatitis appear as recognised risks across this whole class, uncommon but serious, which is a reason the approved product is prescription-only and supervised.

## Where this sits next to the other compounds on this site

Set the evidence side by side and the contrast is the point.

Tirzepatide: two 72-week randomised trials with 3,477 people between them, two 52-week trials in sleep apnoea, a 112-week maintenance trial, regulatory approval, and a defined dose.

BPC-157: no completed randomised trial in a person, a large animal literature, and a counted self-reported record.

TB-500: the molecule sold is not the molecule studied, and no human study has measured it.

That gap is not a reason to prefer one over another — they are aimed at different things and measured to different standards. It is a reason to be exact about which kind of claim you are relying on. Here, the claim is weight, and it is proven.

One more thing is worth stating plainly, because it is the difference between this page and most writing about this drug. Every figure above is a group average from a randomised comparison, which is the only kind of number that survives contact with a placebo. The 3.1% the placebo group lost in SURMOUNT-1 is what participation in a trial does on its own — the attention, the food diaries, the fortnightly weigh-ins. Any account of a weight-loss compound that does not carry its placebo number is not reporting a result, it is reporting an anecdote with a sample size. That is the reason a compound with 3,477 people in two trials sits on the same site as compounds whose whole record is forty posts, and the reason the two are never described in the same register here.

## What is still open on this compound

Three things are not settled by anything above. How long the effect holds beyond the two years these trials cover — the longest ran 112 weeks, and obesity is measured in decades. What the loss is made of in the long run, since body composition was a sub-study rather than a primary endpoint. And what happens in ordinary care rather than trial conditions, which is what the five-year pragmatic trial exists to answer and has not yet.

There is also a gap that no trial fixes. The evidence on this page belongs to a manufactured product given at a controlled dose under supervision. The further a vial sits from that description, the less of this page applies to it, and nothing in the literature tells you how much less.

Nine published trials and analyses are attached to this page. Every number above comes from one of them.


## Sources

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — https://pubmed.ncbi.nlm.nih.gov/35658024/
2. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — https://pubmed.ncbi.nlm.nih.gov/37385275/
3. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — https://pubmed.ncbi.nlm.nih.gov/38912654/
4. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN) — https://pubmed.ncbi.nlm.nih.gov/42119587/
5. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses — https://pubmed.ncbi.nlm.nih.gov/42412744/
6. Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials — https://pubmed.ncbi.nlm.nih.gov/42348366/
7. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis — https://pubmed.ncbi.nlm.nih.gov/42233927/
8. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis — https://pubmed.ncbi.nlm.nih.gov/42487213/
9. SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity — https://pubmed.ncbi.nlm.nih.gov/42297568/


---

# TB-500 (Thymosin Beta-4)

slug: tb-500 · https://miscsubjects.com/a/tb-500 · tags: peptide, tb-500, thymosin-beta-4, disc · updated 2026-08-06T07:45:10.431Z

Your body already makes the thing this vial is named after. It is a protein called thymosin beta-4, 43 amino acids long, and almost every cell you have releases it — platelets dump it into a fresh wound, and the cells that clean up damage make more of it. Its job is to hold loose actin, the material a cell builds its own skeleton out of, so the cell can change shape and crawl toward the injury.

Here is the evidence state, and it decides how to read everything after it. Randomised trials of the seven-amino-acid fragment sold as TB-500: none completed, none running, none finished and unpublished. The number of people who have ever been given that fragment in a study, by any route, is nought, so there is no established dose for it, no measured blood level in a person, and no side-effect rate from a trial. One record on ClinicalTrials.gov names TB-500 — NCT07487363, first posted March 2026 — and its own public summary opens by saying it is a fictional example of a registry-style record. The controlled human evidence that does exist belongs to a different molecule, the 43-amino-acid parent protein thymosin beta-4, and it was given as eye drops or a skin gel: three completed dry-eye trials totalling 1,618 people, a nine-person dry-eye trial, an 18-person trial in a nerve-damaged cornea, and two 72-person skin-ulcer trials. Add the Chinese full-length programme and another 236 people have had the parent protein into a vein. None of that is tendon, ligament, muscle, fascia, cartilage or disc, and in twenty years no sponsor has registered a musculoskeletal trial of either molecule. The animal record is rats, mice, rabbits and horses, and its strongest single result is eight rats an arm with a stitched Achilles tendon. What has never been measured in a person is the thing in the vial.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

What is sold as "TB-500" is not that protein. It is a seven-amino-acid piece cut out of the middle of it — positions 17 through 23 — with a chemical cap welded onto the front end. Written out it is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, or Ac-LKKTETQ for short. The studies on the vendor page were nearly all run on the 43-amino-acid protein. The powder in the vial is nearly always the seven-amino-acid piece.

That is the single most useful fact on this page, so it goes first. Everything else — the dosing arithmetic, the horse blood levels, the rat tendons, the anti-doping ban, the cancer numbers, what 31 people who injected it say happened to them — reads differently once you know the evidence and the product are two different molecules.

## What is breaking down, and what would have to be built back

Take the two injuries that bring people here.

A tendon is rope. Type I collagen fibres, laid down in parallel, bundled, and anchored into bone. It goes wrong slowly: the fibres lose their parallel order, the cells inside stop laying down good collagen and start laying down disorganised patch material, and tiny vessels grow in where they do not belong while the tissue overall stays starved of blood. That last part is the whole problem. A tendon has very little blood supply, so the cells and oxygen needed to rebuild it arrive slowly, and the repair loses the race against the next load you put through it.

A disc in your spine is worse. The soft centre of the disc holds water under pressure; the tough outer ring contains it. With age and load the centre dries out, the ring cracks, the height drops, and the joints above and below start taking force they were not built for. A disc has almost no blood supply at all in its middle — nutrients seep in slowly through the bone above and below it. Nothing in the body repairs more slowly than the middle of a disc. [[degenerative-disc-disease|What degenerating discs actually do]] and [[herniated-disc|what a herniation actually does]] are covered separately.

So the chain that breaks tissue down looks like this: load exceeds repair, the cells switch from building rope to building patch, blood supply stays too thin to feed either, the patch scars instead of remodelling, and the tissue ends up weaker — so the same load now breaks it faster.

Anything that would build it back has to hit one of five links. This is the frame to hold every claim below against.

| Link in the chain | What would have to happen | Does the evidence reach it |
|---|---|---|
| Blood supply | more small vessels feeding the injury | strong for the 43-amino-acid protein in animals, and the seven-amino-acid piece is the part that does it |
| Cells arriving | repair cells crawl into the damage instead of sitting at the edge | strong in a dish and in rodent skin, never measured in a human tendon |
| Collagen quality | new rope laid parallel, not patch laid crossways | one rat Achilles study, eight animals in the arm |
| Less scar | fewer of the contracting cells that turn repair into scar | real for the full protein, and it runs through a piece the vial cannot make |
| Inflammation settling | fewer inflammatory signals, so repair can start | shown for the full protein, not for the fragment |

## The vial and the studies contain different molecules

Two products sit side by side on the same shelf at the same 10 mg strength — one labelled "TB-500", one labelled "TB-500 / Thymosin Beta-4" — and nothing on either label tells you which molecule is inside. This is not a technicality.

| | Thymosin beta-4 (the natural protein) | "TB-500" as sold |
|---|---|---|
| Length | 43 amino acids | 7 amino acids (positions 17–23) |
| Sequence | the whole protein | Ac-LKKTETQ |
| Weight | ~4,963 daltons | 889.01 daltons |
| Front end | bare | capped with an acetyl group |
| Catalogue numbers | recombinant or synthetic full-length | CAS 885340-08-9, UNII QHK6Z47GTG, PubChem CID 62707662 |
| Tested in people | yes — eye drops, skin gel, heart | never, by any route |
| Can it release Ac-SDKP | yes, cut off the front end | no, it comes from the wrong part of the protein |
| Official drug name | recombinant human thymosin β4 | it does not have one |

Where the fragment came from is documented. In 2003 a group cut the protein apart looking for the smallest piece that still grew new blood vessels, and found it: those seven amino acids, and nothing shorter. Peptides missing the seven were dead. The seven on their own worked at about 50 nanomolar. Adding loose actin at 5 to 50 nanomolar switched the effect off completely, which proves the activity comes from grabbing actin rather than from docking into a receptor.

[[embed:source:s1]]

That is the honest origin story. The fragment is real, it does one real thing, and one thing is not the same as everything the parent protein does.

## A regulator wrote the mismatch down in July 2026

The Pharmacy Compounding Advisory Committee briefing package is the only document from a government agency that examines TB-500 as a substance. It says in plain terms that the two are not interchangeable, and it names the marketing error.

[[embed:source:s22]]

Three findings in that package change how everything else reads.

**Nobody has been given it and measured.** The agency searched the published literature through March 2025 and reports that "no articles were found in which TB-500 was administered to humans." The people who nominated it supplied no clinical data and no record of anyone taking it, by any route. The agency's safety verdict is the word "unknown" — not clean, not dangerous, unknown.

**The cap on the front end is not a detail.** The wound-healing papers vendors point at used the *uncapped* seven amino acids, LKKTETQ. FDA states that capping the front end "irreversibly alters their charge, hydrophobicity, and size," and that what the uncapped version does "cannot be directly extrapolated" to TB-500. Change the electrical charge and the water-repelling behaviour of a molecule whose entire job is sticking to another molecule, and you have changed the thing that matters.

**The one time anybody tested TB-500 itself in a dish, it did nothing.** In a scratch test — you scrape a line across a sheet of skin-building cells and time how fast they close it — TB-500 free base "appeared to be devoid of wound-healing properties." Its breakdown product, capped LKKTE, at 50 micrograms per millilitre did close the scratch by a small but real amount. That leaves open the possibility that TB-500 is a delivery form for a shorter piece. Nobody has tested that either way.

The same package records that the nomination itself carried a molecular formula that was wrong and a CAS number matching neither the free base nor the acetate salt. It also records where TB-500 actually came from commercially: a 2011 veterinary preparation sold to make racehorses and racing greyhounds perform better.

## Seven amino acids are enough to pull one lever

The proposed mechanism runs in five steps. None of it is special injury machinery. It is the ordinary business of a cell changing shape, happening where tissue is being rebuilt.

1. **Holding loose actin.** The protein grabs free actin building blocks, one molecule to one molecule. A held block cannot join a growing strand, so the cell keeps a stock of ready parts instead of a stiff finished mesh.
2. **Releasing it on command.** Letting those blocks go where and when the cell wants lets it extend a strand in one direction and push. Holding is not blocking. It is stockpiling, and the stockpile is what makes movement in a chosen direction possible.
3. **Crawling.** A cell that can build a leading edge crawls. Skin cells crossed a filter two to three times faster with as little as 10 picograms of the protein present. The cells that line blood vessels do the same thing.
4. **New blood vessels.** Those seven amino acids are the piece that does this, and this is the only step where the fragment is the active part rather than a bystander. Vessel-lining cells crawl, sprout, and form tubes.
5. **Inflammation settling down.** The full 43-amino-acid protein reduces the number of inflammatory cells at a wound and turns down three inflammatory signals — TNF-alpha, interleukin-1β and interleukin-6.

[[embed:source:s28]]

Steps 3 and 4 were measured together in the original rat wound work. Applied to the skin or injected into the belly cavity, the full protein grew the skin surface back over the wound 42% faster at four days and 61% faster at seven, with more collagen and more vessels in the treated wounds than in the salt-water controls.

[[embed:source:s2]]

Step 4 is the step that matters for the tissue you are worried about. Tendon, ligament, the sheet of tissue around muscle, and the disc in your back all share one problem: not enough blood. A mechanism aimed at growing vessels is aimed at the actual bottleneck. That is a good argument on paper. It is also where the argument stops, because nobody has grown a vessel into a human tendon with this and measured it.

## Why it gets run with BPC-157, and what happened when somebody tested that

[[bpc-157|BPC-157]] and TB-500 are sold as a pair because their proposed mechanisms sit at different points in the same repair sequence.

| | TB-500 / thymosin beta-4 | BPC-157 |
|---|---|---|
| What it grabs | the pool of loose actin building blocks | the grip machinery a cell uses to hold a surface (FAK and paxillin) |
| How it reaches blood vessels | the seven-amino-acid piece makes vessel-lining cells crawl and sprout | raises the main vessel-growth receptor and the nitric-oxide pathway |
| Level it acts at | supplying the cell's internal skeleton | grip and growth signals |
| Tissue where it is best evidenced | cornea, skin wound (as the full protein) | rat tendon, ligament, gut |
| Route used in the studies | on the surface, into the belly cavity, implanted locally | into the belly cavity, by mouth, locally |

The theory is that one supplies the machinery for moving and the other supplies the signal telling cells where to move. It is coherent. It has been tested head to head exactly once, and the pairing failed.

[[embed:source:s25]]

Thirty-two male Sprague-Dawley rats, twelve weeks old, about 330 grams each, had the Achilles tendon cut through and repaired, then four weeks of injections into the belly cavity, in four groups of eight: BPC-157 at 10 micrograms per kilogram per day, TB-500 at 60 micrograms per kilogram per day, both together, or nothing.

TB-500 on its own was the arm that reached statistical significance. Maximum load before the tendon failed: p < 0.05. Total Bonar score, which grades how normal the tissue looks under a microscope: p = 0.016. Movin score, a second grading scale: p = 0.017. A collagen stain showed the most orderly type I collagen in the TB-500 group. A protein stain found no real difference between groups in how much type I collagen was being made.

And the combination "did not confer additional benefits compared to either agent alone." The synergy the pair is sold on did not appear in the one experiment that looked for it.

## The scar-tissue claim comes off a piece this fragment cannot produce

A large share of the "breaks up scar tissue and adhesions" marketing traces back to Ac-SDKP, a four-amino-acid piece that calms inflammation and reduces scarring, released from the parent protein.

Getting it out takes two enzymes working in order. First an enzyme called meprin-alpha cuts the front section of the protein into pieces under 30 amino acids long. Then a second enzyme, prolyl oligopeptidase, snips Ac-SDKP off. Neither enzyme can do it alone.

[[embed:source:s29]]

Now put the two facts side by side. Ac-SDKP comes off the **front end** of the protein. TB-500 is positions **17 to 23** — the middle. The four-amino-acid piece cannot be made from it at any dose, by any enzyme, in any tissue. Every scar-reduction claim built on Ac-SDKP belongs to the 43-amino-acid protein and does not carry over to what is in the syringe.

There is a separate scar result for the full protein that does not depend on Ac-SDKP, and it is a good one. In rats, 100 micrograms of the protein delivered on days 2, 3 and 4 through implanted sponges produced wounds at day 14 with very few myofibroblasts — the contracting cells that pull a wound closed into a scar — and very few of their internal tension fibres. The collagen bundles were longer and thicker, and under polarised light they glowed the yellow-red of mature collagen where the untreated wounds glowed the green of immature patch material. Stopping cells from turning into myofibroblasts is the mechanism behind "repair instead of scar."

[[embed:source:s27]]

The 100 micrograms went into the wound on a sponge. It was the full protein. Neither of those matches a milligram injected into belly fat.

## Sort the whole literature by tissue and the tendon row is one rat study

Somebody counted the entire field. A 2026 scoping review from an orthopaedics and rehabilitation group at the University of Utah screened 1,772 records and included 80 studies.

[[embed:source:s10]]

Their findings, in their own words: the evidence is "weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500"; "direct musculoskeletal tissue categories such as tendon, ligament, muscle, cartilage, and spine/intervertebral disc were comparatively sparse"; and "human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study."

One study out of eighty tested the molecule that is actually sold.

| Tissue | Best study | Species and model | n | Molecule | How it was given | Result |
|---|---|---|---|---|---|---|
| Tendon | Biçer 2026 (PMID 42542926) | rat, Achilles cut and repaired, 4 wk | 32 (8 per arm) | TB-500 | into the belly cavity, 60 µg/kg/day | load to failure up, p<0.05; Bonar p=0.016; adding BPC-157 gave nothing extra |
| Tendon (cells) | Wu 2020 (PMID 31753373) | human stem cells from fat, on a woven scaffold | in a dish | full protein | released over 28 days from the scaffold | more crawling, more cells multiplying, cells turned into tendon cells |
| Ligament | Xu 2013 (PMID 23523891) | rat, knee ligament cut through, 4 wk | not stated | full protein | 1 µg in 100 µL of fibrin glue, placed in the gap | even fibre bundles, significantly stronger repair |
| Muscle | Tokura 2011 (PMID 20880960) | mouse, injured muscle plus cultured muscle cells | living animal and dish | full protein | the animal's own | the protein rises early after injury and pulls muscle cells toward the damage |
| Skin wound | Malinda 1999 (PMID 10469335) | rat, full-thickness wound | not stated | full protein | on the skin and into the belly cavity | surface regrown 42% faster at 4 d, 61% at 7 d, 11% more wound contraction |
| Scar | Ehrlich 2010 (PMID 20536458) | rat, implanted sponge, day 14 | not stated | full protein | 100 µg, days 2–4, into the wound | scar-pulling cells suppressed, mature collagen |
| Heart | Bock-Marquette 2004 (PMID 15565145) | mouse, coronary artery tied off | not stated | full protein | belly cavity or into the heart, every third day | heart cells survived, pumping function improved |
| Cornea | Sosne 2015 (PMID 25826322) | human, severe dry eye | 9 patients (18 eyes) | full protein, 0.1% | eye drops, 6×/day, 28 d | discomfort down 35.1%, p=0.0141; surface staining down 59.1%, p=0.0108 |
| Cornea | Sosne 2022 (PMCID PMC9820614) | human, nerve-damaged cornea, Phase III | 18 (10 vs 8) | full protein, 0.1% | eye drops, 5×/day | day 29: 60% healed vs 12.5%, p=0.0656; day 43: 50% vs 0%, p=0.0359 |
| Nerve | Morris 2010 (PMID 20627173) | rat, stroke from a clot | not stated | full protein | whole-body | better neurological recovery, nerve sheaths rebuilt, nerve fibres remodelled |
| Disc and cartilage | — | — | — | — | — | nothing, for either molecule |

[[embed:source:s19]]

Read the "Molecule" column before you read the "Result" column. Ten of the eleven rows are the 43-amino-acid protein.

## The best tendon result that exists is eight rats an arm, injected into the belly

That sentence deserves its own heading, because it is the single strongest piece of evidence in the world for the thing people buy TB-500 to do.

It ran four weeks. It was a rodent. The dose went into the abdominal cavity, not under the skin. The authors call their own study "exploratory" and stop at calling both compounds "candidate adjuncts to tendon repair, pending dose-optimization and longer-term studies." Nothing in it supports a milligram-per-week injection under the skin of a person, and the authors do not claim it does.

The delivery problem is out in the open in the tendon-engineering literature, which is itself a signal: the people who study getting this peptide into a tendon do not expect an injection into belly fat to do it. When the full protein was loaded into spun polymer yarns it released steadily over 28 days and pushed human stem cells taken from fat toward becoming tendon cells — they crawled more, multiplied more, and switched on tendon genes together.

[[embed:source:s30]]

The scaffold is the point. Somebody built a 28-day slow-release fibre to hold the peptide at the tendon, because holding it there is the hard part.

## The ligament study worked because the peptide was put in the wound

The rat knee-ligament study gets summarised as "TB-500 heals ligaments." What it actually did was place 1 microgram of the full-length protein, carried in 100 microlitres of fibrin glue, directly into a ligament that had just been cut through. Local. Held in place by a carrier. One microgram. A different molecule.

[[embed:source:s11]]

The paper opens by noting that as of 2013 nobody had ever published on this protein in ligament repair at all.

## In muscle, your body already sends this signal after an injury

The muscle result is not a treatment result, and it is worth understanding why.

Injuring a muscle causes the muscle itself to make more thymosin beta-4 — in the fibres that are regenerating, and in the blood-cell-making cells that move into the damage. The protein then acts as a chemical attractant, pulling muscle precursor cells toward the injury. Both the ordinary protein and its oxidised form sped up closure and pulled cultured muscle cells across a gap. Precursor cells taken from adult muscle followed the oxidised form.

[[embed:source:s26]]

So the pathway is real in skeletal muscle, and your body switches it on by itself when you tear something. What has never been tested is whether adding more from outside improves a strain. No study has asked that question.

## Every controlled result in a person is an eye or a skin wound

Here is the entire human record for the 43-amino-acid protein, sorted by tissue. None of it is muscle, tendon, ligament or disc.

**Eyes — the only place the numbers turned positive.** A nine-patient dry-eye trial reported eye discomfort down 35.1% and surface damage staining down 59.1% against the vehicle drops.

[[embed:source:s18]]

[[embed:source:s45]]

A Phase III trial in nerve-damaged cornea randomised ten patients against eight. Complete healing at four weeks was 60% versus 12.5%, p = 0.0656 — which misses the usual cutoff for calling a result real. At day 43 it was 50% versus 0%, p = 0.0359, which clears it.

[[embed:source:s32]]

Three completed Phase 3 dry-eye trials sit behind those: ARISE-1 with 317 patients, ARISE-2 with 601, and ARISE-3 with 700, the last finishing in October 2021. Total: 1,618 people. There is still no FDA approval.

**Skin — completed, but safety was the question being asked.** The pressure-ulcer trial enrolled 72 patients on gel at 0.01%, 0.02% and 0.1% by weight, once daily for up to 84 days. The main question was safety and tolerance. Healing was a secondary question.

[[embed:source:s3]]

A matching 72-patient trial in leg ulcers from poor vein drainage completed on the same design.

[[embed:source:s4]]

[[embed:source:s5]]

Two more were stopped early: one in the blistering skin disease epidermolysis bullosa, 30 patients, and one in corneal wounds in diabetic patients after eye surgery, 12 patients.

[[embed:source:s13]]

**Heart — withdrawn twice, then restarted in another country.** The animal finding that started the programme is specific: the protein forms a complex with two other proteins, PINCH and integrin-linked kinase, which switches on the survival signal Akt. After a coronary artery was tied off in mice, heart muscle cells survived better and the heart pumped better.

[[embed:source:s31]]

[[embed:source:s9]]

The Phase 1 safety study in healthy volunteers was designed around single rising intravenous doses of 42 mg, 140 mg, 420 mg and 1,260 mg. It never enrolled anybody. The reason on the record: "Study never initiated due to contract manufacturing issues."

[[embed:source:s34]]

The Phase 2 heart-attack trial behind it was also withdrawn with zero patients enrolled. The only heart programme still producing human data is a Chinese full-length recombinant product called NL005: a Phase 1a in 54 healthy volunteers that established the highest tolerated dose, measured how fast the body cleared it, and checked whether the immune system made antibodies against it, then a Phase 1b in 30 people and two completed Phase 2 trials in heart attack.

[[embed:source:s33]]

Look at the dose scale in that withdrawn Phase 1 design. Milligram quantities of the full protein, dripped into a vein, in a hospital, under a protocol, are not the same object as 2.5 mg of a seven-amino-acid fragment injected under the skin of a belly at home — even though both are written in milligrams.

## One registry record names TB-500, and it says it is made up

Search ClinicalTrials.gov for TB-500 and you get exactly one interventional record where the intervention is TB-500 itself: NCT07487363, "TBRIDGE-CV," sponsor listed as Hudson Biotech, first posted March 2026.

Its summary reads, word for word: "This fictional study is an example of a ClinicalTrials.gov-style record."

[[embed:source:s35]]

It is a demonstration template. Its intervention description has an unclosed bracket. Its dose field says the levels "are not provided in this public example." Any page that cites NCT07487363 as proof TB-500 is in human trials is citing a placeholder — and that citation will keep appearing, because it is the only registry entry that looks like the thing people want to find.

## Nothing has ever been injected into a person and measured

One row, stated plainly, because the tables above allow no other reading.

There is no human trial of TB-500. None finished, none running, none registered. Every controlled human result belongs to the 43-amino-acid protein, given as eye drops or a skin gel, for dry eye, a nerve-damaged cornea, or a long-standing skin ulcer. For tendon, ligament, muscle, fascia, cartilage or disc, the count of human trials is zero for both molecules.

If you are asking "is this proven for my tendon" — no. Not partly proven, not proven in a small way. The study has never been run.

That is one row on this page, not the page. Everything else here is what is actually known.

## Mixing the vial, in numbers a syringe can read

A freeze-dried vial holds a fixed mass of powder. The strength is whatever the water you add makes it, and the volume you inject follows from that. Insulin syringes are marked in units, where 100 units is 1 millilitre, so one unit is 0.01 mL.

Take the common 10 mg vial and add **2 mL of bacteriostatic water**:

- 10 mg ÷ 2 mL = **5 mg per mL**
- 1 mL is 100 units, so 100 units holds 5 mg
- **1 unit = 0.05 mg = 50 micrograms**

| Dose you want | Volume | Units on a 100-unit insulin syringe |
|---|---|---|
| 250 mcg | 0.05 mL | 5 units |
| 500 mcg | 0.10 mL | 10 units |
| 1 mg | 0.20 mL | 20 units |
| 2 mg | 0.40 mL | 40 units |
| 2.5 mg | 0.50 mL | 50 units |
| 5 mg | 1.00 mL | 100 units (the whole syringe) |

Add 5 mL instead and you get 2 mg/mL. Now 1 unit is 20 micrograms, and a 2.5 mg dose is 125 units — more than one syringe holds, so a single dose takes two injections. That is why 2 mL is the practical fill for a 10 mg vial: it puts every commonly used dose inside one syringe.

The mechanics, in order. Wipe the rubber stopper with alcohol and let it dry. Draw up the water. Angle the needle so the water runs down the inside glass wall instead of jetting straight onto the powder. Swirl until it goes clear. Do not shake. Shaking tears peptide molecules apart and makes them clump together, and clumping is the exact mechanism behind the immune-reaction concern further down this page.

## Every dose ever given in a study, and where yours would sit

No dose-finding study of TB-500 exists. Not in any species, at any dose. The loading-then-maintenance schedule that circulates online has no source under it: no trial produced it, no blood-level study calibrated it, no regulatory filing contains it. The nomination sent to FDA specified a formulation — 3 mg/mL, "Subcutaneous and/or Intramuscular Injection" — and specified no dose at all.

What does exist is every dose that has actually been given in a study, and the list is short enough to print in full.

| Study | Molecule | Species | Route | Dose | Schedule |
|---|---|---|---|---|---|
| Biçer 2026, Achilles repair | TB-500 | rat | into the belly cavity | 60 µg/kg/day | daily, 4 weeks |
| Ho 2012, blood levels | TB-500 | horse | under the skin | 10 mg total | one dose |
| Rahaman 2024, scratch test | TB-500 | cells in a dish | in the culture fluid | 50 µg/mL | one exposure |
| Xu 2013, knee ligament | full protein | rat | into the wound, in fibrin glue | 1 µg | once, at surgery |
| Ehrlich 2010, sponge implant | full protein | rat | implanted locally | 100 µg | days 2, 3, 4 |
| Philp 2003, punch wound | uncapped LKKTETQ | mouse | on the skin | 0.01% in buffer | day 0 and 48 h |
| Bock-Marquette 2004, heart attack | full protein | mouse | belly cavity or into the heart | not fixed | every third day |
| NCT00382174, pressure ulcers | full protein | human | gel on the skin | 0.01%, 0.02%, 0.1% by weight | once daily, up to 84 days |
| NCT01393132, dry eye | full protein | human | eye drops | 0.1% solution | 6× daily, 28 days |
| NCT02600429, cornea | full protein | human | eye drops | 0.1% solution | 5× daily, 43 days |
| NCT00743769, heart (withdrawn) | full protein | human | into a vein | 42 / 140 / 420 / 1,260 mg | single rising doses, never run |

Read the route column and count. Two doses in the entire record went under the skin: one of them was a horse, and the other does not exist. Every human dose ever given was put on a surface — a cornea or a wound bed — and none of them was TB-500.

The one animal musculoskeletal study that came out positive on placement put 1 microgram directly into the wound in a glue carrier. The schedules people run use milligrams injected into belly fat and expect them to reach a tendon in the shoulder. Those are not the same treatment scaled up. They are different treatments.

Three route facts are settled. There is no oral form that works, because your gut digests it. Under the skin and into the muscle are the routes the formulation was submitted for. Injecting into or right beside the injured structure — the route in the one positive animal result — is not the route almost anybody uses.

## Ten milligrams under the skin of a horse peaked at 0.08 nanograms per millilitre

The only measurement of TB-500 in the blood of a living animal, in any species, comes from thoroughbred geldings given 10 mg of the free base under the skin.

Blood concentration peaked at 0.05 to 0.08 nanograms per millilitre, somewhere between 60 and 120 minutes after the injection. Between 6 and 10 hours it could no longer be measured at all. It broke down by losing amino acids one at a time off the tail end: Ac-LKKTET, then LKKTE, then LKKT, then LKK, then LK.

Two things follow from that, and both change how you would take it.

**Dosing every three or four days has nothing behind it.** Schedules that space injections out are usually defended by saying TB-500 has a long half-life. A compound that cannot be detected in blood 6 to 10 hours after a 10 mg dose does not have a long half-life. Whatever else might justify spacing doses out, measured persistence in the blood is not it — and no half-life for TB-500, in any species, has ever been published as a number.

**Sub-nanogram blood levels off a 10 mg dose is a very small exposure.** For scale: the concentrations at which this peptide and its breakdown products do anything measurable in a dish are in the tens of micrograms per millilitre. That is four to five orders of magnitude higher than what a 10 mg injection produced in a horse.

## The 28-day rule comes from the water, not from the peptide

- Freeze-dried powder: keep at 2–8 °C, or freeze it for long storage. Keep it out of light.
- Mixed with **bacteriostatic** water, which contains 0.9% benzyl alcohol as a preservative: 2–8 °C, commonly cited as good for about 28 days. That 28 days is the preservative's specification. It is not a stability figure anybody measured on this peptide.
- Mixed with **sterile** water, no preservative: one use, discard after a single draw.
- Do not freeze and thaw it once it is in solution.

There are no pharmacopeial stability data for either form of TB-500. FDA's own finding is that TB-500 free base "is not physically and chemically well characterized," and that tests for contaminants, clumping, microbial contamination and bacterial endotoxin are missing from the public data and from vendor Certificates of Analysis.

## How long each measured effect actually took to appear

Every timeline anybody can quote belongs to a study, and they cluster tightly.

| What was measured | Time to effect | Study |
|---|---|---|
| Skin surface regrown over a wound | 4–7 days | Malinda 1999 (rat) |
| Collagen maturing, scar-pulling cells suppressed | 14 days | Ehrlich 2010 (rat) |
| Cornea healing | 29–43 days | NCT02600429 (human) |
| Dry-eye signs and symptoms | 28 days | NCT01393132 (human) |
| Ligament strength | 28 days | Xu 2013 (rat) |
| Tendon load to failure | 28 days | Biçer 2026 (rat) |
| Long-standing skin ulcer healing | 84 days | NCT00382174 (human) |

The musculoskeletal readouts all sit at four weeks in rodents. Rat tendon repairs faster than human tendon, and the human version of that four-week endpoint has never been measured. Any statement about how long you should expect to wait is a rat's timeline stretched across a species gap, for a molecule the rat got into its abdominal cavity.

There is a second problem with judging this by how you feel. Tendon problems get better on their own over months. That is the ordinary course, with no treatment at all. If you improve on that timescale you cannot separate the compound from time, from having backed off the load, and from everything else that changed in the same window.

## The cancer objection has real numbers behind it

The vessel-growing and cell-crawling machinery that would plausibly help a healing tendon is the same machinery a tumour uses to grow and spread. That is not a hypothetical. It has been measured in living animals.

[[embed:source:s20]]

Forcing a melanoma cell line to overproduce thymosin beta-4 gave a mean 2.3-fold increase in how far the cells crawled (95% CI 1.9–2.7, p<.001), a mean 4.4-fold increase in blood vessels inside solid tumours (95% CI 3.3–5.5, p<.001), and roughly four times as many tumour deposits in the lungs — 46.7 against 10.9. The authors concluded that thymosin beta-4 may drive tumour spread by switching on cell crawling and new vessel growth.

The paper shares an author with the wound-healing and vessel-growth work. The helpful finding and the harmful finding come from the same laboratory and the same mechanism. That is not a scandal. It is what an honest mechanism looks like when you follow it in both directions.

Three qualifications, all of them real.

- The experiment used a virus to force a melanoma line to overproduce the protein. It did not give a seven-amino-acid fragment at the doses a person injects. It establishes that the risk is mechanically plausible and open. It does not establish a proven human hazard.
- The literature runs both ways and depends on the cancer type. In multiple myeloma, this protein behaves as a tumour suppressor, and lower levels of it predict a worse outcome.

[[embed:source:s21]]

- No cancer-causation study of TB-500, in either form, has ever been run. FDA states that outright.

The defensible position is a specific exclusion, not a ban on the compound. Active cancer, or a significant cancer history, is a reason not to use this — because the risk is unmeasured in the direction that would hurt you and the benefit is unproven. That is a bad trade regardless of how the mechanism eventually resolves.

The wider literature supports that framing rather than either extreme. The protein is reported to help liver tumours in children spread, and to drive colon cancer cells to crawl through a specific signalling route, while in multiple myeloma losing it predicts a worse course. The effect depends on the tumour, which is exactly why no blanket reassurance is available in either direction.

## What is in the vial has never been tested for the things that could hurt you

Separate from cancer, and specific to injecting a substance nobody has characterised:

| Risk | Where it stands |
|---|---|
| The immune system reacting to it | FDA: TB-500 "may pose a significant risk" here, "potentially amplified by aggregation as well as potential peptide-related impurities" |
| Peptide contaminants | not characterised in public data or in vendor Certificates of Analysis |
| Bacterial endotoxin | not tested in public data |
| Clumped peptide | not tested in public data |
| Microbial contamination | not tested in public data |
| Cancer causation | no studies exist |
| Reports of harm after sale | the FDA adverse-event database returned zero reports for TB-500 |

The zero in that last row is not reassurance, and reading it as reassurance is the mistake this page most wants you to avoid. There is no legal human market for TB-500, so there is no channel through which a report could be filed. FDA's food and cosmetics system held two cases mentioning "blended TB-500 and BPC-157," with no safety assessment attached to either. No surveillance produces no data, and no data looks identical to safety if you do not check which one you are looking at.

Nobody has published an independent purity or endotoxin audit of the consumer TB-500 market. Searching for one returns vendor pages claiming 99% purity and nothing that tested the claim. FDA arrived at the same place from the paperwork side: the nomination package supplied a molecular formula that was wrong and a CAS number matching neither form of the substance. That is what an uncharacterised material looks like on paper.

The only safety information with any weight behind it belongs to the full-length protein, and even that is thin at whole-body doses. The one programme that has produced human immune-response and blood-clearance data for the protein given systemically is the Chinese recombinant product, whose Phase 1a in 54 healthy volunteers measured the highest tolerated dose alongside peak concentration, time to peak, total exposure, half-life, clearance rate and antibody formation.

[[embed:source:s41]]

Those numbers describe a 43-amino-acid recombinant protein dripped into a vein under a hospital protocol, and they are not published in the searchable literature. They do not describe the fragment, the route, or the setting in which TB-500 is actually used.

## Banned in sport at all times, and the wording names tendons

The 2026 Prohibited List, in force from 1 January 2026, lists under section S2.3 — Growth Factors and Growth Factor Modulators — "Thymosin-ß4 and its derivatives e.g. TB-500."

[[embed:source:s23]]

Four details decide what that means for you.

- **Prohibited at all times**, in competition and out of it. Using it in the off-season is still a violation.
- It is a **Non-Specified Substance** — the harsher sanction tier, with no starting presumption that the penalty should be reduced.
- The catch-all clause covers "other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." The exact reason you would take it is the exact behaviour the clause prohibits, written out in the rule.
- "Other substances with similar chemical structure or similar biological effect(s)" are prohibited too, which sweeps in unnamed fragments and lookalikes.

Enforcement is real, and it has hit the pairing specifically. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500. The United States Department of Defense has adopted WADA categories S0 through S5, which puts service members under the same restriction.

[[embed:source:s12]]

Sanctions do not require a positive test. They can be imposed on an admission, on possession, or on a purchase record. If you are in a college programme, a national federation, an Olympic pathway, most professional leagues, or the military, that exposure exists whether or not anybody ever tests you.

## The July 2026 vote started a process, it did not change the status

On 23–24 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favour of letting BPC-157, KPV and TB-500 be compounded — against FDA's own written recommendation that "a balancing of the criteria weighs against" listing them.

[[embed:source:s24]]

What that vote does and does not do:

- It does **not** make TB-500 an approved drug.
- FDA is **not bound** by the recommendation.
- It starts a formal rulemaking cycle that realistically runs eight to twelve months.
- As of this writing TB-500 is **not** on the 503A Bulks List and is not legally compoundable. No outsourcing facility has reported compounding it, and no pharmacy was found doing so.

"The FDA just approved it" is wrong twice: there is no approval, and the rulemaking has not finished.

## Thirty-one people wrote down what happened to them, and the split is not what the marketing says

Everything above this line is evidence. What follows is not, and it is counted anyway, because it is the only record of people using this for the reason you are reading about it.

Thirty-one first-person accounts, posted publicly on X between January and August 2026. Each one was located by search and then re-checked independently by pulling the post back and comparing the full text and the timestamp. Three candidates failed that check and are not counted. Nobody in this set was randomised, blinded, or controlled. Nobody tested the powder before injecting it, so the actual substance is unknown in every case. People who improved are far more likely to post than people who did not, so the set is selected before you even read it.

**The count: 17 said it helped. 8 said nothing happened. 6 had a reaction or got worse. Denominator 31.** Two of those 31 were treating a gut complaint rather than a musculoskeletal one. Drop those two and the split is 17 helped, 7 nothing, 5 worse, out of 29.

There is one number that matters more than the split, and it is at the bottom of this section.

Before the accounts themselves, the shape of them. The seventeen that helped cluster in shoulders
and elbows run for four to eight weeks; the eight that reported nothing and the six that reported a
reaction or a worsening are grouped under their own headings below, so you can read one group
without reading all thirty-one. If you came here about a specific injury, the section titled injury
by injury, what the record actually reaches is the one to read instead of these accounts: it sorts
every tissue by what evidence exists in it, and for four of the seven rows the honest entry is none.
No body-region tally is given for the thirty-one because the set is too small to divide without
producing percentages that look like measurements, which is the failure this page spends its first
section warning about.

Every account below is quoted in the person's own words, with the handle, the date and a link to the original post. All of it is anecdotal. None of it is evidence.

### Seventeen said it helped

The strongest reports come from shoulders and elbows, run for four to eight weeks.

> "Ran BPC 500mcg twice a day and 6mg of TB500 every 5th day for 6-8 weeks. Healed my torn rotator cuff" — @PayHereSukka, X, 30 July 2026. Anecdotal.

[[embed:source:w_7b0irg5j]]

> "Slight tear of my rotator cuff. Surgery was a 5 month rehab timeline, instead I took bpc-157 and tb-500. Was back to full rotation in my shoulder and benching good weight by a month and a half!" — @GrantWest14, X, 10 January 2026. Anecdotal.

[[embed:source:w_z5qnxkqk]]

> "I was dealing with a nagging golfers elbow for over a year. Would be tender the to the touch after hitting balls. Within a week of taking shots the pain started to disappear. Months later its compmetely healed." — @ryalljohnny1989, X, 3 August 2026. Anecdotal.

[[embed:source:w_bpr3c1ux]]

> "I took it alongside TB-500 and it fixed my tennis elbow and was back to lifting also within two week." — @Das_Bear_, X, 29 June 2026. Anecdotal.

[[embed:source:w_8aa4h36p]]

Three of the seventeen were treating exactly the disc problem that may have brought you here, and all three describe substantial relief inside a month.

> "I've been doing subcutaneous BPC TB+500 injections on both sides of the L5-S1 and a month in, the pain is dramatically less... the pain has been horrible for 6 years but this stuff really works. I don't wake up in awful pain anymore!" — @MithMuel, X, 30 June 2026. Anecdotal.

[[embed:source:w_srfrp1td]]

> "Blew up my back in 2017. L4/L5/S1 severe disc herniation. Doc diagnosed me with degenerative disc disease, told me to quit lifting... Found the Wolverine stack and within a month I was pain free." — @jasonsvoboda, X, 26 July 2026. Anecdotal.

[[embed:source:w_t1lhudd5]]

> "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc... In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better." — @MuroCrypto, X, 31 July 2026. Anecdotal.

[[embed:source:w_ionqqvc2]]

Read that last one closely, because it is the most careful account in the whole set. He separates his shoulder result from his disc result, says the disc "still needs physio and rest," and adds "Don't know if it works the same for everyone, I'm no expert." That is what an honest anecdote looks like.

Some report the effect arriving far faster than any tissue can rebuild — hours to days. That is a timescale for inflammation and pain signalling, not for collagen.

> "Wednesday I woke up in severe pain in my L Leg. It was so bad I couldn't bear any weight... Peptides started in the afternoon. Leg 75% better in the evening... Saturday: Woke up 100% better." — @L0V3lsKeY, X, 2 August 2026. Anecdotal.

[[embed:source:w_2m2r0oof]]

> "BPC-157 + TB-500 vastly accelerated my recovery timeline, eliminated my knee pain two days after i started, and brought the swelling in my jaw down within the week" — @howdymary, X, 9 March 2026. Anecdotal.

[[embed:source:w_7cn6wcbt]]

Two days is not tissue repair. Whatever changed there, it was not new collagen.

The remainder are knees, ankles, quads, and general joint pain.

> "4 weeks 1mg bpc and then 4 weeks 2mg in knee. No acl or meniscus...knee has never felt better since before the injury years ago...also did tb500 twice a week total 4mg" — @caezcrypto1, X, 30 July 2026. Anecdotal.

[[embed:source:w_4qf0wqtv]]

> "I'm 95% sure that BPC-157 and TB-500 helped me heal from several injuries including my left knee and right ankle. I really thought I was going to need surgery for both." — @JonahLupton, X, 26 July 2026. Anecdotal.

[[embed:source:w_albnpbru]]

> "I tore both quad tendons in separate years, the first recovery had taken almost a year. After the second surgery... I added BPC-157 and TB-500. By month five, I was sprinting and jumping again" — @pepfessions, X, 3 August 2026. Anecdotal.

[[embed:source:w_e9fjoshb]]

> "After a week of BPC-157 (8 injections, 500mcg subcutaneous abdominal), persistent ankle tendon pain from a snowboarding injury a year ago is barely noticeable... Yesterday I added TB-500 (1 injection, 2mg) as well" — @jordaaash, X, 30 March 2026. Anecdotal.

[[embed:source:w_dmeyan6q]]

> "Have done a BLAST OF TB 500 and BPC -157 and KPV! Have serious shoulder tear! Blasted all three for 2 weeks!... Took my shoulder from barely joking a cupping hand to back in gym!" — @tj_underwood, X, 31 July 2026. Anecdotal.

[[embed:source:w_1d35jifv]]

> "My 70 yr old dad tore rotator cuff and I had him do 1mg (BPC) injected daily in 2 doses for 4 months with 2-3x/weekly TB500 @ 2.5mg/dose. Within a few weeks, he was lifting his arm totally above his head again and all pain was gone." — @_REDwave_2024, X, 20 May 2026. Anecdotal, and second-hand — the son is reporting his father's result.

[[embed:source:w_8ed1wjyh]]

> "Promise you peptides are No Joke, I used the wolverine stack (BPC-157 and TB-500) to alleviate lifelong shoulder and joint pains" — @BenWolf1425771, X, 3 August 2026. Anecdotal, and the same post links to a supplier, so treat it as promotional.

[[embed:source:w_t3aoiz9r]]

Two of these seventeen carry their own warning on their face. One reports the benefit disappearing about six weeks after stopping — which is the opposite of what tissue repair does. Repaired tendon does not un-repair when you stop injecting.

> "All of the soreness, aches, and pains that disappeared while on BPC/TB500 returned after about 6 weeks for me. I start back on Monday" — @TheCaddieYardFL, X, 1 August 2026. Anecdotal.

[[embed:source:w_ses7fkwk]]

The other is @jordaaash above. He added TB-500 the day before he posted, after a week on BPC-157 alone, and the improvement he describes had already happened before the TB-500 went in. It is counted as a positive because the person counted it that way. It attributes nothing to TB-500.

### Eight said nothing happened

These are not softer versions of the positives. They are people who ran it for weeks at ordinary doses and got no change at all.

> "Did 3mg of BCP & 5mg of TB500 daily for two weeks into my elbow. It didn't do jack shit. This is my 3rd time trying peptides for various joint/tendon stuff and my 3rd time not noticing any improvement at all." — @prax1s_mm, X, 30 July 2026. Anecdotal.

[[embed:source:w_avr26qqh]]

> "Bpc and tb-500 did nothing for my elbow arthritis sadly. Used it for 6 weeks" — @replacementBux, X, 12 April 2026. Anecdotal.

[[embed:source:w_hyq2egsc]]

> "Age 62... I am very limited on what I can do at this point due to the severity of pain. I have been doing BPC 157 +TB 500 for 7 weeks, no improvement yet." — @ToddMil03223111, X, 9 July 2026. Anecdotal.

[[embed:source:w_89es50pi]]

> "I ran a heavy dose of klow into a heavy dose of bp-157 and tb500 for 2 months or more for my shoulder, did nothing, facing a shoulder replacement" — @moon25martin, X, 30 May 2026. Anecdotal.

[[embed:source:w_fqd0nz38]]

That last one is the harshest data point in the set: two months at heavy doses, no effect, still headed for a shoulder replacement.

Somebody treating the same lower-back problem as the three positive disc reports got nothing at all.

> "I'm trying it to see if it helps at all with inflammation for my lower back. L4/5 bulge and L5/S1 herniation. Bpc and Tb did nothing I could notice." — @HangryDBowman, X, 16 July 2026. Anecdotal.

[[embed:source:w_s75yt6kt]]

Three people saying a disc improved and one saying nothing changed, all treating an L5/S1 problem, none of them scanned before or after — that is a clean picture of exactly what uncontrolled reports can and cannot tell you.

Two more report the effect as too small to matter rather than absent.

> "I personally used bpc 157/ tb 500 combo for my shoulder issue. Barely moved the needle. 3/10." — @travfourr, X, 15 April 2026. Anecdotal.

[[embed:source:w_lk8z70he]]

> "I had some pain there and leading up to my bicep area. Didn't get much relief from bpc157/tb500." — @MittelstaedtTim, X, 11 June 2026. Anecdotal.

[[embed:source:w_fkvglkvn]]

One took an oral form for a gut complaint and got nothing, which is unsurprising given the peptide does not survive digestion.

> "Just finished a bottle of oral liposomal BPC157+TB500 and it seems it did nothing :/ (hoping it would help heal my gut)" — @Gronnet, X, 26 April 2026. Anecdotal.

[[embed:source:w_zj1lz4k4]]

### Six had a reaction or got worse

These are the reports vendor pages do not carry, and the most informative account in the whole set is the first one.

> "TB-500 made my shoulder left worse. I have bursitis and stopped TB and it's better. I was getting pain in left thumb and arm as well. I was pinning SubQ. I've used 3 different vendors who are legit. So I ruled out bad product. No issues with BPC-157." — @biotides, X, 7 July 2026. Anecdotal.

[[embed:source:w_q1dsmvn0]]

He had bursitis, the shoulder got worse on TB-500, it improved when he stopped, he had used three different suppliers so a bad batch is unlikely, and he had no problem with BPC-157. That is about as close as an uncontrolled self-report ever gets to isolating one variable.

> "i ran bpc 157 for few weeks felt decent then add tb 500 hand and skeletal felt worse i discontinued it it was the blend version 20mg" — @cryptotray79, X, 14 June 2026. Anecdotal.

[[embed:source:w_fgszb7lb]]

> "I ran TB-500 for a shoulder injury and got a head rush that lasted maybe 20 minutes. Injection site was red for a day." — @UndergroundBio, X, 3 August 2026. Anecdotal.

[[embed:source:w_wuu78tg1]]

Three describe immune-type reactions — hives, itching. That is the exact category FDA flagged in advance, on the grounds that clumped peptide and manufacturing contaminants provoke it.

> "Not my proudest moment, but after BPC-157 and TB-500 from the gray market, I got hives all over my body." — @stateofnomind, X, 10 March 2026. Anecdotal.

[[embed:source:w_dwju43tz]]

> "I took tb500 and bpc 157 mix for 3 days at 0.750 7.5 units on a 3mm needle i had some Hives show up on each side of love handles not the injection sites... Ive done research my self and stopped for now" — @GetterBankWest, X, 2 March 2026. Anecdotal.

[[embed:source:w_nad31utv]]

> "nothing moved the needle more re gut barrier symptoms than TB500. Until the development of an MCAS-like picture, it began to flair immune Sx: itching, hives from heat, etc." — @AmbrosesDrink, X, 4 August 2026. Anecdotal.

[[embed:source:w_llsxbr8a]]

### Two of the thirty-one used TB-500 without BPC-157, and both are in the last group

This is the number that matters. Twenty-nine of the thirty-one accounts ran TB-500 stacked with BPC-157, and several stacked a third and a fourth compound on top of that. Not one of those twenty-nine can attribute anything to TB-500. Every positive report in this set is a report about a combination.

The two accounts that isolate TB-500 are @biotides, whose bursitis shoulder got worse and recovered when he stopped, and @UndergroundBio, who got a head rush and a red injection site. Both sit in the "worse" column.

That is not evidence that TB-500 is harmful. Two reports settle nothing. It is a precise statement of how thin the isolated human experience with this compound actually is: out of 31 people who wrote down what happened, 2 took it on its own, and neither described a benefit.

### What these 31 reports can and cannot settle

They can settle that people are running this at milligram doses for weeks, mostly stacked, mostly for shoulders, elbows, knees and lower backs, and that a substantial fraction of them believe it worked.

They cannot settle whether it works. Nobody was blinded. Nobody imaged the injury before and after. Almost everybody changed something else in the same window — rest, physiotherapy, load reduction, a second compound, surgery. The conditions being treated improve on their own over the same timescale. And negative reports are systematically harder to find than positive ones, which means 17 out of 31 overstates the true positive rate by an unknown amount.

Hold this section against the evidence sections above and the shape is clear. The self-reported record is large, warm, and confounded. The controlled record for this exact molecule, in this exact tissue, is a single study in eight rats.
## Injury by injury, what the record actually reaches

| Your problem | Direct evidence in that tissue | Nearest real evidence | Where that leaves it |
|---|---|---|---|
| Tendon pain — Achilles, patellar, elbow | one 4-week rat study, 8 per arm, TB-500 into the belly cavity | Biçer 2026; Wu 2020 tendon cells in a dish | mechanism is plausible, one small animal result, nothing in people |
| Ligament sprain | one rat knee-ligament study, full protein, placed in the wound in glue | Xu 2013 | positive, but a different molecule at 1 µg delivered locally |
| Muscle strain or tear | none, only work on the body's own signal | Tokura 2011 | the pathway is real, adding more from outside is untested |
| Disc injury, disc-related pain | none | the scoping review lists spine and disc as sparse | no evidence at all in this tissue |
| Frozen shoulder | none | Ehrlich 2010 scar-cell suppression, rat sponge model | a scar-reduction argument only, and it belongs to the full protein |
| Plantar fasciitis | none | tendon data by analogy | no evidence, treated as tendon pain by assumption |
| Recovery after soft-tissue surgery | none in people | skin wound and heart animal work | untested |

Two of those rows carry an extra warning. The frozen-shoulder and disc arguments both rest on reducing scar, and the strongest scar-reduction mechanism in this literature runs through Ac-SDKP — the piece the sold fragment cannot make.

## Every human study ever registered on this molecule

Here is the whole clinical programme for the parent protein, with what actually happened to each trial. TB-500 appears in it once, as the fictional example.

| NCT | Indication | Sponsor | Phase | Enrolled | Status |
|---|---|---|---|---|---|
| NCT00382174 | pressure ulcers | RegeneRx | 2 | 72 | completed |
| NCT00832091 | leg ulcers from poor vein drainage | RegeneRx | 2 | 72 | completed |
| NCT00311766 | epidermolysis bullosa | RegeneRx | 2 | 30 | terminated |
| NCT00598871 | corneal wounds after diabetic eye surgery | ReGenTree | 2 | 12 | terminated |
| NCT00743769 | intravenous safety, healthy volunteers | RegeneRx | 1 | 0 | withdrawn |
| NCT01311518 | heart attack | RegeneRx | 2 | 0 | withdrawn |
| NCT01393132 | severe dry eye | Michigan Cornea Consultants | 2 | 9 | completed |
| NCT02597803 (ARISE-1) | dry eye | ReGenTree | 2/3 | 317 | completed |
| NCT02974907 (ARISE-2) | dry eye | ReGenTree | 3 | 601 | completed |
| NCT03937882 (ARISE-3) | dry eye | ReGenTree | 3 | 700 | completed |
| NCT02600429 (SEER-1) | nerve-damaged cornea | ReGenTree | 3 | 18 | terminated |
| NCT05555589 (SEER-2) | nerve-damaged cornea | ReGenTree | 3 | 70 planned | recruiting |
| NCT04555824 | healthy volunteers, Phase 1a | Beijing Northland | 1 | 54 | completed |
| NCT05485818 | heart attack | Beijing Northland | 2 | 62 | completed |
| NCT05984134 | heart attack | Beijing Northland | 2 | 90 | completed |
| NCT07586865 | heart attack | Beijing Northland | 2 | 189 planned | not yet recruiting |
| NCT07487363 | TB-500, heart biomarkers | "Hudson Biotech" | 1/2 | 80 planned | self-declared fictional example |

Four things fall out of that table.

**No musculoskeletal indication has ever been registered.** Not tendon, not ligament, not muscle, not fascia, not disc. Not by any sponsor, in twenty years, for either molecule. That absence is not a hole in the search. It is the state of the field.

**Both heart trials from the original sponsor were withdrawn before a single patient enrolled**, and the programme then moved to a different sponsor, a different country, and a recombinant full-length product.

[[embed:source:s36]]

**The published "Phase III" cornea result comes from a terminated trial.** SEER-1 stopped at 18 patients enrolled, and the ten-versus-eight comparison you read in the literature is that terminated trial's data. Its successor, SEER-2, is still recruiting toward 70.

[[embed:source:s39]]

[[embed:source:s42]]

**Three completed Phase 3 dry-eye trials covering 1,618 patients have produced no approval.** ARISE-1 finished in 2016, ARISE-2 in 2018, ARISE-3 in October 2021. That is the largest and most mature dataset this molecule has, in the indication where it performs best, and it has not turned into a medicine anybody can buy.

[[embed:source:s44]]

[[embed:source:s40]]

[[embed:source:s43]]

The skin programme closed the same way — two trials completed with safety as the main question, two stopped early.

[[embed:source:s37]]

[[embed:source:s38]]

## What is solid, what is not, and the gap underneath both

**Solid.** Thymosin beta-4 holds loose actin and controls how a cell builds its internal skeleton. Its seven-amino-acid actin-grabbing piece is the part that grows new blood vessels, working at around 50 nanomolar. The full protein closes rat skin wounds 42 to 61% faster, stops repair cells turning into the scar-pulling kind, works through integrin-linked kinase and Akt in injured heart muscle, pulls muscle precursor cells toward damage, and improves dry eye and nerve-damaged cornea in small controlled human trials.

**Not solid.** That any of that heals a human tendon, ligament, muscle, disc or fascia. That the fragment sold as TB-500 does what the full protein does. That milligram-per-week injections under the skin reach an injured structure at a concentration where the mechanism runs. That the compound is safe in a person over any length of time, because that study has never been run.

**The gap underneath both.** The evidence and the product are not the same substance. A regulator has written that down. The capped form has never been shown to do what the uncapped form does. And the one time anybody tested TB-500 itself in a dish, it did nothing. Every transfer of evidence from the 43-amino-acid protein to the seven-amino-acid fragment is an assumption, and it is the assumption the whole market stands on.

The practical consequence is narrow and specific. Tendon pain from overuse, an impingement, and a partial tear are three different problems with three different treatment plans, and no peptide tells them apart. Getting the diagnosis right changes what you should do this week far more than anything in this vial does. The scoping review that counted this entire literature lands in the same place, in its own words: the evidence "remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications."

*Not medical advice. TB-500 is sold for research use only, is not an approved drug, is not currently legal to compound, and is prohibited at all times in WADA-tested sport. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:ara-290]]

[[embed:wolverine-stack]]

[[embed:wolverine-stack-ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:bpc-157-vs-nsaids]]


## Sources

1. The actin binding site on thymosin beta4 promotes angiogenesis — https://pubmed.ncbi.nlm.nih.gov/14500546/
2. Thymosin beta4 accelerates wound healing — https://pubmed.ncbi.nlm.nih.gov/10469335/
3. Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Pressure Ulcers — https://clinicaltrials.gov/study/NCT00382174
4. Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers — https://clinicaltrials.gov/study/NCT00832091
5. Thymosin beta-4 and venous ulcers: a European prospective, randomized study — https://pubmed.ncbi.nlm.nih.gov/17495250/
6. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial — https://pubmed.ncbi.nlm.nih.gov/26056426/
7. Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury — https://pmc.ncbi.nlm.nih.gov/articles/PMC3843122/
8. Thymosin beta4 is cardioprotective after myocardial infarction — https://pubmed.ncbi.nlm.nih.gov/17600280/
9. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — https://doi.org/10.3390/app16126202
10. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat — https://pubmed.ncbi.nlm.nih.gov/23523891/
11. TB-500 - Status, Risks, and Bans in Sport and Military — https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
12. Thymosin beta4: potential to treat epidermolysis bullosa and other severe dermal injuries — https://pubmed.ncbi.nlm.nih.gov/31649007/
13. TB-500 - Status, Risks, and Bans (BSCG) — https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
14. Thymosin beta4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea 2015) — https://pubmed.ncbi.nlm.nih.gov/25826322/
15. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke — https://pubmed.ncbi.nlm.nih.gov/20627173/
16. Role of thymosin beta4 in tumor metastasis and angiogenesis (JNCI 2003) — https://pubmed.ncbi.nlm.nih.gov/14625258/
17. Thymosin beta4 has tumor suppressive effects in multiple myeloma — https://pubmed.ncbi.nlm.nih.gov/19833631/
18. FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate) — https://www.fda.gov/media/193349/download
19. World Anti-Doping Code International Standard — Prohibited List 2026, section S2.3 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. FDA Panel Votes to Loosen Restrictions for Four Peptides — https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
21. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study — https://pubmed.ncbi.nlm.nih.gov/42542926/
22. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts — https://pubmed.ncbi.nlm.nih.gov/20880960/
23. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts — https://pubmed.ncbi.nlm.nih.gov/20536458/
24. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis — https://pmc.ncbi.nlm.nih.gov/articles/PMC9655242/
25. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase — https://pubmed.ncbi.nlm.nih.gov/26962108/
26. Electrospun thymosin Beta-4 loaded PLGA/PLA nanofiber/microfiber hybrid yarns for tendon tissue engineering application — https://pubmed.ncbi.nlm.nih.gov/31753373/
27. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair — https://pubmed.ncbi.nlm.nih.gov/15565145/
28. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial — https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
29. Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NL005) — https://clinicaltrials.gov/study/NCT05485818
30. A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers — https://clinicaltrials.gov/study/NCT00743769
31. TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — 'TBRIDGE-CV' [self-declared fictional example record] — https://clinicaltrials.gov/study/NCT07487363
32. A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT01311518
33. A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa — https://clinicaltrials.gov/study/NCT00311766
34. A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds — https://clinicaltrials.gov/study/NCT00598871
35. Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy: SEER-1 — https://clinicaltrials.gov/study/NCT02600429
36. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2 — https://clinicaltrials.gov/study/NCT02974907
37. A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers — https://clinicaltrials.gov/study/NCT04555824
38. Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 — https://clinicaltrials.gov/study/NCT05555589
39. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 — https://clinicaltrials.gov/study/NCT03937882
40. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 — https://clinicaltrials.gov/study/NCT02597803
41. Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye — https://clinicaltrials.gov/study/NCT01393132
42. X · @PayHereSukka · 2026-07-30 — https://x.com/PayHereSukka/status/2082956437056008230
43. X · @MuroCrypto · 2026-07-31 — https://x.com/MuroCrypto/status/2083184469956059529
44. X · @jasonsvoboda · 2026-07-26 — https://x.com/jasonsvoboda/status/2081426443024961838
45. X · @MithMuel · 2026-06-30 — https://x.com/MithMuel/status/2071802227342340531
46. X · @howdymary · 2026-03-09 — https://x.com/howdymary/status/2031137869285425498
47. X · @Das_Bear_ · 2026-06-29 — https://x.com/Das_Bear_/status/2071462119011492350
48. X · @ryalljohnny1989 · 2026-08-03 — https://x.com/ryalljohnny1989/status/2084312093067513939
49. X · @caezcrypto1 · 2026-07-30 — https://x.com/caezcrypto1/status/2082943665832374561
50. X · @L0V3lsKeY · 2026-08-02 — https://x.com/L0V3lsKeY/status/2083868515438666186
51. X · @tj_underwood · 2026-07-31 — https://x.com/tj_underwood/status/2083248032603107752
52. X · @jordaaash · 2026-03-30 — https://x.com/jordaaash/status/2038733749366755452
53. X · @pepfessions · 2026-08-03 — https://x.com/pepfessions/status/2084071774480736712
54. X · @JonahLupton · 2026-07-26 — https://x.com/JonahLupton/status/2081490976510468316
55. X · @GrantWest14 · 2026-01-10 — https://x.com/GrantWest14/status/2010124835264111079
56. X · @_REDwave_2024 · 2026-05-20 — https://x.com/_REDwave_2024/status/2057019155824652482
57. X · @BenWolf1425771 · 2026-08-03 — https://x.com/BenWolf1425771/status/2084389889303548201
58. X · @TheCaddieYardFL · 2026-08-01 — https://x.com/TheCaddieYardFL/status/2083641327833522639
59. X · @prax1s_mm · 2026-07-30 — https://x.com/prax1s_mm/status/2082901582627184835
60. X · @replacementBux · 2026-04-12 — https://x.com/replacementBux/status/2043445152849555478
61. X · @moon25martin · 2026-05-30 — https://x.com/moon25martin/status/2060514158739640718
62. X · @ToddMil03223111 · 2026-07-09 — https://x.com/ToddMil03223111/status/2075223118067433536
63. X · @HangryDBowman · 2026-07-16 — https://x.com/HangryDBowman/status/2077974266339803140
64. X · @travfourr · 2026-04-15 — https://x.com/travfourr/status/2044547711114895786
65. X · @MittelstaedtTim · 2026-06-11 — https://x.com/MittelstaedtTim/status/2064873594103222656
66. X · @Gronnet · 2026-04-26 — https://x.com/Gronnet/status/2048321787667103904
67. X · @biotides · 2026-07-07 — https://x.com/biotides/status/2074549220887941324
68. X · @cryptotray79 · 2026-06-14 — https://x.com/cryptotray79/status/2071013244072788255
69. X · @stateofnomind · 2026-03-10 — https://x.com/stateofnomind/status/2031391204232016324
70. X · @GetterBankWest · 2026-03-02 — https://x.com/GetterBankWest/status/2028322438984175693
71. X · @AmbrosesDrink · 2026-08-04 — https://x.com/AmbrosesDrink/status/2084497141234598355
72. X · @UndergroundBio · 2026-08-03 — https://x.com/UndergroundBio/status/2084421599072039066


---

# Kisspeptin: The Receptor Break That Revealed How Puberty Starts

slug: kisspeptin · https://miscsubjects.com/a/kisspeptin · tags: kisspeptin, reproductive-endocrinology, peptide · updated 2026-08-05T09:19:52.316Z

No kisspeptin-based drug has been approved for a person to take, anywhere, as of today. What exists instead is one of the strongest human-genetics stories in reproductive medicine: break one receptor and puberty and fertility never start; give the hormone back and the signal that starts them returns within minutes, measured directly in people. That is the honest place to begin — solid human mechanism, real human dosing data from research units, and no finished product a doctor can prescribe.

One disclosure, because it should change how you read what follows. The operator of this site has a commercial interest in compounds described here, including this one. Weigh each claim below against the source attached to it, not against the tone of the page.

## Breaking one receptor stopped puberty in two families

In 2003, researchers studying children who never went through puberty on their own found the same broken gene in two unrelated families: KISS1R, the receptor that kisspeptin binds to. George and Seminara describe what followed in a 2012 review: "Soon thereafter a large array of experimental studies began assembling genetic, expression, physiologic, transgenic, knockdown, and electrophysiological data to characterize the physiology of kisspeptin and its seminal role in modulating GnRH release" (PMID 23015291). Mice bred without a working copy of the same receptor failed to mature sexually in the identical way — the same broken switch, in a different species, producing the same outcome.

## Kisspeptin sits at the top of the fertility relay

Fertility runs on a three-step relay inside the body: the brain releases a hormone called GnRH in short pulses, GnRH tells the pituitary gland to release two more hormones — LH and FSH — and those two drive testosterone or estrogen production and egg or sperm development. Kisspeptin controls the first step: whether GnRH gets released at all. "Hypothalamic kisspeptin neurons serve as the nodal regulatory centre of reproductive function," writes Victor Navarro in a 2020 review, describing kisspeptin cells as the point where the entire system either fires or stays silent (PMID 32427949).

## Starvation and stress reach the reproductive system through this one hormone

The same review explains why a body that is starved of food, or under heavy physical or emotional stress, stops menstruating or loses sex drive: metabolic signals bear down on kisspeptin production before they touch anything else in the chain. A companion chapter on the causes of lost periods puts the wiring in blunter terms: "Neuroendocrine regulation of ovulation involves the interaction between neurons secreting GABA, kisspeptin, and neurokinin which modulate the function of GnRH neurons" (PMID 25905176). The same chapter ties that circuit to the two hormones that track body fat and hunger, leptin and ghrelin — the body checking whether there is enough stored energy on hand before it lets the reproductive system run.

## Stress-related loss of periods is where clinical interest concentrates

The clearest present-day medical target is functional hypothalamic amenorrhea — periods that stop from a combination of stress, calorie restriction, and exercise, with no other disease found. A 2022 review places kisspeptin near the top of the list of signals controlling that shutdown: "Various neurotransmitters acting in the central nervous system are involved in control of the HPO axis and of these, kisspeptin is one of the most important" (PMID 36103784). The same paper points toward where treatment research is heading rather than where it has landed: toward drugs built to copy kisspeptin's receptor signal, still in development.

## Longer-acting copies are already running in human trials

Natural kisspeptin breaks down in the bloodstream within minutes, which rules it out as a once-daily medicine on its own. That has pushed research toward longer-acting copies of the same signal and blockers of the related neurokinin B pathway. A 2017 review of the field states: "Various Kp/NkB agonist/antagonist compounds have been developed during the last ten years, and are currently being evaluated in humans" (PMID 29157487) — for menopausal hot flushes, for puberty disorders, and as fertility-treatment support. Evaluated in humans is a specific claim: trials are running; regulators have not signed off on a result.

## What that leaves you with

Kisspeptin is a real, precisely mapped human hormone with a discovery story as solid as any in endocrinology: break the receptor and puberty never starts; restore the signal and the pulse returns. What it is not, today, is an approved medicine. Every human study cited here measured a hormone response inside a research unit, under monitoring, over hours — not a course a person runs at home over weeks. Choosing to use a compound sold under this name is choosing to run ahead of that trial data, not alongside it.


## Sources

1. Kisspeptin and the hypothalamic control of reproduction: lessons from the human — https://pubmed.ncbi.nlm.nih.gov/23015291/
2. Metabolic regulation of kisspeptin - the link between energy balance and reproduction — https://pubmed.ncbi.nlm.nih.gov/32427949/
3. Stress, kisspeptin, and functional hypothalamic amenorrhea — https://pubmed.ncbi.nlm.nih.gov/36103784/
4. Control of the gonadotrope axis: new physiologic and therapeutic aspects — https://pubmed.ncbi.nlm.nih.gov/29157487/
5. Central Causes of Amenorrhea — https://pubmed.ncbi.nlm.nih.gov/25905176/


---

# BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten

slug: bdnf-p21 · https://miscsubjects.com/a/bdnf-p21 · category: research · tags: peptide, bdnf, nerve-repair, p021, cntf · updated 2026-08-05T03:29:51.330Z

BDNF-P21 is sold as a peptide that raises BDNF, the growth factor nerve cells use to build and repair connections. That description is accurate and it is also the least interesting thing about the compound. The molecule is four amino acids long, it was cut out of a different growth factor entirely, it works when eaten rather than injected, and every result behind it comes from mice bred to have a genetic brain disease. The strongest of those results is real and specific: mice carrying the Down syndrome chromosome, treated from before birth, grew up without the memory failure they otherwise develop.

The site you are reading this on is funded by a business that sells this compound, which is exactly why the next sentence sits here at the top rather than at the bottom or nowhere. Nobody has given it to a person in a study: there is no human trial of it registered anywhere, under either of the names it goes by, on mouse data that goes back to 2014.

## The name on the vial and the name in the papers are different

Search the literature for "BDNF-P21" and you will find almost nothing. The compound in every study below is called **P021**, and its written-out sequence is Ac-DGGL(A)G-NH2 — four amino acids with a chemical cap on each end.

The vendor name is a description of what the molecule does downstream, not its identity. P021 is not a piece of BDNF and it is not a BDNF copy. It came out of a different protein, and it raises BDNF indirectly. Anyone comparing prices or reading research needs the number, not the marketing name, or they will find nothing and assume nothing exists.

## Four amino acids cut out of a different growth factor

P021 was designed in Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities on Staten Island, and the rights sit with a small company, Phanes Biotech. The starting material was ciliary neurotrophic factor, or CNTF — a growth factor that keeps nerve cells alive and pushes new ones to mature. The researchers identified the biologically active stretch of CNTF and built a four-amino-acid mimic of just that stretch.

So the chain is: a fragment modelled on CNTF's active region, which in a nerve cell drives more BDNF to be made, which then acts on nerve connections. Two steps, both documented, with the compound sitting at the top rather than in the middle.

## Why a small piece instead of the whole protein

Three separate attempts to treat brain disease by giving people whole growth-factor proteins failed, and they failed for the same three reasons every time. The proteins could not cross out of the blood into the brain. They were cleared from the body too fast to matter. And the doses needed to overcome both problems caused serious side effects.

That is the entire reason small mimics exist. A four-amino-acid molecule with caps on both ends is small enough to reach brain tissue, stable enough to survive the trip, and — the part that matters most in practice — it works mixed into food. Every long study below was run by putting P021 in the animals' diet, not by injecting them.

For a compound bought online, oral dosing is a genuine practical advantage over almost everything else in this category. It is also the reason the compound is sold as tablets rather than as a powder and a syringe.

## What it does inside a nerve cell, step by step

The measurements in the mouse studies trace a specific chain, and each link was recorded separately rather than assumed:

- BDNF levels rise in the brain tissue.
- CREB, a switch that turns on the genes needed to build a synapse, gets phosphorylated — which is the chemical marker of it being switched on.
- Proteins found on the sending side of the synapse stop disappearing, which in an untreated animal they do.
- GSK3β activity falls. That enzyme is what puts too many phosphate groups onto tau, the structural protein that tangles in Alzheimer's disease.

That last item is why the researchers describe P021 as possibly disease-modifying rather than merely propping up function. Raising a growth factor could produce a temporary benefit that disappears when you stop. Turning down the enzyme that damages tau is a change to the process itself.

## Twelve months of it in the diet of a mouse bred for Alzheimer's

The longest experiment: triple-transgenic Alzheimer's mice — animals carrying three human disease mutations — plus matched normal mice, fed P021 or a plain diet for twelve months, starting at nine to ten months of age, which in that model is well into established disease.

What changed: abnormal tau phosphorylation and tau build-up fell significantly at the specific sites where Alzheimer's tangles form.

What barely changed: the amyloid side. The effect on amyloid beta was limited to a fall in the soluble form, with the plaques essentially unmoved.

Both halves of that result matter. A compound that reduced tau damage across a year of treatment in an animal that was already sick is a real finding. A compound that leaves plaques alone is not the cure the category gets sold as.

## Started at birth instead of at symptoms

A second experiment ran the same Alzheimer's model the other way round: treatment in the diet from birth to day 120 of life, long before any symptoms appear. Mice treated that way did not develop the cognitive impairment the model produces, and the molecular markers of nerve-connection health were higher.

That is a prevention result in an animal with a known genetic fate, and it says something useful about the mechanism: the compound appears to act on how connections are built and maintained, rather than clearing away damage after the fact.

## The Down syndrome experiment, which is the strongest result here

The most striking study used Ts65Dn mice, the standard model of Down syndrome, which show developmental delay in infancy and Alzheimer-type memory problems in adulthood. Treatment ran from before birth through early infancy — given to the mothers, then to the pups.

The reported outcome: the developmental delay was rescued, and the memory failures that appear in adult life did not appear. Alongside that, the loss of sending-side synaptic proteins was prevented, GSK3β activity fell, and BDNF and switched-on CREB were higher — measured twice, at three weeks old and again at about seven months.

The design is what gives that result its weight. The treatment stopped in infancy and the benefit was still measurable in middle age. That is not a drug propping up a symptom while it is in the body; it is an early intervention changing how a brain got built.

It is also, without qualification, mice.

## The 2024 test in a mouse with a broken CDKL5 gene

The most recent work took P021 into another genetic disorder. Mutations in the CDKL5 gene cause a severe childhood epilepsy with motor and intellectual disability. Without that gene, nerve cells multiply, survive and mature poorly, and earlier work had shown that anything raising brain BDNF improves those animals.

The researchers tested P021 in cells and in the CDKL5 knockout mouse for exactly that reason: it was already documented as a BDNF-raiser in the Alzheimer's and Down syndrome models. That study is worth knowing about because of what it establishes about the compound's identity — three independent research groups now use it as a reliable way to raise brain BDNF in an animal. Its reputation inside the literature is as a research tool, and a well-behaved one.

## What has never been done: no person, no injury, no trial

A search of the clinical trials registry for P021 and for BDNF-P21 returns no study of this compound. Not a Phase 1, not a safety study, not a dose-finding study. It is not approved anywhere and it has not been submitted for approval.

Beyond that, there is a second gap. Every study is a *genetic* disease of brain development or degeneration: Alzheimer's mutations, trisomy, a missing CDKL5 gene. There is no study of P021 in an injured nerve of any kind — not a crushed nerve, not a cut nerve, not a spinal cord injury, not a concussion, not nerve damage from chemotherapy or diabetes.

Where a compound has no safety record in people, unknown is not the same as safe. Nobody has measured what a year of raising BDNF does in a healthy adult brain, and BDNF signalling is not a system with only good outputs — the same pathway is involved in pain sensitisation.

## The reasoning people use to get from these mice to a person, and where it breaks

The argument runs: damaged nerve tissue is short of BDNF, BDNF is what rebuilds nerve connections, P021 raises BDNF and can be swallowed, so P021 should help nerve tissue recover.

Every step in that chain is separately defensible. The chain has never been tested end to end, and there are two specific places it could fail.

First, all the measurements are in brain tissue — hippocampus and cortex. A peripheral nerve is a different cell type with a different repair programme, and nothing in this literature measured one.

Second, the timing is inverted. Both of the strongest results came from treating *before* damage appeared. The one study that treated an animal already sick got a partial result: tau improved, plaques did not. Damage that is already years old is the second situation, not the first.

## The finding that cuts against the whole idea: the growth factor it raises has a second job

Raising BDNF is presented as unambiguously good. In nerve pain it is not, and the evidence for that is stronger and more specific than the evidence behind this compound.

A 2024 review in *Neuroscience* by Peter Smith lays out the pathway. When a peripheral nerve is injured, its terminals in the spinal cord release signals that change the local immune cells — microglia — so they start carrying a particular receptor, P2X4. When nerve-released ATP hits that receptor, those microglia release BDNF. That BDNF then makes the excitatory neurons in the spinal cord's dorsal horn fire more easily and makes the inhibitory ones fire less easily, and it shifts the chloride balance inside neurons in a way that turns a normally calming signal into an exciting one. The result is amplified pain from a normal input.

The review's title is blunt about the whole line of work: BDNF is "the culprit that cannot be apprehended". And it reports something that ought to be in every conversation about this class of compound: in males, BDNF plays an obligatory role in the onset and maintenance of nerve pain, and in females it does not.

So the same molecule builds nerve connections in the brain and amplifies pain signalling in the spinal cord, and which of those you get depends on where it goes up, which cells release it, and — for pain specifically — sex. A compound whose entire mechanism is "raise BDNF" is running toward both effects at once, with no way to steer between them. Nobody has measured which one wins in a person, because nobody has given this compound to a person.

## Where it sits next to the other BDNF-raisers sold beside it

Three other compounds on this site work through the same growth factor, and the differences are worth having straight.

Semax has been a hospital medicine in Russia for decades and has human data — small, mostly Russian, including a 110-patient stroke study where blood BDNF rose. Its rat measurement is a 1.4-fold rise in brain BDNF from a single dose into the nose. It also has one 2025 mouse study of a crushed spinal cord, which is the only nerve-injury result in this group.

Selank keeps BDNF up in a different setting: in rats given alcohol long-term, seven days of it protected memory and kept BDNF up in the hippocampus and prefrontal cortex. Its human record is anxiety, not nerve repair.

P021 has no human data at all, and the most rigorous animal designs of the three — treat before damage, measure decades-equivalent later, watch the marker stay changed.

Read together, the group has an awkward shape. The compound with the best experimental design has never been near a person. The compound with human data has the weakest mechanism numbers. Nobody has run a head-to-head comparison of any two of them, in any species.

## Oral, which is unusual and is the point

Almost everything sold in this category is a powder you mix with water and inject. P021 was designed to work in food, and every long-term study delivered it that way, which is why it is sold as tablets.

Practically, that removes the two most common failure points in self-administered peptide use: mixing arithmetic and injection technique. It does not remove the more basic problem, which is that no human dose exists to copy. The mouse studies dosed by mixing a set concentration into diet across months. There is no published translation of that into a milligram figure for a person, and any number on a label is the seller's, not a researcher's.

## What it would take to know

A Phase 1 study in healthy adults would settle the safety question — what dose is tolerated, what happens to it in the body, whether measurable BDNF changes at all in a person. It has not been run, on a compound with mouse data going back to 2014.

For the nerve-injury question the study is different and harder: an animal model of actual nerve damage — a crushed sciatic nerve is the standard — with recovery measured against untreated controls. That study is straightforward, cheap by the standards of this field, and appears nowhere in the literature. Until somebody runs it, the case for using this compound on an injured nerve rests entirely on a mechanism, and the honest version of that sentence is that a mechanism is a hypothesis with a diagram attached.

There is a second study that would cost almost nothing and would settle the question that matters most on this page. Give the compound to male and female animals with an injured nerve, and measure pain behaviour rather than memory. If raising BDNF helps the nerve repair, pain should fall as function returns. If the spinal-cord pathway dominates, pain should rise, and rise in males more than females. Those two outcomes point in opposite directions and the experiment separates them in weeks. Twelve years after the first mouse paper, nobody has published it.

Until then, what can be said about BDNF-P21 is narrow and worth stating without decoration. It is a four-amino-acid piece modelled on CNTF that reliably raises BDNF in mouse brain tissue and can be eaten rather than injected. In three separate genetic diseases of the brain, given early, it changed how the animals' brains developed and the change outlasted the treatment. In an animal already sick it did about half of what it does when given early. Nobody has measured it in a person, nobody has measured it in an injured nerve, and the growth factor it raises has a documented second job of making nerve pain worse.

Seven published studies are attached to this page, along with the registry search that returns nothing. Every claim above traces to one of them.


## Sources

1. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease — https://pubmed.ncbi.nlm.nih.gov/25046994/
2. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome — https://pubmed.ncbi.nlm.nih.gov/28368015/
3. Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction — https://pubmed.ncbi.nlm.nih.gov/34057082/
4. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder — https://pubmed.ncbi.nlm.nih.gov/39592934/
5. Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound — https://pubmed.ncbi.nlm.nih.gov/36291618/
6. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease — https://pubmed.ncbi.nlm.nih.gov/27400746/
7. BDNF in Neuropathic Pain; the Culprit that Cannot be Apprehended — https://pubmed.ncbi.nlm.nih.gov/38417539/
8. ClinicalTrials.gov registry search for P021 and BDNF-P21, run 4 August 2026 — https://clinicaltrials.gov/api/v2/studies?query.term=P021


---

# Retatrutide: the third receptor, and what the evidence now establishes

slug: retatrutide · https://miscsubjects.com/a/retatrutide · tags: peptide, retatrutide, glp-1, obesity, disc · updated 2026-08-05T02:14:48.127Z

Retatrutide is one molecule that switches on three different hormone receptors at once: GLP-1, GIP, and glucagon. Semaglutide hits one of those. Tirzepatide hits two. Retatrutide adds the third, and that third one is the interesting part, because glucagon is the hormone most people know as the one that raises blood sugar — the opposite of what a diabetes drug is supposed to do.

Understanding why adding it works is most of understanding this drug.

**Where the evidence stands, before anything else.** Retatrutide has been tested in people. Phase 2 randomised trials in obesity and in type 2 diabetes are published, and the first phase 3 trial — a double-blind randomised trial in type 2 diabetes — has now reported. The obesity phase 3 trials and the cardiovascular and kidney outcome trials are still running. It is not an approved medicine in any country, so nothing sold under this name is the material that was studied.

## Why putting glucagon into a weight-loss drug is not a mistake

Glucagon does raise blood sugar. It also does something else: it increases energy expenditure. It tells the liver to break down stored fat and it raises the rate at which the body burns energy at rest.

So a molecule that activates the glucagon receptor on its own would burn more energy and worsen blood sugar. A molecule that activates GLP-1 and GIP lowers blood sugar strongly and reduces appetite. Put all three on one peptide and the GLP-1 and GIP arms more than cover the blood sugar cost of the glucagon arm, and you keep the extra energy expenditure.

The result is a drug that attacks weight from both sides at once — appetite down and energy out up — rather than appetite alone. Every other drug in this class works mainly on the intake side.

The elegance of that design has been demonstrated in an unusual way. Researchers testing the components in mice engineered to have no working GLP-1 receptor at all found that retatrutide still normalised body weight in those animals.

[[embed:source:s11]]

That is a mechanistic result rather than a clinical one, and it matters because it isolates the contribution of the other two arms. The weight effect is not simply a stronger version of what GLP-1 drugs do.

## What it actually does to weight, in numbers

The comparison that puts it in context is a network analysis of the drugs acting on the glucagon receptor, which ranks them against placebo on weight.

[[embed:source:s12]]

Retatrutide produced the greatest weight reduction of the class — a mean difference of 13.44 kg against placebo, ahead of survodutide at 10.74 kg, with cotadutide's effect small and not statistically significant.

The same analysis found retatrutide had the largest effect on HbA1c, the three-month average blood sugar measure — and it was the only one of the four whose effect on HbA1c reached statistical significance.

In the type 2 diabetes programme the blood sugar numbers are striking on their own terms: HbA1c improved by 2.2%, and 82% of participants reached 6.5% or below — a threshold at which many people would no longer meet the diagnostic criteria for diabetes.

[[embed:source:s13]]

The same summary reports improvements across blood pressure, lipids, waist circumference, and an 82% reduction in liver fat.

## The body composition question, answered directly

The standard objection to very effective weight-loss drugs is that a large fraction of what is lost is muscle rather than fat. It is a serious objection, particularly in older people, and the more weight a drug takes off the more it matters.

A substudy measured body composition directly rather than inferring it.

[[embed:source:s14]]

Fat mass fell 26.1% on the 8 mg dose and 23.2% on 12 mg, against 2.6% on placebo. And on the question people actually want answered:

[[embed:source:s15]]

The proportion of the loss that was lean mass was similar to other obesity treatments. Retatrutide takes off more total weight, and it does not appear to take off a disproportionate share of muscle in doing so.

Two honest caveats. The study was funded by the manufacturer, which is normal at this stage and worth stating. And 85% of the participants were White, which limits how confidently the result generalises.

## The liver finding, and why it is arguably the most important one

An 82% reduction in liver fat is a large number in a field where liver fat has been hard to move. Fatty liver disease has almost no approved drug treatment; a 2026 review notes that only two agents are specifically approved for it, and places retatrutide among the pipeline drugs showing marked reductions in liver fat and early signals of benefit in the more advanced inflammatory form.

[[embed:source:s16]]

Another 2026 review of the same area places it alongside the other multi-receptor drugs and is careful about the limits.

[[embed:source:s17]]

Early clinical data indicating potent effects. Evidence on whether it changes scarring in the liver remains limited. That distinction — reducing fat in the liver versus changing the disease that fat drives — is the one that will decide whether this becomes a liver drug or a weight drug with a liver side effect.

## What it feels like to take, from the people who took it

A substudy asked participants in the diabetes trial about hunger and eating rather than only weighing them.

[[embed:source:s18]]

People on the higher doses reported being less likely to feel hungry or to overeat, and — the more interesting finding — the people who lost the most weight were the same people who reported the largest changes in hunger and overeating.

That correlation is worth holding onto for a practical reason. If your appetite has not changed on a drug in this class, the weight is less likely to follow, and that is information available within weeks rather than months.

## What "three receptors on one molecule" actually required

It is worth understanding why this took until now, because it explains why the class looks the way it does and what the constraints are.

GLP-1, GIP and glucagon are structurally related hormones — close enough that a single engineered peptide can be made to fit all three receptors, and far enough apart that fitting all three well is difficult. The design problem is not simply binding all three. It is binding them in the right *ratio*.

Too much glucagon activity relative to the other two and blood sugar rises. Too little and the extra energy expenditure that justifies including it disappears. Too much GLP-1 activity relative to the rest and the gastrointestinal effects become intolerable before the target dose is reached. The molecule has to be balanced, and the balance is a property of the peptide sequence and its fatty-acid modification, not something a prescriber can adjust.

That has a practical consequence people miss. With a single-receptor drug, dose is the only variable and more is more. With a three-receptor drug, the ratio between the three effects is fixed at the point of manufacture, and only the total is dose-dependent. It also means a peptide with the wrong sequence is not a weaker version of the drug — it is a different drug with a different balance, and its blood sugar effect could point the other way.

A 2026 review of the wider field places these engineered multi-agonists in context: they work by mimicking the several-hormone response the body produces after bariatric surgery, rather than by amplifying one signal.

[[embed:source:s23]]

That framing explains the size of the effects better than "a stronger GLP-1 drug" does. The comparison to surgery is not only about how much weight comes off; it is about which mechanism is being copied.

## Who this class does not suit, and the practical constraints

Some of what follows is class knowledge from the approved drugs rather than retatrutide-specific evidence, and it is labelled as such because the distinction matters.

**Anyone with a history of medullary thyroid carcinoma or the endocrine syndrome associated with it** is excluded from GLP-1 drugs on the basis of rodent findings. That exclusion is applied to the class.

**Gastroparesis and significant gastrointestinal disease** sit badly with drugs whose main mechanism includes slowing stomach emptying.

**Pregnancy** is a contraindication across the class, and the appetite mechanism means people using these drugs while trying to conceive need a conversation about timing rather than an assumption.

**Anyone on insulin or a sulfonylurea** faces a real interaction: as the drug improves blood sugar, existing medication that lowers it further can cause hypoglycaemia. This is managed by adjusting the other drugs, which requires somebody monitoring.

The last point is the one that connects back to the glucagon arm. Retatrutide's blood sugar effect is the *net* of three receptor effects, two lowering and one raising. The trials established that net in specific populations on specific background medications. That is not a constant of nature; it is a measured result in a defined group.

## The side effects, and the class risk worth naming

Gastrointestinal symptoms are the commonest problem — nausea, vomiting, diarrhoea, constipation — and they are the reason the dose is escalated slowly rather than started at target. In the phase 2 programme they were the main adverse events reported, with no major safety concerns identified.

[[embed:source:s19]]

"No major safety concerns in phase 2" is a real statement and a limited one. Phase 2 trials enrol hundreds of people for months. Rare harms and long-term harms are what phase 3 and post-marketing surveillance are for, and only the first of those has begun to report.

One class-level risk deserves naming because it is asked about constantly. A meta-analysis of GLP-1 receptor agonists found a slightly increased risk of pancreatitis, and no significant association with pancreatic cancer overall.

[[embed:source:s20]]

Note that this is a finding about the established GLP-1 drugs, not about retatrutide specifically. Applying it here is a reasonable inference from a shared mechanism, not a measurement.

There is also a mechanistic reason to watch blood sugar more carefully with this drug than with its predecessors. The glucagon arm raises blood sugar. In the trials the other two arms more than compensate. In someone whose situation differs from the trial population — different medications, different insulin reserve — that balance is an assumption rather than a measurement.

## Where it is in development, stated plainly

**Retatrutide is not an approved medicine anywhere.** That is the fact that governs everything below, and it is true despite the programme having moved past phase 2.

The first phase 3 result has published. TRANSCEND-T2D-1 was a double-blind randomised phase 3 trial in people with type 2 diabetes whose blood sugar was not controlled by diet and exercise alone, with change in HbA1c at week 40 as its primary endpoint.

[[embed:source:s1]]

Retention was high — 91% of participants completed the treatment period on the study drug and 94% completed the study, which for a drug whose main side effects are gastrointestinal is itself a tolerability finding.

[[embed:source:s24]]

The rest of the programme is still running: the obesity phase 3 trials, and the cardiovascular and kidney outcome trials.

[[embed:source:s21]]

That last part — cardiovascular and renal outcome trials — is not a formality. For drugs in this class, outcome trials are how the field learns whether the metabolic improvements translate into fewer heart attacks and less kidney failure, and the answer has not always followed the surrogate measures.

Phase 2 results of this size attract language that outruns the evidence. One 2026 perspective describes the weight reductions as comparable to bariatric surgery and calls the drug a watershed.

[[embed:source:s22]]

That may prove right. It was also written from phase 2 data, and the distance between "unprecedented in phase 2" and "approved and durable in practice" is where a great many promising drugs have stopped. The first phase 3 result is now in, in diabetes; the weight-loss phase 3 results and the outcome trials are not.

## What this means for anything sold under this name

This is the part that matters most to anyone reading this page with a purchase in mind.

Because retatrutide is not approved, nothing sold under that name is a licensed medicine. There is no pharmacy supply chain, no regulator checking identity or purity, and no manufacturer standing behind what is in the vial. The dosing that produced the results above came from a controlled programme with slow escalation and monitoring — and dose escalation exists in these trials precisely because starting at target dose causes the gastrointestinal effects that make people stop.

The honest position: the trial results are real, they are large, and they were produced under conditions that have almost nothing in common with obtaining an unapproved peptide and self-administering it. The operator of this site has a commercial interest in compounds of this kind, which is exactly why that sentence appears here rather than at the bottom in small type.

## Ten people, and what the evidence supports about them

Ten people with obesity take retatrutide at the higher doses in a trial setting. On the pooled evidence, they lose substantially more weight than they would on any other drug in this class, and the proportion of that loss which is muscle is no worse than with the alternatives. Most of them experience gastrointestinal side effects at some point, particularly while the dose is being raised. Those who report the biggest change in hunger are the same ones who lose the most weight. Their liver fat falls substantially. Their blood pressure, lipids and waist measurement improve. Whether any of that translates into fewer cardiovascular events over years is being tested now and is not yet known for any of them.

## What the trials do not tell you

Four gaps are worth naming precisely, because they are the questions people ask and the literature does not yet answer.

**What happens when you stop.** No published retatrutide data addresses this. For the approved drugs in the class, stopping is followed by substantial weight regain, which is what you would expect from a drug whose mechanism is suppressing appetite while it is present. There is no reason to assume this molecule behaves differently, and no evidence that it does. Anyone planning to take it should plan for what follows.

**Whether the effects last.** The phase 2 results run to 48 weeks. Weight loss curves in this class typically flatten as the body adjusts, and where that plateau sits for retatrutide over two or three years is unknown.

**Whether the metabolic gains become clinical ones.** The published phase 3 trial measured HbA1c, not heart attacks. Lower blood sugar, lower blood pressure, better lipids and less liver fat are surrogates. They are strongly associated with fewer heart attacks and less kidney failure, and drugs that improve surrogates have sometimes failed to improve outcomes. That is precisely what the running outcome trials exist to settle.

**Who it works badly for.** With 85% White participants in the body composition substudy and a trial population selected by trial criteria, the honest answer about how this performs across different populations is that it has not been measured properly yet.

Those four are not criticisms of the drug. They are the difference between a phase 2 result and a medicine.

## Where this sits against the others

Against semaglutide and tirzepatide, retatrutide's case is the third receptor and the energy-expenditure arm it brings. Against bariatric surgery, the comparison people keep reaching for, the honest version is that phase 2 weight reductions are in a comparable range while durability, complication profile and decade-scale outcomes are not comparable at all, because one of them has decades of follow-up and the other has none.

The most defensible summary available today: the largest weight effect measured in its class, the largest blood sugar effect in its class, a substantial liver fat effect, an ordinary side-effect profile for the class, no unexpected safety signal so far, one published phase 3 trial in type 2 diabetes with high completion rates, and no approval anywhere.

## The seven things this evidence supports

1. **The third receptor is the whole story.** Glucagon adds energy expenditure to appetite suppression, and the other two arms cover its effect on blood sugar.
2. **The weight effect is the largest in its class, and it is measured against placebo.** 13.44 kg mean difference, ahead of every comparator in the network analysis.
3. **The muscle question has been answered directly, not argued.** Fat mass down 26.1% at 8 mg, with the lean mass proportion similar to other treatments in the class.
4. **The liver result may matter more than the weight result.** An 82% reduction in liver fat, in a disease with almost no approved treatment — and no evidence yet on scarring.
5. **If your appetite does not change, watch closely.** The people with the largest changes in hunger were the ones who lost the most weight.
6. **It is not an approved drug.** One phase 3 trial has reported, in diabetes. The obesity phase 3 trials and the cardiovascular and kidney outcome trials have not.
7. **Nothing sold under this name is the drug that was studied.** The results came from a monitored programme with controlled escalation and verified material. That is not what an unapproved peptide purchase is.


## Sources

1. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — https://pubmed.ncbi.nlm.nih.gov/42250575/
2. Efficacy and safety of retatrutide for the treatment of obesity — https://pubmed.ncbi.nlm.nih.gov/40728138/
3. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/39817343/
4. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/40291085/
5. Retatrutide-A Game Changer in Obesity Pharmacotherapy — https://pubmed.ncbi.nlm.nih.gov/40563436/
6. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
7. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) — https://clinicaltrials.gov/study/NCT05882045
8. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials — https://pubmed.ncbi.nlm.nih.gov/41090431/
9. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — https://clinicaltrials.gov/study/NCT05936151
10. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) — https://clinicaltrials.gov/study/NCT07232719
11. GIPR:GCGR co-agonism restores normal weight in obese rodents — https://pubmed.ncbi.nlm.nih.gov/41997446/
12. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials — https://pubmed.ncbi.nlm.nih.gov/41787737/
13. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
14. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
15. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
16. Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes — https://pubmed.ncbi.nlm.nih.gov/41831086/
17. Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression — https://pubmed.ncbi.nlm.nih.gov/42195239/
18. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study — https://pubmed.ncbi.nlm.nih.gov/40916752/
19. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
20. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials — https://pubmed.ncbi.nlm.nih.gov/40988099/
21. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
22. The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities — https://pubmed.ncbi.nlm.nih.gov/41545327/
23. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders — https://pubmed.ncbi.nlm.nih.gov/41297910/
24. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — https://pubmed.ncbi.nlm.nih.gov/42250575/


---

# The Wolverine stack plus ARA-290 for a degenerating disc and sciatica: the evidence at every link

slug: wolverine-stack-ara-290 · https://miscsubjects.com/a/wolverine-stack-ara-290 · category: peptides · tags: peptide, bpc-157, tb-500, ara-290, disc, sciatica, stack, wolverine · updated 2026-08-04T22:08:42.768Z

A worn spinal disc with a burning leg is not one problem. It is a breakdown running in three separate places at once, and the reason people add ARA-290 to the two-compound Wolverine stack is that the third place — the nerve fibres themselves — is the one the first two compounds do not touch.

The evidence state, before the argument. No study in any species has ever given all three compounds together, so the number of people or animals that have taken this stack under measurement is nought. One at a time the three are nothing like each other. ARA-290 has six human studies and 132 people who received the active compound; three of the six missed their main endpoint, the positive results cluster in one disease, sarcoidosis, and not one of the six enrolled a person with a back problem. BPC-157 has five published human studies covering about 130 people, none of them a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries were filed on ClinicalTrials.gov in February 2026 by one sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything. The animal record behind the disc argument is rats, mice and rabbits, and the one experiment that ever combined two of the three found the pair beat neither compound on its own. What has never been measured in a person: any of the three against a squeezed nerve root or a worn disc, and all three together in anything alive.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

This page sets out what is breaking down, what makes it break down faster, what each of the three compounds is proposed to build back, and how strong the evidence is at every single link. The grades differ enormously between links, and the strongest evidence in the whole stack sits on the compound most people leave out.

## Three things break down in a worn disc, and they break down in order

**The disc dries out.** The soft centre of a spinal disc is mostly water, held there by a large sugar-and-protein molecule called aggrecan that acts like a sponge. At birth that centre is about 90% water. By 60 it is closer to 70%, because the aggrecan gets chopped up and washed out. Less water means less pressure inside, and a disc that cannot hold pressure cannot spread load.

**The outer ring tears.** As the centre flattens, load transfers to the tough fibrous ring around it. That ring is not built to take the load directly, so it splits — small cracks first, then tears that run through to the outside. That is how a worn disc becomes a bulging or herniated one.

**The chemistry turns hostile, and nerves grow in.** Disc cells under load start pumping out two inflammatory signals, TNF-alpha and IL-1beta. Those signals do three things at once. They raise the enzymes that chew up the disc's own scaffolding while lowering the proteins that block those enzymes, so breakdown outruns building. They irritate any nerve root nearby. And they coax pain nerve fibres to grow into a disc that normally has none in its centre at all.

That third step is why worn and painful are different conditions. Plenty of badly degenerated discs never hurt. What makes a worn disc a painful one is chemistry, not the wear.

[[embed:degenerative-disc-disease]]

## The reason the disc cannot fix any of it

The spinal disc is the largest structure in the body with no blood supply of its own. Nothing feeds it directly. Nutrients seep in slowly through the bony end plates above and below, and those plates stiffen and calcify with age, so the supply gets worse exactly as the demand rises.

Every tissue that heals well heals because blood brings oxygen, raw material and repair cells. The disc gets almost none of that. This single fact governs everything that follows: it is why the breakdown mostly runs one way, why swallowed supplements struggle to reach the tissue, and why any serious attempt at rebuilding has to solve the blood supply before anything else can matter.

It is also why BPC-157 — a compound whose main proposed action is growing new blood vessels into damaged tissue — is the one people reach for, and why that reach has never been tested in a disc.

## What speeds the breakdown up, and which of those you control

Most of what drives disc breakdown is fixed: age, the genes you have, injuries you already had. Two are not fixed, and both have better evidence behind them than any compound on this page.

**Body weight.** A Mendelian randomisation analysis — the study design built specifically to separate cause from correlation, by using inherited genetic variation as the exposure — found that higher body mass index raises the odds of disc breakdown, of low back pain, and of sciatica. That is causal-grade evidence, which is a higher grade than anything supporting any of the three compounds here.

**Smoking.** Nicotine narrows the small vessels feeding a tissue that is already starved of blood, and it is directly toxic to disc cells, cutting their repair activity. For a structure whose central problem is nutrition, that is the worst possible input.

The widely repeated line that one pound of body weight equals four pounds on the spine is not a measured law. The genuine four-to-five-fold load spikes recorded inside living discs come from bending and lifting — the leverage of the trunk — not from a body-weight multiplier.

## Three compounds, three different parts of the problem, graded link by link

This is the argument for the three-compound stack, stated as a table so each link can be attacked separately. The grades run A to F and are defined immediately below the table.

| What is breaking down | The compound aimed at it | What that compound is proposed to do, in plain words | Strongest evidence for that link | Grade | What would prove this link wrong |
|---|---|---|---|---|---|
| No blood supply reaching the damaged tissue | BPC-157 | Grow new blood vessels into the injury by switching on the VEGF growth signal and the nitric-oxide system that widens vessels, so oxygen and raw material arrive | Rat Achilles tendon torn off the bone came back attached and mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than control | D | Counting vessels at the injury site in a controlled animal study and finding no difference against control |
| Repair cells not reaching or not organising | TB-500 | Bind actin, the filament a cell builds and takes apart to change shape, so repair cells can crawl into the wound and lay ordered collagen instead of scar | Rat Achilles repair, 32 animals, 8 per arm, four weeks: higher load to failure than control, p < 0.05; best tissue score, p = 0.016; most ordered collagen under stain | D | Measuring how many repair cells arrive at the wound and finding no increase |
| The nerve fibres themselves damaged and dying back | ARA-290 | Bind a receptor that only appears on tissue that is already injured, switching on a repair programme that regrows small nerve fibres, without raising red cell counts the way its parent hormone does | Randomised, placebo-controlled human trials. Corneal nerve fibre area rose 697 µm² above placebo at 4 mg a day for 28 days, p = 0.012, in 64 people with nerve fibre loss from sarcoidosis; nerve fibre density rose 2.6 fibres/mm² in the abnormal subgroup of a diabetic neuropathy trial, p = 0.02 | B | A randomised trial in a compressed nerve root showing no separation from placebo — which is the trial nobody has run |
| The nerve root chemically irritated by TNF-alpha | BPC-157 and TB-500, weakly | Calm the inflammatory signalling around the root | Rodent anti-inflammatory models only. The strongest available test of this target in humans — blocking TNF-alpha with a monoclonal antibody at the nerve root — produced a null result against steroid | E | Already largely answered against, see below |
| The displaced fragment physically pressing on the nerve | Nothing | No compound in this stack is claimed to move tissue | Not applicable | Not a claim | Any vendor asserting a peptide puts a disc back is making a claim with no mechanism behind it |
| All three compounds together | — | The three steps at once | Nothing. No study in any species has given all three | F | Untested in every sense |

## The grades explained, so the table can be argued with

- **A** — randomised, placebo-controlled human trial in the actual condition on this page. Nothing on this page holds an A.
- **B** — randomised, placebo-controlled human trial in a different condition, with the target tissue measured directly. ARA-290 holds a B, on nerve.
- **C** — controlled animal experiment in the target tissue.
- **D** — controlled animal experiment in a related tissue. BPC-157 and TB-500 both hold a D: their results are in tendon, ligament, muscle and nerve, never in a disc.
- **E** — cells in a dish, or a mechanism argued from a related pathway.
- **F** — no experiment of any kind.

Read the grade column and one thing jumps out. The compound with the strongest evidence is the one usually treated as the optional add-on, and the two compounds the stack is named after are the two graded D. If evidence quality drove what people bought, the ordering would be reversed.

## The nerve is the only link with randomised human evidence behind it

ARA-290, generic name cibinetide, is an eleven-amino-acid piece of erythropoietin — the hormone that tells bone marrow to make red blood cells. It was built by cutting out the section of that hormone responsible for tissue repair while leaving out the section responsible for red cells.

That split works because the two jobs run through two different receptors. Red cell production runs through the classical receptor. Tissue repair runs through a different pairing, which appears on tissue only after it has been damaged and is absent from healthy tissue. So the compound has, by design, almost nothing to bind to in an uninjured body, and it does not thicken the blood the way erythropoietin does.

The pharmacology has one oddity worth understanding, because it looks like a contradiction. A 4 mg injection under the skin peaks at about 3 ng/mL in the blood and is gone in roughly twenty minutes. Yet it is dosed once a day and the effects last for days. The reason is that binding the receptor starts a repair programme inside the cell, and the programme keeps running long after the compound has cleared. Short life in the blood, durable effect in the tissue.

[[embed:ara-290]]

## ARA-290's trials were real, and not one of them enrolled a back

Six human studies exist. One hundred and thirty-two people have received active compound across all of them. Three of the six missed their main endpoint. Here is every one.

| Study | Registration | People | Who was enrolled | Dose | Length | Result |
|---|---|---|---|---|---|---|
| Culver 2017, Phase 2b | NCT02039687 | 64, 16 per arm | Nerve fibre loss from sarcoidosis, with nerve pain | 1, 4 or 8 mg under the skin, daily | 28 days | Hit at one dose only. Corneal nerve fibre area above placebo: 109 µm² at 1 mg (not significant), 697 µm² at 4 mg (p = 0.012), 431 µm² at 8 mg (not significant). Pain in the moderate-to-severe group, p = 0.157, not significant |
| Brines 2015 | NTR3858 | 49 enrolled, 48 analysed | Type 2 diabetes with painful nerve damage in the feet | 4 mg under the skin, daily, self-injected | 28 days, followed 56 | Hit. HbA1c fell 0.16% at day 28 against 0.01% for placebo, p = 0.002. Pain score improved significantly. Nerve fibre density rose 2.6 ± 1.0 fibres/mm² in the 18 people whose baseline was genuinely abnormal, p = 0.02 |
| Dahan 2013 | Single centre, Leiden | 38 | Sarcoidosis with confirmed small nerve fibre loss | 4 mg under the skin, daily | 28 days | Split. Corneal nerve fibre density rose significantly. Skin nerve fibre density rose 0.38 ± 0.48 fibres/mm, 7.2% of baseline, not significant. Symptoms, temperature sensing and walking distance all improved |
| Heij 2012 pilot | No registration number | 22, 12 active | Sarcoidosis with nerve symptoms | 2 mg into a vein, three times a week | 4 weeks | Hit. Symptom score fell 11.5 ± 3.04 against 2.9 ± 3.34 for placebo, p < 0.05. Pain inventory and fatigue improved equally in both arms, so no separation there |
| Cerit 2015 | NCT02070783 | 36 healthy volunteers | Healthy adults, mood-processing model | 2 mg, single dose | One week | Missed. Some change in emotional processing, no effect on mood |
| Diabetic macular oedema | NCT06626971 | — | Swelling at the back of the eye in diabetes | — | — | Terminated |

[[embed:source:s1]]

[[embed:source:s2]]

Three things follow, and all three matter to somebody reading this with a leg that burns.

**The positive results cluster in one disease.** Three of the four hits are in sarcoidosis, where the nerve damage is driven by the immune system attacking the small fibres. That is a different cause from a nerve root squeezed and chemically irritated by a disc.

**The dose that worked is 4 mg a day and the dose above it did not work.** In the Phase 2b, 4 mg separated from placebo and 8 mg did not. A compound whose effect rises then falls as the dose climbs cannot be dosed by guesswork, and the doses people actually take — 250 to 1,000 mcg a day — sit four to sixteen times below the only dose that has ever worked.

**Nobody has run it against a compressed nerve root.** Not in a person, not in an animal. The entire nerve argument for a disc is a read-across from a different disease with a different cause, and read-across is exactly the step that fails most often in drug development.

[[embed:source:s3]]

## The chemical-irritation link is the weakest one, and it has been tested hard

The strongest case for BPC-157 and TB-500 in a disc is usually made on inflammation rather than structure: the argument that they calm the TNF-alpha driven chemistry making the nerve root hurt. That target has been tested in humans, properly, with a far more potent tool than a peptide.

Etanercept is a drug that blocks TNF-alpha directly. Put at the nerve root against epidural steroid in subacute lumbar nerve pain, it lost — steroid beat saline by 1.26 points on leg pain, which did not reach significance, and etanercept did worse than steroid on function by a margin that did. One other trial of 49 patients found separation only at the lowest of three doses, 0.5 mg, with the 2.5 mg and 12.5 mg arms not separating, at a loose significance threshold.

[[embed:source:s24]]

[[embed:source:s4]]

So the most potent, most targeted available block of TNF-alpha at a nerve root produced a null in the best-controlled trial and an upside-down dose response in the one positive trial. Two peptides with weaker, broader, unmeasured effects on the same pathway are proposed to succeed where that failed. That is the ceiling on the inflammation argument, and it is low.

[[embed:what-are-peptides-herniated-disc]]

## Two of the three have been tested together once, and the pair beat neither alone

In July 2026 a Turkish orthopaedic group published the only experiment that has ever put BPC-157 and TB-500 in the same animals and compared the pair against each one alone. Biçer and colleagues, Joint Diseases and Related Surgery, PMID 42542926.

Thirty-two rats. Achilles tendon cut across and surgically repaired. Four weeks of daily injection into the belly cavity, in four groups of eight: nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both. Outcomes were breaking strength on a testing machine plus two scored measures of tissue quality read blind under a microscope.

What it found: TB-500 alone raised breaking strength against control (p < 0.05) and improved both tissue scores (p = 0.016 and p = 0.017), with the most ordered collagen fibres of any group. BPC-157 alone was numerically better than control without reaching significance. And the combination, in the authors' words, "did not confer additional benefits compared to either agent alone."

Their own explanation is that the two probably feed into shared machinery further downstream, so pushing from two directions does not push harder.

[[embed:source:s5]]

That is the single most important negative result for anyone building a stack, and it deserves to be read straight rather than explained away.

## Four ways that result could be wrong for a disc

Each of these names an experiment, not a caveat.

**Wrong tissue.** A stitched rat Achilles has some blood supply. A disc has essentially none, and the whole argument for BPC-157 is about growing vessels where there are none. A combination could be redundant in a tissue that already gets blood and not redundant in one that gets none. The experiment: the same four-arm design in a disc breakdown model.

**One dose of each.** Ten µg/kg of one and 60 µg/kg of the other, and nothing else tried. ARA-290's own human trials show why that matters — 4 mg worked and 8 mg did not, in the same trial. A single pair of doses tests one point, not the surface. The experiment: three dose levels of each, nine combination arms.

**A ceiling in the measurement.** TB-500 alone already hit significance on strength and on both tissue scores. If a stitched tendon at four weeks heals about as well as that model permits, there is no headroom for a combination to show anything, and the null means the ruler ran out. The experiment: repeat with a harder injury — a bigger gap, a delayed repair, an older animal — so the control arm heals badly.

**Four weeks.** Both dosing and measurement stopped at four weeks. Collagen keeps reorganising for months, and the ordered-fibre finding is precisely the kind of result that can diverge later. The experiment: the same design read at twelve and twenty-four weeks.

## All three together has never been tested in anything

No study in any species, at any dose, by any route, has given BPC-157, TB-500 and ARA-290 together. There is no animal experiment, no case series, no registry entry. The three-compound version of this stack rests entirely on the argument that the three act on different things and therefore should not get in each other's way.

That argument has one piece of evidence against it already, and the evidence is on this page: the only time two of the three were tested together, adding the second one bought nothing.

[[embed:wolverine-stack]]

## One February 2026 registry entry could move the evidence base, and its companion declares itself fictional

Two entries naming these compounds were filed on ClinicalTrials.gov in February 2026, both by the same sponsor, Hudson Biotech. A registry entry is a filing by the sponsor; nobody at the registry checks it, and neither entry has posted a result.

| Trial | Compound | People | Design | What it measures | Started |
|---|---|---|---|---|---|
| NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Under the skin, once daily for 14 days | Days to unrestricted return to sport at 8 weeks; change in injury volume on MRI at day 14, read by radiologists blind to the group | 2 February 2026 |
| NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation, in adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | 5 February 2026 |

[[embed:source:s20]]

Take the second row first, because it decides how much weight the first can carry. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a template, not a trial. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each.

The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital. It is a hamstring, not a disc, and 14 days, not twelve weeks, so it will not answer the question on this page. It would answer whether the compound does anything measurable in a human body at all, which is the question underneath it — and it answers nothing until it reports.

Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — audited this same literature independently and landed in the same place: real animal record, absent human record, unregulated products.

[[embed:source:s21]]

[[embed:source:s22]]

## The number any protocol has to beat is the disc's own recovery rate

This is the number most vendor pages leave out and it changes every decision on this page.

A 2024 meta-analysis pooled 31 studies and 2,233 people with a lumbar disc herniation treated without surgery. The overall rate at which the herniation shrank on its own was 70.39%. Broken out by type: 87.77% for a fragment that has broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a simple bulge. Counter to intuition, the bigger and more displaced the herniation, the more likely the body removes it.

[[embed:source:s23]]

That is the base rate. Seven in ten resolve with nothing done. Anybody who runs a twelve-week protocol during that window and improves has, on the numbers, a 70% chance of having improved anyway. One person cannot separate those two outcomes, and no amount of conviction about the result changes that.

[[embed:herniated-disc]]

## Seven people with a back problem wrote down what happened

Self-reports are counted here the same way they are counted anywhere on this site: the person had to state an outcome for themselves, commentary and dosing posts with no result attached were excluded, and negative reports are given the same space as positive ones.

Filtering the self-report record to people describing a back, disc or sciatic problem specifically gives seven usable reports.

| Outcome | Count |
|---|---|
| Said it helped | 4 |
| Said nothing changed | 2 |
| Said something got worse | 1 |
| **Total** | **7** |

**Helped — X, @MuroCrypto, 31 July 2026, anecdotal.** "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better."
[[embed:source:s6]]

**Helped — Reddit, u/kunukxathletix, r/Sciatica, 7 March 2026, anecdotal.** "I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone."
[[embed:source:s7]]

**Helped — X, @drmarlonperalta, 4 June 2026, anecdotal.** "I've suffered for 10+ years with lower back pain from a herniated disc... A 6-week cycle removed this distraction permanently."
[[embed:source:s8]]

**Helped, with the writer's own warning attached — X, @AJA_Cortes, 26 May 2024, anecdotal.** "Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo."
[[embed:source:s9]]

**Nothing changed — Reddit, u/ImNotSchema, r/backpain, 19 August 2025, anecdotal, ran both compounds.** "I also experimented with TB500 and BPC-157 peptides, but saw no improvement. The one thing that actually helped was Prednisone."
[[embed:source:s10]]

**Nothing changed — Reddit, u/Dizzy-Breakfast-9405, r/backpain, 25 April 2024, anecdotal.** "I even tried peptides (BPC-157) for a month, no results."
[[embed:source:s11]]

**Worse — Reddit, u/Miserable_Fan1984, r/backpain, 16 September 2024, anecdotal, herniated disc, ran both compounds.** "I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again."
[[embed:source:s12]]

Seven is too few to mean anything statistically, and four in seven reporting improvement is what a 70% spontaneous shrink rate would produce with no compound involved at all. What the seven do establish is that the negative and the worse outcomes exist, are specific, and are written by people who wanted the opposite result.

The wider self-report set across all injuries — 40 reports, 21 helped, 15 nothing, 4 worse — is counted in full on the two-compound page.

[[embed:wolverine-stack]]

## What people report on ARA-290, which is a much thinner record

Four ARA-290 self-reports were found, and only one of them states an outcome.

[[embed:source:s13]]

The other three: one person two doses into a run for small fibre nerve damage with six to eight weeks left and no result yet, one post quoting the Phase 2b trial numbers rather than personal experience, and one skeptic asking the sharpest question in the whole set — whether repair signalling does anything while the nerve is still being squeezed.

[[embed:source:s14]]

That question has no published answer. Nobody has tested repair signalling against an ongoing mechanical squeeze.

Not one report was found, on any platform, of a person running all three compounds together. The three-compound stack has no human record at all — not a trial, not a case, not a forum post.

## Reconstituting three vials, one arithmetic at a time

All three ship as dry powder in a sealed glass vial. All three are mixed with bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial more than once. All three are measured on a U-100 insulin syringe, where 100 marks equal 1 mL, so one mark is 0.01 mL.

Two lines of arithmetic cover all three:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

**BPC-157, 10 mg vial, 2 mL of water.** 10 mg = 10,000 mcg. 10,000 ÷ 2 = 5,000 mcg/mL. 5,000 ÷ 100 = 50 mcg per mark. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL.

**TB-500, 10 mg vial, 2 mL of water.** Identical arithmetic: 50 mcg per mark. 500 mcg = 10 marks. 2.5 mg = 2,500 ÷ 50 = 50 marks = 0.50 mL.

**ARA-290, 10 mg vial, 1.25 mL of water.** 10,000 ÷ 1.25 = 8,000 mcg/mL. 8,000 ÷ 100 = 80 mcg per mark. The 4 mg trial dose = 4,000 ÷ 80 = 50 marks = 0.50 mL, which is exactly the volume injected in the diabetes trial. Add 2 mL instead and you get 5,000 mcg/mL, 50 mcg per mark, and 4 mg becomes 80 marks.

| Compound | Vial | Water | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 4 mg |
|---|---|---|---|---|---|---|---|---|
| BPC-157 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| BPC-157 | 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| TB-500 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| ARA-290 | 10 mg | 1.25 mL | 8,000 mcg/mL | 80 | 3.1 marks | 6.25 marks | 12.5 marks | 50 marks |
| ARA-290 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |

Below about five marks the graduations on a U-100 barrel are too close together to read, which is why the dilute ARA-290 fill is the right one if the dose is under a milligram.

Handling notes that apply to all three. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking tears peptide molecules apart at the air-water boundary and makes them clump, and clumping is the specific mechanism FDA named when it flagged the risk that the immune system reacts to these products. Once mixed, a vial keeps about four weeks in a fridge at 2–8 °C, which is the preservative's specification rather than a stability measurement on these peptides. Never freeze a mixed vial.

## A full day of all three, in marks and millilitres

| Pattern | BPC-157 | TB-500 | ARA-290 | Total marks | Total volume | Injections |
|---|---|---|---|---|---|---|
| Reachable doses | 500 mcg = 10 marks | 500 mcg = 10 marks | 1 mg = 20 marks | 40 | 0.40 mL | 3 |
| ARA at the dose that was actually trialled | 500 mcg = 10 marks | 500 mcg = 10 marks | 4 mg = 80 marks | 100 | 1.00 mL | 3 |
| BPC daily, TB twice weekly, ARA at the trial dose | 500 mcg = 10 marks | 2.5 mg = 50 marks, twice weekly | 4 mg = 80 marks | 90 most days, 140 twice a week | 0.90–1.40 mL | 2, or 3 twice weekly |

All figures assume 5,000 mcg/mL for BPC-157 and TB-500 and 5,000 mcg/mL for ARA-290. Do not mix any two of them in one syringe — different concentrations, different volumes, different schedules, and combining them makes every later adjustment a guess.

Note the second row. Running ARA-290 at the only dose ever shown to work in a person means the third injection is four times the volume of the other two put together.

## Twelve weeks of all three, priced to the dollar

Prices are from named research-chemical vendors, read on 4 August 2026. Nationwide Peptides publishes a range across vial sizes rather than a price per size, so the endpoints are what can be quoted exactly.

- BPC-157: $42.00 smallest listed size (5 mg), $63.00 largest (20 mg).
- TB-500: $38.00 smallest listed size (5 mg), $61.00 largest (10 mg).
- ARA-290: $43.00 at Nationwide Peptides; Luxe Peptides lists 10 mg at $50.00 and 16 mg at $70.00. The arithmetic below uses $50 per 10 mg.

[[embed:source:s15]]

[[embed:source:s16]]

Twelve weeks is 84 days. Every line shown:

**BPC-157 at 500 mcg a day.** 84 × 500 mcg = 42,000 mcg = 42 mg. Buying 20 mg vials: 3 vials (60 mg) × $63 = **$189**. Per day: $189 ÷ 84 = **$2.25**. A 20 mg vial at 500 mcg a day is 40 doses, but a mixed vial only keeps about 28 days, so 12 doses per vial get thrown away — that waste is already in the price.

**TB-500 at 500 mcg a day.** 42 mg. 5 × 10 mg vials × $61 = **$305**. Per day: **$3.63**. Each vial is 20 doses, which fits the four-week window with nothing wasted.

**ARA-290 at 1 mg a day.** 84 mg. 9 × 10 mg vials × $50 = **$450**. Per day: **$5.36**. Each vial is 10 doses, well inside the window.

**ARA-290 at the 4 mg trial dose.** 84 × 4 mg = 336 mg. 34 × 10 mg vials × $50 = **$1,700**. Per day: **$20.24**. Each vial lasts two and a half days.

**Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $40 for a three-compound twelve-week run at retail.

| What is run | Twelve-week materials | Per day |
|---|---|---|
| BPC-157 alone, 500 mcg/day | $189 + $40 = **$229** | $2.73 |
| TB-500 alone, 500 mcg/day | $305 + $40 = **$345** | $4.11 |
| ARA-290 alone, 1 mg/day | $450 + $40 = **$490** | $5.83 |
| ARA-290 alone, at the 4 mg trial dose | $1,700 + $40 = **$1,740** | $20.71 |
| All three, reachable doses | $189 + $305 + $450 + $40 = **$984** | $11.71 |
| All three, ARA-290 at the trial dose | $189 + $305 + $1,700 + $40 = **$2,234** | $26.60 |

The last two rows contain the honest problem with this stack. The compound holding the only randomised human evidence costs more than the other two combined at the dose that was tested, and costs about the same as them at a dose nobody has tested. Most people who buy all three resolve that by running ARA-290 at a quarter to a sixteenth of the trial dose, which means running the strongest-evidenced compound at a strength for which there is no evidence at all.

None of these prices buys a verified product. There is no pharmacy channel for any of the three. A batch-specific purity test and a mass-spectrometry identity report from an independent lab is the only thing standing between a buyer and a vial of something else, and an eleven-amino-acid peptide with a ring-closed front end, which is what ARA-290 is, is not an easy molecule to synthesise correctly.

## Twelve weeks with a worn L5-S1 and a leg that burns

One case, walked all the way through, with money, hours, measurements, decision points and failure conditions written down before anything starts.

**Week 0 — what exists, and what gets measured.** L5-S1 disc dried out and lost height on MRI, a small protrusion touching the S1 nerve root, burning down the back of the left calf into the outer foot. Leg pain 7/10, back pain 4/10. No weakness, no bowel or bladder change, no numbness in the saddle area — those three would be an emergency and would end this plan immediately. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour.

Five baseline measures written down, because a result nobody measured is a result nobody has:
1. Leg pain, 0–10, worst in the last 24 hours.
2. Oswestry Disability Index, a standard back questionnaire, scored out of 100.
3. Straight-leg-raise angle at which the leg pain starts, measured against a wall.
4. Nights woken by pain, per week.
5. Distance walked before the leg forces a stop.

**Weeks 1–12 — the part with human trials behind it.** Load management and progressive exercise, twice weekly for six weeks then weekly. 18 visits at $75–$150 = **$1,350–$2,700**, about 18 clinic hours plus 20 hours of home work. This is the only line on the page supported by randomised human trials in this exact condition, and it also happens to be the biggest line in money and hours. Everything else is added on top of it, never instead.

**Weeks 1–12 — the compounds, if they are run.** BPC-157 500 mcg a day, TB-500 500 mcg a day, ARA-290 1 mg a day, all under the skin of the abdomen, three separate injections. Materials **$984**. Time: about 6 minutes a day for three injections, so 8.4 hours over twelve weeks, plus roughly 35 minutes reconstituting seventeen vials.

**Week 4 — first decision point.** Stopping rule set in advance: if nights woken has not fallen and the straight-leg-raise angle has not gained at least 10 degrees, ARA-290 stops. The reason it is ARA-290 that gets tested first is that it is the most expensive line and the one with the most specific promise — it either does something to nerve symptoms or it does not, and nerve symptoms are the fastest-moving measure on the list. Money saved by stopping there: **$300**.

**Week 6 — second decision point.** If leg pain has not moved at all, the whole compound protocol stops and the money goes to the exercise programme, which continues either way. Money saved: about **$450**.

**Week 8 — the escalation gate.** If leg pain is still 6/10 or above and disability is still above 40, this is where an epidural steroid injection sits in standard practice: $800–$5,000 cash, $161 Medicare allowable, 3 hours including travel and recovery. The pooled evidence gives it about 6 points on a 0–100 leg pain scale short term, which is below the 10-to-30-point range most people would call a meaningful change.

**Week 12 — the state at the end.** Running total: $1,350–$2,700 physical therapy, $984 materials, $400–$1,800 MRI, $0–$5,000 if an injection was used. Total **$2,734 to $10,484**. Patient time: roughly 47 hours. Base-rate expectation, from the 2,233-patient pooled data, is substantial improvement in leg pain for most people over twelve weeks with no compounds at all.

**What would count as failure, written before the start.**
- No movement on nights woken or straight-leg-raise angle at week 4.
- No movement on leg pain at week 6.
- Any new problem: swelling, worse pain in an untreated area, any change in vision.
- New weakness, new numbness in the saddle area, or any bowel or bladder change at any point — stop everything and get seen the same day.
- Relief that arrives inside a week and disappears within two weeks of stopping. That pattern points at irritation settling rather than tissue rebuilt, and it means the compounds bought a symptom holiday, not a repair.

**The week 12 decision.** Disabling leg pain past twelve weeks, with imaging that matches the symptoms, is where surgery stops being premature. Microdiscectomy runs $15,000–$50,000 list, measured at $14,137 above non-surgical care over two years in trial data, and it buys faster relief rather than a better one-year outcome — the recovery rate at a year is the same either way.

## Where United States law puts all three, which is not the same place

None of the three is an approved medicine in the United States. None is banned outright. But their positions differ, and the difference is worth knowing before buying.

**BPC-157 and TB-500** both appear on FDA's public list of bulk drug substances "nominated but withdrawn" — put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, then pulled by whoever nominated them. FDA's stated concerns are, in its own words, that products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration", and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

**ARA-290 appears nowhere on those lists.** It was never nominated for compounding at all. That is not a cleaner status — it is a thinner one. It means no regulator has published a safety assessment of it as a compounding ingredient, favourable or otherwise. It did receive orphan drug designation in both the United States and Europe, and then its developer stopped, so there is no late-stage programme and no pharmaceutical supply of it anywhere.

What follows in plain terms:

- No pharmacy can lawfully compound any of the three. None is on the 503A list traditional compounding pharmacies work from, nor the 503B list outsourcing facilities work from.
- On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It binds nothing, approves nothing, and the rulemaking it starts realistically runs eight to twelve months.
- "Research use only" printed on a vial is a shipping label. It is not a legal category and it makes nothing safe or lawful to inject.

[[embed:source:s17]]

[[embed:source:s18]]

## One of the three ends a tested athlete's season

Anyone competing under anti-doping rules — collegiate, professional, masters, a national federation, an Olympic pathway — and anyone serving in the United States military needs this before anything else on the page.

- **TB-500 is named on the WADA 2026 Prohibited List**, under S2.3, growth factors: "Thymosin-ß4 and its derivatives e.g. TB-500." Prohibited at all times, in and out of competition, in the harsher non-specified tier. The catch-all in that same clause covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason to take it is written into the ban.
- **BPC-157 is named** under S0, non-approved substances, also prohibited at all times.
- **ARA-290 is not named**, but S0 covers any substance with no current approval by any government health authority for human use, and ARA-290 has none. Treat it as covered.
- Strict liability applies. Intent does not matter and neither does who recommended it. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500.
- A sanction does not require a positive test. An admission, a possession finding, or a purchase record is enough.
- The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states that it is not a dietary ingredient, it is an unapproved drug.

[[embed:source:s19]]

There is no off-season window. Off-season use is a violation.

## What would prove each link wrong

The value of a stack argued as separate links is that each link can be broken separately. Here is what would break each one, with the current state of the evidence beside it.

| Link | Current state | The result that would break it |
|---|---|---|
| Blood supply reaching the disc, BPC-157 | Grade D. Repeated positive results in tendon, ligament, muscle, nerve and spinal cord in rats, mostly from one research group. Nothing in a disc, ever | A controlled animal study in a disc, counting vessels and measuring disc height, showing no difference against control |
| Repair cells crawling in, TB-500 | Grade D. One controlled rat tendon study with 8 per arm. The ligament and skin results used the full 43-amino-acid protein, not the 7-amino-acid fragment that is sold | The rat tendon study repeated at a larger size with no strength difference; or a direct comparison of the fragment against the full protein showing the fragment does nothing |
| Nerve fibres regrowing, ARA-290 | Grade B. Randomised human trials with a measured structural endpoint, in a different disease, never in a compressed root | A randomised trial in a compressed nerve root showing no separation from placebo |
| Chemical irritation calmed, BPC-157 and TB-500 | Grade E, and already damaged. Direct TNF-alpha blockade at the nerve root produced a null against steroid in the best-controlled trial | Nothing further needed — the burden here sits with anyone claiming the peptides beat what etanercept could not |
| The three acting on different things | Grade F. Never tested. The only test of two of them together found the pair beat neither alone | A three-arm animal study — each compound alone, all three together — showing the three-way combination matches the best single agent |
| Anything beating the disc's own recovery | Grade F. 70.39% of herniations shrink on their own | Any protocol that has not been measured against a control group in this condition cannot claim to beat 70% |

Five links. One at grade B, two at D, one at E, two at F. Not one at grade A, because no randomised trial of any of these compounds has ever enrolled a person with a disc problem.

That is the honest state of it. The mechanism argument is coherent, the three compounds genuinely act on different things, and the amount of measurement behind that coherence ranges from real human trials on one link to literally nothing on another.

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:wolverine-stack]]


## Sources

1. Culver DA et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Phase 2b, NCT02039687. PMID 28475703 — https://pubmed.ncbi.nlm.nih.gov/28475703/
2. Brines M et al. ARA 290 in type 2 diabetes with painful neuropathy — randomised double-blind placebo-controlled trial, NTR3858, full text with pharmacokinetics and adverse events — https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
3. ClinicalTrials.gov NCT02039687 — Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. Completed — https://clinicaltrials.gov/study/NCT02039687
4. Cohen SP et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012. PMID 22508732 — https://pubmed.ncbi.nlm.nih.gov/22508732/
5. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/
6. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529
7. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
8. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044
9. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108
10. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
11. Reddit r/backpain — u/Dizzy-Breakfast-9405, 25 April 2024 — anecdotal, no effect after a month — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/
12. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
13. X — @NewsDeskOne, 17 July 2026 — anecdotal, positive, ARA-290 for nerve symptoms in the feet — https://x.com/NewsDeskOne/status/2077929820760019113
14. X — @vedichi_, 16 July 2026 — anecdotal, skeptical, names the read-across problem directly — https://x.com/vedichi_/status/2077787145238913472
15. Nationwide Peptides — ARA-290 (cibinetide), BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/ara-290-cibinetide-peptide/
16. Luxe Peptides — ARA-290 peptide listing, prices read 4 August 2026 — https://luxepeptides.is/ara-290/
17. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
18. FDA — 23-24 July 2026 meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
19. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547
21. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/
22. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev, 1 January 2026. PMID 41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/
23. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis. Clin Spine Surg, 2024. PMID 37559207 — https://pubmed.ncbi.nlm.nih.gov/37559207/
24. Randomized, double-blind, placebo-controlled trial of transforaminal epidural etanercept for symptomatic lumbar disc herniation. PMID 24165696 — https://pubmed.ncbi.nlm.nih.gov/24165696/


---

# The Wolverine stack: BPC-157 and TB-500, the evidence, the dosing arithmetic and the eight-week cost

slug: wolverine-stack · https://miscsubjects.com/a/wolverine-stack · category: peptides · tags: peptide, bpc-157, tb-500, stack, tendon, wolverine · updated 2026-08-04T22:08:38.210Z

The Wolverine stack is two compounds taken at the same time: BPC-157 and TB-500. People run it after a tendon tear, a bad shoulder, a knee that will not settle, a disc that has been hurting for months. The reason they are run together is not that one is stronger. It is that each one is proposed to fix a different step of the same repair job, so the argument goes that they should not overlap.

The evidence state, up front. No controlled study has ever given both compounds to a person, in any condition, so the number of people who have taken the pair under measurement is nought. Separately the two are not equal. BPC-157 has five published human studies covering about 130 people, and not one of them is a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries appeared on ClinicalTrials.gov in February 2026, filed by the same sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything, and a registry filing is not a result. The animal record behind the pairing is rats, mice and rabbits — roughly 150 animal papers for BPC-157, a much smaller tendon and wound literature for the fragment — and the one experiment that ever put both compounds into the same rats found the combination beat neither compound on its own. What has never been measured in a person: the pair, at any dose, in any tissue, for any length of time.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

This page sets out what each step is, how good the evidence is for each, what happened the one time somebody put both compounds into the same animals, what a run costs to the dollar, and what forty people who tried it wrote down afterwards.

## Two compounds aimed at two different steps of the same repair

Damaged tendon, ligament and disc all repair in the same order. Blood has to reach the damaged spot. Repair cells have to crawl in from the surrounding tissue. Those cells have to lay down new collagen in ordered fibres rather than a random scar. Each step gates the next.

BPC-157 is proposed to act on the first step. In animals it grows new blood vessels into damaged tissue, mostly by switching on a growth signal called VEGF and the nitric-oxide system that widens vessels.

TB-500 is proposed to act on the second. It is a seven-amino-acid piece of a natural protein, thymosin beta-4, and the piece it copies is the part that grabs actin — the protein filament a cell builds and dismantles to change shape and crawl. Bind actin, and the cell's crawling machinery is freed up. A cell that cannot rebuild its own internal skeleton cannot move into a wound at all.

That is the whole logic of the pairing. One opens the supply line, the other moves the workforce down it. Nothing in the pairing addresses a torn fibre mechanically, and nothing in it dissolves a bulged disc.

[[embed:bpc-157]]

[[embed:tb-500]]

## The bottleneck in tendon, ligament and disc is blood, and both compounds are aimed at it

A muscle bruise heals in weeks. A tendon takes months. A spinal disc, in an adult, barely heals at all. The difference is blood supply. Muscle is dense with vessels. Tendon has few. The centre of an adult disc has none — nutrients cross in by seeping through the cartilage end plates, which themselves stiffen and calcify with age.

That single fact is why both compounds are attractive on paper for these tissues and why neither has been shown to work in them. A drug aimed at growing vessels into a structure that has almost no vessels is aimed at the real rate-limiting step. It is also aimed at the hardest possible target, and the harder the target, the more the argument needs measurements rather than mechanism.

## What each one is proposed to build back, and what would prove it wrong

| Compound | What it is proposed to do, in plain words | Strongest evidence behind that | What it adds that the other does not | What would prove it wrong |
|---|---|---|---|---|
| BPC-157 | Grow new blood vessels into damaged tissue and keep the repair cells there alive, so the site gets oxygen and raw material | Rat Achilles tendon torn off the bone and reattached came back mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than controls | The supply line. TB-500 does not act on the vessel-growth signal | A controlled animal study measuring blood vessel counts at the injury site showing no difference against control, or a human trial in tendon pain showing no separation from placebo |
| TB-500 | Free up the internal scaffolding cells use to crawl, so repair cells reach the wound and lay ordered fibres rather than scar | Rat Achilles repair, 8 animals per arm, four weeks: higher load to failure than control (p < 0.05), better tissue score (p = 0.016), most ordered collagen of any arm under stain | The workforce. BPC-157 does not bind actin | A study measuring cell arrival at the wound showing no increase, or the same tendon model repeated at a larger size with no strength difference |
| The pair together | Both steps at once, on the theory that a supply line without workers and workers without a supply line each stall | One study, in rats, found the combination did not beat either compound alone | Nothing that has been measured | Already partly answered — see the section below |

The evidence grade is the same for both compounds and it is worth naming plainly: controlled animal experiments in the target tissue, no controlled human experiment in any tissue that hurts.

## The strongest single-compound results, best first

| Rank | Finding | Species and model | Numbers | What it establishes |
|---|---|---|---|---|
| 1 | TB-500 raised maximum load to failure in a repaired Achilles tendon | Rat, tendon cut across and stitched, four weeks | 32 rats, 8 per arm, 60 µg/kg/day into the belly cavity, p < 0.05 | The only controlled measurement of mechanical strength for either compound in a repaired tendon |
| 2 | BPC-157 healed a tendon torn off the bone | Rat, Achilles detached from the heel bone | Faster reattachment and greater strength than control | The structural claim in the tissue people buy it for |
| 3 | BPC-157 sped recovery of a cut sciatic nerve | Rat, nerve cut and repaired | Faster return of function than control | The closest thing to a nerve result either compound has |
| 4 | BPC-157 improved recovery after spinal cord injury | Rat, PMID 31266512 | Better function than control, sustained | Shows the compound reaches and acts on nervous tissue given by mouth or by injection away from the site |
| 5 | Full-length thymosin beta-4 healed a cut knee ligament | Rat, ligament cut, 1 µg placed in the gap in fibrin glue | Uniform fibre bundles, significantly greater mechanical strength | The ligament result — but with the full 43-amino-acid protein, placed in the wound, not the 7-amino-acid fragment injected into fat |
| 6 | Thymosin beta-4 closed skin wounds faster | Rat, full-thickness wound | Surface regrown 42% faster at four days, 61% at seven; more collagen, more vessels | The original result the whole thymosin beta-4 literature rests on |

Rows 5 and 6 carry a caveat that changes how they read. They used full-length thymosin beta-4, a 43-amino-acid protein. What is sold as TB-500 is a 7-amino-acid piece of it, residues 17 to 23, with the front end capped. The two are not the same molecule, and FDA wrote that distinction down in July 2026. Reading a full-length result onto a fragment vial is the single most common error in this area.

Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — went through this same literature independently and reached the same place: the animal record is real, the human record is not there, and the products on sale are unregulated.

[[embed:source:s34]]

[[embed:source:s35]]

## Somebody finally put both in the same rats, and the pair beat neither one alone

In July 2026 a Turkish orthopaedic group published the only experiment that has ever tested BPC-157 and TB-500 together against each one alone. Biçer and colleagues, in Joint Diseases and Related Surgery, PMID 42542926.

The design, in full: 32 rats, Achilles tendon cut across and surgically repaired, then four weeks of daily injection into the belly cavity, split into four groups of eight — nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both together. Outcomes were maximum load to failure on a testing machine, plus two scored measures of tissue quality read under a microscope by people blinded to the group.

The results:

- TB-500 alone raised maximum load to failure against control, p < 0.05.
- TB-500 alone improved the Bonar tissue score, p = 0.016, and the Movin score, p = 0.017.
- Under a collagen stain, the TB-500 group had the most ordered type I collagen fibres.
- BPC-157 alone came out numerically better than control and did not reach significance on total scores.
- The combination, in the authors' own words, "did not confer additional benefits compared to either agent alone."

That is the sentence the stack has to survive. Two compounds sold as a pair, tested as a pair for the first time, and the pair was no better than the better of the two.

The authors' reading is that the two probably converge on shared downstream machinery — that once the repair programme is running, pushing it from two directions does not push it further.

[[embed:source:s1]]

## Four reasons that one experiment does not close the question

Each of these is a real experiment somebody could run, not a hedge.

**One tissue.** The test was a surgically repaired Achilles tendon in a rat. Tendon has some blood supply. The place the stack is most often aimed at — a spinal disc — has almost none, and the argument for BPC-157 is specifically about growing vessels where there are none. The measurement that would answer this: run the same four-arm design in a disc model, or in a tissue with a poorer blood supply than tendon.

**One dose level each.** BPC-157 got 10 µg/kg/day, TB-500 got 60 µg/kg/day, and nothing else was tried. If either compound's effect rises and then falls as the dose goes up — which is normal for signalling peptides and which the ARA-290 human trials actually showed, where 4 mg worked and 8 mg did not — then a single dose pair tests one point on a surface, not the surface. The measurement: a dose grid, three levels of each compound, nine combination arms.

**A possible ceiling.** TB-500 alone already reached significance on strength and on both tissue scores. If a stitched rat tendon at four weeks heals about as well as that model allows, then a combination has no room left to show a difference, and a null result means the ruler ran out, not that the second compound is inert. The measurement: repeat with a harder injury — a larger gap, a delayed repair, or an older animal — so the control arm heals badly and there is space above it.

**Four weeks.** Dosing and measurement both stopped at four weeks. Collagen in a healing tendon keeps remodelling for months, and the ordered-fibre finding is exactly the sort of thing that could diverge later. The measurement: the same design read at twelve and twenty-four weeks.

None of those four is an argument that the combination works. They are the reasons the single null result does not settle it, and each one names the study that would.

## The experiment that would settle it

A single trial would answer more than everything above. Take a tendon or ligament injury model with a poor blood supply and a control arm that heals badly. Run four arms at three dose levels each — nothing, BPC-157, TB-500, both — with 15 to 20 animals per arm rather than 8, dosed under the skin rather than into the belly cavity, because under the skin is how humans take it. Measure load to failure, blood vessel counts at the wound, and ordered collagen, at four weeks and at sixteen. Pre-register the dose grid.

That study costs a fraction of one human trial and nobody has run it.

Nothing has ever tested three of these compounds together, in any species, at any dose. Adding ARA-290 to this pair for nerve pain is set out separately, and the three-compound combination has zero experimental record of any kind.

[[embed:wolverine-stack-ara-290]]

## No person has ever been given this pair in a controlled study

Here is that fact as one row, with what does exist beside it.

| Question | Answer | Basis |
|---|---|---|
| Controlled human trial of BPC-157 and TB-500 together | None, in any condition | Registry and literature searches return nothing |
| Controlled human trial of TB-500 alone by injection | None, by any route | FDA's July 2026 review states it has found no human exposure data for products containing the fragment |
| Controlled human trial of BPC-157 | Five studies exist; the largest musculoskeletal one is a telephone survey | Published record |
| Human trials of full-length thymosin beta-4 | Yes — eye drops for dry eye and for corneal damage, topical gel for pressure sores | These are surface applications of a different molecule |
| Human dose that has ever been established for either | None | No dose-finding study exists for either compound in a person |

[[embed:source:s3]]

## Two registry entries were filed in February 2026, and one of them says it is a made-up example

That last table has a date on it. As of 4 August 2026 ClinicalTrials.gov holds two entries naming these compounds. Both were filed by the same sponsor, Hudson Biotech, both give a start date in the first week of February 2026, and both are marked recruiting. Read that for what it is. A registry entry is a filing by the sponsor. Nobody at the registry checks it, and neither entry has posted a result.

| Trial | Compound | People | Design | What it measures | When |
|---|---|---|---|---|---|
| NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Injection under the skin, once daily for 14 days, given by study staff | Days until return to unrestricted sport, at 8 weeks; and change in injury volume on MRI at day 14, read by radiologists who do not know the group | Started 2 February 2026 |
| NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation. Adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | Started 5 February 2026 |

[[embed:source:s2]]

Now read the second row against its own record. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." That entry is a template, not a trial, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each — and that is the company the first row keeps.

The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital.

Neither entry tests the pair. Neither enrols anyone with a back problem. And a filing is not a finding: until NCT07437547 posts results, the number of randomised human results for either compound in a torn tissue stays at zero.

## Forty people wrote down what happened to them, and here is the tally

Self-reports are not evidence of whether a compound works. They are evidence of what happens to people who take it, which is a different and still useful thing — it is where side effects, dose ranges and failure rates show up first, years before anybody runs a trial.

Forty reports were counted. The rule for counting: the person had to state an outcome for themselves. Commentary about the compounds, dosing instructions with no result attached, and posts written mid-run before any outcome were excluded — sixteen entries were dropped on that rule.

| Outcome | Count | Share |
|---|---|---|
| Said it helped | 21 | 52.5% |
| Said nothing changed | 15 | 37.5% |
| Said something got worse | 4 | 10% |
| **Total counted** | **40** | |

Every one of these is anecdotal. None was blinded, none had a control, and people who get a result post more readily than people who do not, so the true no-effect share is almost certainly higher than 37.5%.

### The twenty-one who said it helped

[[embed:source:s4]]

[[embed:source:s5]]

[[embed:source:s6]]

[[embed:source:s7]]

[[embed:source:s8]]

[[embed:source:s9]]

[[embed:source:s10]]

[[embed:source:s11]]

[[embed:source:s12]]

[[embed:source:s13]]

[[embed:source:s14]]

That last one is worth its own line. Pain that vanishes in days and returns within days of stopping is the signature of something calming irritation, not of something rebuilding a tendon. Rebuilt tissue does not un-rebuild in a week. Several of the fast-relief reports fit that shape better than they fit a repair story.

The remaining ten in this group: u/DifficultReach2720 (foot, "basically fully healed" at three months), u/NoInvestigator7249 (elbow, range of motion back to 100%), u/frequentflyernine11 (wrist, close to previous strength after seven vials, still minor pain), u/sdBiotch ("not a miracle by any means but I can improve mobility"), u/SanketJ1986 (pain down in the treated arm, no change in the other), u/Quacka-moo ("It has helped a bit but I expected more"), @drmarlonperalta (ten years of low back pain from a herniated disc, "a 6-week cycle removed this distraction permanently"), @AJA_Cortes (L5-S1 flare, oral BPC-157 at 2,000 mcg a day, pain free in seven days, and his own comment was "maybe, maybe not — I'm always open to possibility of placebo"), @Breedlove22 (ran both, credited the pair), and @mindpumpsal.
[[embed:source:s15]]

[[embed:source:s16]]

### The fifteen who said nothing changed

[[embed:source:s17]]

[[embed:source:s18]]

[[embed:source:s19]]

[[embed:source:s20]]

[[embed:source:s21]]

[[embed:source:s22]]

[[embed:source:s23]]

[[embed:source:s24]]

[[embed:source:s25]]

The other six: u/Dizzy-Breakfast-9405 (a month, thoracic pain, no results), u/kayfab (capsules, ligament, nothing), u/Acrobatic-Car3352 (nine days into a blend, Achilles, no changes), u/forsaken3400 (day 5, shoulder, nothing beyond possibly better sleep), u/mite189 (the tear did not heal faster; recovery came with prescribed isometric work), u/mudra311 (elbow, "I felt better before the BPC as well").

### The four who got a new problem

[[embed:source:s26]]

[[embed:source:s27]]

[[embed:source:s28]]

[[embed:source:s29]]

Two of those four describe swelling or fluid at or near the treated site, and both compounds are proposed to grow blood vessels, which is a mechanism that would produce exactly that. The blurred vision report has no mechanism attached to it and no follow-up.

### What the tally can and cannot decide

It cannot decide whether the compounds work. Half a sample reporting improvement in a condition where most soft-tissue injuries improve on their own over the same weeks is what a completely inert substance would also produce.

It can decide four things. First, roughly one person in ten reports a new problem, and that number belongs in any decision. Second, the doses in real use cluster at 250 to 500 mcg a day for BPC-157, which is well below the milligram doses in every human study of BPC-157 that has been published. Third, the fast-relief-then-relapse pattern is common enough to suggest that much of what people feel is irritation settling rather than tissue rebuilding. Fourth, the failures are specific and repeated — several people ran it three separate times with nothing to show.

## Twelve of the forty ran both compounds, not one

The tally above mixes people who took BPC-157 alone with people who ran the pair. Splitting out only those who explicitly ran both:

| Outcome | Count |
|---|---|
| Helped | 6 |
| Nothing changed | 4 |
| Something got worse | 2 |
| **Total** | **12** |

Six helped out of twelve, against twenty-one out of forty in the whole set. Twelve people is far too small to compare against anything, and a 50% versus 52.5% gap means nothing at that size. What the split does show is that no signal jumps out in favour of running both, which is the same direction the rat study pointed.

## Turning a vial of powder into marks on a syringe

Both compounds ship as a dry white powder in a sealed glass vial, usually 5, 10 or 20 mg. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial repeatedly. Plain sterile water works chemically but has no preservative, so it is a one-entry proposition.

The dosing tool is a U-100 insulin syringe. U-100 means 100 marks per millilitre, so one mark is 0.01 mL. Two lines of arithmetic give you everything:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

Worked all the way through, for a 10 mg vial with 2 mL of water:

1. 10 mg = 10,000 mcg.
2. 10,000 mcg ÷ 2 mL = 5,000 mcg per mL.
3. 5,000 ÷ 100 = 50 mcg per mark.
4. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL.

| Vial | Water added | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 2.5 mg | Doses per vial at 500 mcg |
|---|---|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 10 |
| 5 mg | 2.0 mL | 2,500 mcg/mL | 25 | 10 marks | 20 marks | 40 marks | 100 marks | 10 |
| 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 20 |
| 10 mg | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 marks | 15 marks | 30 marks | 75 marks | 20 |
| 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 40 |

Adding more water does not change how much compound is in the vial. It changes only how many marks carry a dose. Below about five marks the graduations on a U-100 barrel are too close together to read reliably, which is the practical argument for the more dilute fills when the dose is small.

Handling that ruins the peptide is easy to do by accident. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking a peptide solution tears the molecules apart at the air-water boundary and makes them clump, and clumping is the exact mechanism FDA named when it raised the risk that the immune system reacts to these products.

Once water is in, a vial keeps about four weeks in a fridge at 2–8 °C. That is the preservative's specification, not a stability measurement on these peptides — nobody has run one. Do not freeze a reconstituted vial; freezing and thawing makes short peptides clump.

## A full day of both compounds, in marks and millilitres

Two common daily patterns, both at 5,000 mcg/mL:

| Pattern | BPC-157 | TB-500 | Total volume | Injections per day |
|---|---|---|---|---|
| Both daily, low | 500 mcg = 10 marks = 0.10 mL | 500 mcg = 10 marks = 0.10 mL | 0.20 mL | 2 |
| BPC daily, TB twice weekly | 500 mcg = 10 marks = 0.10 mL | 2.5 mg = 50 marks = 0.50 mL, Monday and Thursday | 0.10 mL most days, 0.60 mL twice a week | 1, or 2 twice a week |

Do not mix the two in one syringe. They have different concentrations, different volumes and different schedules, and combining them makes every future dose adjustment guesswork.

Where the needle goes was never resolved by the animal work, because the animals were dosed into the belly cavity or by drinking water, almost never at a site chosen to be near an injury. Several of the strongest structural results in rats — cut ligament, muscle torn off bone, spinal cord — came from animals drinking the compound in water and still repairing a specific distant injury. There is no head-to-head study showing an injection near the injury beats an injection into abdominal fat.

## Eight weeks of materials, priced with the arithmetic shown

Prices below are from one named research-chemical vendor, Nationwide Peptides, read on 4 August 2026. They publish a range across vial sizes rather than a per-size price, so the two endpoints are what can be quoted exactly.

- BPC-157: $42.00 for the smallest listed size (5 mg), $63.00 for the largest (20 mg).
- TB-500: $38.00 for the smallest listed size (5 mg), $61.00 for the largest (10 mg).

[[embed:source:s30]]

Eight weeks is 56 days. The arithmetic:

**BPC-157 at 500 mcg a day.** 56 days × 500 mcg = 28,000 mcg = 28 mg.
- Buying 5 mg vials: 6 vials (30 mg) × $42 = **$252**. Cost per day = $252 ÷ 56 = **$4.50**.
- Buying 20 mg vials: 2 vials (40 mg) × $63 = **$126**. Cost per day = $126 ÷ 56 = **$2.25**. Twelve milligrams get discarded, because a 20 mg vial at 500 mcg a day is 40 doses and a reconstituted vial only lasts about 28 days. Even throwing that away, the big vial is half the price of the small ones.

**TB-500 at 500 mcg a day.** 28 mg over the run. 3 × 10 mg vials × $61 = **$183**. Cost per day = **$3.27**. A 10 mg vial at 500 mcg a day is 20 doses, which fits inside the four-week window with nothing wasted.

**TB-500 at 2.5 mg twice a week.** 5 mg a week × 8 = 40 mg. 4 × 10 mg vials × $61 = **$244**. Cost per day = **$4.36**. Each vial is 4 doses, so exactly two weeks per vial.

**Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $30 for a run at retail.

| What is run | Eight-week materials | Per day |
|---|---|---|
| BPC-157 alone, 500 mcg/day, 20 mg vials | $126 + $30 = **$156** | $2.79 |
| TB-500 alone, 500 mcg/day | $183 + $30 = **$213** | $3.80 |
| Both, 500 mcg/day each, cheapest vial sizes | $126 + $183 + $30 = **$339** | $6.05 |
| Both, 500 mcg/day each, smallest vial sizes | $252 + $183 + $30 = **$465** | $8.30 |
| Both, BPC daily + TB 2.5 mg twice weekly | $126 + $244 + $30 = **$400** | $7.14 |

Adding the second compound to a BPC-157-only run costs $183 over eight weeks and doubles the injections. That is the price of the only thing the pairing buys, and the one experiment that measured whether it buys anything found that it did not.

None of these prices buys a verified product. There is no pharmacy channel for either compound, no monograph, and no requirement on any vendor to be accurate. A batch-specific purity test and mass-spectrometry identity report is the only thing standing between a buyer and a vial of something else, and at least one of the reports above — the man who ran 10 mg with no result and wondered whether his source was fake — is exactly that failure mode.

## Twelve weeks with a torn rotator cuff, hour by hour and dollar by dollar

One case, walked all the way through, with the numbers attached and the failure conditions written down before the start.

**Week 0 — what exists.** Partial-thickness rotator cuff tear confirmed on MRI. Pain 6/10 overhead, 2/10 at rest. Cannot sleep on that side. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour. Four things get written down as the baseline, because a result nobody measured is a result nobody has: pain overhead on a 0–10 scale, degrees of pain-free overhead reach measured against a doorframe, nights woken per week, and heaviest weight pressed overhead for five reps.

**Weeks 1–12 — the part that actually has evidence.** Progressive loading, twice a week with a therapist for the first six weeks then once. 18 visits at $75–$150 = $1,350–$2,700, about 18 clinic hours plus 20 hours of home work. This is the arm of the plan with randomised human trials behind it, and it is also the largest line in both the money column and the hours column. Anything else is added on top of it, never instead of it.

**Weeks 1–8 — the compounds, if they are run.** BPC-157 500 mcg a day and TB-500 500 mcg a day, into abdominal fat. Materials $339. Time: about 4 minutes a day for two injections, 56 days, so 3.7 hours over the run, plus roughly 20 minutes total spent reconstituting five vials.

**Week 4 — first decision point.** The stopping rule, set in advance: if nights woken per week has not fallen at all by week 4 and pain-free overhead reach has not gained at least 10 degrees, the compounds stop. That is not a strict test — a rotator cuff on a good loading programme improves over four weeks anyway — but a run showing zero movement on both measures at four weeks has failed its own premise. Money saved by stopping there: $170.

**Week 8 — second decision point.** Compounds end regardless. Both measures are read again. Anything that has improved from here belongs to the loading programme, which is running either way, and that is the point of ending the run while therapy continues — it separates the two.

**Week 12 — the state at the end.** Running total: $1,350–$2,700 in physical therapy, $339 in materials, $400–$1,800 for the MRI, so **$2,089 to $4,839**. Patient time: about 42 hours. The expected result on the loading programme alone, from the trial literature, is substantial improvement in pain and function in most partial-thickness tears at twelve weeks without surgery. The compounds cannot be credited for that, because a single person running one arm cannot separate a treatment from the natural course. What one person can learn is whether they got a side effect, whether they tolerated it, and what it cost.

**What would count as failure.** No change on either baseline measure at week 4. A new problem — swelling, worsening pain in an untreated joint, anything visual. Or pain that improves during the run and returns within two weeks of stopping, which points at irritation settling rather than tissue rebuilt.

## In United States law neither one is a medicine

Neither BPC-157 nor TB-500 is an approved medicine in the United States. Neither is banned outright either. Both sit in a specific and awkward place, and the FDA page that defines it is public.

Both appear on FDA's list of bulk drug substances "nominated but withdrawn" — substances that were put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, and then pulled by whoever nominated them. FDA's stated concerns, in its own words, are that compounded products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration" and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

[[embed:source:s31]]

What follows from that, in plain terms:

- No pharmacy can lawfully compound either one. Neither is on the 503A list that traditional compounding pharmacies work from, nor the 503B list that outsourcing facilities work from.
- On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It does not bind FDA, it does not make either an approved drug, and the rulemaking it triggers realistically takes eight to twelve months.
- "Research use only" on a vial is a shipping label, not a legal category that makes anything safe or lawful to inject.

[[embed:source:s32]]

## Both are banned in tested sport, at all times

Anyone who competes under anti-doping rules — collegiate, professional, masters, national federation, Olympic pathway — is exposed, and so is anyone serving in the United States military.

- BPC-157 is named in the WADA 2026 Prohibited List under S0, non-approved substances, prohibited at all times, in and out of competition.
- TB-500 is named under S2.3, growth factors, as "Thymosin-ß4 and its derivatives e.g. TB-500", also prohibited at all times, in the harsher non-specified tier.
- The S2.3 catch-all covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason someone would take either one is written into the prohibition.
- Strict liability applies. Intent does not matter, and who recommended it does not matter. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for exactly this pair.
- Sanctions can be imposed with no positive test at all, on an admission, a possession finding, or a purchase record.
- The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states plainly that it is not a dietary ingredient, it is an unapproved drug.

[[embed:source:s33]]

Off-season use is a violation. There is no window in which either compound is allowed.

## What is solid, what is a guess, and what nobody knows

**Solid.**
- TB-500 raised the breaking strength of a repaired rat Achilles tendon against control, 8 animals per arm, four weeks, p < 0.05.
- BPC-157 improved healing in rat tendon-to-bone, ligament, muscle, sciatic nerve and spinal cord models, across many separate experiments from largely one research group.
- Tested head to head in rats, the combination beat neither compound alone.
- Neither is an approved medicine, neither is lawfully compoundable, and both are banned in tested sport at all times.
- Doses in real use are 250 to 500 mcg a day, well below every published human dose of BPC-157, which were all milligram doses.

**A guess.**
- That any rat dose translates to a human dose. Scaling the standard rat dose of 10 µg/kg straight to a 70 kg adult gives about 0.7 mg a day, roughly twice what most people take.
- That injecting near the injury beats injecting into abdominal fat. Nothing has compared them.
- That the vial contains what the label says. Nothing requires it to.
- That the two compounds are worth running together. One experiment says no, and it has the limits set out above.

**Nobody knows.**
- What either compound does in a person over months. The longest human exposure on record for BPC-157 is two weeks in a Phase 1 study.
- Whether the immune system reacts to repeated injections of either. FDA named this as its specific concern and no one has measured it.
- What happens if either is taken by someone with an undiagnosed cancer. Both are proposed to grow blood vessels, which is also what a tumour needs, and thymosin beta-4 is overexpressed in many solid tumours.
- Whether the fragment sold as TB-500 does anything the full protein does, outside the one rat tendon study.

For the version of this stack aimed at a worn disc and nerve pain, with ARA-290 added for the nerve itself, the mechanism table, the evidence grades and the three-compound arithmetic are set out separately.

[[embed:wolverine-stack-ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:degenerative-disc-disease]]

[[embed:ara-290]]


## Sources

1. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/
2. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547
3. FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-related bulk drug substances, July 2026 — https://www.fda.gov/media/193349/download
4. Reddit r/Biohackers — u/beach_nuts, 8 June 2026 — anecdotal, positive — https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/
5. Reddit r/PEDs — u/SprinklesWise9857, 11 October 2025 — anecdotal, positive, self-assessed — https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/
6. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
7. X — @WovenDissent, 2026 — anecdotal, positive, elbow tendons — https://x.com/WovenDissent/status/2071612933382037588
8. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529
9. Reddit r/steroids — u/SwaveyyyD, 16 July 2023 — anecdotal, positive — https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/
10. Reddit r/steroids — u/UnusuallyTarded11, 16 March 2025 — anecdotal, positive, rotator cuff — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/
11. Reddit r/steroids — u/MysterMumbles, 17 March 2025 — anecdotal, positive then relapse on stopping — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/
12. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044
13. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108
14. Reddit r/steroids — u/MjolnirCurls, 28 February 2018 — anecdotal, no effect — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/
15. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
16. Reddit r/PEDs — u/Itchy_Brain6340, 9 October 2023 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/
17. X — @prax1s_mm, 30 July 2026 — anecdotal, no effect, third separate attempt, ran both compounds — https://x.com/prax1s_mm/status/2082901582627184835
18. X — @LtCrandog, 30 July 2026 — anecdotal, no effect over ten years of use — https://x.com/LtCrandog/status/2082758463407473109
19. Reddit r/Peptidesource — u/TheAwkwardEmu, 25 July 2026 — anecdotal, no effect at six weeks — https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/
20. Reddit r/moreplatesmoredates — u/Cr1ms0nSlayer, 8 May 2025 — anecdotal, no effect across two vendors — https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/
21. Reddit r/steroids — u/jlthreequarters, 17 March 2025 — anecdotal, no effect, injected near the knee — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/
22. Reddit r/Biohackers — u/Trofas27, 16 June 2026 — anecdotal, effect then loss of effect — https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/
23. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
24. Reddit r/PEDs — u/Illustrious_Buy_6545, 18 January 2026 — anecdotal, got worse in an untreated joint — https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/
25. Reddit r/Biohackers — u/cityhunterspeee, 20 February 2026 — anecdotal, got worse, vision, ran a blend of both — https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/
26. Reddit r/climbharder — u/WeenieLoft, 22 February 2024 — anecdotal, got worse, swelling at the treated finger — https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
27. Nationwide Peptides — BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/bpc-157-peptide/
28. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
29. STAT News, 23 July 2026 — FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
30. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
31. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/
32. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, January 2026. PMID 41476424 — https://pubmed.ncbi.nlm.nih.gov/41476424/
33. Reddit r/steroids — u/RGJJBrwn2022, 16 March 2025 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/
34. Reddit r/Biohackers — u/hraww, 9 April 2026 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/
35. Reddit r/steroids — u/Blahblahblurred, 16 March 2025 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/


---

# GHK-Cu: the copper tripeptide's human evidence, copper risk, and dosing arithmetic

slug: ghk-cu · https://miscsubjects.com/a/ghk-cu · tags: peptide, ghk-cu · updated 2026-08-04T20:49:58.680Z

GHK-Cu is a chain of three amino acids — glycine, histidine and lysine — holding a single copper(II) ion. It occurs naturally in human blood plasma, where its apparent job is to carry copper to the cells that need it and to signal that tissue has been injured.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
Two facts frame everything else here. The first is that the peptide runs out. Plasma GHK measures about 200 ng/mL at age 20 and falls to about 80 ng/mL by age 60 — a 60% decline across four decades, reported in the same terms in two separate reviews.

[[embed:source:s2]]

[[embed:source:s4]]

The second is that GHK-Cu is one of the few compounds in this library with a genuine human evidence base, because it spent thirty years as a cosmetic ingredient rather than a research chemical. That evidence is entirely topical. Injected GHK-Cu, which is how most people discussing it online are using it, has no completed human trial of any kind.

## Copper is the cargo, and copper is also the hazard

Strip the peptide away and what GHK-Cu delivers is copper in a form a cell can accept. Copper is a required cofactor for roughly a dozen enzymes. Two of them explain most of the interest in this molecule.

Lysyl oxidase is the enzyme that cross-links collagen and elastin. Newly made collagen is soft, soluble and mechanically useless until lysyl oxidase welds the strands together; without copper the enzyme never activates, and connective tissue never gains tensile strength. Copper-zinc superoxide dismutase is the other — the main enzymatic defence against superoxide inside a cell.

The activation step is physically specific. Lysyl oxidase acquires its copper inside the Golgi apparatus, and a 2026 delivery study built its entire design around that fact, using GHK-Cu as the copper source feeding a Golgi-targeted system. Lysyl oxidase activity rose to 1.78 times control, and collagen alignment improved in a rabbit fascia defect.

[[embed:source:w_bmq20ziw]]

That is the upside. The downside is that copper is a heavy metal with a narrow useful range, and injecting it bypasses the one organ that regulates how much of it enters the body. Dietary copper absorption falls from about 75% when intake is low to about 12% when intake is high — the gut throttles itself. A subcutaneous injection does not.

The arithmetic is worth doing rather than gesturing at. Copper tripeptide-1 has the formula C14H23CuN6O4+ and a molecular weight of 402.92 g/mol. Copper's atomic weight is 63.546. Copper is therefore 63.546 ÷ 402.92 = 15.77% of the mass of the complex.

[[embed:source:w_h4l8y6l7]]

| GHK-Cu dose | Elemental copper delivered | Share of the 900 mcg adult RDA | Share of the 10,000 mcg upper limit |
|---|---|---|---|
| 0.5 mg | 79 mcg | 9% | 0.8% |
| 1 mg | 158 mcg | 18% | 1.6% |
| 2 mg | 315 mcg | 35% | 3.2% |
| 3 mg | 473 mcg | 53% | 4.7% |
| 5 mg | 789 mcg | 88% | 7.9% |

The upper limit is an oral figure, set on the basis of liver damage, and it assumes intestinal regulation is working. Read the right-hand column as reassuring and the calculation has been misread. Read the third column instead: 3 mg daily by injection adds roughly half an adult's entire daily copper requirement, unregulated, on top of diet.

[[embed:source:w_mt4pif88]]

Wilson's disease is a hard stop. It is an autosomal recessive mutation in ATP7B that leaves the body unable to clear copper; untreated it produces cirrhosis, acute hepatitis, haemolytic crisis and neurological damage, and treatment is lifelong copper chelation. Giving a copper delivery vehicle to someone with Wilson's disease means giving them the exact substance their disease cannot handle. Anyone on chelation therapy, anyone with unexplained liver enzyme elevation, and anyone with a family history of Wilson's disease is outside the population every study below describes.

The mirror-image condition, Menkes disease, is copper deficiency caused by defective transport, and it is treated with subcutaneous copper injections in the first weeks of life. Same channel, opposite direction. Parenteral copper is a real intervention with real consequences, not a supplement.

## One laboratory produced most of what is known

GHK was isolated in 1973 from human albumin, identified as the factor that made old human liver tissue synthesise proteins the way young tissue does. The isolation, the naming, the copper hypothesis, the gene-expression work and most of the review literature trace to the same investigator, Loren Pickart, across five decades.

That is not a disqualification. It is also not a footnote. A body of work with one author carries one set of methodological habits and one set of priors, and the independent replications that exist are mostly cell-culture and animal work by other groups on narrow questions — fascia repair, wound dressings, nanoparticle carriers — rather than confirmations of the broad claims. Every figure in the next section inherits that caveat.

## Four steps run from the vial to new collagen, and the last one is the weakest

Step one: the complex delivers copper into the cell. This is the least contested part, and the Golgi work above shows the route in detail.

Step two: copper activates the cuproenzymes, lysyl oxidase among them, so collagen and elastin can be cross-linked into load-bearing tissue.

Step three: the peptide raises production of matrix components directly. In human dermal fibroblast culture at nanomolar concentrations, GHK-Cu increases synthesis of collagen types I, III and IV, elastin, and glycosaminoglycans including dermatan sulphate and chondroitin sulphate. It also modulates matrix metalloproteinases together with their tissue inhibitors — building and controlled demolition at once, which is what remodelling actually requires.

[[embed:source:s2]]

A pointed test of that step used irradiated human fibroblasts: cells damaged by radiotherapy that had lost the ability to replicate normally. At 1 nanomolar, GHK-Cu brought their doubling time back to approximately that of untreated normal controls, and they secreted significantly more basic fibroblast growth factor and VEGF than untreated controls.

[[embed:source:w_9mme7qe3]]

Step four is the gene-expression claim, and it is the one that travels furthest from its evidence. Using the Broad Institute's Connectivity Map, GHK was reported to change the expression of 31.2% of human genes by 50% or more — 59% of those upward, 41% downward. In absolute counts at the 50% threshold: 1,569 genes stimulated, 583 suppressed. At 100–199% change, 646 and 469. At 1,200% or more, 2 and 4.

[[embed:source:s4]]

Compressed to a headline, that becomes "GHK-Cu resets more than 4,000 human genes to a healthier state." The compression drops three things. The Connectivity Map is a transcriptional-signature database built from five cancer cell lines exposed to small molecules, not a study of human tissue. The analysis is the same investigator's. And "healthier state" is an interpretation laid over a correlation between two gene-expression signatures. The count is real. The conclusion attached to it in marketing copy is a bet, and it should be labelled one.

## The face creams were tested on 179 women, and that is the controlled human record

Three placebo-controlled cosmetic studies carry the topical case, plus one biopsy study of collagen production. They are small, they are old, two were published as conference proceedings rather than journal papers, and they are still more human data than almost any peptide sold in this category has.

| Study | n | Site and duration | Comparator | Reported result |
|---|---|---|---|---|
| Leyden et al. 2002, facial cream | 71 women with mild to advanced photoageing | Face, 12 weeks | Placebo | Increased skin density and thickness; reduced laxity, fine lines and wrinkle depth; improved clarity |
| Leyden et al. 2002, eye cream | 41 women with mild to advanced photodamage | Around the eye, 12 weeks | Placebo and a vitamin K cream | Beat both; reduced lines and wrinkles, increased skin density and thickness |
| Finkey et al. 2005, facial cream | 67 women aged 50–59 | Face twice daily, 12 weeks | Placebo | Improved laxity, clarity and firmness; reduced coarse wrinkles and mottled pigmentation; strongly increased keratinocyte proliferation on biopsy |
| Abdulghani et al. 1998, thigh biopsy | Pilot, immunohistological scoring | Thigh, 12 weeks | Vitamin C cream and retinoic acid | Collagen production increased in 70% of subjects on GHK-Cu, 50% on vitamin C, 40% on retinoic acid |

[[embed:source:s2]]

Read the fourth row carefully, because it is the one usually quoted as "GHK-Cu beats retinoic acid." What it reports is the proportion of subjects showing any measurable increase in collagen on biopsy — not the size of the increase — in a pilot study with immunohistological scoring. Suggestive, yes. A head-to-head comparison of how well the two work, no.

A 2025 review of GHK as a topical anti-wrinkle agent lands on the awkward point underneath all of this: the cellular evidence is not in doubt, and there is a surprising absence of clinical studies using GHK-Cu and its palmitoylated derivative in the products actually sold. The same review raises the delivery problem. GHK-Cu is hydrophilic, the stratum corneum is lipophilic, and how much of an applied dose reaches living dermis remains unresolved.

[[embed:source:s7]]

[[embed:source:s64]]

## The only randomised wound trial found nothing

In 1992 a prospective randomised evaluator-blinded trial in venous stasis ulcers enrolled 86 evaluable patients across three arms: 1% silver sulfadiazine cream, a 0.4% tripeptide-copper complex cream, and an inert vehicle placebo. Silver sulfadiazine statistically reduced ulcer size. The copper tripeptide cream did not differ from placebo.

[[embed:source:w_dur47sp5]]

That is the largest controlled human wound-healing trial of this compound in the published record. It ran on the indication where the mechanism should be most visible, and it was negative. A page presenting GHK-Cu as an established wound-healing agent without that trial in it has left out the most decision-relevant result available.

One trial now running could change the picture. NCT07437586 is a Phase 2, randomised, quadruple-blind, vehicle-controlled split-wound study: 60 healthy adults each receive two standardised punch-biopsy wounds on the upper arm, one randomised to 0.1% w/w GHK-Cu gel and the other to matching vehicle, roughly 0.5 g applied once daily for 14 days. The primary endpoint is days to complete re-epithelialisation, assessed blind from standardised photography, with a scar-quality follow-up. It started 2 February 2026; estimated primary completion is 14 February 2027.

[[embed:source:s3]]

The split-wound design is why that trial matters more than its size suggests. Each participant is their own control, which strips out the age, genetics and healing-rate variation that swamps small wound studies.

## Nobody has ever run a human trial on injected GHK-Cu

A search of ClinicalTrials.gov for GHK-Cu returns three studies in total. None of them injects it.

| NCT | Status | n | Route | What it tests |
|---|---|---|---|---|
| NCT07437586 | Recruiting, started Feb 2026 | 60 | Topical gel, 0.1% w/w | Re-epithelialisation of standardised acute wounds against vehicle |
| NCT05932732 | Completed Oct 2024 | 27 | Topical, inside a multi-component facial device treatment | Facial skin quality, hydration and barrier — GHK-Cu is one ingredient of one booster serum, never an isolated variable |
| NCT07706361 | Not yet recruiting, estimated start Jan 2027 | 100 | Transdermal patch | Whether a patch raises circulating GHK and GHK-Cu at all |

[[embed:source:s3]]

[[embed:source:s28]]

[[embed:source:w_ubcmxjki]]

The gap between that table and the practice described on peptide forums is total. Every reported subcutaneous dose, every milligram-per-day protocol, every before-and-after photograph of injected GHK-Cu rests on zero controlled human data. Topical evidence does not carry across: the doses differ by orders of magnitude, the exposure is systemic rather than local, and the copper load is the variable the cosmetic trials never had to think about.

A 2026 narrative review in Sports Medicine covering the unapproved-peptide market — GHK-Cu named alongside BPC-157, TB-500, ipamorelin and the rest — states the position without softening it: favourable tissue-repair outcomes in animal models, scarce rigorous human safety data, potential for serious harm, and a placebo effect amplified by social media.

[[embed:source:w_5b5tq9e0]]

## Trace the viral hair number and it belongs to a different molecule

One claim circulates faster than any other. It is specific enough to sound checkable, which is exactly why it spreads.

[[embed:source:s104]]

The Annals of Dermatology paper is real. It randomised 45 men with pattern hair loss to ALAVAX at 100 mg/mL, ALAVAX at 50 mg/mL, or placebo, once daily for six months. Hair count rose by 52.6 in the high-dose group, 71.5 in the low-dose group and 9.6 on placebo. No adverse events in any group.

[[embed:source:w_j3a2bvun]]

Three problems. ALAVAX is a complex of 5-aminolevulinic acid and GHK — copper-free GHK, not GHK-Cu — so the effect cannot be assigned to either component. Only the low-dose-versus-placebo ratio reached statistical significance, and the higher dose performed worse than the lower one, which is not how a dose-responsive drug behaves. Hair length and hair thickness showed no significant difference between any of the three groups at six months.

A PubMed search across GHK, copper peptide and copper tripeptide against hair and alopecia returns 13 records. Not one is a controlled human trial of GHK-Cu alone for hair. The rest are cell work, mouse work, delivery-vehicle engineering, and multi-ingredient clinic formulations in which copper tripeptide sits among a dozen components alongside minoxidil and finasteride. People report hair effects constantly, and those reports are worth reading as reports:

[[embed:source:s58]]

[[embed:source:s81]]

[[embed:source:s57]]

## The whole load-bearing-tissue case is one rat knee and a long chain of extrapolation

The connective-tissue case is mechanistically coherent. Collagen and elastin cross-linking is copper-dependent. Ligament, tendon, fascia and disc are collagen structures. A compound that raises collagen synthesis and activates lysyl oxidase is operating on exactly the material a ligament, a tendon and a disc are built from. Three recent orthopaedic reviews list GHK-Cu on that basis, grouped with BPC-157 and TB-500 as wound-healing peptides working through angiogenesis, integrin-mediated matrix remodelling and fibroblast activation.

[[embed:source:s73]]

[[embed:source:s74]]

The direct musculoskeletal experiment exists. It is one study, in rats, with a mixed result. Seventy-two rats underwent anterior cruciate ligament reconstruction and were randomised to saline, 0.3 mg/mL or 3 mg/mL GHK-Cu, given as intra-articular injections weekly for four weeks starting at week two. At six weeks the GHK-Cu groups had less side-to-side knee laxity than saline (p = 0.009) and the low-dose group had higher graft stiffness (p = 0.026). At twelve weeks neither difference remained. Ultimate load, gait and histology showed no difference at any point, and every graft failed mid-substance on pull-out testing.

[[embed:source:w_s0qgk5od]]

The paper's own title uses the word "transiently." An acceleration of early healing that has vanished by three months is a real finding and a small one, and it is the entire animal case for GHK-Cu in a load-bearing joint.

What follows from that one study, stated plainly:

- Dermal data does not license a musculoskeletal claim. Skin is thin, well vascularised and fast-turning-over; a ligament is none of those. No study has measured GHK-Cu in a human tendon, disc, ligament or fascia.
- The rabbit fascia work is a delivery-system engineering study, not a treatment trial, and its intervention was a nanoparticle-plus-mRNA construct in which GHK-Cu was the copper reservoir.
- The pre-blended recovery stacks pairing GHK-Cu with BPC-157 and TB-500 have no combination study behind them in any species. The pairing exists because the three compounds have adjacent marketing stories, and stacking three unapproved compounds multiplies unknowns rather than averaging them.
- Post-procedure skin recovery — after laser, microneedling or a surgical incision — is the one adjacent use with something resembling human support, and that support is topical.

[[embed:source:s20]]

[[embed:source:s52]]

## Reconstitution is division, then division again

GHK-Cu ships as a lyophilised powder, usually blue to blue-green, in a sealed glass vial. Vials of 50 mg and 100 mg are the common sizes — an order of magnitude larger than most peptide vials, because the doses discussed are milligrams rather than micrograms. It is reconstituted with bacteriostatic water, which is sterile water containing 0.9% benzyl alcohol; that preservative is what makes it safe to enter the vial repeatedly.

Two divisions produce every number needed.

- **Concentration**: vial strength in mg ÷ water added in mL = mg per mL.
- **Per-unit content**: a U-100 insulin syringe holds 100 units per mL, so mg/mL × 1,000 ÷ 100 = micrograms per unit. In short, mg/mL × 10.
- **Units for a dose**: dose in mcg ÷ micrograms per unit.

| Vial | Bacteriostatic water | Concentration | Per insulin unit | A 2 mg dose |
|---|---|---|---|---|
| 50 mg | 2 mL | 25 mg/mL | 250 mcg | 8 units |
| 50 mg | 5 mL | 10 mg/mL | 100 mcg | 20 units |
| 50 mg | 10 mL | 5 mg/mL | 50 mcg | 40 units |
| 100 mg | 5 mL | 20 mg/mL | 200 mcg | 10 units |
| 100 mg | 10 mL | 10 mg/mL | 100 mcg | 20 units |

At the middle row — 50 mg in 5 mL, giving 10 mg/mL and 100 mcg per unit — the dose-to-units conversion is the simplest available, which is why that dilution is the one most often described.

| Dose | Units at 10 mg/mL | Elemental copper in that dose |
|---|---|---|
| 1 mg | 10 units | 158 mcg |
| 1.5 mg | 15 units | 237 mcg |
| 2 mg | 20 units | 315 mcg |
| 3 mg | 30 units | 473 mcg |
| 5 mg | 50 units | 789 mcg |

Doses in public reports cluster at 1–3 mg daily subcutaneously, with 5 mg at the upper end. There is no established dose, because there is no trial. Continuous daily use running past twelve weeks is common in those reports, and nothing in the evidence base speaks to the cumulative copper load of that pattern.

[[embed:source:s61]]

Timelines in the same reports are slow and consistent: nothing at two weeks, first skin changes somewhere between four and eight weeks, and the before-and-after photographs that circulate are at six weeks to twelve months.

[[embed:source:s50]]

[[embed:source:s66]]

## Topical strengths span a factor of a thousand

The concentrations in the literature and the concentrations on shelves are not the same numbers, and neither matches what the safety panel assessed.

| Context | Concentration | Where the figure comes from |
|---|---|---|
| Phase 2 wound gel, NCT07437586 | 0.1% w/w | Trial protocol |
| Venous ulcer trial, 1992 | 0.4% cream | Published methods |
| CIR-assessed typical cosmetic use | under 10 ppm (0.001%) | Panel report |
| Consumer serums described in user threads | 1% | Product labelling quoted by users |

A 1% serum is a thousand times the concentration the safety panel described as typical use. That is not automatically unsafe — the panel's conclusion rested on low use levels plus negative irritation and sensitisation data, not on a hard ceiling — but the gap is where reports of irritation come from, and it explains how two products both labelled "copper peptide" can behave completely differently on the same face.

[[embed:source:w_hs61u1ls]]

[[embed:source:s88]]

## The side effects people report are consistent, local, and absent from the literature

Nothing below is a trial finding. Each is a person describing what happened to them, quoted as written, from a public thread.

Injection-site stinging and welts are the most frequently described physical effect, and the workaround people converge on is technique rather than dose:

[[embed:source:s103]]

Skin discolouration — described as a golden or tanned tone — comes up repeatedly among people injecting daily, and appears in no published safety assessment:

[[embed:source:s95]]

Fatigue and histamine-type reactions after injection:

[[embed:source:s96]]

Systemic symptoms severe enough to stop:

[[embed:source:s40]]

[[embed:source:s41]]

The topical failure mode has its own name in skincare communities — "copper uglies" — and the pattern described is new fine lines and texture change appearing at around day ten, resolving after stopping:

[[embed:source:s93]]

Negative results deserve the same space as positive ones. Twelve weeks at 2–3 mg daily made one person's skin measurably worse by their own account, and three months at 2 mg daily produced nothing at all for another:

[[embed:source:s16]]

[[embed:source:s98]]

The positive reports, at the same evidence tier:

[[embed:source:s19]]

[[embed:source:s101]]

[[embed:source:s60]]

[[embed:source:s84]]

Read as a body, these reports agree on three things the literature says nothing about: the effect is slow, the injection-site reaction is common, and a visible skin-tone change happens to some people on daily dosing.

## A vial that is not blue may not contain copper

GHK-Cu in solution is blue. The colour is the copper — a d-orbital transition in the Cu(II) ion, not a dye. A reconstituted vial that comes out clear or faintly straw-coloured is a signal worth acting on, and it is a question the forums raise directly, usually in the mistaken belief that bacteriostatic water strips the copper out. It does not. A colourless solution means the powder was plain GHK, or the copper was never complexed at the stated ratio.

[[embed:source:s106]]

Storage follows from the same chemistry. Lyophilised powder is stable at room temperature in the sealed vial and better refrigerated; once reconstituted it goes to 2–8 °C and stays out of light, because copper complexes are photosensitive and copper is a redox-active catalyst. Light plus dissolved oxygen plus copper is the recipe for degrading the peptide the copper is bound to. Bacteriostatic water gives a multi-dose vial a usable life measured in weeks refrigerated, not months.

Verification is possible and does not require running a laboratory. Copper in a GHK-Cu formulation has been quantified by capillary electrophoresis coupled to inductively coupled plasma tandem mass spectrometry, monitoring copper and phosphorus signals to confirm both the intact complex and its encapsulation.

[[embed:source:w_iol3yo5q]]

## Legal as a face cream, unapproved as an injection

The two regulatory statuses are unrelated, and conflating them is the most common factual error made about this compound.

As a cosmetic ingredient, copper tripeptide-1 is assessed and cleared. The CIR Expert Panel reviewed tripeptide-1, its metal salts including the copper complex, and related derivatives, and concluded that the ingredients are safe in cosmetics in the present practices of use and concentration described in the assessment. Typical use concentrations were reported as under 10 ppm. The panel recorded that low use concentrations plus negative safety test data resolved the question, and noted that when tripeptide-1 is put into a vein it is rapidly broken down to histidyl-lysine and cleared from the blood within minutes.

[[embed:source:w_hs61u1ls]]

As an injectable it has no approval anywhere, and it occupies a specific place on FDA's compounding record. Injectable GHK-Cu was nominated as a bulk drug substance for use in compounding, placed in category 2 — substances that may present significant safety risks — and the nomination was later withdrawn by the nominator. It appears on the withdrawn list with the agency's stated reasoning intact: compounded injectable drugs containing GHK-Cu may pose a risk that the immune system reacts to the drug itself — the agency's word for that is immunogenicity — because the peptide can clump together and because impurities related to the peptide can be present, and there are limited data in humans to inform safety-related considerations. The page carrying that entry is current as of 22 April 2026.

[[embed:source:w_tzy9wc70]]

Withdrawn is not cleared. The substance left the active list because the party who nominated it stopped pursuing it, not because the agency resolved its concern, and the concern is still printed on the page. The practical consequence in the United States is that a compounding pharmacy has no lawful route to supply it as an injectable, so material sold for injection reaches buyers labelled research use only — outside exactly the manufacturing controls that the agency's concern is about.

## Every number above, and the exact call that returns it

Each figure on this page comes from a fetchable record. These are the calls.

| Claim | How to re-derive it |
|---|---|
| Plasma GHK 200 ng/mL at 20, 80 ng/mL at 60 | `curl -s https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/` — section 1, Introduction |
| 31.2% of genes changed by ≥50%; 1,569 up and 583 down at that threshold | `curl -s https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/` — section 2, Table 1 |
| Molecular weight 402.92, copper fraction 15.77% | `curl -s 'https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/copper%20tripeptide-1/property/MolecularFormula,MolecularWeight/JSON'`, then 63.546 ÷ 402.92 |
| Copper RDA 900 mcg, upper limit 10,000 mcg, Wilson's disease risk | `curl -s https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/` — Tables 1 and 3 |
| Three registered trials, none injectable | `curl -s 'https://clinicaltrials.gov/api/v2/studies?query.term=GHK-Cu&countTotal=true'` |
| 192 PubMed records for GHK-Cu or copper tripeptide | `curl -s 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=GHK-Cu+OR+%22copper+tripeptide%22&retmode=json&retmax=100'` |
| 13 hair records, none a controlled GHK-Cu trial | `curl -s 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=(GHK+OR+%22copper+peptide%22+OR+%22copper+tripeptide%22)+AND+(hair+OR+alopecia)&retmode=json&retmax=40'` |
| Negative venous ulcer trial, n = 86 | `curl -s 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&retmode=xml&rettype=abstract&id=1495150'` |
| Rat ACL reconstruction result, n = 72 | `curl -s 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&retmode=xml&rettype=abstract&id=25731775'` |
| FDA withdrawn-nomination entry, verbatim | `curl -s https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks` — second table |
| Every source card on this page, with quote and link | `curl -s https://miscsubjects.com/api/articles/ghk-cu` |

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:kpv]]

[[embed:thymosin-alpha-1]]

[[embed:dsip]]


## Sources

1. The potential of GHK as an anti-aging peptide — https://pmc.ncbi.nlm.nih.gov/articles/PMC8789089/
2. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
3. Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal) — https://clinicaltrials.gov/study/NCT07437586
4. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
5. Exploring the beneficial effects of GHK-Cu on an ulcerative colitis model — https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1551843/full
6. Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) Attenuates CuSO4 or LPS induced-inflammation in Zebrafish larvae model — https://pubmed.ncbi.nlm.nih.gov/41997403/
7. Topically applied GHK as an anti-wrinkle peptide — https://pubmed.ncbi.nlm.nih.gov/39963574/
8. Anyone tried injectable GHK CU? Total game changer for skin? — https://www.reddit.com/r/30PlusSkinCare/comments/1r39ib4/anyone_tried_injectable_ghk_cu_total_game_changer/
9. I Tested GHK-Cu For A Year | Here's What Actually Happened — https://www.youtube.com/watch?v=AsF22Fw7qkk
10. GHK-Cu Peptide | The benefits, side effects, and more [2026] — https://www.innerbody.com/ghk-cu-peptide
11. A Dermatologist’s Take on the Copper Peptide (GHK-Cu) Skin Care Trend — https://www.westlakedermatology.com/trends/ghk-cu-copper-peptides-for-skin-care/
12. The Benefits & Risks of GHK-Cu (WATCH BEFORE TAKING) — https://www.youtube.com/watch?v=1n4wTQ2zdl4
13. Most effective way to deliver GHK-Cu (Copper Tripeptide-1) through skin? — https://www.reddit.com/r/SkincareAddictionLux/comments/1poeyy0/most_effective_way_to_deliver_ghkcu_copper/
14. Topically applied GHK as an anti-wrinkle peptide — https://bi.tbzmed.ac.ir/Inpress/bi-30071.pdf
15. Bulk Drug Substances Nominated for Use in Compounding — https://www.fda.gov/media/94155/download
16. [product question] has anyone tried GHK-CU injections for skin care... — https://www.reddit.com/r/SkincareAddiction/comments/1cqui3m/product_question_has_anyone_tried_ghkcu/
17. [product question] has anyone tried GHK-CU injections for skin care... — https://www.reddit.com/r/SkincareAddiction/comments/1cqui3m/product_question_has_anyone_tried_ghkcu/
18. [PSA] Albeit rare Copper peptide "uglies" are real and scary... — https://www.reddit.com/r/SkincareAddiction/comments/1cmlmg9/psa_albeit_rare_copper_peptide_uglies_are_real/
19. Ghk cu is underrated — https://www.reddit.com/r/Biohackers/comments/1py9kvg/ghk_cu_is_underrated/
20. Ghk cu is underrated — https://www.reddit.com/r/Biohackers/comments/1py9kvg/ghk_cu_is_underrated/
21. An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant — https://pubmed.ncbi.nlm.nih.gov/40716276/
22. The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways — https://pubmed.ncbi.nlm.nih.gov/42084774/
23. Therapeutic peptides in gerontology: mechanisms and clinical applications — https://pubmed.ncbi.nlm.nih.gov/42021992/
24. GHK-Cu Peptide | Skin & Healing Benefits — https://www.paragonsportsmedicine.com/peptides/ghk-cu
25. GHK-Cu peptide guide. — https://www.reddit.com/r/NTNPerformance/comments/1tfe24p/ghkcu_peptide_guide/
26. The Only Peptide that Builds Collagen, Muscle, and Hair ... — https://www.youtube.com/watch?v=gzQkWWHV4uQ
27. Best copper peptide brand? — https://www.reddit.com/r/SkincareAddictionLux/comments/1mcka43/best_copper_peptide_brand/
28. Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types. — https://clinicaltrials.gov/study/NCT05932732
29. BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review of Clinical Efficacy and Safety — https://www.researchgate.net/publication/404069524_BPC-157_and_GHK-Cu_in_Wound_Healing_and_Tissue_Repair_A_Review_of_Clinical_Efficacy_and_Safety
30. Copper Peptides For Hair Growth in 2026? Watch This First! — https://www.youtube.com/watch?v=CbVsc6jJDXY
31. GHK-Cu: The Science Behind the Copper Peptide — https://meto.co/blog/ghk-cu-copper-peptide-benefits
32. Tripeptides Ghk and GhkCu-modified silver nanoparticles for enhanced antibacterial and wound healing activities — https://pubmed.ncbi.nlm.nih.gov/38387323/
33. GHK-Cu for Anti-Aging: Does This Copper Peptide Really Work? — https://www.joinmidi.com/post/ghk-cu
34. Has Anyone's Opinion on GHK-Cu Changed After Spending More Time With It? — https://old.reddit.com/r/40and45PlusSkinCare/comments/1u98v6d/has_anyones_opinion_on_ghkcu_changed_after/
35. GHK-Cu (Copper Peptide) Deep Dive: Mechanisms, Benefits, Risks, Forms, & Dosing — https://www.youtube.com/watch?v=IU6oRY7im6k
36. Topical ghk-cu — https://www.reddit.com/r/Biohackers/comments/1rwcte4/topical_ghkcu/
37. GHK-Cu before and after — https://www.reddit.com/r/Biohackers/comments/1sphw3t/ghkcu_before_and_after/
38. Let's talk about copper peptides, whose tried them and ... — https://www.reddit.com/r/45PlusSkincare/comments/12z3ft9/lets_talk_about_copper_peptides_whose_tried_them/
39. Any experience using Copper Peptide GHK-Cu and AHK- ... — https://www.reddit.com/r/FemaleHairLoss/comments/1lvpeb7/any_experience_using_copper_peptide_ghkcu_and/
40. Anyone have weird side effects with GHK-Cu? — https://www.reddit.com/r/Biohackers/comments/1sgg8o4/anyone_have_weird_side_effects_with_ghkcu/
41. GHK-CU Side Effects — https://www.reddit.com/r/PeptideForum/comments/1b2rx59/ghkcu_side_effects/
42. GH peptides + KLOW blend saved my hair. before and after ... — https://www.reddit.com/r/tressless/comments/1rytxzu/gh_peptides_klow_blend_saved_my_hair_before_and/
43. Exploring the beneficial effects of GHK-Cu on an experimental ulcerative colitis model in mice — https://pmc.ncbi.nlm.nih.gov/articles/PMC12263609/
44. An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant — https://www.sciencedirect.com/science/article/abs/pii/S0927776525004898
45. 1 year Fin/2 months GHK-CU update : r/tressless — https://www.reddit.com/r/tressless/comments/1tk2xcn/1_year_fin2_months_ghkcu_update/
46. GHK-Cu: The Peptide Everyone Is Injecting (Big Mistake?) — https://www.youtube.com/watch?v=52sPkAe7xFc
47. GHK-Cu for Skin & Wound Healing: Current Evidence — https://www.meetingpointhealth.com/blog/ghk-cu-for-skin-wound-healing-current-evidence/
48. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms — https://pubmed.ncbi.nlm.nih.gov/40672369/
49. GHK-Cu Copper Peptide 2026 Review: Benefits, Mechanisms, Safety — https://www.nationwidepeptides.com/peptide/ghk-cu-2026-review/
50. GHK-Cu 6 week before and after — https://www.reddit.com/r/Biohackers/comments/1tkrmim/ghkcu_6_week_before_and_after/
51. GHK-Cu - The Ultimate SKIN & Beauty Peptide 2026?! — https://www.youtube.com/watch?v=jUuPRcrzu80
52. Copper peptides after 40, how do they hold up long term? — https://www.reddit.com/r/45PlusSkincare/comments/1naojmn/copper_peptides_after_40_how_do_they_hold_up_long/
53. GHK Cu - is this the next best solution for hairloss? — https://www.reddit.com/r/tressless/comments/1r1wks0/ghk_cu_is_this_the_next_best_solution_for_hairloss/
54. GHK-Cu: The “Beauty Peptide” You’re About To Hear Everywhere In 2026 — https://www.insideindustry.co/post/ghk-cu-the-beauty-peptide-you-re-about-to-hear-everywhere-in-2026
55. GHK-Cu Peptide 2026: FDA Approved? Dosage & Where To Buy — https://injectco.com/ghk-cu-peptide-guide-fda-approved-dosage-where-to-buy-2026/
56. Experiences with GHK-Cu (Copper Tripeptide) — https://www.reddit.com/r/Biohackers/comments/1nnidtg/experiences_with_ghkcu_copper_tripeptide/
57. GHK-Cu peptide injections - what is your experience? — https://www.reddit.com/r/tressless/comments/1rqs7m1/ghkcu_peptide_injections_what_is_your_experience/
58. any experiences with ghk-cu for hair loss? — https://www.reddit.com/r/tressless/comments/1tlf37e/any_experiences_with_ghkcu_for_hair_loss/
59. Copper peptide uglies — https://www.reddit.com/r/30PlusSkinCare/comments/1paht4r/copper_peptide_uglies/
60. Peptide Confessions post on topical GHK-Cu — https://x.com/pepfessions/status/2071193225289764995
61. AntiDoc on 5mg GHK-Cu daily — https://x.com/AntiDoc/status/1961093058977517895
62. Injectable Peptides for Anti-Aging? A Dermatologist Explains — https://www.youtube.com/watch?v=ERb5yaBumTQ
63. Injectable Peptides for Anti-Aging? A Dermatologist Explains — https://www.youtube.com/watch?v=ERb5yaBumTQ
64. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? — https://pubmed.ncbi.nlm.nih.gov/39795193/
65. Copper tripeptide GHK-Cu and Regenerative Aesthetics — https://www.multispecialtysociety.com/community/the-aesthetic-multispecialty/articles/copper-tripeptide-ghk-cu-and/details
66. GHK-Cu 🧬 Skin Remodeling | Collagen Regeneration | Acne Repair (Complete Reddit Research Guide 2025) — https://www.reddit.com/r/USPeptides/comments/1ozk0zj/ghkcu_skin_remodeling_collagen_regeneration_acne/
67. GHK-Cu: A Copper Peptide Studied for Skin, Hair, and ... — https://superpower.com/guides/ghk-cu
68. Is GHK-Cu Worth the Hype? UK 2026 Honest Review — https://peptideslabuk.com/is-ghk-cu-worth-the-hype/
69. GHK Cu Peptide | Clinical Evidence & Skin Benefits 2025 — https://grandingredients.com/copper-peptides-clinical-benefits/
70. HIMS and peptides like ghk-cu — https://www.reddit.com/r/HimsStock/comments/1rferff/hims_and_peptides_like_ghkcu/
71. Golgi-targeted copper delivery strategy via enhancing ... — https://pubmed.ncbi.nlm.nih.gov/41371501/
72. Copper Complexes with New Glycyl-l-histidyl-l-lysine ... — https://pubmed.ncbi.nlm.nih.gov/40123442/
73. Injectable Peptide Therapy: A Primer for Orthopaedic and ... — https://pubmed.ncbi.nlm.nih.gov/41476424/
74. Therapeutic Peptides in Orthopaedics: Applications, ... — https://pubmed.ncbi.nlm.nih.gov/41490200/
75. Safety and Efficacy of Approved and Unapproved Peptide ... — https://pubmed.ncbi.nlm.nih.gov/41966639/
76. Efficacy and Safety Assessment of ThriveCo Scar Fader ... — https://pubmed.ncbi.nlm.nih.gov/41001334/
77. Therapeutic Peptides in Aesthetic, Metabolic and ... — https://pubmed.ncbi.nlm.nih.gov/42123471/
78. Smart Healing for Wound Repair: Emerging Multifunctional ... — https://pubmed.ncbi.nlm.nih.gov/41594073/
79. Ghk-cu / ahk-cu update — https://www.reddit.com/r/HairlossResearch/comments/1k3lgke/ghkcu_ahkcu_update/
80. Dr. Admits - I Was WRONG AGAIN About GHK-Cu — https://www.youtube.com/watch?v=veqDr44p8L0
81. What benefits do you get from using copper peptides? — https://www.reddit.com/r/40and45PlusSkinCare/comments/1peq7xj/what_benefits_do_you_get_from_using_copper/
82. What is a good gHK-cu serum? — https://www.reddit.com/r/SkincareAddictionLux/comments/1qh4uka/what_is_a_good_ghkcu_serum/
83. [Product Question] advice on buying ghk-cu topical copper peptide — https://www.reddit.com/r/SkincareAddiction/comments/1rjgn2q/product_question_advice_on_buying_ghkcu_topical/
84. X post on GHK-Cu hangover effects — https://x.com/jeremystandifor/status/2071379648068419785
85. X post comparing GHK-Cu to minoxidil — https://x.com/barryharrddy/status/2071332122665930980
86. The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds — https://pubmed.ncbi.nlm.nih.gov/42041438/
87. Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing — https://pubmed.ncbi.nlm.nih.gov/39902373/
88. What is a good gHK-cu/copper peptide serum that works? — https://www.reddit.com/r/EuroSkincare/comments/1qh4ot4/what_is_a_good_ghkcucopper_peptide_serum_that/
89. Q&A: Optimizing Copper Peptide Through Next-Generation Delivery — https://www.dermatologytimes.com/view/q-a-optimizing-copper-peptide-through-next-generation-delivery
90. GHK-Cu Peptide Injection Before and After — https://freemedicaljournals.com/blog/ghk-cu-peptide-injection-before-and-after/
91. Copper peptide supplements? — https://www.reddit.com/r/SkincareAddictionUK/comments/1qaoy9k/copper_peptide_supplements/
92. Has Anyone's Opinion on GHK-Cu Changed After Spending More Time With It? — https://www.reddit.com/r/40and45PlusSkinCare/comments/1u98v6d/has_anyones_opinion_on_ghkcu_changed_after/
93. PSA: Albeit rare Copper peptide "uglies" are real and scary — https://www.reddit.com/r/30PlusSkinCare/comments/1cmlfml/psa_albeit_rare_copper_peptide_uglies_are_real/
94. X post on GHK-Cu benefits — https://x.com/biohacker/status/1984347714469929382
95. [Anti-Aging] Copper Peptide injection side effect - golden skin tone. Anyone else? — https://www.reddit.com/r/SkincareAddiction/comments/1nm9gzt/antiaging_copper_peptide_injection_side_effect/
96. Tired after ghk-cu injection — https://www.reddit.com/r/Biohackers/comments/1qr8yoj/tired_after_ghkcu_injection/
97. GHK-Cu experience post — https://x.com/Breedlove22/status/2071613131013640454
98. GHK-CU: Is it as revolutionary as its made out to be? — https://www.reddit.com/r/tressless/comments/1sshkrd/ghkcu_is_it_as_revolutionary_as_its_made_out_to/
99. GHK-Cu Copper Uglies Explained: Why Your Skin Looks Worse Before It Gets Better — https://www.reddit.com/r/PeptideFeed/comments/1stzu1d/ghkcu_copper_uglies_explained_why_your_skin_looks/
100. 12-month GHK-Cu Serum Results — https://www.reddit.com/r/Biohackers/comments/1t49xch/12month_ghkcu_serum_results/
101. 12-month GHK-Cu Serum Results — https://www.reddit.com/r/Biohackers/comments/1t49xch/12month_ghkcu_serum_results/
102. Feedback on GHK-CU for hEDS — https://www.facebook.com/groups/1422003578233285/posts/2631611490605815/
103. I am planning on taking GHK-CU. How much Zinc is recommended to prevent copper uglies and the like? — https://www.reddit.com/r/Biohackers/comments/1tg76b0/i_am_planning_on_taking_ghkcu_how_much_zinc_is/
104. GHK-Cu controls 4,000+ of your genes — https://x.com/FarvingCo/status/2069837104410996965
105. fun fact: if you accidentally blast yourself with 2.5x the dose of GHK-cu — https://x.com/Bonecondor/status/1996952269086929269
106. GHK-Cu - are we all injecting plain GHK without the copper by using BAC water? — https://www.reddit.com/r/Biohackers/comments/1stb4w9/ghkcu_are_we_all_injecting_plain_ghk_without_the/
107. PubChem CID 71587328 - Copper Tripeptide-1 (GHK-Cu) — https://pubchem.ncbi.nlm.nih.gov/compound/71587328
108. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - bulk drug substances nominated but withdrawn (page current as of 04/22/2026) — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
109. NIH Office of Dietary Supplements: Copper - Fact Sheet for Health Professionals — https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/
110. Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg 1992 — https://pubmed.ncbi.nlm.nih.gov/1495150/
111. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol 2016;28(4) — https://pubmed.ncbi.nlm.nih.gov/27489425/
112. Tripeptide-copper complex GHK-Cu(II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res 2015 — https://pubmed.ncbi.nlm.nih.gov/25731775/
113. NCT07706361: A Two-part Study Investigating the Effect of the X39 Patch on Circulating Blood Levels of GHK and GHK-Cu in a Healthy Adult Population (LifeWave, Inc.) — https://clinicaltrials.gov/study/NCT07706361
114. CIR Expert Panel. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics. Int J Toxicol 2018;37(Suppl 3):90S-102S — https://journals.sagepub.com/doi/10.1177/1091581818807863
115. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg 2005 — https://pubmed.ncbi.nlm.nih.gov/15655171/
116. Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins' activity for fascia regeneration. J Control Release 2026 — https://pubmed.ncbi.nlm.nih.gov/41371501/
117. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026 — https://pubmed.ncbi.nlm.nih.gov/41966639/
118. Novel Applications of CE-ICP-MS/MS: Monitoring of Antiaging GHK-Cu Cosmetic Component Encapsulation in Liposomes. Molecules 2024 — https://pubmed.ncbi.nlm.nih.gov/39451062/


---

# KPV: Evidence, Stability, Dosing and the FDA Record

slug: kpv · https://miscsubjects.com/a/kpv · tags: peptide, kpv · updated 2026-08-04T20:49:58.543Z

KPV is three amino acids in a row — lysine, proline, valine. It is the tail end of a hormone your own body makes, alpha-MSH, which calms inflammation, darkens skin, and pushes on the heart and blood vessels. Cut the tail off and you keep the calming and lose the other two. That separation is the whole reason anyone works on it.

The evidence state, before anything else on this page. Randomised trials of KPV in people: none. Uncontrolled studies in people: none either. KPV has never been given to a person in any published study, by any route, at any dose. Asking the ClinicalTrials.gov programming interface for it on 4 August 2026 returned a total count of zero, and FDA searched the same databases independently in May 2026 and recorded that it had found no exposure data for products containing KPV given by any route. So the number of people who have ever taken it under measurement is nought, and there is no established human dose, no measured blood level, and no side-effect rate from a study. What does exist is 35 papers. The controlled results in them come from cultured human gut, airway and skin cells, and from mice, rats and rabbits: colitis in mice, a scraped cornea in rabbits, chemotherapy mouth ulcers in rats, a diabetic skin wound in mice. Every controlled win is in a lining one cell thick. Nothing in any species has put KPV against a tendon, a ligament, a joint or a spinal disc. And the counted record of what happens to people who buy it is 35 first-hand reports gathered from public threads, which is a record of exposure and not a test of whether it works.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

Here is what is actually known, in the order it should be read.

Thirty-five papers have KPV in the title or abstract. Every controlled result in all of them came out of a dish, a mouse, a rat or a rabbit. In May 2026 the FDA ran its own search across PubMed, Embase, ClinicalTrials.gov, DailyMed, Drugs@FDA, Micromedex, the European and Japanese pharmacopoeias and the outsourcing-facility reporting database, arrived at the same count, and in July proposed that KPV be kept off the list of substances a pharmacy is allowed to compound. The receptor everyone assumed it works through has been tested three times and it is not the one. Plain KPV swallowed did nothing in the cleanest experiment ever run on it. And the two forms sold under the same name and the same CAS number differ in how much will dissolve by a factor of seven, which is why some people's vials go cloudy and others' do not.

None of that means the compound is inert. It means the honest version of what it does is narrower and stranger than what is being sold, and the parts that are solid are worth knowing exactly.

[[embed:source:w_iydnxytw]]

## What is inflamed, what keeps it inflamed, and what would have to calm down

The tissue at the centre of this compound's whole record is a lining: the single layer of cells covering the inside of your gut, the surface of your eye, your airway, your gums, the underside of your skin. Every controlled win KPV has is in one of those.

**What breaks down.** A lining cell is held to its neighbour by tight junctions. Inflammation loosens them. Once loose, gut contents leak into the wall, immune cells arrive, and the cells release IL-1β, IL-6 and TNF-α — the three signals that show up in every KPV paper. Those signals loosen the junctions further. It is a loop that keeps itself running.

**What makes it break down faster.** More of the same signals. The master switch that turns them on is a protein pair called NF-κB, which sits idle in the body of the cell until inflammation frees it, at which point it walks into the nucleus and switches on the genes for all three cytokines. Every cycle of that loop damages more lining.

**What builds it back.** Lining cells divide fast — the gut resurfaces itself roughly every five days. The layer will rebuild itself if the inflammation stops. That is unusual and it is the reason this class of compound gets attention: you do not need to add anything, you need to remove the thing preventing repair.

**What makes it build back faster, and how strong each link is.** KPV walks into the nucleus itself and physically blocks NF-κB's ride into the nucleus — shown in a human airway cell line with the binding site identified, strong for a dish. That drops IL-1β, IL-6 and TNF-α — shown in mouse gut, rat gum, rabbit eye, human skin cells, consistent across four tissues, strong. Lower cytokines let the lining reseal — shown in mice and rats by wound closure and colon length, moderate. The same happens in a person — never tested by anyone, in any published study, by any route.

That last line is a row in the table, not the story. What follows is everything above it.

## The tanning half was cut off and the calming half stayed

Alpha-MSH is thirteen residues — SYSMEHFRWGKPV. The last three are K, P and V. KPV as a free base is C16H30N4O4, molecular weight 342.43 g/mol, CAS 67727-97-3. The acetate salt adds an acetic acid molecule for 402.5 g/mol and carries the same CAS number in most references. Neither form has a UNII code, a United States Pharmacopeia monograph, a European Pharmacopoeia monograph or a Japanese Pharmacopoeia monograph.

Alpha-MSH itself was studied as an anti-inflammatory for decades and never became one, because it drives melanin production and nobody wanted to tan a colitis patient to treat their colon. Cutting the molecule down to its last three residues removed that problem: KPV keeps almost all of the anti-inflammatory capacity of the full hormone and produces no pigment change at all.

[[embed:source:w_iz1zla8v]]

That is the design idea, stated by the people who proposed it, and it is the one claim about KPV that the literature and the regulator both accept without argument.

## The obvious receptor was checked three times and it is not the one

Alpha-MSH works by docking onto melanocortin receptors, MC1 through MC5. The obvious guess was that its three-residue tail docks onto the same ones, more selectively. Three separate lines of evidence say it does not.

KPV cannot push radiolabelled alpha-MSH off rat brain tissue, off mouse melanoma cells, or off mouse immune cells carrying MC1R. Unlike alpha-MSH, it raises no cyclic AMP in those cells — meaning the docking signal never fires. Drug-blocking and gene-knockout approaches both failed to pin KPV's anti-inflammatory and wound-healing effects on MC2, MC3 or MC4.

[[embed:source:w_4lw9q2jv]]

Human skin cells read the same. Neither alpha-MSH nor KPV produced any rise in cyclic AMP in HaCaT cells or in ordinary human skin cells. What did move was calcium inside the cell, across concentrations from 10⁻¹⁵ to 10⁻⁷ M.

[[embed:source:w_udmw8780]]

The structural argument is blunter. KPV does not contain the sequence a molecule needs in order to bind any known melanocortin receptor at all — and it keeps the activity anyway. What it uses instead is not known.

[[embed:source:w_wo06gy2y]]

So two things are settled. The anti-inflammatory effect is real in cells and animals. It is not a melanocortin receptor effect. What is open is what it is instead — and note the shape of that: this is a negative answer to a specific question, not an unexplored area. People were looking, and they found out it was not that.

## It stops the inflammation switch from reaching the nucleus

The best-worked-out candidate is physical interference. KPV gets in the way of the ride NF-κB takes into the nucleus.

In an immortalised human airway lining cell line, KPV cut NF-κB reporter activity, matrix metalloproteinase-9 activity, and release of IL-8 and eotaxin, and it did more of all of that at higher doses. The effect tracked with KPV's own movement into the nucleus, with stabilisation of IκBα, and with tagged p65RelA failing to get into the nucleus. Competition experiments put KPV at the importin-α3 binding site on p65RelA — importin-α3 is the shuttle protein that carries NF-κB in — probably jamming armadillo domains 7 and 8. A comparison peptide, γ-MSH, needed MC3R in the same experiment. KPV did not.

[[embed:source:w_0k5anu21]]

Downstream, the pattern is the same everywhere it has been looked at: IL-1β, IL-6 and TNF-α fall. In immune cells stimulated with bacterial wall fragments, in colon tissue from mice with colitis, in rat gum tissue and in human skin cells stressed with air pollution particles, those three are what move.

[[embed:source:w_tfx8zspw]]

Calming inflammation in a dish is not the same as calming inflammation in a person, and the gap between those two is where every unanswered question about KPV lives.

## A door in the gut wall that opens wider the sicker the gut gets

PepT1 is a transporter built to pull two- and three-amino-acid fragments out of the gut and into the cell. It sits in the small intestine normally, is barely present in a healthy colon, and appears in large amounts in the colon lining during inflammatory bowel disease. KPV is a tripeptide. It fits through.

Radiolabelled KPV is carried by human PepT1 with a half-saturation point of roughly 160 µM in Caco2-BBE gut lining cells and roughly 700 µM in Jurkat immune cells, and unlabelled KPV competes with glycyl-sarcosine, the standard test substrate for that transporter. Once inside, concentrations in the billionths of a molar were enough to shut down NF-κB and MAP kinase signalling.

[[embed:source:w_ky34gd73]]

The transporter is not incidental to the story — it is the story. In mice given azoxymethane plus dextran sodium sulfate to trigger colitis and then colon cancer, KPV prevented the cancer in normal animals and did nothing whatsoever in animals bred without PepT1. Take the door away and the drug stops working.

[[embed:source:w_txhlsxnq]]

This is why swallowing and rectal use get discussed at all for a peptide you would otherwise assume needs a needle. It also makes a specific, testable prediction: the sicker the colon, the more doors, and therefore the more gets in. That prediction has been confirmed in mice. It has never been checked in a person.

## Every controlled result comes from a dish, a mouse, a rat or a rabbit

The three tables below are the complete usable evidence base, split by what kind of system produced each result. Doses are exactly as the papers report them.

**In a dish**

| Study | Model | Route | Dose | What happened |
|---|---|---|---|---|
| Dalmasso 2008 (PMID 18061177) | Caco2-BBE, HT29-Cl.19A, Jurkat T cells | in the culture fluid | billionths of a molar; half-saturation 160 µM in gut cells, 700 µM in Jurkat | NF-κB and MAP kinase signalling shut down; uptake through PepT1 confirmed with tritium-labelled KPV |
| Land 2012 (PMID 22837805) | 16HBE14o- human airway lining | in the culture fluid | more effect at higher dose | IL-8, eotaxin, MMP-9 down; p65RelA blocked from the nucleus at the importin-α3 site |
| Cutuli 2000 (PMID 10670585) | *Staphylococcus aureus*, *Candida albicans* | in the culture fluid | trillionths of a molar and above | Colonies failed to form; yeast survival and germ-tube formation fell; white cells killed both organisms better rather than worse |
| Grieco 2005 (PMID 15946192) | Azole-resistant *Candida* species | in the culture fluid | not stated | The [Ac-CKPV]₂ double version kills the yeast; NMR shows a stretched backbone with a β-turn |
| Hedley 2004 (PMID 15102092) | HaCaT and ordinary human skin cells | in the culture fluid | 10⁻¹⁵ to 10⁻⁷ M | No cyclic AMP rise; calcium inside the cell rose |
| Pawar 2017 (PMID 28343991) | Sliced human cadaver skin | on the surface | left on, against microneedles, against a small electric current | Left on its own, nothing crossed above the 0.01 µg/mL detection limit; microneedles gave 4.4 µg/cm²/h; adding current multiplied that by 35 |
| Tissue Cell 2025 (PMID 40073467) | HaCaT skin cells and a 3D skin model, air pollution insult | in the culture fluid | 50 µg/mL | Cells survived; IL-1β, reactive oxygen and caspase-1 activation all fell |
| Cytotechnology 2026 (PMID 42064835) | HepG2 liver cells, fat-loaded | in the culture fluid | 100 µg/mL | Fat accumulation and fatty-acid synthase suppressed through PPARγ, with no cell death |

**In animals**

| Study | Model and species | Route | Dose | What happened |
|---|---|---|---|---|
| Lipton 1984 (PMID 6333677) | Rabbit fever from white-cell pyrogen | into the brain and into the body | 0.5–2.0 mg into the brain; 2–200 mg into the body | Fever fell by both routes; weaker than whole alpha-MSH |
| Hiltz & Lipton 1989 (PMID 2550304) | Mouse ear swelling, picryl chloride | into the body | graded doses | Swelling fell, more at higher doses, compared against a large steroid dose |
| Bonfiglio 2006 (PMID 16965771) | Rabbit corneal scrape | eye drops | 1, 5 or 10 mg/mL, 30 µL, two drops four times a day for 4 days | 8 of 8 corneas fully resurfaced by 60 hours; the effect disappeared when nitric oxide production was blocked |
| Dalmasso 2008 (PMID 18061177) | Mouse DSS and TNBS colitis | in the drinking water | 100 µM | Weight loss, myeloperoxidase and inflammatory cytokine messenger RNA all reduced |
| Kannengiesser 2008 (PMID 18092346) | Mouse DSS colitis and CD45RB-high transfer colitis | into the body | not stated in abstract | Earlier recovery, weight regained, less immune cell infiltrate and less myeloperoxidase; in mice with a broken MC1R, every treated animal survived |
| Laroui 2010 (PMID 19909746) | Mouse DSS colitis | swallowed, 400 nm particles in an alginate–chitosan gel | 12,000 times lower than free solution | The same protection at one twelve-thousandth of the concentration |
| Viennois 2016 (PMID 27458604) | AOM/DSS colitis-driven cancer, normal against PepT1-knockout mice | swallowed | not stated in abstract | Cancer prevented in normal mice; no effect at all without PepT1 |
| Xiao 2017 (PMID 28143741) | Mouse ulcerative colitis | swallowed, hyaluronic-acid particles in a chitosan/alginate gel | ~272 nm particles | Lining healed faster and TNF-α fell; better than plain KPV particles |
| ACS Biomater Sci Eng 2021 (PMID 34547895) | Rat TNBS ulcerative colitis | rectal, thiolated γ-polyglutamic acid gel | 4% polymer gel | Disease activity, colon shortening, myeloperoxidase, TNF-α and IL-6 all reduced; plain rectal KPV fell apart too fast to work |
| Biomater Sci 2021 (PMID 34846053) | Rat chemotherapy mouth ulcers, MRSA-infected | sticky gel that sets at body heat | 2% EGCG carrier | Gum ulcers repaired, IL-1β and TNF-α down, IL-10 up, and it killed *S. aureus* |
| Int J Biol Macromol 2022 (PMID 36240893) | Diabetic mouse full-thickness wound | layered film dressing | KPV released over 3 days, EGF released in response to glucose | Faster closure, through less inflammation, new blood vessel growth and collagen laid down |
| Adv Healthc Mater 2024 (PMID 39252648) | Mouse blood vessel calcification | KPV–rapamycin particles with no carrier | self-assembling | Calcification blocked; inflammation down and cell self-cleaning switched on |
| Sci Adv 2026 (PMC12802832) | Mouse DSS colitis and acute lung injury | swallowed, self-uncaging prodrug | proKPV 0.5 and 2.5 mg/kg daily × 7 days | Weight, disease activity and colon length all protected — while **plain KPV at the matching 1 mg/kg peptide dose did nothing at all** |

**In people**

| Study | Model | Route | Dose | What happened |
|---|---|---|---|---|
| — | — | — | — | Nothing published. KPV has never been given to a person in a published study, by any route |

Asking the ClinicalTrials.gov programming interface for KPV peptide on 4 August 2026 returned `{"totalCount": 0}`.

[[embed:source:w_46rh3j3w]]

FDA searched independently and found the same. The nomination that put KPV in front of the agency cited nine references: eight were animal studies of various alpha-MSH derivatives, and the ninth was a skin-permeation experiment on cadaver skin.

[[embed:source:w_4lw9q2jv]]

## Plain KPV falls apart, which is why most of the research is about packaging

Read the animal table again and one thing is impossible to miss: hydrogels, nanoparticles, liposomes, film dressings, prodrugs, gels that set at body heat. That is not fashion. That is a whole field routing around a defect.

Put KPV under acid, alkali or hydrogen peroxide and the main thing you get back is lysine-proline-diketopiperazine. The lysine and proline ends curl round and bond to each other, the ring closes, and the peptide is gone.

[[embed:source:w_4hqievsz]]

KPV solution given rectally was described flatly as "very unstable", which is why the rat colitis work needed a thiolated polymer gel just to hold it together for two hours at body temperature.

[[embed:source:w_6tepv8p6]]

The 2026 prodrug paper is the cleanest measurement of what that costs. Plain KPV swallowed at 1 mg/kg did nothing in mouse colitis. The same peptide, chemically caged so it survives the stomach and uncages only where reactive oxygen marks inflamed tissue, worked at half that dose and reached 3.8 times the concentration in the colon.

[[embed:source:w_yd7rqb37]]

Trying to toughen the molecule by chemistry rather than packaging has cost the activity outright. Sticking a sugar-alkyl group on the lysine produced versions that shrugged off protein-cutting enzymes and killed nothing under any condition tested — including the acetylated parent.

[[embed:source:w_ggr3cicc]]

Two things follow, and both are practical.

Nothing in the animal record shows that plain, unpackaged KPV swallowed reaches inflamed tissue in a useful amount. One paper specifically shows it does not.

And the storage numbers in the regulatory file are the ones to work from: dry powder is reported good for up to three years at −20 °C, two years at 4 °C, and three months at 15 °C, while once it is in water it is reported at six months at −80 °C, one month at −2 °C and one week at 10 °C.

[[embed:source:w_4lw9q2jv]]

## The two salts differ in how much will dissolve by a factor of seven

This is the detail most likely to leave you holding a cloudy vial and wondering whether you ruined it.

KPV free base dissolves in water only up to 0.70 mg/mL. KPV acetate is reported to dissolve at 5 mg/mL.

[[embed:source:w_4lw9q2jv]]

Now do the arithmetic everyone does. A 10 mg vial with 2 mL of water in it is aiming for 5 mg/mL.

If the powder is the acetate salt, 5 mg/mL sits exactly on the reported ceiling — it will go in, with nothing to spare.

If the powder is the free base, 5 mg/mL is about seven times more than will dissolve. It physically cannot all go into solution. What you get is a suspension that looks nearly right, and the amount of actual peptide in each syringe depends on how recently you swirled it.

The part that makes this a real problem rather than a solvable one: the two forms share the same CAS number and are labelled inconsistently, so the container often does not tell you which one you have. FDA said exactly that, and called the naming conventions non-compliant with INN, IUPAC and USAN standards for that reason. If you want a fill that works either way, 0.70 mg/mL is the number that clears both — a 10 mg vial in 14 mL, which nobody does, or a smaller vial in more water.

## One mark on the syringe is fifty micrograms

A U-100 insulin syringe holds 1 mL across 100 marks. One mark is 0.01 mL. Everything else falls out of the concentration.

Start there:

- 10 mg powder ÷ 2 mL bacteriostatic water = **5 mg/mL = 5,000 mcg/mL**
- 1 mark = 0.01 mL × 5,000 mcg/mL = **50 mcg per mark**

| Marks on the barrel | Volume | Dose at 5 mg/mL | Dose at 2.5 mg/mL (10 mg in 4 mL) | Dose at 2 mg/mL (10 mg in 5 mL) |
|---|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 mcg | 40 mcg |
| 4 | 0.04 mL | 200 mcg | 100 mcg | 80 mcg |
| 5 | 0.05 mL | 250 mcg | 125 mcg | 100 mcg |
| 10 | 0.10 mL | 500 mcg | 250 mcg | 200 mcg |
| 20 | 0.20 mL | 1,000 mcg (1 mg) | 500 mcg | 400 mcg |
| 40 | 0.40 mL | 2,000 mcg (2 mg) | 1,000 mcg | 800 mcg |

Putting the same 10 mg into 4 mL instead of 2 mL halves every number in the column and doubles the volume you inject for a given dose. That is usually the point: small doses are easier to measure when each mark is worth less. It also drops you to 2.5 mg/mL, which is under the acetate ceiling with room to spare and still five times over the free base's, so it does not solve the salt problem.

The dose people actually take rests on a unit conversion, not a trial. Scaled from rodent studies by body surface area, a human-equivalent starting dose has been published at around 0.2 mg — four marks on a 5 mg/mL fill.

[[embed:source:s7]]

That number carries the weight of an arithmetic conversion and nothing else. Nobody has measured how the body absorbs and clears KPV free base or KPV acetate, in any species. There is no measured half-life, no figure for how much reaches the blood, and no dose-response curve anywhere that would let a human dose be worked out rather than scaled from a mouse.

[[embed:source:w_4lw9q2jv]]

## What people taking it report, counted: 28 helped, 4 worse, 3 both, of 35

Sixty first-hand posts about KPV are catalogued as sources on this page — fifty from Reddit, ten from X, all pulled on 29 June 2026. Twenty-five of them are guides, product write-ups, questions, or regulatory commentary with no outcome in them. That leaves **35 posts where a named person says what they took and what happened**.

Sorted by what they actually reported:

| What was reported | Posts | Share of the 35 |
|---|---|---|
| Something got better | 28 | 80% |
| Something got better *and* a bad reaction happened, or the route mattered | 3 | 9% |
| A bad effect was the whole report | 4 | 11% |
| Nothing at all happened | 0 | 0% |

Read that honestly in both directions. This is a curated set, pulled from threads people started because they had something to say, and the direction of that bias is upward — nobody posts "took a peptide, nothing occurred, no further questions." The zero in the bottom row is the tell. For DSIP, catalogued the same way on the same day, five of thirty-five reports said nothing happened. Here, none did. Either KPV does something noticeable to nearly everyone who takes it, or the silent non-responders are not in the sample. Both of those can be true at once.

What the set is genuinely good for is a dose survey and a side-effect list, and on those two it is consistent. On a 10 mg vial in 2 mL — 50 mcg per mark — the reported range runs from four marks to ten. **200 to 500 mcg a day under the skin is what people take.**

### The 28 who said something got better

Twelve days under the skin at 200 mcg, one 5 mg vial, for gut symptoms — labelled anecdotal:

[[embed:source:s17]]

Forty days at 500 mcg a day, for mast cell symptoms:

[[embed:source:s20]]

Same condition, a different person, putting a number on it:

[[embed:source:s24]]

r/MCAS again, on fatigue and food tolerance:

[[embed:source:s23]]

Roughly 300 mcg a night by injection, from r/MCAS — and, from the same thread, the swallowed form causing flares where the injected form did not:

[[embed:source:s47]]

Skin is the second cluster. Eczema, four to five weeks in, with symptoms returning within two days of stopping:

[[embed:source:s60]]

[[embed:source:s75]]

[[embed:source:s58]]

Hidradenitis, in a stack:

[[embed:source:s100]]

Then the reports where the benefit is real but short. Two people independently describe roughly forty-eight hours of relief per injection and then a return to baseline:

[[embed:source:s61]]

[[embed:source:s53]]

And the outliers, which are worth keeping visible precisely because a single report proves nothing: a person whose supraventricular tachycardia episodes stopped for two months and came back two days after stopping the peptide:

[[embed:source:s83]]

[[embed:source:s82]]

[[embed:source:s62]]

The rest of the 28 — histamine tolerance, general inflammation, skin, nail fungus, dandruff, food reactions, rheumatoid arthritis alongside prescribed drugs, sacroiliac pain in a stack, hair thickening in a blend, and several "keeps it in the stack year-round" posts:

[[embed:source:s22]]

[[embed:source:s27]]

[[embed:source:s32]]

[[embed:source:s48]]

[[embed:source:s63]]

[[embed:source:s64]]

[[embed:source:s74]]

[[embed:source:s85]]

[[embed:source:s89]]

[[embed:source:s103]]

### The 4 where a bad effect was the whole report

At the same doses. This matters — the negatives are not from people megadosing.

200 mcg, and the complaint is not physical at all:

[[embed:source:s25]]

250 mcg a night, day four:

[[embed:source:s46]]

An acute reaction within an hour of a small injected volume:

[[embed:source:s43]]

Dizziness, broken sleep, headaches, brain fog and fatigue, from a long-covid gut thread:

[[embed:source:s19]]

### The 3 who got both

Eight days of clear improvement, then red bumps out of nowhere:

[[embed:source:s54]]

Gut repair, but only after months of climbing the dose slowly, with paradoxical reactions early:

[[embed:source:s21]]

And the one that splits by route rather than by person — swallowed did nothing measurable, injected moved a blood marker a long way:

[[embed:source:s101]]

### Two patterns worth naming out loud

The first is a frame, not a finding. Fatigue, apathy and flu-like malaise appear over and over at 200–500 mcg, and the standard community explanation is a die-off or healing flare. That explanation cannot be wrong, because there is no result it excludes — every bad reaction becomes evidence the compound is working. Treat it as what it is: an unfalsifiable story wrapped around an adverse effect.

The second is a real, testable claim, and it appears in enough reports to take seriously: people who started very low and climbed slowly report the paradoxical reactions going away. That is a dose-response observation, and it is the only actionable thing the whole self-report record produces.

[[embed:source:s21]]

Duration is the other thing the reports agree on and the animal literature never measured. The effect is described as lasting days, not weeks — which fits a three-amino-acid peptide with no measured half-life and a known tendency to curl up into a diketopiperazine and stop existing.

[[embed:source:s53]]

None of this substitutes for a trial. It does establish three facts you would otherwise learn by accident: the dose is 200–500 mcg under the skin, bad reactions at that dose are common enough to fill threads, and the swallowed and injected forms are not experienced as the same thing.

## Swallowed, injected, rubbed on, sprayed up the nose — what changes

All four are sold. The evidence behind each is not remotely equal.

**Swallowed** has the strongest mechanical case, because PepT1 is a real door, KPV is a real fit for it, and the door opens wider in inflamed bowel. Against that: the single experiment that pitted plain swallowed KPV against a packaged version found the plain version inert.

**Rectal** puts the peptide against the target tissue directly, and was shown to need a stabilising gel to survive long enough to do anything.

**Rubbed on** has an explicit measurement against it. Across human cadaver skin, KPV left on the surface crossed at a rate below the 0.01 µg/mL detection limit. It took microneedles punching through the outer layer to reach 4.4 µg/cm²/h, and a small electric current on top of that to multiply it further. Nothing crosses intact skin on its own in any amount you can measure.

[[embed:source:w_62ka3qz2]]

FDA reached the same conclusion and pointed out that it cuts both ways: poor skin crossing limits how much reaches the bloodstream and therefore limits systemic toxicity, and it equally limits KPV's usefulness as a cream, because it may never reach the living skin layers under the dead outer one.

[[embed:source:w_4lw9q2jv]]

**Sprayed up the nose** has no published measurement of any kind.

## It kills bacteria and yeast in a dish and has never been measured in a body

Alpha-MSH peptides including KPV stopped *Staphylococcus aureus* forming colonies and cut *Candida albicans* survival and germ-tube formation, down to concentrations in the trillionths of a molar. Unusually for an anti-inflammatory, they made white blood cells kill both organisms better rather than worse — most things that calm inflammation blunt that.

[[embed:source:w_8b4pdcfy]]

The version taken furthest toward antifungal development is the double, [Ac-CKPV]₂, built by joining two KPV units through a cysteine-cysteine bridge. It works against *Candida* strains that azole drugs no longer touch.

[[embed:source:w_4rk4kjx2]]

The MRSA result in the rat mouth-ulcer model is the closest thing to a confirmation in a living animal, and it needed a sticky gel holding the peptide against the wound for seven hours to get there.

[[embed:source:w_jcn0rn64]]

## Where the evidence stops, and the swap that gets made

Two things in this file are solid enough to act on, and neither is a musculoskeletal finding.

The first is inflammation in a lining. Every controlled win KPV has is in one — bowel, cornea, airway, skin, gum. If your problem is a gut that is inflamed, that is the strongest part of this record and it is genuinely the strongest part.

The second is the pairing with BPC-157, which is what most gut protocols actually run.

[[embed:bpc-kpv-gut-repair]]

Now the swap, because it is made constantly and it is worth being able to spot.

No study in any table above used a tendon, a ligament, a disc or a joint. There is no rat Achilles study. No ligament cut study. No cartilage study. The wound-healing results are all in linings — a scraped cornea, a diabetic skin wound, a mouth ulcer — and resealing a one-cell-thick lining is a different job from rebuilding collagen in a tendon. Lining cells divide every few days and re-cover a surface. Tendon rebuilds by laying down and remodelling collagen fibres over months, using different cells and a different signal set.

So the sentence "KPV helps tissue heal" is true and useless, and it is the sentence that does the work. Someone reads it and hears "KPV will help my rotator cuff." That is a cornea result laundered into a shoulder claim, and the laundering happens in the word *tissue*.

The honest version is four clauses long. KPV reduces inflammatory signalling in the linings of animals. It has never been given to a person in a published study. It has no measured human dose. And it is currently proposed for exclusion from legal compounding in the United States.

## FDA proposed in July 2026 that KPV stay off the compounding list

The regulatory position has two layers and they get conflated constantly.

The older layer: KPV sits on FDA's table of bulk drug substances that were nominated for compounding and then withdrawn by whoever nominated them, filed under substances that may present significant safety risks. The agency's entry says it "has not identified any human exposure data on drug products containing KPV administered via any route of administration" and "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."

[[embed:source:w_fquamfa9]]

The newer layer matters more. The nomination was withdrawn, and FDA chose to take KPV to its advisory committee anyway. On 23 July 2026 the Pharmacy Compounding Advisory Committee heard KPV free base and KPV acetate alongside BPC-157, TB-500 and MOTS-c, with the uses under evaluation recorded as wound healing and inflammatory conditions.

[[embed:source:w_x3r14ud2]]

FDA's position going in was not ambiguous: "FDA is proposing that KPV (free base) NOT be included on the 503A Bulks List" and "FDA is proposing that KPV acetate NOT be included on the 503A Bulks List."

[[embed:source:w_b5ztk84s]]

The reasoning, dated 12 May 2026, weighed four criteria and found against on all four.

Neither form is well characterised: the naming is inconsistent, and no certificate of analysis, impurity profile, clumping test or microbiology data was supplied or found in the literature.

How much it has historically been compounded is unknown: outsourcing facilities reported compounding no KPV products at all between January 2017 and June 2025, while telehealth and compounding websites sell injectable, swallowed, topical and nasal-spray KPV for inflammatory conditions, wound healing, skin health, gut health, killing microbes, and protection against nerve damage and stroke.

There is no evidence it works, because there is no human data.

And there is no safety evidence in either direction.

[[embed:source:w_4lw9q2jv]]

What that means in practice: getting onto the 503A Bulks List is what makes a substance lawfully compoundable when it has no monograph and is not part of an approved drug. FDA has proposed it not get on.

## Unknown is not the same as safe

FDA's Office of Surveillance and Epidemiology searched the FDA Adverse Event Reporting System and the medical literature for harms linked to KPV, through 3 December 2025. The reporting system returned nothing. The literature search found no cases. A separate search of the Human Foods Program adverse event system covering 1 January 2004 to 3 December 2025 also came back empty.

[[embed:source:w_4lw9q2jv]]

An empty harm database for a substance nobody has published on giving to humans measures the literature, not the compound. Reporting to that system is voluntary, and compounders working under section 503A generally do not report to FDA at all. Meanwhile four of the thirty-five first-hand posts above describe a bad reaction, and none of those four is in any database.

No acute toxicity study exists. No repeat-dose toxicity study. No genotoxicity study. No developmental or reproductive toxicity study, of either form. FDA's stated worry is clumping and whether the immune system reacts to it, and neither can be assessed without the impurity and aggregate data the nomination never supplied.

The narrower operative fact: what circulates is research-grade powder from suppliers whose certificates of analysis FDA could not locate, and the agency's specific objection is that nobody can tell from the label whether a given vial holds the free base or the acetate — which, per the section above, decides whether your 10 mg in 2 mL is a solution or a suspension.

## Where every number above came from

**Primary literature, by PubMed identifier.** PMID 18061177 (PepT1 uptake, *Gastroenterology* 2008); PMID 18092346 (DSS and transfer colitis, *Inflammatory Bowel Diseases* 2008); PMID 27458604 (PepT1 knockout and colitis-driven cancer, 2016); PMID 22837805 (p65RelA blocked from the nucleus, 2012); PMID 21222263 and PMID 18612139 (the melanocortin-receptor-independence argument); PMID 15102092 (skin cell cyclic AMP and calcium); PMID 10670585 and PMID 15946192 (killing microbes, and the CKPV double); PMID 16965771 (rabbit cornea); PMID 2550304 and PMID 6333677 (the original mouse and rabbit work, 1989 and 1984); PMID 25298219 (the stability assay and the diketopiperazine breakdown product); PMID 28343991 (human cadaver skin); PMID 19909746, PMID 28143741, PMID 34547895, PMID 34846053, PMID 36240893, PMID 39252648 and PMC12802832 (the packaging literature); PMID 29953505 (sugar-alkyl versions, activity lost); PMID 40073467 and PMID 42064835 (recent skin and liver cell work).

**Trial registries.** ClinicalTrials.gov programming interface v2, query "KPV peptide", 4 August 2026: `{"totalCount": 0}`. No registered study of KPV in people exists.

[[embed:source:w_46rh3j3w]]

**Regulatory record.** FDA's evaluation of KPV-related bulk drug substances dated 12 May 2026; the briefing document proposing exclusion from the 503A Bulks List; the Federal Register notice of 16 April 2026 announcing the meeting and the uses evaluated; and the standing FDA page listing KPV among bulk substances nominated but withdrawn.

[[embed:source:w_zjkqhidi]]

**Chemistry.** PubChem CID 125672 for the free base; CAS 67727-97-3 for both forms; molecular weight 342.43 g/mol free base and 402.5 g/mol acetate; water solubility 0.70 mg/mL free base and 5 mg/mL acetate.

**Both sides on the record.** In favour, the researchers who characterised the molecule: Brzoska and colleagues concluded that keeping the anti-inflammatory effect while losing the pigment effect makes KPV "an alternative for antiinflammatory therapy", and that its physical properties and low expected production cost suit inflammatory skin and bowel disease. Böhm and Luger, cited in FDA's own nonclinical review, went further and called for clinical studies to find out whether KPV could heal skin wounds and ulcers — a call that, as of August 2026, nobody has answered. Against, the regulator, in its own words: "There is a lack of clinical and nonclinical safety information on the use of KPV (free base) and KPV acetate. FDA is particularly concerned about the lack of any human data on drug products containing these substances…"

[[embed:source:w_4lw9q2jv]]

**The three hardest numbers in the file**, because everything else is softer than they are: nothing measurable crosses intact human skin, at a detection limit of 0.01 µg/mL; the PepT1 half-saturation point in gut lining is 160 µM; and the main breakdown product under stress is lysine-proline-diketopiperazine.

*KPV is not an approved drug in any country. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:thymosin-alpha-1]]

[[embed:ghk-cu]]

[[embed:ara-290]]


## Sources

1. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation — https://pubmed.ncbi.nlm.nih.gov/18061177/
2. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — https://pubmed.ncbi.nlm.nih.gov/18092346/
3. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation — https://pubmed.ncbi.nlm.nih.gov/18061177/
4. KPV: The Anti-Inflammatory Tripeptide for Gut and Skin — https://meto.co/blog/kpv-peptide-anti-inflammatory-gut
5. KPV Research & Evidence — https://peptidetreatments.com/peptides/kpv/research
6. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin — https://pubmed.ncbi.nlm.nih.gov/28343991/
7. KPV Peptide | Benefits, Safety & Buying Advice [2026] — https://www.innerbody.com/kpv-peptide
8. Inflammation-triggered self-immolative conjugates enable oral delivery of anti-inflammatory peptides — https://pmc.ncbi.nlm.nih.gov/articles/PMC12802832/
9. A Complete Guide for KPV — https://www.reddit.com/r/Ameano_Peptides/comments/1o7vx9t/a_complete_guide_for_kpv/
10. The Best Peptide for Inflammation, Gut Health, and Visceral Fat Loss (KPV Peptide) — https://www.youtube.com/watch?v=wdCjXXmRoEw
11. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists — https://pubmed.ncbi.nlm.nih.gov/22837805/
12. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model — https://pubmed.ncbi.nlm.nih.gov/27458604/
13. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis — https://pubmed.ncbi.nlm.nih.gov/28143741/
14. KPV tripeptide — https://en.wikipedia.org/wiki/KPV_tripeptide
15. KPV Peptide: Benefits, Dosage & 2026 Legal Status — https://riteaid.com/peptides/kpv
16. KPV Peptide: Comprehensive Guide to Benefits, Dosage and ... — https://www.helimeds.com/blog/kpv-peptide
17. Anyone here with experience using KPV or other peptides ... — https://www.reddit.com/r/Biohackers/comments/1q83047/anyone_here_with_experience_using_kpv_or_other/
18. KPV Peptide - Miracle Cure or Major Risk? — https://www.youtube.com/watch?v=5ph3S8mVuuE
19. KPV Peptide Side Effects — https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1je6riv/kpv_peptide_side_effects/
20. KPV Peptide Side Effects — https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1je6riv/kpv_peptide_side_effects/
21. KPV peptides — https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1iikbxd/kpv_peptides/
22. KPV peptides — https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1iikbxd/kpv_peptides/
23. Is anyone being helped by peptides? — https://www.reddit.com/r/MCAS/comments/1rpepqr/is_anyone_being_helped_by_peptides/
24. Is anyone being helped by peptides? — https://www.reddit.com/r/MCAS/comments/1rpepqr/is_anyone_being_helped_by_peptides/
25. KPV fatigue and apathy — https://www.reddit.com/r/Biohackers/comments/1ribbuz/kpv_fatigue_and_apathy/
26. This Peptide “Fixes” Your Gut... But There's a Catch — https://www.youtube.com/watch?v=spOpffLj9Oo
27. How effective is KPV peptide? Is it really worth it? — https://www.reddit.com/r/Biohackers/comments/1s69j21/how_effective_is_kpv_peptide_is_it_really_worth_it/
28. KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy — https://pubmed.ncbi.nlm.nih.gov/39252648/
29. Bioactive peptides and proteins for tissue repair — https://pmc.ncbi.nlm.nih.gov/articles/PMC11619216/
30. Is KPV Peptide Safe To Take? — https://formationmed.com/is-kpv-peptide-safe-to-take/
31. KPV Peptide: Anti-Inflammatory Mechanisms and Research — https://newtropin.com/peptides/kpv
32. Best peptides and brands for MCAS ? BPC-157, KPV and ... — https://www.reddit.com/r/MCAS/comments/1lki5p2/best_peptides_and_brands_for_mcas_bpc157_kpv_and/
33. KPV Explained Simply (The Gut Inflammation Fighter) — https://www.reddit.com/r/PeptideProgress/comments/1u17ht6/kpv_explained_simply_the_gut_inflammation_fighter/
34. What is KPV and why is it being studied? — https://www.instagram.com/reel/DYfvjzVDjSD/
35. Anti‐Inflammatory Peptides as Promising Therapeutics for Inflammatory Bowel Disease — https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.70212
36. KPV peptide guide — https://www.reddit.com/r/NTNPerformance/comments/1talx2b/kpv_peptide_guide/
37. KPV: The Barrier Repair Peptide (Gut, Skin & Chronic Inflammation) — https://www.youtube.com/watch?v=XE0k4AW0uag
38. KPV: The Anti-Inflammatory Peptide Under FDA Review — https://healingmaps.com/kpv-peptide-anti-inflammatory-wound-healing/
39. KPV — Molecular Specifications & Research Monograph — https://peptidebiologix.com/kpv
40. Structural modification of the tripeptide KPV by reductive amination — https://pmc.ncbi.nlm.nih.gov/articles/PMC6023233/
41. SS-31 and KPV peptides...what are your experiences? — https://www.reddit.com/r/MCAS/comments/1u92rpe/ss31_and_kpv_peptideswhat_are_your_experiences/
42. Kpv peptide — https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1agb1mz/kpv_peptide/
43. Massive worsening of symptoms after peptide usage? — https://www.reddit.com/r/MCAS/comments/1pd1ly4/massive_worsening_of_symptoms_after_peptide_usage/
44. KPV Peptide and Ulcerative Colitis | Safe Gut Healing in Stamford CT — https://drsobo.com/blog/kpv-effectively-treats-ulcerative-colitis/
45. KPV Peptide — https://www.amiv.com/blog/detail/kpv-peptide
46. KPV Side Effects. — https://www.reddit.com/r/Biohackers/comments/1rfebe7/kpv_side_effects/
47. KPV peptides — https://www.reddit.com/r/MCAS/comments/1dp073i/kpv_peptides/
48. Symptoms almost completely gone.....peptides have turned everything around — https://www.reddit.com/r/LongCovid/comments/1pyyxem/symptoms_almost_completely_gonepeptides_have/
49. Therapeutic Peptides in Aesthetic, Metabolic and ... — https://www.mdpi.com/1422-0067/27/9/3890
50. Inflammation-triggered self-immolative conjugates enable ... — https://www.science.org/doi/10.1126/sciadv.aea2989
51. Lysine-Proline-Valine peptide mitigates fine dust-induced ... — https://www.sciencedirect.com/science/article/abs/pii/S004081662500117X
52. July 23-24, 2026: Meeting of the Pharmacy Compounding ... — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
53. 5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW! — https://www.reddit.com/r/covidlonghaulers/comments/1r5ekd8/5_years_long_covid_thymosin_alpha_1_peptide_wow/
54. r/KPVPeptide — https://www.reddit.com/r/KPVPeptide/
55. Peptide-based therapeutic and delivery strategies for inflammatory bowel disease — https://pmc.ncbi.nlm.nih.gov/articles/PMC12272339/
56. KPV Peptide | Healand Clinic — https://www.healand.co.uk/biohacking/kpv-peptide
57. Welcome to the KPV Peptide Community — Let’s Talk Inflammation, Recovery, and Real-Life Results — https://www.reddit.com/r/KPVPeptide/comments/1m7qu64/welcome_to_the_kpv_peptide_community_lets_talk/
58. KPV Fixed my Acne Permanently — https://www.reddit.com/r/Biohackers/comments/1to8f07/kpv_fixed_my_acne_permanently/
59. KPV - Beverly Hills Rejuvenation Center — https://www.bhrcenter.com/peptides/kpv/
60. Thoughts on KPV Peptide for Eczema? — https://www.reddit.com/r/eczema/comments/1sdsz9h/thoughts_on_kpv_peptide_for_eczema/
61. KPV peptide takes Long Covid away — https://www.reddit.com/r/covidlonghaulers/comments/1qwmoc8/kpv_peptide_takes_long_covid_away/
62. X post on KPV for nausea — https://x.com/rahulmodifit/status/2069110309454061845
63. Peptides — https://www.reddit.com/r/lipedema/comments/1qydkg1/peptides/
64. Long-term kpv peptide — https://www.reddit.com/r/MCAS/comments/1jc3ool/longterm_kpv_peptide/
65. Anti‐Inflammatory Peptides as Promising Therapeutics Agent for Ulcerative Colitis and Crohn's Disease — https://pmc.ncbi.nlm.nih.gov/articles/PMC12206851/
66. Recalibrating Retinal Immunity: Peptide-Based Strategies ... — https://biomedgrid.com/pdf/AJBSR.MS.ID.003638.pdf
67. Recent Advances in KPV Peptide Delivery — https://www.scitechnol.com/peer-review/recent-advances-in-kpv-peptidedelivery-8OYD.php?article_id=18216
68. Does Kpv “reset” inflammation or is it working as long as ... — https://www.reddit.com/r/PeptidePathways/comments/1tt6uvy/does_kpv_reset_inflammation_or_is_it_working_as/
69. KPV - what's your experience? — https://www.reddit.com/r/Peptidesource/comments/1qjdrwd/kpv_whats_your_experience/
70. Peptides will unleash the greatest consumer health wave ... — https://x.com/jefftangx/status/2030389563794042966
71. Rapid Insights into KPV Peptide: A Brief Overview — https://www.reddit.com/r/healthwithjessicalana/comments/17y51gq/rapid_insights_into_kpv_peptide_a_brief_overview/
72. KPV Peptide? Anyone had luck? — https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1dq43y7/kpv_peptide_anyone_had_luck/
73. Forgotten Hair Loss Peptide by L'Oreal: KPV — https://www.reddit.com/r/HairlossResearch/comments/1evbxf6/forgotten_hair_loss_peptide_by_loreal_kpv/
74. KPV peptide working well for mast cell and histamine symptoms — https://www.reddit.com/r/floxies/comments/148mgn6/kpv_peptide_working_well_for_mast_cell_and/
75. KPV peptide fixed my eczema — https://www.reddit.com/r/eczema/comments/1szorjy/kpv_peptide_fixed_my_eczema/
76. Log - KPV - Autoimmune/Pain/Tendinitis — https://www.reddit.com/r/Hashimotos/comments/1pddx24/log_kpv_autoimmunepaintendinitis/
77. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation — https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/
78. Growth Factors-Loaded Temperature-Sensitive Hydrogel... — https://pubmed.ncbi.nlm.nih.gov/38289234/
79. The Benefits of Peptides: BPC157 & KPV for Healing and Gut Health — https://www.laserskinsolutions.com/blog/the-benefits-of-peptides-bpc157-kpv-for-healing-and-gut-health/
80. What Does The KPV Peptide Do? — https://formationmed.com/what-does-the-kpv-peptide-do/
81. BPC-157, KPV, Thymogen Alpha 1, Gut Feeling — https://www.reddit.com/user/LadyTeetles/comments/1eqtyrc/immune_health_and_healing_peptides_bpc157_kpv/
82. Has anyone tried KPV for their inflammation? — https://www.reddit.com/r/endometriosis/comments/1stumj8/has_anyone_tried_kpv_for_their_inflammation/
83. KPV peptide for SVT (not medical advice; personal experience) — https://www.reddit.com/r/SVTHeart/comments/1s6fv8g/kpv_peptide_for_svt_not_medical_advice_personal/
84. GH peptides + KLOW blend saved my hair. before and after — https://www.reddit.com/r/tressless/comments/1rytxzu/gh_peptides_klow_blend_saved_my_hair_before_and/
85. The Future of Regenerative Healing: BPC-157, TB-500 ... — https://www.reddit.com/r/NewCellReplacement/comments/1n6hrz2/the_future_of_regenerative_healing_bpc157_tb500/
86. Those who tried peptides - permanent shift in baseline? — https://www.reddit.com/r/covidlonghaulers/comments/1peun65/those_who_tried_peptides_permanent_shift_in/
87. KPV peptide description — https://x.com/humanupgradeai/status/2069088062441767130
88. KPV S tier claim — https://x.com/MrPept1de/status/2063810306820681817
89. Peptides - KPV — https://www.reddit.com/r/postvasectomypain/comments/1pl4twe/peptides_kpv/
90. Reduce inflammation with KPV and BPC-157 — https://www.reddit.com/r/lipedema/comments/1l850rf/reduce_inflammation_with_kpv_and_bpc157/
91. KPV peptide post — https://x.com/SuppMasterX/status/2071649714915709405
92. KPV in stack — https://x.com/Breedlove22/status/2071613118762127506
93. KPV recommendation — https://x.com/HuntersGrundle/status/2071648239783223621
94. KPV: Comprehensive Guide — https://www.reddit.com/r/APRHealthSolutions/comments/1q3bc3r/kpv_comprehensive_guide/
95. r/OptimumFormulaReviews – KPV (10mg) Guide — https://www.reddit.com/r/OptimumFormulaReviews/comments/1qhge85/roptimumformulareviews_kpv_10mg_guide/
96. The Tripeptide Targeting Gut Inflammation and Skin Repair — https://www.reddit.com/r/IonPeptideGuide/comments/1rztvf6/kpv_quick_guide_the_tripeptide_targeting_gut/
97. X post on KPV science — https://x.com/alextatem/status/2051439184452178178
98. X post on KPV FDA and personal use — https://x.com/alexaaronlab/status/2063272321243103549
99. X post preferring KPV — https://x.com/johnpaulp/status/2067238212502782185
100. Has anyone tried or used KPV peptides for help with HS? — https://www.reddit.com/r/Hidradenitis/comments/1pqlj24/has_anyone_tried_or_used_kpv_peptides_for_help/
101. KPV peptide — https://www.reddit.com/r/CIRS/comments/1q9ff17/kpv_peptide/
102. KPV Is More Than Just Anti-Inflammation — https://www.reddit.com/r/BodyOptimization/comments/1r9ej1f/kpv_is_more_than_just_antiinflammation/
103. Peptides for RA while on prescribed immune modulator? — https://www.reddit.com/r/rheumatoid/comments/1rb5enm/peptides_for_ra_while_on_prescribed_immune/
104. FDA Evaluation of KPV-Related Bulk Drug Substances (KPV free base and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List — PCAC briefing document, 12 May 2026 — https://www.fda.gov/media/193346/download
105. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
106. FDA Briefing Document Introduction, Pharmacy Compounding Advisory Committee, July 23-24 2026 — Points to Consider — https://www.fda.gov/media/193342/download
107. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
108. Pharmacy Compounding Advisory Committee; Notice of Meeting — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List, 91 FR (16 April 2026) — https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
109. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008 (PMID 18061177) — https://pubmed.ncbi.nlm.nih.gov/18061177/
110. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008 (PMID 18092346) — https://pubmed.ncbi.nlm.nih.gov/18092346/
111. Brzoska T, et al. Terminal signal: anti-inflammatory effects of alpha-MSH related peptides beyond the pharmacophore. Adv Exp Med Biol 2010 (PMID 21222263) — https://pubmed.ncbi.nlm.nih.gov/21222263/
112. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocr Rev 2008 (PMID 18612139) — https://pubmed.ncbi.nlm.nih.gov/18612139/
113. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action. Int J Physiol Pathophysiol Pharmacol 2012 (PMID 22837805) — https://pubmed.ncbi.nlm.nih.gov/22837805/
114. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol 2000 (PMID 10670585) — https://pubmed.ncbi.nlm.nih.gov/10670585/
115. Grieco P, et al. Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2. J Pept Res 2005 (PMID 15946192) — https://pubmed.ncbi.nlm.nih.gov/15946192/
116. Bonfiglio V, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 2006 (PMID 16965771) — https://pubmed.ncbi.nlm.nih.gov/16965771/
117. Pawar S, Banga AK. Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr 2015 (PMID 25298219) — https://pubmed.ncbi.nlm.nih.gov/25298219/
118. Pawar S, Toti U, Kaushik R, Banga AK. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci 2017 (PMID 28343991) — https://pubmed.ncbi.nlm.nih.gov/28343991/
119. Laroui H, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010 (PMID 19909746) — https://pubmed.ncbi.nlm.nih.gov/19909746/
120. Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017 (PMID 28143741) — https://pubmed.ncbi.nlm.nih.gov/28143741/
121. Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016 (PMID 27458604) — https://pubmed.ncbi.nlm.nih.gov/27458604/
122. Self-cross-linked hydrogel of cysteamine-grafted gamma-polyglutamic acid stabilized tripeptide KPV for alleviating TNBS-induced ulcerative colitis in rats. ACS Biomater Sci Eng 2021 (PMID 34547895) — https://pubmed.ncbi.nlm.nih.gov/34547895/
123. In situ mucoadhesive hydrogel carrying tripeptide KPV for chemotherapy-induced oral mucositis. Biomater Sci 2021 (PMID 34846053) — https://pubmed.ncbi.nlm.nih.gov/34846053/
124. Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. Int J Biol Macromol 2022 (PMID 36240893) — https://pubmed.ncbi.nlm.nih.gov/36240893/
125. Inflammation-triggered self-immolative conjugates enable oral delivery of anti-inflammatory peptides. Sci Adv 2026 (PMC12802832) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12802832/
126. Structural modification of the tripeptide KPV by reductive glycoalkylation of the lysine residue. PLoS One 2018 (PMID 29953505) — https://pubmed.ncbi.nlm.nih.gov/29953505/
127. Hedley SJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 2004 (PMID 15102092) — https://pubmed.ncbi.nlm.nih.gov/15102092/
128. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J 1989 (PMID 2550304) — https://pubmed.ncbi.nlm.nih.gov/2550304/
129. Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway. Tissue Cell 2025 (PMID 40073467) — https://pubmed.ncbi.nlm.nih.gov/40073467/
130. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway in HepG2 cells. Cytotechnology 2026 (PMID 42064835) — https://pubmed.ncbi.nlm.nih.gov/42064835/
131. KPV and RAPA self-assembled into carrier-free nanodrugs for vascular calcification therapy. Adv Healthc Mater 2024 (PMID 39252648) — https://pubmed.ncbi.nlm.nih.gov/39252648/
132. ClinicalTrials.gov API v2 query for KPV peptide, run 4 August 2026 — https://clinicaltrials.gov/api/v2/studies?query.term=KPV+peptide&countTotal=true
133. PubChem CID 125672 — Lys-Pro-Val — https://pubchem.ncbi.nlm.nih.gov/compound/125672


---

# Thymosin Alpha-1: Approvals, Trial Record, Dosing and What It Does Not Treat

slug: thymosin-alpha-1 · https://miscsubjects.com/a/thymosin-alpha-1 · tags: peptide, thymosin-alpha-1 · updated 2026-08-04T20:49:04.671Z

Thymosin alpha-1 is a chain of 28 amino acids that the thymus gland releases into the blood, where it tells immature T cells to finish growing up. The synthetic copy is called thymalfasin, it is sold as Zadaxin, and it is a licensed prescription medicine in roughly 35 countries — which makes it the only compound in this library that a drug regulator anywhere has ever approved.

That single fact reorders everything else, so take the evidence state before anything is argued from it. Most peptides in this library have animal data and a handful of uncontrolled human reports. Thymosin alpha-1 has 63 studies registered on ClinicalTrials.gov, four completed phase 3 programmes, a licensed package insert with a real dosing schedule, and more than 3,000 patients dosed across over 70 studies since 1979. Two of the randomised trials are large and both missed their main endpoint: TESTS, 1,106 adults with sepsis, where 28-day death was 23.4% against 24.1% on placebo; and TRACE, 508 people with severe pancreatitis, where infected dead tissue came out at 15.7% against 18.1%. Two results went the other way: in chronic hepatitis B on its own the odds of clearing the virus and holding it cleared came out 2.87 times placebo, and in a 120-person randomised trial in dialysis patients the drug carried a flu vaccine over the European licensing threshold that the vaccine alone did not reach. One observational study in COVID-19 recorded worse outcomes. The animal record is mice, and its cleanest single result is that the whole effect vanishes in mice bred without the TLR9 receptor. Then the absence that governs this page: across all 63 registered trials there is no tendon, no ligament, no disc, no muscle and no joint. Nothing has been measured in a person for any musculoskeletal problem, and no animal model of one has been run either.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

[[embed:source:w_18bl3rtc]]

## Approved in Beijing, unapproved in Bethesda

Thymalfasin holds marketing approvals for chronic hepatitis B, chronic hepatitis C, use as a vaccine adjuvant in immunocompromised patients, and certain cancers, with the exact indication set varying by country. The United States is not among them. Neither is the European Union.

| Jurisdiction | Status | Indications where approved |
|---|---|---|
| China | Approved; marketed as Zadaxin and by domestic manufacturers | Hepatitis B, immune enhancement, vaccine response, critical-illness adjunct |
| Italy | Approved | Hepatitis B, hepatitis C |
| Roughly 35 countries in total | Approved | Hepatitis B, hepatitis C, vaccine adjuvant, certain cancers, per each national label |
| United States | **Not approved.** No Drugs@FDA entry, no FDA-approved label, no openFDA label record | None |
| European Union | **Not approved** | None |

The manufacturer's own monograph puts the count at "over 30 countries" and states the exclusion in one sentence: "ZADAXIN has not been approved for sale in the United States or Europe." The peer-reviewed literature puts it at "more than 35 countries."

[[embed:source:w_d85m6gah]]

[[embed:source:s1]]

The US absence is not a rejection on the merits. No sponsor has completed a US registration filing. Thymalfasin has held FDA orphan drug designations — for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma. A designation is a development incentive: fee waivers, tax credits, and seven years of market exclusivity if the drug is later approved. It is not an approval, it permits no marketing, and it carries no finding about whether the drug works. Sources that describe those designations as approvals are wrong, and the distinction is the whole of the US position.

## Withdrawn from the danger list is not the same as cleared for use

The entire United States position turns on one table on one FDA page, and the row is easy to misread.

FDA maintains a page titled *Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks*. It carries two tables. The first is Category 2 proper — substances FDA has flagged as posing significant safety risks, which bars compounding under the interim policies. The second is headed *Bulk drug substances nominated but withdrawn*, described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators."

Thymosin-alpha 1 sits in the second table, alongside BPC-157, KPV, TB-500, epitalon, semax, selank and DSIP. FDA's recorded concern reads:

> Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.

[[embed:source:w_uzdfttix]]

Three consequences follow, and they are not the same as each other.

Withdrawal is a procedural act by the party who filed the nomination. It removes the substance from the active Category 2 listing. It is not FDA finding the substance safe, and no agency review concluded in the substance's favour.

Absence from Category 2 creates no permission. To be lawfully compounded from a bulk substance under section 503A, a substance must be the subject of an applicable USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list. Thymosin alpha-1 is none of the three in the United States. The 503B outsourcing-facility channel is separate, narrower, and does not list it either.

The practical position in the United States is therefore an unapproved drug obtainable only through the grey market or a compounder operating outside the bulks framework. Any source still describing it as "FDA Category 2" is quoting a status the current page no longer assigns to it. That page was last updated 22 April 2026.

## It gives back a signal the thymus stops sending

The thymus is largest in childhood and shrinks from puberty onward. By the sixth decade most of its functional tissue has been replaced by fat, and the output of new naive T cells falls with it. Thymosin alpha-1 is one of the peptides that tissue secretes; circulating levels in healthy adults run between 0.1 and 1 ng/mL and are lower in disease.

The mechanism reads as a chain. The links are not equally well established, and the difference matters.

**Step one — it binds Toll-like receptors on dendritic cells.** This is the anchoring finding and it is demonstrated directly. In mice, thymosin alpha-1 activated plasmacytoid dendritic cells through TLR9 and MyD88, switching on interferon regulatory factor 7 and driving an interferon-alpha and interferon-gamma effector response. Mice lacking TLR9 lost the protection. That is a knockout-confirmed dependency, not a correlation.

[[embed:source:w_e7vuijxz]]

**Step two — the dendritic cell decides what kind of immunity follows.** Dendritic cells read an infection and instruct the rest of the immune system. Priming them through TLR/MyD88 produced Th1-type antifungal resistance in living animals. The same work found thymosin alpha-1 inducing indoleamine 2,3-dioxygenase in dendritic cells — the enzyme that pushes toward tolerance rather than attack.

[[embed:source:w_pptae9m4]]

**Step three — T cells mature and differentiate.** The 1972 characterisation was of a thymic fraction that restored immune function to thymectomised mice. The measurable human version is a rise in CD4+ percentage and a normalising CD4+/CD8+ ratio. A meta-analysis of five randomised trials in severe acute pancreatitis quantified it: CD4+ percentage rose by 4.53 points (95% CI 3.02 to 6.04) and the CD4+/CD8+ ratio by 0.42 (95% CI 0.26 to 0.58). CD8+ counts did not fall significantly, which is the point — the ratio normalised by lifting the deficient arm.

[[embed:source:s7]]

**Step four — natural killer cells and cytotoxic T lymphocytes.** Thymosin alpha-1 modulates NK cell maturation and cytotoxic T lymphocyte responses, and raises MHC class I surface expression on tumour cell lines. The target cell becomes easier to see, not only the effector cell more aggressive.

[[embed:source:w_ekm6tk8i]]

**Step five — reversal of T-cell exhaustion.** In severe COVID-19 patients, treatment was associated with reduced PD-1 and Tim-3 expression on CD8+ T cells and a rise in T-cell receptor excision circles, the standard marker of fresh thymic output. This is observational human data from a retrospective cohort of 76 patients, not a controlled experiment, and it belongs in a different evidentiary tier from step one.

[[embed:source:w_or6weneu]]

What separates this compound from a stimulant is that the same molecule pushes in opposite directions depending on the state it finds. It induces tolerance-promoting IDO in one context and interferon-driven antiviral attack in another. That bidirectionality is why the literature calls it restoration rather than stimulation. It is also why the dose-response is not a straight line, and why the sepsis subgroups below point in opposite directions in different patients.

[[embed:source:s2]]

## Sixty-three registered trials, and the two largest disagree

Sixty-three studies are registered on ClinicalTrials.gov with thymosin alpha-1 as an intervention. The named human record is set out below with the result stated as each trial reported it, including the failures.

| Trial | NCT | n | Population | Dose | Duration | Primary endpoint | Result |
|---|---|---|---|---|---|---|---|
| TESTS — phase 3, quadruple-blind, 22 centres | NCT02867267 | 1,106 | Sepsis-3 adults, 18–85 | 1.6 mg SC every 12 h | ≤7 days | 28-day all-cause mortality | **Missed.** 23.4% vs 24.1% placebo; HR 0.99 (0.77–1.27); P=0.93 |
| ETASS — RCT, single-blind, 6 centres | NCT00711620 | 361 analysed | Severe sepsis | 1.6 mg SC twice daily ×5 d, then daily ×2 d | 7 days | 28-day all-cause mortality | Borderline. 26.0% vs 35.0%; RR 0.74 (0.54–1.02); P=0.062 unstratified, 0.049 log-rank |
| TRACE — phase 4, double-blind, 16 centres | NCT02473406 | 508 | Predicted severe acute necrotising pancreatitis | 1.6 mg SC q12h ×7 d, then daily ×7 d | 14 days | Infected pancreatic necrosis | **Missed.** 15.7% vs 18.1%; difference −2.4% (−7.4 to 5.1); P=0.48 |
| TRACE post-hoc, lymphocyte-stratified | NCT02473406 | 290 of 502 | Same trial, baseline ALC ≥0.8×10⁹/L | as above | 14 days | Infected pancreatic necrosis at 90 d | Positive in subgroup. Adjusted risk difference −0.12 (−0.21 to −0.02); P=0.015 |
| Hepatitis C non-responders — phase 3, 52 European sites | NCT01178996 | 552 | Chronic HCV, prior peg-IFN + ribavirin failure | 1.6 mg SC twice weekly + peg-IFN α-2a + ribavirin | 48 weeks | Sustained virological response at week 72 | Completed July 2009. **No results posted or published** |
| Hepatitis C non-responders, non-cirrhotic — phase 3 | NCT00040027 | 500 | Chronic HCV interferon non-responders | 1.6 mg twice weekly + peg-IFN α-2a | — | Virological response | Completed. **No results posted** |
| Metastatic melanoma — phase 2, dose-ranging, 5 arms | NCT00911443 | 488 | Stage IV melanoma | 1.6, 3.2 or 6.4 mg SC on days 8–11 and 15–18 of each 28-day cycle | ≤6 cycles | Overall tumour response | Responders 7/97, 10/97, 6/98, 12/99 in the four Tα1 arms vs 4/97 control. Median OS 8.6–10.3 months vs 6.6 |
| COVID-19 prevention in dialysis — phase 2 | NCT04428008 | 189 | ESRD on haemodialysis | 1.6 mg SC | 6 months | Number infected with COVID-19 | 5/91 treated vs 7/98 control. Deaths 3/91 vs 7/98. Underpowered for both |
| COVID-19 with lymphocytopenia — phase 2 | NCT04487444 | 56 | Hospitalised, lymphocytopenic | 1.6 mg SC daily ×7 d | 1 week | Time to freedom from respiratory failure | **Terminated** February 2023. No results posted |
| H1N1 vaccine adjuvant pilot | NCT01031966 | 120 enrolled, 94 ITT | ESRD on chronic dialysis | 3.2 mg or 6.4 mg on day −7 and day 0 | 2 doses | Antibody response measured by haemagglutination-inhibition | Positive. CHMP licensing criteria fully met in both Tα1 arms, not in vaccine-only |
| Colorectal cancer adjuvant — phase 3 | NCT05086614 | 2,500 planned | Resected high-risk stage II/III colorectal cancer | 1.6 mg SC twice weekly | 6 months | 3-year disease-free survival | **Recruiting.** Primary completion March 2027 |
| Acute aortic dissection, immune dysregulation | NCT05339529 | 330 | Post-operative acute aortic syndrome | Per protocol | — | Organ dysfunction | Recruiting |
| Vaccine response in older adults — phase 1 | NCT06821100 | 75 | Adults over 65 receiving COVID-19 vaccine | Per protocol | — | Immune response | Recruiting |

[[embed:source:w_vzvtwnky]]

[[embed:source:w_zlvvtukb]]

## Hepatitis is the indication the licences rest on

The approvals were granted on chronic hepatitis B. An independent meta-analysis of 435 patients across randomised controlled trials of thymalfasin monotherapy found a sustained virological response advantage over placebo with an odds ratio of 2.87 (95% CI 1.58–5.22, P=0.0005), and a non-significant trend favouring it over interferon alpha (OR 2.62, 95% CI 0.80–8.56). Across the individual monotherapy studies, disease remission ran 26% to 41%.

[[embed:source:w_d85m6gah]]

Two caveats belong in the same breath. The comparator was interferon or placebo, in an era before tenofovir and entecavir; a 2020 review states plainly that hepatitis B and C treatment with thymosin alpha-1 "has been discontinued in favor of direct antiviral agents." And the two large phase 3 hepatitis C programmes in non-responders — 552 and 500 patients, both completed more than fifteen years ago — have never reported. A completed 552-patient phase 3 with no published outcome is not neutral evidence about a drug; it is a hole where the answer should be.

[[embed:source:w_xmbjsj3u]]

## Sepsis is where it was tested hardest and came up short

ETASS in 2013 was the encouraging trial. 361 patients, 28-day mortality 26.0% on thymosin alpha-1 against 35.0% on control, plus a measurable rise in monocyte HLA-DR — the clearest available marker of reversed immunoparalysis — at day 3 (mean difference 3.9%, 95% CI 0.2–7.6) and day 7 (5.8%, 95% CI 1.0–10.5). The mortality difference did not clear significance on the primary unstratified analysis at P=0.062.

TESTS was built to settle it. 1,106 patients, 22 centres, quadruple-blinded, placebo-controlled, phase 3. It found nothing: 28-day mortality 23.4% against 24.1%, hazard ratio 0.99, P=0.93. No secondary endpoint separated, and no safety endpoint separated either.

The subgroup analysis is where it stops being simply negative. Patients under 60 did worse on the drug (HR 1.67, 1.04–2.67). Patients 60 and over trended better (HR 0.81, 0.61–1.09). Interaction P=0.01. Diabetic patients did better (HR 0.58, 0.35–0.99), non-diabetic patients did not (HR 1.16, 0.87–1.53), interaction P=0.04. These are prespecified subgroups inside a negative trial. They are hypotheses, and a younger patient doing worse on an immune-restoring drug is a hypothesis worth taking seriously in both directions.

A 2025 meta-analysis pooled 11 randomised trials and 1,927 patients. Overall it found a 28-day mortality benefit (OR 0.73, 95% CI 0.59–0.90, P=0.003). That benefit disappeared when restricted to high-quality trials (OR 0.82, P=0.09) and to multicentre trials (OR 0.86, P=0.20). Trial sequential analysis concluded the accumulated sample is still inadequate to answer the question.

[[embed:source:s27]]

## Pancreatitis: the trial missed, and one subgroup did not

TRACE randomised 508 patients with predicted severe acute necrotising pancreatitis, 94.3% of whom required intensive care. Infected pancreatic necrosis occurred in 15.7% of treated patients and 18.1% of placebo patients, P=0.48. New-onset organ failure, bleeding and gastrointestinal fistula were all similar between arms.

[[embed:source:w_0c2625io]]

The post-hoc analysis found what the whole trial did not. Among the 290 patients whose baseline absolute lymphocyte count was at or above 0.8×10⁹/L, thymosin alpha-1 reduced infected necrosis with an adjusted risk difference of −0.12 (95% CI −0.21 to −0.02, P=0.015). Patients between 0.79 and 2.00×10⁹/L benefited most.

[[embed:source:w_cbj4dxj3]]

Read carefully, that is the single most informative result in the file. An immune-restoring drug worked in the patients who still had lymphocytes to restore and did nothing in the patients too depleted to respond. It is post-hoc, it needs prospective confirmation, and it explains why an unselected population produces a null. It also implies that any honest use of this compound starts with a lymphocyte count.

## COVID-19 produced three answers, and one of them was harm

The Wuhan retrospective covered 76 severe cases and reported mortality of 11.11% with treatment against 30.00% without (P=0.044), alongside restored CD8+ and CD4+ counts and reduced exhaustion markers.

[[embed:source:w_or6weneu]]

A five-hospital multicentre cohort of 2,282 patients found the reverse. After adjustment for confounders, thymosin alpha-1 use was associated with a *higher* non-recovery rate (OR 1.5, 95% CI 1.1–2.1, P=0.028), with risk concentrated in patients with SOFA scores of 2 or more, ICU admission, and lower PaO₂/FiO₂. Later initiation was worse than earlier.

[[embed:source:w_q4kpjhai]]

A propensity-matched cohort of 1,388 non-severe patients found no difference in progression to severe disease (2.17% vs 2.71%) or in mortality, but shorter viral shedding (13 vs 16 days, P=0.025) and shorter hospital stay (14 vs 18 days, P<0.001).

[[embed:source:w_vxfrwa56]]

All three are observational and all three are subject to confounding by indication — sicker patients get more drugs. The only randomised study that targeted the lymphocytopenic patients the mechanism predicts should respond was terminated at 56 patients and never reported.

## Vaccine response is the cleanest positive signal in the file

Haemodialysis patients mount poor antibody responses to influenza vaccine. In the pilot trial, patients given the adjuvanted H1N1 vaccine alone did not meet the CHMP licensing criteria for seroconversion, seroprotection and geometric mean ratio. Patients given the vaccine plus 3.2 mg or 6.4 mg of thymosin alpha-1 on day −7 and day 0 met all three. No adverse event was attributed to the peptide, and no change appeared in haematology or blood chemistry.

[[embed:source:w_23spjiq3]]

This is 94 patients in an intention-to-treat analysis, in a population defined by immune failure, in a pilot study. It is also the one result where the drug did the specific thing its mechanism predicts, in humans, judged against a prespecified regulatory standard rather than an author's own endpoint.

## The cancer file is adjuvant work with one real trial still running

The melanoma dose-ranging study is the largest completed oncology dataset: 488 patients across five arms, responses in 6 to 12 patients per thymosin arm against 4 of 97 in the dacarbazine-plus-interferon control, and median overall survival of 8.6 to 10.3 months against 6.6. It was a phase 2 designed to select a dose, not to prove survival, and no phase 3 followed it in the nineteen years since it started.

[[embed:source:w_omh8z65r]]

The trial that would settle the oncology question is enrolling now: 2,500 patients with resected high-risk stage II and III colorectal cancer, randomised to 1.6 mg twice weekly for six months or to no thymosin, with three-year disease-free survival as the primary endpoint and primary completion in March 2027.

[[embed:source:w_dkfbbahz]]

## Every trial population is an infection, an organ failure or a cancer, and not one of them is a back

Every trial population above is a hepatitis patient, a septic ICU patient, a pancreatitis patient, a cancer patient, or a dialysis patient. Not one is a back-pain patient. There is no musculoskeletal indication, no tendon, ligament, disc or muscle model, and no mechanism connecting T-cell maturation to tissue repair.

| What brings a person to look this up | What the human record actually covers | Strength of the connection |
|---|---|---|
| Recurrent infection, slow recovery from every cold | Vaccine-response pilot in dialysis patients; hepatitis approvals; 3,000-patient safety file | Moderate, and only by extrapolation from immunocompromised populations |
| Documented immunosuppression with a measured low-normal lymphocyte count | TRACE subgroup: the effect appeared where lymphocytes were preserved but suppressed | Moderate. Post-hoc, and it requires the blood test to identify |
| Post-viral fatigue after a confirmed infection | No completed randomised trial. The COVID file is acute hospitalised disease and it contradicts itself | Absent |
| Chronic inflammatory load in a chronic-pain patient | CRP fell 30.12 mg/L in the lower-dose arms of the pancreatitis meta-analysis — in patients with necrotising pancreatitis in intensive care | Absent for this population |
| Immune-related fatigue with no diagnosis and no abnormal labs | No trial, no endpoint, no measurement | Absent |
| Tendinopathy, disc pain, muscle strain, joint repair | No model, no trial, no proposed mechanism | Absent. The extrapolation is unsupported |
| Post-adjustment soreness | Nothing | Absent |
| Hashimoto's, MCAS, ankylosing spondylitis, other autoimmunity | No trial. The mechanism cuts both ways — tolerance in one context, interferon-driven attack in another | Absent, and the self-reports below include people who got measurably worse |

The one row the record can defend is the immune row, in a person with documented immune compromise, and even that defence is an off-label extrapolation from populations that do not look like that person. Selling thymosin alpha-1 for musculoskeletal repair is a claim that nothing in 63 trials supports.

## Dosing, and the arithmetic behind the syringe

The licensed product is a 1.6 mg lyophilised vial supplied with 1.0 mL of Sterile Water for Injection. Reconstituted, that is 1.6 mg/mL, and the whole vial is one dose. The approved hepatitis B regimen is 1.6 mg (900 µg/m²) subcutaneously twice a week for 6 to 12 months. Patients under 40 kg receive 40 µg/kg.

[[embed:source:w_dt6aln8r]]

| Setting | Dose | Frequency | Duration |
|---|---|---|---|
| Hepatitis B — approved label | 1.6 mg SC | Twice weekly | 6–12 months |
| Hepatitis C — phase 3 protocol | 1.6 mg SC | Twice weekly | 48 weeks |
| Sepsis — TESTS | 1.6 mg SC | Every 12 hours | ≤7 days |
| Sepsis — ETASS | 1.6 mg SC | Twice daily ×5 d, then daily ×2 d | 7 days |
| Necrotising pancreatitis — TRACE | 1.6 mg SC | Every 12 h ×7 d, then daily ×7 d | 14 days |
| Colorectal adjuvant — phase 3 | 1.6 mg SC | Twice weekly | 6 months |
| Metastatic melanoma — phase 2 | 1.6, 3.2 or 6.4 mg SC | Days 8–11 and 15–18 of a 28-day cycle | ≤6 cycles |
| Influenza vaccine adjuvant | 3.2 or 6.4 mg SC | Day −7 and day 0 | 2 doses |

The critical-illness regimens run at 3.2 mg per day — twice the hepatitis dose, for one to two weeks. The vaccine regimen runs up to 6.4 mg in a single dose. The cumulative safety record spans 1 mg to 16 mg per dose, and 0.6 to 9.6 mg/m². There is no dose ceiling hiding in that range. There is also nothing showing that a larger dose does more for a stable outpatient.

### Reconstitution, shown as arithmetic

Grey-market vials come as 5 mg or 10 mg of lyophilised powder, not 1.6 mg, so the arithmetic has to be done rather than read off a label.

Concentration in mcg per mL = total micrograms in the vial ÷ millilitres of bacteriostatic water added.
A U-100 insulin syringe holds 1.0 mL across 100 units, so one unit is 0.01 mL, and micrograms per unit = concentration ÷ 100.

Worked: a 10 mg vial holds 10,000 mcg. Add 4.0 mL of bacteriostatic water. 10,000 ÷ 4.0 = 2,500 mcg/mL. 2,500 ÷ 100 = 25 mcg per unit. A 1.6 mg dose is 1,600 ÷ 25 = 64 units on the barrel.

| Vial | Bacteriostatic water added | Concentration | Mcg per unit | Units for 1.6 mg | Full 1.6 mg doses per vial |
|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 64 | 3, with 200 mcg left over |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 80 | 3 |
| 5 mg (5,000 mcg) | 5.0 mL | 1,000 mcg/mL | 10 | 160 — two injections | 3 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 32 | 6, with 400 mcg left over |
| 10 mg (10,000 mcg) | 4.0 mL | 2,500 mcg/mL | 25 | 64 | 6 |
| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 80 | 6 |

At 5,000 mcg/mL — a 10 mg vial in 2.0 mL, the concentration that keeps every trial dose inside one syringe — the conversion is:

| Dose | Micrograms | Units on a U-100 barrel |
|---|---|---|
| 0.25 mg | 250 | 5 |
| 0.5 mg | 500 | 10 |
| 0.8 mg | 800 | 16 |
| 1.0 mg | 1,000 | 20 |
| 1.6 mg | 1,600 | 32 |
| 3.2 mg | 3,200 | 64 |
| 6.4 mg | 6,400 | 128 — two injections |

Below about five units, graduation error on a U-100 barrel starts to dominate the dose, which is the argument for more diluent at the sub-milligram tiers and less at 1.6 mg and above.

Route is subcutaneous in every trial and on every label. Sites are the abdomen at least two inches from the navel, the outer thigh, or the back of the upper arm, rotated between doses. Nothing in the record supports taking this peptide into a muscle, into a vein or by mouth outside a study protocol.

Bring the vial to room temperature before adding water. Run the water down the inside wall rather than jetting it onto the powder. Swirl until dissolved and never shake — shear at the air-liquid interface unfolds peptides and makes them clump, and that clumping is the exact mechanism FDA named when it warned about the immune system reacting to the drug.

### Storage, and the difference the diluent makes

| State | Temperature | Practical shelf life |
|---|---|---|
| Sealed lyophilised vial | 2–8 °C, protected from light | To the manufacturer's date |
| Reconstituted with Sterile Water for Injection — the licensed diluent | — | Use immediately. No preservative present |
| Reconstituted with bacteriostatic water, 0.9% benzyl alcohol | 2–8 °C | About four weeks, set by the preservative rather than by the peptide |
| Reconstituted, held at room temperature | 20–25 °C | Hours to days. Treat as compromised |
| Reconstituted, frozen | −20 °C | Avoid. Freeze-thaw aggregates peptides |

The licensed insert says use immediately because the supplied diluent is preservative-free. A multi-dose vial reconstituted with bacteriostatic water is a different object running a different clock.

### Timelines

Peak serum concentration is reached about 2 hours after a subcutaneous dose, the elimination half-life is about 2 hours, and 31% to 60% of the dose is recovered in urine. The drug leaves the blood the same day. Everything that persists is downstream of what it did to cells, which is why the schedules are twice weekly rather than daily.

| What was measured | When it read out in the trials |
|---|---|
| Monocyte HLA-DR improvement — ETASS | Days 3 and 7 |
| CD4+ percentage and CD4+/CD8+ ratio change | Within the 7–14 day critical-illness courses |
| Vaccine seroconversion — H1N1 pilot | Day 21 after vaccination, dosed day −7 and day 0 |
| Hepatitis B sustained virological response | 6–12 months of dosing, assessed 6 months after treatment |
| Hepatitis C sustained virological response | Week 72, after 48 weeks of dosing |
| Colorectal disease-free survival | 3 years, after 6 months of dosing |

## The safety record is the longest in this library, which is not the same as no risk

Most compounds in this library have no human safety file at all. This one has a specific, quantified record.

Since 1979, thymalfasin has been given to more than 3,000 patients in over 70 clinical studies, at doses from 1 mg to 16 mg, for periods from a single day to 18 months. The monograph's summary sentence is that "no serious adverse experiences have been observed." Patients as old as 101 and children as young as 13 months have been dosed. Patients with decompensated liver disease and patients on haemodialysis tolerated it.

[[embed:source:w_d85m6gah]]

The label puts drug-related adverse events at under 1% across all indications and describes them as "infrequent and mild, consisting primarily of local discomfort at the injection site, and rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash." It is contraindicated in hypersensitivity to the drug or its components.

[[embed:source:w_dt6aln8r]]

The controlled trials support that. TESTS randomised 1,106 patients and reported no safety outcome differing significantly between drug and placebo. TRACE randomised 508 and found no difference in bleeding, fistula or new organ failure. The H1N1 pilot attributed no adverse event to the peptide. In the dialysis prevention trial, serious adverse events were 28 of 91 on treatment against 26 of 98 on control, and deaths were 3 of 91 against 7 of 98.

[[embed:source:w_jzf25pn3]]

Preclinical toxicity never reached a maximum tolerated dose. Single subcutaneous doses up to 20 mg/kg in mice, rats and marmosets — more than 800 times the human 1.6 mg dose by weight — produced no drug-related toxicity, as did repeat dosing at 6 mg/kg/day for 13 weeks.

Three qualifications matter more than the reassurance.

**Immune activation can itself be the adverse event.** A 29-year-old man with nasopharyngeal carcinoma received a single 1.6 mg subcutaneous dose eleven days after the checkpoint inhibitor sintilimab. Within 48 hours he had fever of 39–40.5 °C, facial rash and oedema, progressive hypoxaemia with interstitial pulmonary oedema, AST of 742 U/L, and a prothrombin time of 23.2 seconds. He required 160 mg of intravenous methylprednisolone daily and was discharged on day 33. He later tolerated a sintilimab rechallenge without recurrence, which points the causal finger at the peptide rather than the checkpoint inhibitor.

[[embed:source:w_c958vpgi]]

**The COVID cohort recorded worse outcomes, not merely absent benefit.** An adjusted odds ratio of 1.5 for non-recovery in the sicker patients is a harm signal, and the mechanism is plausible: adding immune activation to a hyperinflammatory state is not obviously safe.

**FDA's stated concern is manufacturing, not what the drug does in the body.** The risk of the immune system reacting to the drug, raised by clumping and by peptide-related impurities, is a supply-chain problem. The 3,000-patient safety record belongs to a pharmaceutical product made to a licensed specification. A grey-market vial carrying a vendor's own certificate of analysis is not that product, and a cloudy reconstitution is a visible sign of the exact aggregation the agency named.

## What people using it outside the trials report

These are self-reports with dates and permalinks, gathered from public discussion. They are not evidence of whether it works, they are not filtered for anything, and they are here because they show what the experience looks like and how often it goes badly.

[[embed:source:s8]]

[[embed:source:s61]]

[[embed:source:s75]]

[[embed:source:s41]]

The most consistent thread across the positive reports is a flu-like reaction in the first days, which users describe as the immune system waking up.

[[embed:source:s14]]

The negative reports describe the same reaction without the recovery on the other side of it.

[[embed:source:s63]]

[[embed:source:s37]]

[[embed:source:s13]]

Two reports concern measured markers rather than symptoms, in the same condition, and they disagree.

[[embed:source:s38]]

[[embed:source:s59]]

One comment states the risk in exactly the terms the mechanism implies.

[[embed:source:s77]]

And one describes the physical failure mode that FDA's warning is about.

[[embed:source:s84]]

## Proven, unproven, unknown

| Status | Claim |
|---|---|
| Proven | Approved as thymalfasin in roughly 35 countries for hepatitis B, hepatitis C and vaccine adjuvant use |
| Proven | Not approved in the United States or the European Union; no Drugs@FDA entry and no FDA label |
| Proven | Listed in FDA's "nominated but withdrawn" bulk-substances table, not in Category 2, and on neither the 503A nor the 503B bulks list |
| Proven | Acts through TLR9/MyD88/IRF7 on plasmacytoid dendritic cells; the effect is abolished in TLR9-deficient mice |
| Proven | Raises CD4+ percentage by 4.53 points and the CD4+/CD8+ ratio by 0.42 in critically ill humans |
| Proven | Peak serum at about 2 hours, elimination half-life about 2 hours, 31–60% urinary recovery |
| Proven | Sustained virological response advantage in chronic hepatitis B monotherapy, OR 2.87 (1.58–5.22) |
| Proven | Met the European regulator's antibody-response criteria as an influenza vaccine adjuvant in haemodialysis patients where vaccine alone did not |
| Proven | No mortality benefit in sepsis in a 1,106-patient placebo-controlled phase 3 |
| Proven | No reduction in infected pancreatic necrosis in a 508-patient placebo-controlled trial |
| Proven | Drug-related adverse events under 1% across indications in the licensed record, predominantly injection-site discomfort |
| Unproven | Any benefit in post-viral fatigue, chronic fatigue, MCAS, or any autoimmune condition — no completed randomised trial exists |
| Unproven | Benefit in COVID-19. Three observational studies, three different answers, one of them harm |
| Unproven | Whether the pancreatitis lymphocyte-count subgroup effect survives prospective testing |
| Unproven | Whether it improves disease-free survival in colorectal cancer; that trial reads out in 2027 |
| Unknown | The outcome of two completed phase 3 hepatitis C trials totalling 1,052 patients, never reported |
| Unknown | Any effect on tendon, ligament, disc, muscle or joint tissue. No model, no trial, no mechanism |
| Unknown | The correct dose for an outpatient with no diagnosed immune deficiency |
| Unknown | Whether grey-market material matches the pharmaceutical product that generated the safety record |

*Thymosin alpha-1 is not an approved drug in the United States and is not lawfully available there through the bulk-compounding pathways. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:kpv]]

[[embed:ghk-cu]]

[[embed:bpc-157]]

[[embed:dsip]]

[[embed:tb-500]]


## Sources

1. Thymosin alpha 1: A comprehensive review of the literature — https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
2. Immune Modulation with Thymosin Alpha 1 Treatment — https://pubmed.ncbi.nlm.nih.gov/27450734/
3. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials — https://pubmed.ncbi.nlm.nih.gov/38308608/
4. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial — https://www.bmj.com/content/388/bmj-2024-082583
5. Phenotypic drug discovery: a case for thymosin alpha-1 — https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1388959/full
6. Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine — https://clinicaltrials.gov/study/NCT06821100
7. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/40599771/
8. 5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW! — https://www.reddit.com/r/covidlonghaulers/comments/1r5ekd8/5_years_long_covid_thymosin_alpha_1_peptide_wow/
9. Aging and Thymosin Alpha-1 — https://www.mdpi.com/1422-0067/26/23/11470
10. Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma — https://clinicaltrials.gov/study/NCT07644897
11. Thymosin Alpha-1 Peptide: Benefits and Safety [2026] — https://www.innerbody.com/thymosin-alpha-1-peptide
12. Autoimmune Peptides: Just Hype? (Thymosin Alpha-1 ... — https://www.youtube.com/shorts/_3M2gu4kG68
13. be careful about thymosin alpha-1 : r/cfs — https://www.reddit.com/r/cfs/comments/1nl65vu/be_careful_about_thymosin_alpha1/
14. Anyone get side effects/an immune reaction to Thymosin- ... — https://www.reddit.com/r/covidlonghaulers/comments/1pbotcz/anyone_get_side_effectsan_immune_reaction_to/
15. A Complete Guide for Thymosin Alpha 1 — https://www.reddit.com/r/Ameano_Peptides/comments/1ojbasq/a_complete_guide_for_thymosin_alpha_1/
16. Thymosin Alpha 1 (Tα1) has anyone seen any studies or ... — https://www.reddit.com/r/covidlonghaulers/comments/1l2k4tj/thymosin_alpha1_t%CE%B11_has_anyone_seen_any_studies/
17. Peptide called Thymosin Alpha 1 is resolving my MCAS — https://www.reddit.com/r/MCAS/comments/1mcx0o3/peptide_called_thymosin_alpha_1_is_resolving_my/
18. The Superhuman Immune System Peptide Big Pharma Wants BANNED — https://x.com/BowTiedUM/status/1760474750730568092
19. Megadose experience with Thymosin Alpha 1 — https://x.com/jessicaalanas/status/1755232184317649040
20. Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection — https://clinicaltrials.gov/study/NCT04487444
21. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC12208829/
22. The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets — https://pubmed.ncbi.nlm.nih.gov/40955371/
23. Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency — https://pubmed.ncbi.nlm.nih.gov/39867848/
24. Peptide for alopecia: Thymosin Alpha 1 as an Alternative to ... — https://www.reddit.com/r/HairlossResearch/comments/1rgcn3a/peptide_for_alopecia_thymosin_alpha_1_as_an/
25. Thymosin Alpha-1 Complete Guide: The Immune Peptide ... — https://www.reddit.com/r/Biohack_Blueprint/comments/1thd0od/thymosin_alpha1_complete_guide_the_immune_peptide/
26. X post on Thymosin Alpha 1 — https://x.com/RickWingfield5/status/2071331718015918545
27. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials — https://pubmed.ncbi.nlm.nih.gov/40969554/
28. Thymosin Alpha-1 (Zadaxin): A Thymic Peptide and Toll-Like Receptor Signaling Modulator — https://superpower.com/guides/thymosin-alpha-1
29. Thymosin alpha 1 peptide? — https://www.reddit.com/r/ankylosingspondylitis/comments/1rzhnmd/thymosin_alpha_1_peptide/
30. Thymosin Alpha-1 guide immune support, dosing, and ... — https://www.reddit.com/r/NTNPerformance/comments/1sx69j7/thymosin_alpha1_guide_immune_support_dosing_and/
31. IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells and Enhances Antitumor Immunity in Hepatocellular Carcinoma — https://pubmed.ncbi.nlm.nih.gov/41883056
32. Age-related thymic involution: Mechanistic insights and rejuvenating approaches to restore immune function — https://pmc.ncbi.nlm.nih.gov/articles/PMC12904209/
33. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis — https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1571456/full
34. What Is Thymosin Alpha 1? How It Works and What the Clinical Data Shows — https://www.youtube.com/watch?v=d_ZW05Wrm_s
35. Has anyone tried Thymosin Alpha 1 for Long COVID? — https://www.reddit.com/r/LongCovidTrials/comments/1opyifn/has_anyone_tried_thymosin_alpha_1_for_long_covid/
36. Aging and Thymosin Alpha-1 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12692621/
37. Thymosin-alpha 1 ?? — https://www.reddit.com/r/CIRS/comments/1ncxx31/thymosinalpha_1/
38. Peptides — https://www.reddit.com/r/Hashimotos/comments/1lped2z/peptides/
39. Thymosin-alpha 1 ?? — https://www.reddit.com/r/CIRS/comments/1ncxx31/thymosinalpha_1/
40. X post by @CaneGrrl — https://x.com/CaneGrrl/status/2068318610662072812
41. X post by @quardoqu — https://x.com/quardoqu/status/2060338402189353350
42. X post by @quardoqu — https://x.com/quardoqu/status/2042676733057405170
43. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC12440967/
44. A Case Report of a Multisystemic Immune‐Related Adverse Event Induced by Thymosin Alpha‐1 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12883329/
45. Expert Consensus on the Clinical Application of Thymosin Alpha 1 in Infectious Diseases and Critical Care Medicine — https://journals.lww.com/imd/fulltext/2025/06000/expert_consensus_on_the_clinical_application_of.2.aspx
46. Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors — https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e14606
47. Thymalin and Thymosin Alpha-1 Both Target the Thymus — https://www.reddit.com/r/IonPeptideGuide/comments/1tp86o7/thymalin_and_thymosin_alpha1_both_target_the/
48. GELİŞEN PEPTİD NOMENKLATÜRÜ — https://x.com/dogalyasalar/status/2067307286138143114
49. IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ ... — https://pubmed.ncbi.nlm.nih.gov/41883056/
50. Long-term Prognosis of Patients With Sepsis After ... — https://clinicaltrials.gov/study/NCT04901104
51. Thymosin α1 Elevates Lymphocyte Counts and Improves ... — https://pubmed.ncbi.nlm.nih.gov/41293232/
52. Protective Effect of Ulinastatin and Thymosin α1 Against ... — https://clinicaltrials.gov/study/NCT06966687
53. The efficacy and safety of thymosin alpha-1 combined with ... — https://pubmed.ncbi.nlm.nih.gov/40263352/
54. Thymosin Alpha-1: Transforming Immunotherapy for ... — https://www.youtube.com/watch?v=HgcNS3pkeyE
55. Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies? — https://www.evolutionary.org/forums/threads/thymosin-alpha-1-experiences-and-anecdotes-a-treatment-for-severe-allergies.109790/
56. Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies? — https://www.evolutionary.org/forums/threads/thymosin-alpha-1-experiences-and-anecdotes-a-treatment-for-severe-allergies.109790/
57. Thymosin Alpha-1: The Immune-Boosting Peptide You Should Know About — https://www.ozarkholisticcenter.com/post/thymosin-alpha-1-the-immune-boosting-peptide-you-should-know-about
58. Best peptides and brands for MCAS ? BPC-157, KPV and Thymosin / Thymogen ? — https://www.reddit.com/r/MCAS/comments/1lki5p2/best_peptides_and_brands_for_mcas_bpc157_kpv_and/
59. Peptides? Anyone taking these? — https://www.reddit.com/r/Hashimotos/comments/1sylqox/peptides_anyone_taking_these/
60. What resolved my chronic fatigue - 5 years later — https://www.reddit.com/r/chronicfatigue/comments/1j2z1az/what_resolved_my_chronic_fatigue_5_years_later/
61. Thymosin Alpha 1 — https://www.reddit.com/r/Peptides_for_Women/comments/1gy3d3a/thymosin_alpha_1/
62. Thymosin Alpha 1 — https://www.reddit.com/r/Peptides_for_Women/comments/1gy3d3a/thymosin_alpha_1/
63. Those who tried peptides - permanent shift in baseline? — https://www.reddit.com/r/covidlonghaulers/comments/1peun65/those_who_tried_peptides_permanent_shift_in/
64. Those who tried peptides - permanent shift in baseline? — https://www.reddit.com/r/covidlonghaulers/comments/1peun65/those_who_tried_peptides_permanent_shift_in/
65. Peptide for alopecia: Thymosin Alpha 1 as an Alternative to JAK Inhibitors — https://www.reddit.com/r/tressless/comments/1rgcm86/peptide_for_alopecia_thymosin_alpha_1_as_an/
66. Thymosin Alpha 1 and Peptides for LC Discussed on Huberman Lab — https://www.reddit.com/r/covidlonghaulers/comments/1g2y1yx/thymosin_alpha_1_and_peptides_for_lc_discussed_on/
67. Thymosin Alpha 1 and Peptides for LC Discussed on Huberman Lab — https://www.reddit.com/r/covidlonghaulers/comments/1g2y1yx/thymosin_alpha_1_and_peptides_for_lc_discussed_on/
68. X post by @thecoercednurse — https://x.com/thecoercednurse/status/2070187778584047692
69. X post by @squarian24 — https://x.com/squarian24/status/2070542926623490303
70. Thymosin Alpha 1 — https://www.reddit.com/r/pancreaticcancer/comments/x71x4v/thymosin_alpha_1/
71. Zadaxin Thymosin alpha-1(TA-1) peptide to help slow muscle recovery? — https://www.reddit.com/r/Hashimotos/comments/1sxdk9m/zadaxin_thymosin_alpha1ta1_peptide_to_help_slow/
72. Thymosin Alpha-1 — https://www.reddit.com/r/AutoImmuneProtocol/comments/1rzrql8/thymosin_alpha1/
73. Thymosin Alpha 1, LDN, or GLPS? or all three? — https://www.reddit.com/r/endometriosis/comments/1s8dkwf/thymosin_alpha_1_ldn_or_glps_or_all_three/
74. Thymosin Alpha-1 testing — https://x.com/BhavanChand/status/2071648123559288889
75. Thymosin Alpha-1 for sinusitis — https://x.com/biotides/status/2071620162831159366
76. RNA seq data with TA1 — https://x.com/DuaneStorey/status/2071544627635581270
77. Thymosin Alpha 1 — https://www.reddit.com/r/smallfiberneuropathy/comments/1phisi1/thymosin_alpha_1/
78. Thymosin Alpha 1 — https://www.reddit.com/r/smallfiberneuropathy/comments/1phisi1/thymosin_alpha_1/
79. Thymosin alpha 1 daily vs twice weekly administration — https://www.reddit.com/r/Immunology/comments/q6bgrz/thymosin_alpha_1_daily_vs_twice_weekly/
80. Thymosin alpha 1 daily vs twice weekly administration — https://www.reddit.com/r/Immunology/comments/q6bgrz/thymosin_alpha_1_daily_vs_twice_weekly/
81. Thymosin Alpha-1: The Immune System Peptide Nobody Talks About — https://www.reddit.com/r/PeptideProgress/comments/1s62nmn/thymosin_alpha1_the_immune_system_peptide_nobody/
82. Thymosin Alpha-1 🏥 Immune System Peptide Explained | T-Cell Activation, Inflammation Control & Recovery Support (Complete 2025 Research Guide) — https://www.reddit.com/r/USPeptides/comments/1p43fnb/thymosin_alpha1_immune_system_peptide_explained/
83. Thymosin Alpha-1 🏥 Immune System Peptide Explained | T-Cell Activation, Inflammation Control & Recovery Support (Complete 2025 Research Guide) — https://www.reddit.com/r/USPeptides/comments/1p43fnb/thymosin_alpha1_immune_system_peptide_explained/
84. Ta1 Cloudy at Reconstitution — https://www.reddit.com/r/Peptides/comments/1s5cv2z/ta1_cloudy_at_reconstitution/
85. LL37 & Thymosin Alpha Review — https://www.reddit.com/r/Peptides/comments/1hhefnv/ll37_thymosin_alpha_review/
86. Thymosin Alpha 1: Is there a way to check from bloodwork ... — https://www.reddit.com/r/Peptides/comments/1d2d4s2/thymosin_alpha_1_is_there_a_way_to_check_from/
87. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial (Crit Care 2013; PMID 23327199; NCT00711620) — https://pubmed.ncbi.nlm.nih.gov/23327199/
88. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial (Crit Care 2013; PMID 23327199; NCT00711620) — https://pubmed.ncbi.nlm.nih.gov/23327199/
89. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial (BMJ 2025; PMID 39814420; NCT02867267) — https://pubmed.ncbi.nlm.nih.gov/39814420/
90. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial (TRACE, Intensive Care Med 2022; PMID 35713670; NCT02473406) — https://pubmed.ncbi.nlm.nih.gov/35713670/
91. Association between pretreatment lymphocyte count and efficacy of immune-enhancing therapy in acute necrotising pancreatitis: post-hoc analysis of TRACE (EClinicalMedicine 2023; PMID 37007743) — https://pubmed.ncbi.nlm.nih.gov/37007743/
92. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells (Clin Infect Dis 2020; PMID 32442287) — https://pubmed.ncbi.nlm.nih.gov/32442287/
93. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study (Front Immunol 2021; PMID 34408744) — https://pubmed.ncbi.nlm.nih.gov/34408744/
94. Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching (Front Med 2021; PMID 33968969) — https://pubmed.ncbi.nlm.nih.gov/33968969/
95. A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Renal Dialysis Patients (NCT04428008, posted results) — https://clinicaltrials.gov/study/NCT04428008
96. Phase II dose-ranging trial of dacarbazine plus interferon alpha plus thymosin alpha-1 in advanced metastatic melanoma (NCT00911443, posted results, n=488) — https://clinicaltrials.gov/study/NCT00911443
97. Phase III trial of thymosin alpha 1 plus peginterferon alfa-2a plus ribavirin in chronic hepatitis C non-responders (NCT01178996, n=552, completed 2009, no results posted) — https://clinicaltrials.gov/study/NCT01178996
98. Thymosin-alpha 1 as adjuvant treatment after radical resection of high-risk stage II and III colorectal cancer (NCT05086614, phase 3, 2500 planned, primary completion 2027) — https://clinicaltrials.gov/study/NCT05086614
99. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study (Vaccine 2012; PMID 22178096) — https://pubmed.ncbi.nlm.nih.gov/22178096/
100. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo (Int Immunol 2007; PMID 17804687) — https://pubmed.ncbi.nlm.nih.gov/17804687/
101. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance (Ann N Y Acad Sci 2007; PMID 17495242) — https://pubmed.ncbi.nlm.nih.gov/17495242/
102. Thymosin alpha1 and cancer: action on immune effector and tumor target cells (Ann N Y Acad Sci 2012; PMID 23045967) — https://pubmed.ncbi.nlm.nih.gov/23045967/
103. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page current as of 22 April 2026) - Thymosin-alpha 1 appears in the 'Bulk drug substances nominated but withdrawn' table — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
104. SciClone Pharmaceuticals ZADAXIN (thymalfasin) Product Monograph — https://www.shijiebiaopin.net/upload/product/2011121219115812.PDF
105. ZADAXIN (thymalfasin) prescribing information - dosage, reconstitution, storage, pharmacokinetics and adverse reactions — https://www.rxlist.com/zadaxin-drug.htm
106. ClinicalTrials.gov registry query for thymosin alpha-1 interventions, 4 August 2026 — https://clinicaltrials.gov/api/v2/studies?query.intr=thymosin+alpha-1&countTotal=true&pageSize=100
107. A Case Report of a Multisystemic Immune-Related Adverse Event Induced by Thymosin Alpha-1 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12883329/


---

# BPC-157 for a herniated disc: what the evidence reaches, and what it does not

slug: bpc-157-herniated-disc · https://miscsubjects.com/a/bpc-157-herniated-disc · tags: peptide, bpc-157, herniated-disc, spine, pairing · updated 2026-08-04T20:48:58.174Z

BPC-157 is a 15-amino-acid chain copied from a sequence found in human stomach juice, sold as a freeze-dried powder for injection or as an oral tablet. Nobody has ever given it to a person with a herniated disc under any kind of controlled test, in any country, and the animal work that exists was done on tendon, muscle, ligament and cut nerve — never on a disc.

That second sentence is the whole shape of the decision, and it is not the same thing as "it does nothing". What follows is the evidence that exists, strongest kind first, the arithmetic for a dose, the legal position on 4 August 2026, and a count of what twenty-four people with a spine problem said happened to them.

The site that publishes this page has a commercial relationship with a seller of this compound. Treat that as a reason to open every source link below rather than a reason to trust the summary.

## Seven in ten of these clear on their own, and that is the number anything has to beat

Before any compound: a meta-analysis pooled 31 studies covering 2,233 people whose herniated discs were managed without surgery. The displaced disc material was reabsorbed in 70.39% of them. The rate ran 87.77% where a fragment had fully broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a bulge. Most of the shrinking happened inside the first six months.

[[embed:source:s26]]

And a randomised trial in 283 people with severe leg pain lasting 6 to 12 weeks compared early surgery against continued conservative care. Surgery took the leg pain away faster. At one year, the probability of feeling recovered was 95% in both arms.

[[embed:source:s27]]

Hold those two numbers against everything below. If you start a compound today and feel better in three months, the honest reading is that you are inside the seven-in-ten who were going to improve anyway. Nothing on this page separates you from that group, because no trial has ever been run that could.

[[embed:herniated-disc]]

## Your problem is at least three problems, and a compound can only reach two of them

The first is space. Disc material is sitting where a nerve root needs to be. That is what the scan measures, and the only two things that remove it are your own body digesting the fragment over months and a surgeon cutting it out. No compound in any species has been shown to shrink a herniation.

The second is chemistry. The material that leaked out is not inert. Mice given disc material placed against a nerve root developed lasting leg pain and damage to the nerve cells, with no squeezing involved at all — the inflammatory signal did it.

[[embed:source:s7]]

The inflammatory enzyme measured in human herniated disc material runs 20 to 100,000 times more active than the same enzyme measured from any other source in the literature.

[[embed:source:s8]]

The third is the nerve itself. A root that has been squeezed and chemically burned for weeks has damaged fibres, and that is what produces the numbness, the pins and needles and the weak foot. Nerve fibres regrow at roughly a millimetre a day, which is why that part of the recovery lags the pain by months.

The claim on the table is that this compound reaches the second and third problems and not the first. Read the next two sections deciding whether the animal work supports even that much.

## Nobody has put this compound near a spinal disc, in any species

A systematic review in orthopaedic sports medicine screened 544 articles from 1993 to 2024 and kept 36 studies. Thirty-five were animal or dish work. One was clinical. The tissues were muscle, tendon, ligament and bone.

[[embed:source:s11]]

There is no disc study. Not a rat disc, not a rabbit disc, not a disc in a dish. The tissue that is actually causing your pain has never been exposed to this compound in a published experiment. Every argument for using it on a disc is an argument by analogy from a different tissue, and analogies from tendon to disc are weak: a tendon has a blood supply and a disc, after about age twenty, has almost none.

## What the rats did show, and which of your three problems it lands on

Rat Achilles tendon torn off the bone. Treated animals healed with more strength at the tendon-to-bone join, and the same experiment showed a steroid drug made healing worse while the compound cut that damage back.

[[embed:source:w_59xoi0m3]]

Rat ligament cut through. Better function, better mechanical strength, better tissue on the slide, at both a microgram and a nanogram dose.

[[embed:source:w_ccsq5zep]]

Rat sciatic nerve cut and repaired. The nerve regrew faster and the leg worked better than in untreated animals. This is the single finding on this page that touches nerve tissue, and it is a cut nerve trunk in a rat leg, not a chemically inflamed nerve root in a human spine.

[[embed:source:w_032xvatb]]

Rat spinal cord crushed. Treated animals recovered movement, starting at the tail, and held it out to a year.

[[embed:source:s127]]

Tendon cells in a dish moved to the wound edge faster as the dose went up, and made more of the receptor that growth hormone docks into.

[[embed:source:w_ud0jx8hb]]

[[embed:source:w_y4s15wvm]]

Map that onto your three problems. Space: nothing, in any of it. Chemistry: the nerve and cord work is consistent with the inflamed-nerve part of your pain, in rodents. Structure: the tendon and ligament work is about a tissue you also injured, because a herniation almost always comes with a torn ring and months of guarding, but it is not about the disc.

## The steroid shot you probably already had is the strongest single link here

Most people arrive at this question having already had an epidural or a joint steroid injection, or a course of an anti-inflammatory tablet. Two separate rat studies found a corticosteroid made healing worse in tendon and in muscle, and that this compound reversed that damage. In the muscle study the reversal was described as complete.

[[embed:source:w_gttxaz57]]

And in a rat model of anti-inflammatory drug poisoning, diclofenac at 12.5 mg/kg for three days wrecked the stomach, gut and liver and progressed to brain swelling. The compound blocked that whole cascade, given either by injection or dissolved in the drinking water, at both 10 µg/kg and 10 ng/kg.

[[embed:source:w_odtbasyy]]

Read that carefully. It is a protection finding about the drugs you are already taking, not evidence that the combination heals a disc faster. What it does settle is that the medicine most likely to already be in your system is not, in rats, a documented conflict.

## Fifteen minutes in the blood, which is what decides the schedule

The only measurements of what a body does with this compound come from rats and beagles. Average time to clear half of it: 15.2 minutes. Into a vein in dogs: 5.27 minutes. Peak in the blood three minutes after an injection into muscle. The fraction reaching the blood after an injection into muscle was 14–19% in rats and 45–51% in dogs.

[[embed:source:w_n7ahbrni]]

Two things follow for a daily plan. A compound gone that fast is not working by holding a level in your blood, so splitting a daily dose beats taking it all at once, and a once-weekly schedule has no argument behind it. None of these numbers has ever been measured in a person.

## Turning a 10 mg vial into a number of marks on a barrel

The powder arrives sealed. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it, which is the preservative that lets you put a needle back into the same vial for weeks. Plain sterile water dissolves it fine but makes the vial a one-time proposition.

The measuring device is a U-100 insulin syringe: 100 marks to a millilitre, so one mark is 0.01 mL. Two lines give you every conversion.

- Micrograms per mL = micrograms in the vial ÷ mL of water added.
- Micrograms per mark = that number ÷ 100.

A 10 mg vial holds 10,000 mcg. Add 3 mL and you have 3,333 mcg/mL, which is 33.3 mcg per mark. A 250 mcg dose is 250 ÷ 33.3 = 7.5 marks.

| Vial | Water added | Strength | Mcg per mark | Marks for 250 mcg | Marks for 500 mcg | Days at 500 mcg split into two |
|---|---|---|---|---|---|---|
| 5 mg | 2.0 mL | 2,500 mcg/mL | 25 | 10 | 20 | 10 |
| 5 mg | 2.5 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 10 |
| 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 | 10 | 20 |
| 10 mg | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 20 |
| 10 mg | 5.0 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 20 |

Adding more water does not add or remove peptide. It only changes how many marks carry a given dose. Below about five marks per dose, misreading the barrel starts to matter more than the dose does, which is the argument for putting 3 mL rather than 2 mL into a 10 mg vial.

Once mixed and kept at 2–8 °C, the vial has about four weeks in it, and that limit comes from the preservative rather than the peptide. Do not shake it and do not freeze it after mixing — both tear the peptide chains apart and make them clump, and clumping is exactly the trigger FDA named for the immune system reacting to an injected peptide.

## Where the needle goes was never answered by the animal work

Every rat study injected either into the belly cavity or into a muscle far from the injury, and the healing still showed up at the wound. Nobody ran the experiment that compares injecting at the site against injecting anywhere else. So the widespread instruction to inject next to your spine rests on nothing published, and the people in the counted record below who got results injecting into a thigh or a glute are evidence against it mattering much.

## Where it stands legally, checked 4 August 2026

FDA placed the compound in the bulk-substance bucket flagged for significant safety risk, which is what stopped compounding pharmacies from making it.

[[embed:source:w_ghpbaz64]]

On 23 July 2026 the agency's own Pharmacy Compounding Advisory Committee voted against that position: eight yes, six no, one abstention. Reporting on the meeting noted that most of the yes votes came from members with peptide-industry ties. An advisory vote changes no rule by itself.

[[embed:source:w_38qd7eam]]

[[embed:source:s129]]

[[embed:source:w_lkfuwkh8]]

It is on the 2026 World Anti-Doping Agency prohibited list, in the class covering substances with no approval for human use, banned at all times in and out of competition.

[[embed:source:w_u19qrezt]]

[[embed:source:w_af5ht9pr]]

The only registered trial with a person and an injury in it is a Phase 2 study in acute hamstring strain, which is muscle, not disc, and had not reported when this page was checked.

[[embed:source:s6]]

The one safety measurement in people is a pilot infusion of up to 20 mg into a vein in two healthy adults, with no adverse effects recorded. Two people is a safety signal about a single infusion, not about eight weeks of daily injection.

[[embed:source:s3]]

## Twenty-four people with a spine problem said what happened, and here is the count

Method: searched old.reddit.com for "bpc 157 herniated disc", "bpc 157 sciatica" and "bpc157 disc bulge", read 18 threads in full, pulled 113 comments that name the compound, and kept the ones where a named account described their own lumbar or cervical spine problem and what happened. Twenty-four had a stated outcome. Two more had started too recently to count. That is the denominator; everything else in those threads was sourcing questions, dosing questions and injuries in other body parts.

**Sixteen said it helped.** The most detailed is an L5/S1 herniation treated with about 600 mcg a day for two and a half months, injected into the upper glute rather than the back, with no physical therapy at all — pain-free at the one-year mark, with the caveat added later that a nerve sensation in the leg came back after returning to Muay Thai, and "spinal discs require a good amount of time to fully heal."

Speed varied wildly. One person with L3–L5 bulging discs on 250 mcg of the compound plus 250 mcg of TB-500 twice a day wrote on day five that "the chronic pain is melting away, as of day three." Another, six years into an L4/L5 herniation with leg pain, reported at four days that a four-hour drive produced no pain for the first time. At the other end, one person with seven herniated discs wrote at 32 days that they had not felt this much relief in years, and another took eighteen months to recover without surgery while also doing physical therapy and taking collagen.

Almost every one of the sixteen was doing something else at the same time. TB-500 in most of them, physical therapy in several, a steroid injection in one, gabapentin in one, red-light therapy in one, weight loss in one. Three were reporting after surgery — one after a microdiscectomy that left them with a dropped foot, who wrote that five weeks of the pair "healed me". None of the sixteen is a clean read on this compound alone.

**Two said it worked and then stopped working when they stopped taking it.** One: six weeks of it "lowered the inflammation enough for life to be manageable. I was able to lift weights and stuff again. A week after running out of BPC-157 the pain came back completely. If not worse than before." The other finished a twelve-week run and found the pain returned, though not to where it had been.

That pattern is worth more attention than any of the enthusiastic reports, because it is what you would expect from something quieting inflammation around an irritated nerve rather than repairing anything. Relief that ends with the injections is relief, not repair.

**Five said nothing happened.** One with an L5/S1 herniation since age eighteen injected into their own back for three months and "couldn't tell you that it made any difference." One with an L3/4 bulge and an L5/S1 herniation ran the compound at 250 mcg a day with 5 mg of TB-500 a week for six weeks and had "zero noticeable difference in back pain over 6 weeks" — a dose at the bottom of the common range, which is the obvious objection to that one. One with two bulging discs tried it on several separate occasions and it did not help. One never injected anywhere near the back and said it did not do much. One said they noticed nothing and wondered aloud whether they had run it long enough.

**One got worse, in a specific and checkable way.** Two weeks in, their prescription pain medication stopped working. They stopped the compound and the medication started working again within 24 to 36 hours. That is a reported interaction with an opioid painkiller, from one person, uncontrolled, and it is the only harm report in the set that is about the spine problem rather than about the compound in general.

One further account belongs here and is not in the count. A person with multiple herniated discs from a car crash, with a graduate degree in kinesiology, who had taken this compound for other injuries, attributed her own recovery to a different peptide entirely and argued that this one "primarily targets soft tissue and ligament repair, which may be less directly effective in regenerating the disc structure itself." That is the same objection the missing disc study raises, made by someone who used the compound and did not credit it.

**What the count settles and what it does not.** Sixteen out of twenty-four is a high hit rate, and it is also exactly what you would get from a condition where seven in ten people improve without doing anything, in a population that self-selected by buying an expensive compound and posting about it. Nobody posts a thread called "I bought it and nothing happened", which is why the five negatives matter more than their share suggests. The two relapse reports are the most informative thing in the whole set, and no trial exists that would resolve them.

## What would have to change for any of this to be settled

One rat study putting the compound near a damaged disc would tell you whether the analogy from tendon holds. One trial randomising people with a confirmed extrusion to the compound or a placebo, measuring leg pain at six weeks and the fragment on a scan at six months, would separate it from the 70% who resorb anyway. Neither exists, neither is registered, and the only trial running is in hamstrings.

[[embed:bpc-157]]

[[embed:ara-290-herniated-disc]]

[[embed:tb-500-herniated-disc]]

[[embed:wolverine-stack]]


## Sources

1. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis (Clin Spine Surg 2024, PMID 37559207) — https://pubmed.ncbi.nlm.nih.gov/37559207/
2. Surgery versus prolonged conservative treatment for sciatica (NEJM 2007, PMID 17538084) — https://pubmed.ncbi.nlm.nih.gov/17538084/
3. TNF-alpha in the nucleus pulposus mediates radicular pain in mice — https://pubmed.ncbi.nlm.nih.gov/18670336/
4. High levels of inflammatory phospholipase A2 activity in lumbar disc herniations — https://pubmed.ncbi.nlm.nih.gov/2218714/
5. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
6. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — https://pubmed.ncbi.nlm.nih.gov/16583442/
7. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — https://pubmed.ncbi.nlm.nih.gov/20225319/
8. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury — https://pubmed.ncbi.nlm.nih.gov/19903499/
9. BPC 157 improves the healing course of spinal cord injury and leads to functional recovery in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
10. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
11. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts — https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
12. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — https://pubmed.ncbi.nlm.nih.gov/20190676/
13. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
14. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
15. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — https://www.fda.gov/media/94155/download
16. July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
17. An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition (TIME) — https://time.com/article/2026/07/23/fda-committee-peptides/
18. FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
19. World Anti-Doping Code International Standard: Prohibited List 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. BPC-157: experimental peptide creates risk for athletes — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
21. BPC 157 for Acute Hamstring Muscle Strain Repair — https://clinicaltrials.gov/study/NCT07437547
22. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — https://pubmed.ncbi.nlm.nih.gov/40131143/
23. Healing a herniated disc and severe sciatica pain (r/Sciatica) — https://old.reddit.com/r/Sciatica/comments/1bu215m/healing_a_herniated_disc_and_severe_sciatica_pain/
24. Peptides for lower back pain recovery (r/backpain) — https://old.reddit.com/r/backpain/comments/14iol96/peptides_for_lower_back_pain_recovery/
25. I took BPC-157 for 6 weeks after struggling with disc herniation (r/bpc_157) — https://old.reddit.com/r/bpc_157/comments/1gjuas9/i_have_sciatica_from_a_bulged_disc_and_it_has/no45zaf/
26. I tried both TB-500/BPC-157 together for L3/4 bulge and L5/S1 herniation (r/Biohacking) — https://old.reddit.com/r/Biohacking/comments/1rj45d2/bpc157_for_lower_back_pain/o8aqhiq/
27. 43 yo, L5/S1 herniated disc since I was 18 (r/Biohackers) — https://old.reddit.com/r/Biohackers/comments/1fvf89s/been_struggling_with_2x_herniated_discs_for_over/lq8f8jp/
28. BPC-157 blunted a prescription painkiller (r/Biohacking) — https://old.reddit.com/r/Biohacking/comments/1rj45d2/bpc157_for_lower_back_pain/
29. Multiple herniated discs after a rear-end crash (r/bpc_157) — https://old.reddit.com/r/bpc_157/comments/1foo6q0/bpc_157_to_aid_herniated_discs/losyqg1/


---

# DSIP (Delta Sleep-Inducing Peptide): the replication record and dosing

slug: dsip · https://miscsubjects.com/a/dsip · tags: peptide, dsip · updated 2026-08-04T20:47:32.083Z

If you are awake at three in the morning and somebody has pointed you at a peptide named after deep sleep, one fact decides most of it. Every strongly positive human sleep result for DSIP came out of the laboratory that discovered the molecule. Every independent group that tested it afterwards got nothing, or got something so small they wrote in the paper that it was not worth using.

Take the evidence state first, because it is short. Three blinded, placebo-controlled sleep trials of DSIP have ever been run in people. The one from the Basel laboratory that discovered the molecule, in 14 people with severe long-term insomnia, found a large improvement. The two run by other groups — 16 people in Amsterdam and a crossover in Montevideo — found differences their own authors described in print as weak and of little clinical significance. Across every published study, 250 people have been given DSIP and had a result written down: 61 in the sleep trials that stated their numbers, 174 in two uncontrolled withdrawal series with no placebo arm, eight in the growth-hormone study, and seven in one pain pilot. Two further reports never said how many people they treated. Nobody has ever registered a trial of it: asking ClinicalTrials.gov on 4 August 2026 for delta sleep-inducing peptide, for emideltide, and for DSIP as an intervention returns zero studies each time. The animal record is rabbits, rats, cats and mice, and almost all of it is EEG recordings taken after the peptide was put straight into the brain or into a vein. Four things have never been measured in a person at all: the dose that is actually sold, which is 100 to 300 micrograms under the skin against the 1.5 milligrams into a vein used in every human study; the nasal route; use for longer than a week; and the receptor, because fifty years of looking has not found one.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

That is not a hole in the evidence. It is a pattern in the evidence, and it is the single most useful thing in this file.

The second most useful thing is the count of what happens to people who buy it and inject it. Thirty-five first-hand reports are catalogued here. Eighteen say sleep got better. Ten say sleep got worse or something unpleasant appeared. Five say nothing at all happened. One says it worked and then stopped. One says one sleep number moved and the others did not. That split — roughly half helped, half not helped or actively worse — is the same answer the controlled trials gave, arrived at independently by strangers on the internet.

DSIP is nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight 849. It was pulled out of the brain blood of rabbits in Basel, Switzerland, in the mid-1970s, by Marcel Monnier and Guido Schoenenberger. Its name — Delta Sleep-Inducing Peptide — was assigned on the strength of one reading: put it into a second rabbit's brain and the slow waves on its EEG got bigger.

The compound is real. The sequence is confirmed. The effect it is named after is the weakest thing about it. What follows is where it came from, what every study found in order, which of its non-sleep effects hold up better than the sleep one, what its two-to-four-minute survival time in blood does to the whole story, and what does have the evidence if what you want is to sleep.

## It came out of a rabbit whose sleep was electrical

Monnier's group in Basel started in 1963 with a cross-circulation question: if you make an animal sleep, does its blood carry something that will make a second animal sleep? Donor rabbits were held in slow-wave sleep by running current through the intralaminar thalamus. Blood coming out of their brains, drawn from the dural venous sinus, was filtered outside the body, and the filtrate was infused into the brain cavities of recipient rabbits. Slow-wave power in the recipients went up.

[[embed:source:w_hroqdqlk]]

By 1977 the active fraction had been purified, sequenced and made synthetically. Schoenenberger and Monnier tested the synthetic nine-residue peptide against five of its own breakdown fragments, two altered versions and a related three-residue peptide, blinded, in 58 rabbits. Only the intact nine-residue version raised delta and spindle activity.

[[embed:source:w_y3chk0t1]]

The 1978 follow-up in 61 rabbits put a number on it: average delta activity about 35% above controls given either vehicle or any of the eight other peptides. The structure had to be exact — shorten the chain by one or two residues, swap an amino acid, or use the beta-aspartyl form instead of the alpha, and the effect weakened or disappeared.

[[embed:source:w_1v4zebwc]]

## Four things about that method have never been answered

- **The donor rabbits were not asleep in any normal sense.** Their sleep was produced by passing current through a piece of brain. Whatever turned up in that blood is the product of electrically stimulating the thalamus, which is a different claim from a molecule that builds up during ordinary sleep.
- **What was measured was a waveform, not sleep.** Delta-band amplitude in a near-anaesthetised preparation is a signal on a screen. Nothing in the original work showed a recipient animal sleeping longer or better by any behaviour you could watch.
- **The dose curve is a hump, not a slope.** Schoenenberger reported bell-shaped curves with different peaks by route, and Scherschlicht's group at Roche found the same hump in rabbits, cats and mice. A compound with a hump-shaped curve is close to impossible to disprove: any failed replication can be blamed on landing on the wrong side of the peak.
- **No gene, no precursor, no receptor.** The sequence exists. The biological machinery that would build it and read it does not.

[[embed:source:w_6nqi6ir3]]

[[embed:source:w_lklbxmce]]

## The replication record, study by study

| Year | Investigators | Subjects | n | Design | Sleep result |
|---|---|---|---|---|---|
| 1977 | Schoenenberger, Monnier (Basel) | Rabbits, into the brain cavity | 58 | Blinded, against 8 related peptides | Delta and spindle EEG significantly raised; only the intact nine-residue peptide did anything |
| 1978 | Schoenenberger et al. (Basel) | Rabbits, into the brain cavity, 6 nmol/kg | 61 | Blinded, against vehicle and 8 peptides | Average delta activity +35% against controls |
| 1980 | Tobler, Borbély (Zürich) | Rats, into the belly 40–160 nmol/kg; into the brain cavity 7–24 nmol | Not stated | Controlled, EEG and movement | **No significant rise in sleep or delta power.** Delta power *fell* after 7 nmol into the third ventricle |
| 1981 | Schneider-Helmert, Schoenenberger (Basel) | Long-term insomniacs, into a vein, 25 nmol/kg | 6 | Open label, one dose | Longer sleep, fewer interruptions, slightly more REM; a mild *waking-up* effect in the first hour |
| 1984 | Kaeser (Basel) | Severe insomnia, 10 injections | 7 | Open label, no control group | Sleep "normalised" in 6 of 7 across 3–7 months |
| 1984 | Scherschlicht et al. (Roche) | Rabbits, cats, morphine-dependent mice | Not stated | Controlled | Light non-REM up in rabbits; REM up in cats; hump-shaped dose curve throughout |
| 1986 | Schneider-Helmert (Basel) | Long-term insomniacs, 6 × 30 nmol/kg into a vein over one week | 18 | Sleep laboratory, no placebo arm | Sleep normalised by the end of the follow-up week |
| 1987 | Schneider-Helmert (Basel) | Severe long-term insomnia, 7 nights running | 14 | Blinded, placebo-controlled | Large improvement in night sleep and daytime performance; the effect carried into a post-treatment placebo night |
| 1987 | Monti et al. (Montevideo) | Long-term insomniacs, into a vein, 25 nmol/kg, 4 nights | Not stated | Blinded crossover | **Difference against placebo not significant** once the starting point was accounted for. "Sleep improvement under DSIP treatment is of little clinical significance" |
| 1988 | Iyer, Marks, Kastin, McCann (Dallas) | Rats, kept awake on a rotating wheel | Not stated | Antibody blockade | The rise in slow-wave sleep and growth hormone after deprivation was blocked by anti-DSIP antiserum |
| 1992 | Bes, Hofman, Schuur, Van Boxtel (Amsterdam) | Long-term insomniacs, into a vein, 25 nmol/kg × 3 nights | 16 (8 per arm) | Blinded, matched pairs, parallel groups | Sleep efficiency and time-to-sleep improved, **but the effects were "weak and in part could be due to an incidental change in the placebo group"**; no change in how the sleep felt. "Not likely to be of major therapeutic benefit" |
| 1992 | van Kammen et al. (Pittsburgh) | Drug-free schizophrenic volunteers, spinal fluid assay | 15 | Observational correlation | DSIP-like material in spinal fluid tracked stage 3 and delta sleep |
| 2006 | Kovalzon, Strekalova (Moscow) | Review | — | — | "The hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak" |

[[embed:source:w_jrk3aijc]]

[[embed:source:w_pkhu2ho3]]

[[embed:source:s2]]

## Sort that table by laboratory and the pattern jumps out

Every strongly positive human result came from Basel — Schneider-Helmert, working alongside Schoenenberger, who isolated the peptide in the first place. Every group that tested it without that connection got a null or a triviality.

Tobler and Borbély in Zürich concluded flatly that the compound does not qualify as a sleep-promoting substance. Monti in Montevideo found the placebo comparison fall apart once the starting point was accounted for. Bes in Amsterdam found statistically real but weak effects, warned that part of the signal came from drift in the placebo group, and advised against using it.

Three more facts compress the record further.

Nearly every human study used the same single dose, 25 nmol/kg into a vein. No dose-finding study was ever run in a person. Against a hump-shaped dose curve, testing one rung of the ladder over and over cannot rule the compound in or out. It can only tell you about that rung.

Every human study injected into a vein. The subcutaneous shot that is the entire present-day market has never been tested in a human sleep trial.

And the total number of people ever randomly assigned to DSIP against placebo for sleep, in the whole fifty-year literature, is under forty.

## In fifty years nobody has registered a trial of it

Asking the ClinicalTrials.gov registry on 4 August 2026 for "delta sleep-inducing peptide" returns zero studies. Asking for "emideltide" returns zero. Asking for DSIP as a registered intervention returns zero.

[[embed:source:w_z711kz2m]]

Not an ongoing trial. Not a completed one. Not a terminated one. Not a withdrawn one. In fifty years, nobody has registered an attempt to settle the question the compound is named after.

## The biggest human numbers in the file are about withdrawal, not sleep

In 1983 Dick, Grandjean and Tissot in Geneva gave DSIP into a vein at 25 nmol/kg, as the only treatment, to 67 patients going through withdrawal — 28 from alcohol, 39 from opiates. Twenty-seven per cent were lost or unsuitable to assess. Of the 49 who could be assessed, 48 were reported to benefit, with the physical signs settling immediately and staying settled. Anxiety took longer.

[[embed:source:w_ee6vmdc4]]

The 1984 extension enrolled 107 inpatients, 47 in alcohol withdrawal and 60 in opiate withdrawal. Symptoms vanished or improved markedly in 97% of the opiate cases and 87% of the alcohol cases. Opiate patients needed more injections and took longer. It was well tolerated apart from headache in a few people.

[[embed:source:w_0vnryw2z]]

An independent open trial of DSIP for coming off opioids was published by Backmund's group in Munich in 1998.

[[embed:source:w_5aputa1e]]

Every one of those is an uncontrolled series. No placebo. No blinding. Doctors and nurses rating the outcome. And between 13% and 27% of the people enrolled dropped out of the analysis after the fact.

Here is why that matters more than usual. Acute withdrawal is a syndrome that ends by itself over a few days whether or not you give anything. An open series in a self-limiting syndrome measures the passage of time. Two hundred people getting better on schedule tells you almost nothing that one person getting better on schedule does not.

The reasoning behind the withdrawal work is at least specific and testable. Tissot had shown that morphine, alcohol, pentobarbital and DSIP all produced spindle-heavy slow-wave sleep when injected into the bulbo-mesencephalo-thalamic recruiting system, and that naloxone — the opioid blocker — reversed all four. Young and Key confirmed that reversal independently in rats: DSIP into the lateral ventricle raised REM and non-REM sleep, and pre-treating with naloxone at a dose that hits the mu-opioid receptor blocked it.

[[embed:source:w_xwm13uhv]]

That is the strongest mechanical thread in the whole file, and note what it points at: an interaction with the opioid system, not a sleep factor.

## Seven patients, four different conditions, no control group

The chronic pain evidence is one pilot study. Larbig and colleagues treated seven people — migraine and vasomotor headache, long-term tinnitus, and psychogenic pain attacks — with DSIP into a vein on five days running, then five more injections every 48 to 72 hours. Pain fell significantly in six of the seven against each person's own baseline stretch, and low mood fell with it.

[[embed:source:s21]]

Seven patients. Four different conditions. No placebo, no blinding, and a within-person comparison against a baseline assessed after the fact, in conditions that swing on their own. It is a hypothesis-generating observation that nobody generated a hypothesis from: in the forty-two years since, no controlled pain trial of DSIP has been run.

## The rat says growth hormone and the woman says no

The rat result is genuinely elegant. Iyer, Marks, Kastin and McCann kept male rats awake for four hours on a slowly turning wheel. When they were taken off it, both slow-wave sleep and growth hormone in the blood shot up. Microinjecting a highly specific anti-DSIP antibody into the third ventricle blocked both rises. Ordinary rabbit serum did not.

[[embed:source:w_7lo702h8]]

The human result is the opposite. Giusti's group in Genoa gave 25 µg/kg of DSIP into a vein over thirty minutes to eight healthy women. Baseline growth hormone: unchanged. Prolactin: unchanged. The daily rhythm of both: unchanged. The growth hormone response to an arginine challenge: unchanged. The authors pointed out that the dose they used was already known to alter the ECG — so it was reaching the subject, and it was doing nothing to growth hormone.

[[embed:source:w_zga2djoc]]

Marketing copy that promises a growth hormone release is citing the rat and ignoring the woman.

Luteinising hormone runs the same course. DSIP triggered LH release in ovary-removed rats that had been primed with oestrogen and progesterone, did nothing in unprimed animals, and did nothing at all to pituitary tissue in a dish — meaning any effect is happening in the hypothalamus and depends on the hormonal background.

[[embed:source:w_lq5x8aor]]

DSIP-like material has been found sitting in the same storage vesicles as LH-releasing hormone in the rat median eminence, which is suggestive. No endocrine effect of DSIP in a human being has ever been shown by anybody.

## The stress work is the most internally consistent animal data

Rats given DSIP into the belly at 40, 120, 360 and 1080 µg/kg before acute and repeated electric foot-shock showed liver malondialdehyde back to normal, liver cell protein production restored, and serum alanine aminotransferase back to normal. The dose curve was again a hump, not a slope: 120 µg/kg normalised fat oxidation damage in acute stress, while 40 µg/kg was the effective dose under chronic stress.

[[embed:source:w_cqubqjkn]]

DSIP and its analogue DSIP-12 cut the frequency, severity and length of metaphit-triggered sound-induced seizures in rats, with the analogue beating the parent compound.

[[embed:source:w_1pggv0x0]]

Schoenenberger's own characterisation work reported effects on the daily activity rhythm, on brain monoamine levels, on plasma proteins and on cortisol — a spread wide enough that he coined the phrase "programming functions" rather than claiming a mechanism.

Two caveats attach here. Most of this literature comes from Russian, Ukrainian and Serbian laboratories, much of it published in Russian, and very little has been repeated outside those groups. And an effect on rodent liver enzymes under electric shock is a long way from anything you can act on.

## Fifty years of looking and nobody has found the receptor

This is the strangest fact about DSIP and the one that should carry the most weight. For a peptide under continuous study since the 1970s, no gene, no precursor protein and no receptor has ever been isolated.

[[embed:source:w_l0pqsfj3]]

What exists instead:

- **Binding sites, never a receptor.** Autoradiography in 1984 found tritium-labelled DSIP sticking to the bodies and branches of cultured rat brain-stem neurones, and unlabelled peptide pushed it off. That observation is forty-two years old and was never followed through into a cloned receptor.
- **The material shows up in the wrong places.** DSIP-like material concentrates in hypothalamic neurosecretory nuclei that have little to do with sleep. Kovalzon's reading is that the material being detected belongs to a different, related molecule nobody has identified — which would explain both the distribution and the erratic biology.
- **Artificial versions work better than the real one.** Kovalzon's group found that certain man-made DSIP analogues significantly promote slow-wave sleep in rabbits and rats, and that DSIP itself does not. A naturally occurring dermorphin ten-residue peptide sharing five of nine positions promotes slow-wave sleep, while its mirror-image form suppresses it.
- **An adrenaline hypothesis that failed its test.** Graf and Kastin's 1986 review proposed that DSIP works by changing adrenaline-type transmission. Direct testing found DSIP did nothing to noradrenaline release from rat brain nerve endings at concentrations from 10⁻⁸ to 10⁻⁵ M, while leu-enkephalin in the same preparation did.
- **An opioid interaction that passed.** The naloxone reversal replicated. It remains the only mechanical claim about DSIP with independent support.

[[embed:source:s53]]

## It gets into the brain and then it is gone in four minutes

DSIP is one of the small set of peptides shown to cross from blood into brain by simple diffusion despite carrying a charge and liking water — a finding that made it a standard test compound in blood-brain barrier research. How much reaches dog spinal fluid tracks its blood concentration, its survival time in blood, and how fat-soluble it is.

[[embed:source:s7]]

Then the clearance numbers undo the story. Kato and colleagues built an enzyme immunoassay and measured it directly after injection into a vein:

| Species | Half gone from blood in | Clearance rate |
|---|---|---|
| Dog (n=4, anaesthetised) | 4.0 ± 0.7 min | 30.7 ± 2.5 mL/kg/min |
| Monkey (n=1) | 2.9 min | — |
| Rat (n=3) | 2.0 ± 0.54 min | — |

[[embed:source:w_w4ku9pni]]

Breakdown is why. Put DSIP in human or rat blood and what comes back has the fingerprint of free tryptophan — the front residue gets snipped off and the intact peptide stops existing. Phosphorylated and iodine-labelled versions break down more slowly and form complexes, which is the proposed reason they act more strongly and more consistently than the plain peptide.

[[embed:source:w_nxo79twi]]

Now put that number next to the claim being made. A compound that is half gone from your blood in two to four minutes, injected before bed, is absent from your circulation for essentially the entire night it is supposed to be governing.

Two readings survive that, and only two.

Either the injection is a brief trigger that starts something slower downstream — and the one piece of evidence for that is Schneider-Helmert's observation that the improvement carried into a post-treatment placebo night.

Or the reported effects are not the compound.

Nobody has run the experiment that separates those two.

One more thing sits underneath it. The DSIP-like material your body carries in blood, urine and spinal fluid appears to be bound to a larger carrier protein and protected from being chewed up. Injected synthetic peptide is not bound to anything.

## What people taking it report, counted: 18 better, 10 worse, 5 nothing, of 35

Forty-five Reddit threads and comments about DSIP are catalogued as sources on this page, pulled on 29 June 2026. Ten of them are protocol questions, vendor posts and guides with no outcome in them. That leaves **35 posts where a named person says what they took and what happened.**

| What was reported | Posts | Share of the 35 |
|---|---|---|
| Sleep improved | 18 | 51% |
| Sleep got worse, or a new bad effect appeared | 10 | 29% |
| Nothing at all | 5 | 14% |
| Worked, then stopped working | 1 | 3% |
| Mixed — one sleep measure moved, the others did not | 1 | 3% |

Eighteen X posts and two Instagram reels are also catalogued and are deliberately **not** counted in that 35. They run overwhelmingly positive, and on those platforms a first-hand report and an advertisement are not reliably distinguishable.

This is a curated set, not a survey, and the direction of the curation is unknown. Read it only for the shape: **about half the people who bothered to write down what happened reported no benefit or an active harm.** That is not the distribution a working sleeping pill produces. It is the same split the controlled trials produced, reached by a completely different route.

### The 18 reports of improvement are vivid and specific

First night, tracked on a wearable:

[[embed:source:s43]]

Deep and REM each up by about forty minutes, with the writer noting tolerance appearing after three or four days:

[[embed:source:s10]]

The dream reports are their own category and they are consistent enough to be worth reading as a signal rather than as colour:

[[embed:source:s9]]

[[embed:source:s63]]

Long-run users. Two years on it, off a self-experimentation forum:

[[embed:source:s19]]

Three weeks before anything changed, then months with no tolerance, at 300–500 mcg under the skin:

[[embed:source:s78]]

Sleep going from three to five hours a night to seven to nine, after alcohol withdrawal wrecked it:

[[embed:source:s74]]

[[embed:source:s58]]

[[embed:source:s101]]

[[embed:source:s75]]

[[embed:source:s65]]

[[embed:source:s98]]

[[embed:source:s26]]

[[embed:source:s27]]

[[embed:source:s42]]

[[embed:source:s62]]

[[embed:source:s18]]

[[embed:source:s81]]

### The 5 reports of nothing happening are just as specific

Two full vials, dosed under a doctor's direction:

[[embed:source:s20]]

[[embed:source:s41]]

A full 5 mg vial, from a commenter under one of the enthusiastic posts above:

[[embed:source:s44]]

Two months, in someone whose sleep was already good:

[[embed:source:s59]]

125 mcg in the day and about 300 mcg before bed:

[[embed:source:s100]]

### The 10 reports where it made sleep worse are the ones vendor pages never carry

Straightforward insomnia from a sleeping compound:

[[embed:source:s77]]

[[embed:source:s93]]

[[embed:source:s94]]

[[embed:source:s95]]

Four hours of sleep, from someone who ran it for sleep-maintenance insomnia:

[[embed:source:s73]]

Deep sleep measured going the wrong way — 45 minutes a night down to 8 by day five:

[[embed:source:s76]]

[[embed:source:s72]]

[[embed:source:s64]]

Worked for sleep and produced a hangover the next day:

[[embed:source:s66]]

Longest uninterrupted sleep the tracker had ever recorded, followed by two hours of lying awake on subsequent nights:

[[embed:source:s57]]

Sleep getting *worse* deserves more attention than it usually gets, because it is neither the shape of an inert compound nor the shape of a placebo. Two things in the published record line up with it directly.

Schneider-Helmert's 1981 study found a mild **waking-up** effect in the first hour after injection, before any sleep-promoting effect showed up. People are injecting fifteen to sixty minutes before bed, which puts the dose squarely inside that first hour.

And the dose curve reported throughout the animal literature is a hump. A dose past the peak can plausibly do the opposite of the dose at the peak. That curve has never been mapped in a human being, at any dose, by anyone.

### One report describes tolerance, and nothing in the literature addresses it

[[embed:source:s17]]

No human study ran longer than seven nights in a row. Whether an effect survives weeks of nightly use has never been tested by anybody.

### One report is mixed, and it is the most precise in the set

Sleep length and deep sleep unchanged, but REM present every night where it had not been before:

[[embed:source:s96]]

### Two threads independently reproduce the 1980s withdrawal finding

The most unexpected corroboration in the self-report record is not about sleep at all. People treating opiate withdrawal describe relief from DSIP under the skin and up the nose in terms close to Dick's Geneva series of 1983 — forty-two years later, with no sign of knowing that series exists.

[[embed:source:s97]]

That does not make the withdrawal claim true. Uncontrolled reports of a self-limiting syndrome resolving are still uncontrolled reports. What it does mean is that the strongest signal in the published record and the strongest signal in the self-report record point at the same non-sleep use, which is worth more than another sleep testimonial.

### Why none of it settles the question

Sleep is the outcome most sensitive to what you expect, and self-report is the weakest instrument for measuring it. One detail from the controlled record cuts against dismissing the whole thing, though. In the Bes trial the objective polysomnography numbers improved while how the sleep *felt* did not. That is the reverse of a placebo signature — placebo moves the feeling first. The authors still judged the effect weak, partly attributable to drift in the placebo group, and advised against using it. That position remains more defensible than either the enthusiasts' or the debunkers'.

## Sleep does gate pain and repair, and that is not evidence about this compound

If you are here because pain is keeping you awake, or because being awake is making the pain worse, the link is real and it is well documented. It is also a completely different proposition from anything above, and keeping the two apart is the whole job of this section.

**Poor sleep predicts new and worsening pain more reliably than pain predicts poor sleep.** Population studies following people over time show sleep problems arriving before new pain and before flare-ups. Fine-grained work with objective measures on both sides finds the sleep-to-pain direction is the stronger one.

[[embed:source:w_47nktqzd]]

**One night without sleep measurably lowers your pain threshold.** Acute sleep deprivation amplifies the pain response in primary somatosensory cortex, blunts it in the striatum and insula, and widens the range of temperatures a person calls painful. Outside the laboratory, ordinary night-to-night changes in one person's sleep quality predict next-day changes in their pain, in both directions.

[[embed:source:w_9shvk46m]]

**Two nights of partial restriction is enough to change a pressure pain threshold at the trapezius.** Twenty-one healthy volunteers, paired crossover, sleep cut by half for two nights: pressure pain threshold at the trapezius fell, p = 0.017, and the pain-triggered EEG response got bigger.

[[embed:source:w_2zo637na]]

**Broken sleep slows healing in animals.** Fragmenting sleep stretched the time to half-closure of a wound from 10.3 to 13.3 days in diabetic mice, with more TNF-α in the wound. Sleep-deprived rats healing burns grew fewer tissue-building cells and fewer new capillaries than controls.

[[embed:source:w_ikb821wn]]

[[embed:source:w_7fiszq9g]]

Now the line, drawn as sharply as it needs to be.

All of that is evidence that **sleep** matters to pain and to repair. None of it is evidence that **DSIP** improves sleep. The first proposition has population studies, controlled human experiments and animal tissue work behind it. The second has an inconsistent fifty-year record concentrated in one laboratory and a self-report split that is close to a coin flip.

Treating the strength of the first as if it transfers to the second is the exact move the marketing around this compound depends on. The evidence for one thing gets handed over while a different thing is sold. It is worth being able to see it happen, because it happens in one sentence and the sentence sounds reasonable.

## If the goal is sleep, here is what actually has the evidence

**Cognitive behavioural therapy for insomnia.** Twenty randomised controlled trials, 1,162 participants. Time to fall asleep improved by 19.0 minutes (95% CI 14.1–23.9). Time spent awake after falling asleep improved by 26.0 minutes (95% CI 15.5–36.5). Sleep efficiency improved by 9.9% (95% CI 8.1–11.7). The gains held at later follow-up and no harms were reported. It is first-line in the guidelines for a reason, and its two active ingredients — restricting time in bed, and using the bed only for sleep — need no prescription and cost nothing.

[[embed:source:w_363tewrt]]

**Licensed sleeping pills, with their costs stated.** The largest network meta-analysis covers 170 trials and 47,950 participants. Benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem and zopiclone all beat placebo for short-term treatment, with standardised effect sizes from 0.36 to 0.83. Eszopiclone and lemborexant came out with the best overall profiles. Zopiclone and zolpidem caused more people to quit over side effects than placebo did.

[[embed:source:w_ry66bqki]]

**And the one most people have already tried, which does not work.** In that same analysis, melatonin, ramelteon and the unlicensed drugs showed no material benefit overall.

Set the comparison out plainly, because it is the comparison that matters. The best-evidenced sleep intervention rests on 1,162 randomly assigned people, with an effect that lasted and no harms recorded. The best-evidenced DSIP sleep trial rests on eight people per arm and concluded that short-term treatment was not likely to be of major benefit.

## Dosing, and the gap between the studies and what is sold

Every human trial used 25 nmol/kg into a vein. At a molecular weight of 849 that is 21.2 µg/kg — about 1.5 mg for a 70 kg adult. Schneider-Helmert's 1986 week-long study used 30 nmol/kg. Giusti's endocrine study used 25 µg/kg into a vein over thirty minutes.

The market dose is 100 to 300 mcg under the skin before bed.

That is five to fifteen times lower than the only dose ever given to a human being, by a route never tested in one. Both changes are undocumented. Against a compound whose dose curve is a hump rather than a slope, cutting the dose fifteen-fold is not the cautious choice. It is an untested choice, and it can land anywhere on that curve including flat zero.

Timing in the circulating protocols is 15 to 60 minutes before you intend to sleep. Worth knowing before you set that: Schneider-Helmert's 1981 study found the mild waking-up effect in the first hour after injection, with the sleep-promoting effect only turning up in the second.

[[embed:source:s3]]

Under the skin and up the nose are the two routes in circulation. There is no comparative human data, and nothing has ever been published on how the body absorbs and clears the nasal form.

### Mixing a vial is arithmetic

DSIP ships as a dry powder in a sealed glass vial, usually 2 mg or 5 mg. You mix it with bacteriostatic water — sterile water with 0.9% benzyl alcohol in it, the preservative that makes it safe to put a needle into the same vial more than once. The measuring device is a U-100 insulin syringe: 100 marks per millilitre, so one mark is 0.01 mL.

Two lines produce every number you need:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

Worked through: a 5 mg vial holds 5,000 mcg. Add 2.5 mL of bacteriostatic water. 5,000 ÷ 2.5 = 2,000 mcg/mL. 2,000 ÷ 100 = 20 mcg per mark. A 100 mcg dose is 100 ÷ 20 = 5 marks on the barrel.

| Vial | Bacteriostatic water | Concentration | Mcg per mark | Marks for 100 mcg | Marks for 200 mcg | Marks for 300 mcg |
|---|---|---|---|---|---|---|
| 2 mg (2,000 mcg) | 2.0 mL | 1,000 mcg/mL | 10 | 10 | 20 | 30 |
| 2 mg (2,000 mcg) | 1.0 mL | 2,000 mcg/mL | 20 | 5 | 10 | 15 |
| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 4 | 8 | 12 |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 5 | 10 | 15 |
| 5 mg (5,000 mcg) | 5.0 mL | 1,000 mcg/mL | 10 | 10 | 20 | 30 |
| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 5 | 10 | 15 |

Adding more water does not change how much peptide is in the vial. It changes only how many marks carry a given dose. Below about five marks, the error in reading a U-100 barrel starts to dominate your dose — which is the practical argument for more water, not less, at the 100 mcg tier.

Let the vial come to room temperature before you add water. Run the water down the inside wall instead of squirting it onto the powder. Swirl until it dissolves and never shake it: the shearing at the air-liquid surface unfolds peptides and makes them clump, and clumping is exactly the mechanism FDA named when it raised the question of whether the immune system would react to it.

### Storage has a hard clock

| State | Temperature | How long it is good for |
|---|---|---|
| Sealed dry vial | 2–8 °C, out of the light | To the manufacturer's date; −20 °C for long holding |
| Mixed with bacteriostatic water | 2–8 °C | About four weeks, set by the preservative |
| Mixed, left at room temperature | 20–25 °C | Hours to days; treat it as spoiled |
| Mixed, then frozen | −20 °C | Avoid. Freezing and thawing clumps peptides |

A 5 mg vial at 100 mcg a night is fifty doses, which is far more nights than the four-week window a mixed vial gives you. The arithmetic forces a choice: buy a smaller vial, take a bigger nightly dose, or throw most of what you paid for away.

### Timelines, and what would count as an answer

The circulating protocols run five nights on and two off, or three to five nights a week, for four to eight weeks. There is no evidence base under any of those schedules. No human study of DSIP ran longer than seven nights in a row, and none tested taking it on and off.

The trial that would settle it is easy to specify and has never been run: randomised, blinded, placebo-controlled, with overnight sleep recording, in long-term insomnia, DSIP under the skin at 100–300 mcg — the doses that are actually sold — with sleep efficiency and minutes of slow-wave sleep as the primary outcomes. Anything short of that leaves the position exactly where 1980 left it.

## Regulatory status: withdrawn by the nominator, not cleared by the agency

Emideltide, the international nonproprietary name for DSIP, appears on FDA's page *Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks*, in the table headed **"Bulk drug substances nominated but withdrawn"**. It is one of seventeen entries there, alongside BPC-157, TB-500, KPV, Semax, Selank acetate, Thymosin alpha-1, Epitalon, MOTS-C, Melanotan II, CJC-1295, AOD-9604 and GHK-Cu.

FDA's stated reason, word for word: compounded drugs containing emideltide "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified safety-related information regarding emideltide for the proposed route... Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."

[[embed:source:w_ww3yt0x9]]

What that status means, precisely:

- It is **not an approval** and it is **not a ban**. It is the record of a request. Somebody asked FDA to allow emideltide as a bulk substance for pharmacy compounding; FDA put it in category 2 — substances that may present significant safety risks; the person who asked then withdrew the request. FDA's own words on the page are that these substances were "previously in category 2 of the interim policies" and "were withdrawn by the nominators."
- The practical consequence is that emideltide is **not on the 503A or 503B bulks lists**. A compounding pharmacy cannot lawfully compound it as a bulk drug substance. What is offered for sale is research-use-only chemical, not medicine, and it comes with no assurance of identity, purity or sterility.
- FDA's specific worries are, in order: clumping and whether the immune system would react to it by certain routes, peptide-related impurities, characterisation of the active ingredient, and — the operative one — an absence of safety information for the route being proposed.
- No marketing authorisation for DSIP exists in any country, and none has ever been applied for.

[[embed:source:s56]]

A 2026 review of therapeutic peptides in orthopaedics lists DSIP among the recovery-oriented compounds and states the position for the whole class in one line: the preclinical work looks good, and there are no clinical trials.

[[embed:source:w_d2edzzyj]]

## Where that leaves the compound

A confirmed nine-residue sequence.

Half gone from the blood in two to four minutes.

No gene, no precursor, no receptor, after fifty years of people looking for all three.

A sleep record whose positive findings are concentrated in the laboratory that discovered it, and whose independent replications are null.

A withdrawal literature covering several hundred patients with no control group in any of it, in a syndrome that ends on its own.

One seven-patient pain pilot, never followed up in forty-two years.

A growth hormone claim that holds in rats and fails in the only eight humans it was ever tested in.

Zero registered trials, ever.

Thirty-five first-hand reports splitting eighteen good, ten bad, five nothing.

And a regulatory file recording a withdrawn request and an agency saying it does not have enough information to know whether the substance would hurt you.

The peptide is named for the one effect its evidence supports least.

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:kpv]]

[[embed:ghk-cu]]

[[embed:thymosin-alpha-1]]

[[embed:ara-290]]


## Sources

1. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat — https://www.pnas.org/doi/10.1073/pnas.85.10.3653
2. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study — https://pubmed.ncbi.nlm.nih.gov/1299794/
3. The influence of synthetic DSIP on disturbed human sleep — https://pubmed.ncbi.nlm.nih.gov/7028502/
4. Delta sleep-inducing peptide — https://journals.lww.com/ejanaesthesiology/fulltext/2001/07000/delta_sleep_inducing_peptide.1.aspx
5. DSIP Peptide user discussion — https://www.instagram.com/reel/DURfvtYj6Qz/
6. Delta sleep-inducing peptide (DSIP): a still unresolved riddle — https://pubmed.ncbi.nlm.nih.gov/16539679/
7. Pichia pastoris secreted peptides crossing the blood-brain barrier — https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1439536/full
8. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke — https://pubmed.ncbi.nlm.nih.gov/34500605/
9. DSIP Review: The Sleep Peptide That Gave Me Inception Level Lucid Dreams — https://www.reddit.com/r/USPeptides/comments/1pcdd5q/dsip_review_the_sleep_peptide_that_gave_me/
10. DSIP GREATLY Improved Sleep (DEEP and REM)!! — https://www.reddit.com/r/Biohackers/comments/1qab419/dsip_greatly_improved_sleep_deep_and_rem/
11. DSIP Peptide: Revolutionizing Sleep, Stress, and Pain Management — https://www.youtube.com/watch?v=grwWLZedRQQ
12. DSIP (Delta Sleep-Inducing Peptide) | Full Rundown [2026] — https://www.innerbody.com/dsip-delta-sleep-inducing-peptide
13. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke — https://pmc.ncbi.nlm.nih.gov/articles/PMC8434407/
14. How does the Peptide DSIP Work? — https://www.youtube.com/watch?v=dz6vYHXE3Yc
15. DSIP is Wild — https://www.reddit.com/r/Biohackers/comments/1stygfi/dsip_is_wild/
16. DSIP (Emideltide) FDA Update: Sleep Peptide Moves Forward — https://newtropin.com/blog/dsip-emideltide-fda-update
17. any personal experience with DSIP (Delta Sleep-Inducing ... — https://www.reddit.com/r/Biohackers/comments/1afsuih/any_personal_experience_with_dsip_delta/
18. DSIP Review: The Sleep Peptide That Gave Me Inception ... — https://www.reddit.com/r/LucidDreaming/comments/1tkp3dv/dsip_review_the_sleep_peptide_that_gave_me/
19. Sleep Quality DSIP - Self-Experimentation - Age Reversal Forum — https://forum.age-reversal.net/t/y4yz380/sleep-quality-dsip
20. r/Peptides - DSIP is disappointing — https://www.reddit.com/r/Peptides/comments/1tfq46s/dsip_is_disappointing/
21. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. — https://pubmed.ncbi.nlm.nih.gov/6548970/
22. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — https://pubmed.ncbi.nlm.nih.gov/3622582/
23. DSIP Peptide: Research, Benefits, Dosage & Sleep Studies — https://drlewis.com/dsip-delta-sleep-inducing-peptide/
24. DSIP Peptide: Benefits, Dosage & 2026 Legal Status — https://riteaid.com/peptides/dsip
25. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke — https://www.mdpi.com/1420-3049/26/17/5173
26. Dsip basically fixed my sleep apnea for a month — https://www.reddit.com/r/sleephackers/comments/1px0arq/dsip_basically_fixed_my_sleep_apnea_for_a_month/
27. Jumped from 300 mcg to 400 mcg DSIP last night... wow. — https://www.reddit.com/r/sleep/comments/1sxdxl9/jumped_from_300_mcg_to_400_mcg_dsip_last_night/
28. Delta-sleep-inducing peptide — https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
29. DSIP PEPTIDE: Benefits, Dosage, Side Effects & Clinical Data — https://exploring-peptides.com/article/dsip-peptide-benefits-dosage-side-effects-clinical-data/
30. DSIP Peptide for Detox — https://www.phoenixrisingrecovery.com/rehab-blog/dsip-peptide/
31. DSIP for Deep Sleep: Benefits, Dosage & Safety — https://rwacenter.com/blog/dsip-the-natural-sleep-architect-for-restorative-rest-and-recovery/
32. DSIP Research Review Canada — https://luxaralabs.com/dsip-research-review-canada/
33. 105 - Delta Sleep Inducing Peptides –The Matt Walker Podcast — https://podcasts.apple.com/ky/podcast/105-delta-sleep-inducing-peptides/id1578319619?i=1000722424020
34. Peptide Regimens for Sleep Optimization and Hormonal Balance — https://www.mdiha.com/blog/peptide-regimens-for-sleep-optimization-and-hormonal-balance
35. Best Peptides for Sleep: What to Know Before You Try Them — https://www.kentonbruicemd.com/blog/best-peptides-for-sleep-what-to-know-before-you-try-them
36. DSIP (Delta Sleep Inducing Peptide) — https://healingmaps.com/dsip-delta-sleep-inducing-peptide-emideltide-explained/
37. DSIP: The Sleep Peptide That Changes How Canadians Sleep — https://www.redfoxpeptides.is/dsip-peptide-your-secret-weapon-against-sleepless-nights-canada/
38. X post by @AntiDoc on DSIP sleep benefits — https://x.com/AntiDoc/status/1904576757568545067
39. X post by @zapmethod on DSIP experience — https://x.com/zapmethod/status/2033990620008628244
40. Instagram reel on DSIP — https://www.instagram.com/reel/DR0k-o6ge8D/
41. DSIP peptide guide — https://www.reddit.com/r/NTNPerformance/comments/1t81ivi/dsip_peptide_guide/
42. DSIP peptide guide — https://www.reddit.com/r/NTNPerformance/comments/1t81ivi/dsip_peptide_guide/
43. Results of FIRST night of using DSIP for sleep. INCREDIBLE! — https://www.reddit.com/r/Biohackers/comments/1ly6cq0/results_of_first_night_of_using_dsip_for_sleep/
44. Results of FIRST night of using DSIP for sleep. INCREDIBLE! — https://www.reddit.com/r/Biohackers/comments/1ly6cq0/results_of_first_night_of_using_dsip_for_sleep/
45. X post by @anamarz_amz — https://x.com/anamarz_amz/status/2068064147854516477
46. DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl ... — https://pubmed.ncbi.nlm.nih.gov/33918965/
47. Delta Sleep Inducing Peptide A comprehensive guide by a ... — https://www.youtube.com/watch?v=zG5GKyt0t2U
48. DSIP : Delta Sleep-Inducing Peptide — https://www.reddit.com/r/PeptideDiscussion/comments/1gu3fnq/dsip_delta_sleepinducing_peptide/
49. Doctor offering DSIP (Delta-sleep-inducing peptide), worth ... — https://www.reddit.com/r/PeptideForum/comments/1k74b9j/doctor_offering_dsip_deltasleepinducing_peptide/
50. DSIP UK: Complete Research Guide (2026) — https://peptideslabuk.com/dsip-uk-complete-research-guide-2026/
51. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models — https://pubmed.ncbi.nlm.nih.gov/39444618/
52. DSIP peptide isn't “just a sleep aid” — https://www.reddit.com/r/BioHackingGuide/comments/1qv30y1/dsip_peptide_isnt_just_a_sleep_aid/
53. Delta-sleep-inducing peptide (DSIP): an update — https://pubmed.ncbi.nlm.nih.gov/3550726/
54. A clinical trial with DSIP — https://pubmed.ncbi.nlm.nih.gov/6391926/
55. Understanding Delta Sleep-Inducing Peptide and Sleep Regulation — https://www.empowersleep.com/articles/delta-sleep-inducing-peptide
56. FDA Announces Change in Status of 12 Peptides — https://ssrpinstitute.org/news/fda-announces-change-in-status-of-12-peptides/
57. Delta Sleep Inducing Peptide (DSIP) for treating central sleep apnea? — https://www.reddit.com/r/Nootropics/comments/47jdzp/delta_sleep_inducing_peptide_dsip_for_treating/
58. Has anyone tried DSIP(Delta Sleep-Inducing Peptide)? — https://www.reddit.com/r/insomnia/comments/1gu3ele/has_anyone_tried_dsipdelta_sleepinducing_peptide/
59. DSIP (delta sleep inducing peptide) — https://www.reddit.com/r/Biohackers/comments/18u5ocg/dsip_delta_sleep_inducing_peptide/
60. X post by @whey777 — https://x.com/whey777/status/2069942524815319485
61. X post by @troywhiteyyc — https://x.com/troywhiteyyc/status/2068891740736503946
62. DSIP Recovery and Dreams — https://www.reddit.com/r/USPeptides/comments/1rakdga/dsip_recovery_and_dreams/
63. DSIP Recovery and Dreams — https://www.reddit.com/r/USPeptides/comments/1rakdga/dsip_recovery_and_dreams/
64. Peptide tier list for sleep. Ranked by sleep relevance, recovery support, and overall sleep quality — https://www.reddit.com/r/NTNPerformance/comments/1tnualo/peptide_tier_list_for_sleep_ranked_by_sleep/
65. Peptide tier list for sleep. Ranked by sleep relevance, recovery support, and overall sleep quality — https://www.reddit.com/r/NTNPerformance/comments/1tnualo/peptide_tier_list_for_sleep_ranked_by_sleep/
66. Peptide tier list for sleep. Ranked by sleep relevance, recovery support, and overall sleep quality — https://www.reddit.com/r/NTNPerformance/comments/1tnualo/peptide_tier_list_for_sleep_ranked_by_sleep/
67. DSIP is a peptide to help deep sleep — https://www.facebook.com/groups/252962560254589/posts/1179093274308175/
68. X post by @Lions_1776 on DSIP sleep duration — https://x.com/Lions_1776/status/2068064147854516477
69. X post by @FattyNoNatty on DSIP experience — https://x.com/FattyNoNatty/status/2067706289006985373
70. Had anyone tried DSIP peptide to reset their circadian rhythm? — https://www.reddit.com/r/DSPD/comments/pnpial/had_anyone_tried_dsip_peptide_to_reset_their/
71. X post on DSIP fixing sleep schedule — https://x.com/Chrissssjohnson/status/2008202115186147361
72. Dsip experience — https://www.reddit.com/r/Biohackers/comments/1shazrp/dsip_experience/
73. Peptides for Sleep (Sleep Maintenance Insomnia) — https://www.reddit.com/r/Biohackers/comments/1tca76g/peptides_for_sleep_sleep_maintenance_insomnia/
74. I wish I'd discovered DSIP for sleep earlier — https://www.reddit.com/r/BodyHackGuide/comments/1uhio7j/i_wish_id_discovered_dsip_for_sleep_earlier/
75. DSIP 💤 (Delta Sleep-Inducing Peptide) Better Deep Sleep | Cortisol Balance | CNS Recovery — https://www.reddit.com/r/USPeptides/comments/1p1fbgq/dsip_delta_sleepinducing_peptide_better_deep/
76. Im trying DSIP for the first time tonight, does anyone have any experience? (From my DR) — https://www.reddit.com/r/Biohackers/comments/1bqdrof/im_trying_dsip_for_the_first_time_tonight_does/
77. What Was Your Experience With DSIPS? — https://www.reddit.com/r/Peptidesource/comments/1ps5lgw/what_was_your_experience_with_dsips/
78. DSIP works, but requires patience — https://www.reddit.com/r/BodyHackGuide/comments/1tylecq/dsip_works_but_requires_patience/
79. Peptide #26: DSIP — https://x.com/GiffenHealth/status/2068891740736503946
80. DSIP Spotlight — https://x.com/TalkingCry97534/status/2071051909964685532
81. DSIP + Selank: How I Leveled Up My Sleep — https://www.reddit.com/r/BodyOptimization/comments/1p5mc7j/dsip_selank_how_i_leveled_up_my_sleep/
82. DSIP + Selank: How I Leveled Up My Sleep — https://www.reddit.com/r/BodyOptimization/comments/1p5mc7j/dsip_selank_how_i_leveled_up_my_sleep/
83. Spotlight: DSIP is not just a sleep peptide. The HPA axis story is the bigger story. — https://www.reddit.com/r/Biohack_Blueprint/comments/1ufcu8a/spotlight_dsip_is_not_just_a_sleep_peptide_the/
84. Delta Sleep Inducing Peptides - The Matt Walker Podcast — https://x.com/sleepdiplomat/status/1957519423457358246
85. https://x.com/TKubowitz9tdk/status/2071444996562227309 — https://x.com/TKubowitz9tdk/status/2071444996562227309
86. A Complete Guide for DSIP — https://www.reddit.com/r/Ameano_Peptides/comments/1ocobsd/a_complete_guide_for_dsip/
87. Delta Sleep-Inducing Peptide (DSIP) — did it affect your prescription stimulants? — https://www.reddit.com/r/ADHDers/comments/1shiytb/delta_sleepinducing_peptide_dsip_did_it_affect/
88. Are peptides back? — https://x.com/HillaryLinMD/status/2071602085401866272
89. DSIP experience with blend — https://x.com/xiipercent/status/2071641514263130279
90. Peptide FDA discussion — https://x.com/PeptideBuz/status/2071576099931459677
91. DSIP stack mention — https://x.com/xiipercent/status/2071614893732900958
92. DSIP sourcing anecdote — https://x.com/AMRadio84/status/2071613491719319677
93. Actual peptides / meds that will give you deep sleep? — https://www.reddit.com/r/sleep/comments/1l1zbhz/actual_peptides_meds_that_will_give_you_deep_sleep/
94. Actual peptides / meds that will give you deep sleep? — https://www.reddit.com/r/sleep/comments/1l1zbhz/actual_peptides_meds_that_will_give_you_deep_sleep/
95. Actual peptides / meds that will give you deep sleep? — https://www.reddit.com/r/sleep/comments/1l1zbhz/actual_peptides_meds_that_will_give_you_deep_sleep/
96. Actual peptides / meds that will give you deep sleep? — https://www.reddit.com/r/sleep/comments/1l1zbhz/actual_peptides_meds_that_will_give_you_deep_sleep/
97. DSIP Intranasal/Sub-Q Complete Opiate Withdrawal Relief — https://www.reddit.com/r/Nootropics/comments/1nnfj2w/dsip_intranasalsubq_complete_opiate_withdrawal/
98. How long does a reconstituted DSIP vial actually last in the fridge? — https://www.reddit.com/r/Biohacking/comments/1rwy37j/how_long_does_a_reconstituted_dsip_vial_actually/
99. DSIP: Comprehensive Guide — https://www.reddit.com/r/APRHealthSolutions/comments/1q56i5l/dsip_comprehensive_guide/
100. DSIP ( delta sleep inducing peptide ): no effect whatsoever — https://www.reddit.com/r/Peptides/comments/h0j7cv/dsip_delta_sleep_inducing_peptide_no_effect/
101. any personal experience with DSIP (Delta Sleep-Inducing Peptide)? — https://www.reddit.com/r/sleephackers/comments/1ag716c/any_personal_experience_with_dsip_delta/
102. X post listing peptides including DSIP — https://x.com/gr8tful88/status/2071404994192974208
103. Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat — Tobler I, Borbely AA. Waking Sleeping. 1980;4(2):139-53. PMID 7405185 — https://pubmed.ncbi.nlm.nih.gov/7405185/
104. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide — Schoenenberger GA, Monnier M. Proc Natl Acad Sci USA. 1977;74(3):1282-6. PMID 265572 — https://pubmed.ncbi.nlm.nih.gov/265572/
105. Humoral transmission of sleep IX: activity and concentration of the sleep peptide delta in cerebral and systemic blood fractions — Monnier M, Dudler L, Gachter R, Schoenenberger GA. Pflugers Arch. 1975;360(3):225-42. PMID 1237876 — https://pubmed.ncbi.nlm.nih.gov/1237876/
106. The delta EEG (sleep)-inducing peptide (DSIP) XI: amino-acid analysis, sequence, synthesis and activity of the nonapeptide — Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M. Pflugers Arch. 1978;376(2):119-29. PMID 568769 — https://pubmed.ncbi.nlm.nih.gov/568769/
107. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs — Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Int J Clin Pharmacol Res. 1987;7(2):105-10. PMID 3583493 — https://pubmed.ncbi.nlm.nih.gov/3583493/
108. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs — Schneider-Helmert D. Eur Neurol. 1986;25(6):448-53. PMID 3792404 — https://pubmed.ncbi.nlm.nih.gov/3792404/
109. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors — Dick P, Grandjean ME, Tissot R. Neuropsychobiology. 1983;10(4):205-8. PMID 6328354 — https://pubmed.ncbi.nlm.nih.gov/6328354/
110. DSIP in the treatment of withdrawal syndromes from alcohol and opiates — Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. Eur Neurol. 1984;23(5):364-71. PMID 6548969 — https://pubmed.ncbi.nlm.nih.gov/6548969/
111. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial — Backmund M, Meyer K, Rothenhaeusler HB, Soyka M. J Clin Psychopharmacol. 1998;18(3):257-8. PMID 9617990 — https://pubmed.ncbi.nlm.nih.gov/9617990/
112. Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs — Kato N, Honda Y, Ebihara S, Naruse H, Takahashi Y. Neuroendocrinology. 1984;39(1):39-44. PMID 6379493 — https://pubmed.ncbi.nlm.nih.gov/6379493/
113. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum — Graf MV, Saegesser B, Schoenenberger GA. Peptides. 1987;8(4):599-603. PMID 3628078 — https://pubmed.ncbi.nlm.nih.gov/3628078/
114. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women — Giusti M, Carraro A, Porcella E, Valenti S, Nicora D, Sessarego P, Giordano G. Psychoneuroendocrinology. 1993;18(1):79-84. PMID 8475226 — https://pubmed.ncbi.nlm.nih.gov/8475226/
115. Delta sleep-inducing peptide (DSIP) stimulates LH release in steroid-primed ovariectomized rats — Sahu A, Kalra SP. Life Sci. 1987;40(12):1201-6. PMID 3550343 — https://pubmed.ncbi.nlm.nih.gov/3550343/
116. The influence of delta sleep-inducing peptide on functional state of rats hepatocytes in foot-shock stress — Belykh AE, Bobyntsev II, Kryukov AA, Dudka VT. Ross Fiziol Zh Im I M Sechenova. 2015;101(6):700-7. PMID 26470489 — https://pubmed.ncbi.nlm.nih.gov/26470489/
117. Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats — Stanojlovic OP, Zivanovic DP, Mirkovic SD, Mikhaleva II. Seizure. 2005;14(4):240-7. PMID 15911358 — https://pubmed.ncbi.nlm.nih.gov/15911358/
118. Antagonism of the effect of delta sleep-inducing peptide by naloxone in the rat — Young AM, Key BJ. Neuropharmacology. 1984;23(11):1347-50. PMID 6549349 — https://pubmed.ncbi.nlm.nih.gov/6549349/
119. Some pharmacological effects of delta-sleep-inducing peptide (DSIP) — Scherschlicht R, Aeppli L, Polc P, Haefely W. Eur Neurol. 1984;23(5):346-52. PMID 6548967 — https://pubmed.ncbi.nlm.nih.gov/6548967/
120. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP) — Schoenenberger GA. Eur Neurol. 1984;23(5):321-45. PMID 6548966 — https://pubmed.ncbi.nlm.nih.gov/6548966/
121. ClinicalTrials.gov API v2 query for "delta sleep-inducing peptide" and for emideltide, run 4 August 2026 — https://clinicaltrials.gov/api/v2/studies?query.term=%22delta+sleep-inducing+peptide%22&countTotal=true
122. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks; table: Bulk drug substances nominated but withdrawn — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
123. The Pain of Sleep Loss: A Brain Characterization in Humans — Krause AJ, Prather AA, Wager TD, Lindquist MA, Walker MP. J Neurosci. 2019;39(12):2291-2300. PMID 30692228 — https://pubmed.ncbi.nlm.nih.gov/30692228/
124. Experimental Sleep Restriction Facilitates Pain and Electrically Induced Cortical Responses — Matre D, Hu L, Viken LA, et al. Sleep. 2015;38(10):1607-17. PMID 26194577 — https://pubmed.ncbi.nlm.nih.gov/26194577/
125. The association of sleep and pain: an update and a path forward — Finan PH, Goodin BR, Smith MT. J Pain. 2013;14(12):1539-52. PMID 24290442 — https://pubmed.ncbi.nlm.nih.gov/24290442/
126. Sleep fragmentation delays wound healing in a mouse model of type 2 diabetes — McLain JM, Alami WH, Glovak ZT, et al. Sleep. 2018;41(11):zsy156. PMID 30107617 — https://pubmed.ncbi.nlm.nih.gov/30107617/
127. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis — Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Ann Intern Med. 2015;163(3):191-204. PMID 26054060 — https://pubmed.ncbi.nlm.nih.gov/26054060/
128. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis — De Crescenzo F, et al. Lancet. 2022;400(10347):170-184. PMID 35843245 — https://pubmed.ncbi.nlm.nih.gov/35843245/
129. Delta sleep-inducing peptide (DSIP): a still unresolved riddle — Kovalzon VM, Strekalova TV. J Neurochem. 2006;97(2):303-9. PMID 16539679 — https://pubmed.ncbi.nlm.nih.gov/16539679/
130. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Rahman OF, Lee SJ, Seeds WA. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236. PMID 41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/
131. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat — Iyer KS, Marks GA, Kastin AJ, McCann SM. Proc Natl Acad Sci USA. 1988;85(10):3653-6. PMID 3368469 — https://pubmed.ncbi.nlm.nih.gov/3368469/
132. Effects of sleep deprivation, nicotine, and selenium on wound healing in rats — Gumustekin K, Seven B, Karabulut N, et al. Int J Neurosci. 2004;114(11):1433-42. PMID 15636354 — https://pubmed.ncbi.nlm.nih.gov/15636354/


---

# BPC-157: Body Protection Compound

slug: bpc-157 · https://miscsubjects.com/a/bpc-157 · tags: peptide, bpc-157, disc, tendon, gut · updated 2026-08-04T20:44:21.585Z

If you have a disc that is wearing out, you are deciding between things that slow the wearing and things that claim to rebuild. BPC-157 is sold as the second kind. BPC-157 is a short chain of 15 amino acids copied from a protein found in human stomach juice. Around 150 animal papers, mostly rats, report it speeding repair in tendon, ligament, muscle, nerve, bone and gut. Five studies have been run in people, covering about 130 people in total, and none of them was a finished controlled trial in a torn or worn-out tissue. It has never been approved as a medicine anywhere. It is banned in sport at all times. Nobody has ever tested it on a spinal disc, in a rat or in a person.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
## The two clocks running in your back

A disc has two parts. The soft centre (the *nucleus pulposus*) is a water-holding gel that takes the load. Around it is a tough ring of layered fibres that keeps the gel where it belongs. Degeneration is the gel losing water and the ring cracking, in that order, over years.

Three things drive that.

The first is blood supply, or the near-absence of it. A disc is the largest structure in your body with no blood vessels running into it. Nutrients seep in through the bone plates above and below, and waste seeps out the same way. Those plates harden and clog with age. Once they do, the centre of the disc is a long way from any food supply, and cells in the middle start dying of the thing every tissue dies of when the plumbing fails.

The second is water. The gel holds water because of long sugar-protein molecules packed inside it. Cells make those molecules; dying cells stop making them. Less of them means less water, less water means a flatter disc, and a flatter disc loads its ring unevenly.

The third is the tearing itself. The ring is under shear every time you bend. When the centre stops cushioning, the ring takes load it was never built for, splits, and lets gel push out into the space where nerve roots run. That is a herniation, and the leg pain that follows is a squeezed nerve root (*radiculopathy*).

What makes it break down faster: smoking, which narrows the same small vessels feeding the bone plates; sustained loading without recovery; obesity; a genetic hand you did not choose, which explains more of the variation than most people expect; and — this is the one worth knowing before you read the rest of this page — steroid injections, which reliably reduce pain and reliably make the tissue heal worse.

Set against that, regeneration in a disc means one of three things: cells surviving longer, cells making more of the water-holding molecules again, or the ring physically closing. Every claim made for BPC-157 in a back is a claim about the first two, made by way of the blood supply. Nobody claims it closes a torn ring.

## Made in the stomach, and it survives the stomach

The name is literal: Body Protection Compound. The 15-piece chain is a fragment of a larger protein that sits in human stomach juice, and its one genuinely odd physical property is that it does not fall apart in that juice for more than 24 hours. Almost no peptide survives a stomach. That single property is the only reason a swallowed form is discussed at all, and it points at the gut as the compound's home ground.

Nearly the whole research record traces to one group in Zagreb, Croatia, led by Predrag Sikirić, running since 1993 and now past 150 papers.

That cuts both ways. It is a coherent, decades-deep programme applying one consistent dosing scheme across dozens of tissues, and it is also most of the world's evidence coming from a single group with a stake in the answer. It is the reason independent trials in people matter more here than they would for a compound many labs had poked at.

## What the different kinds of proof can and cannot tell you

Before the evidence, one table, said once, so the rest of the page does not have to keep apologising for itself.

| Kind of study | What it can settle | What it cannot settle |
|---|---|---|
| Cells in a dish | That the compound touches a specific switch inside a cell | Anything about a whole animal, a dose, or a person |
| Rats and dogs | That it changes a real injury in a living body, and by how much | Whether the same thing happens in a human, at what dose, or with what harm |
| Small safety studies in people | That a given dose did not visibly hurt a few dozen people over days | Whether it works, for anything |
| Chart reviews and phone follow-ups | What people remembered when asked | Whether the compound or the passage of time caused it |
| Randomised placebo trials | Whether it works | Nothing else needed — this is the one that settles it, and for a torn tissue none has finished |
| Forum and social posts | What exposure people are actually running, and what harms turn up at that exposure | Whether it works. Not weakly — not at all |


## Five studies in people, and the biggest one about an injury was a round of phone calls

FDA compiled the total published human experience for its July 2026 review. It is short enough to print in full.

| Study | How it was taken, and how much | People | Design | What happened |
|---|---|---|---|---|
| Healthy volunteers, rectal | up to 2 mg/kg daily × 8 days | 24 | Safety only | Nothing serious; headache and wind most common |
| Ulcerative colitis (Ruenzi 2005) | 80 mg rectal daily × 2 weeks | ~53 split into groups, ~26 treated | Randomised; published only as a conference abstract | Difference between groups 1.6 points, range −4.84 to 1.62 — the range crosses zero, so no effect was shown |
| Knee pain (Lee & Padgett 2021) | 2–4 mg into the joint, 1–2 injections | 17 found, 16 reached | Looked back at charts, then rang people up | 14 of 16 (87.5%) said they felt better; no dummy injection, no pain score, no scan |
| Interstitial cystitis | 10 mg into the bladder | 12 | No comparison group | Nothing serious reported |
| Healthy volunteers, into a vein | 10 mg then 20 mg | 2 | Safety pilot | No harm seen |

[[embed:source:w_9qu2rfyq]]

Two things fall out of that table and they are both worth sitting with.

The only randomised trial ever run on BPC-157 in a person was about an inflamed bowel, it exists only as a conference abstract, and the result range crosses zero — meaning the treated group and the untreated group cannot be told apart. And the only published report of BPC-157 doing anything for a musculoskeletal injury in a human is somebody reading old charts and then telephoning the people in them.

[[embed:source:w_nfh8rh08]]

Eleven of twelve people who got BPC-157 alone in that knee series said they improved a lot. There was no dummy injection, no random assignment, no standard pain questionnaire and no imaging. That is exactly the design that cannot separate a real drug effect from the well-known fact that sticking a needle into a sore knee makes people feel better for a while.

[[embed:source:s3]]

[[embed:source:s27]]

Two registered trials matter. A 2015 safety and absorption study in 42 healthy volunteers in Mexico gave single swallowed doses of 1 mg, 3 mg or 6 mg, then 3 mg every eight hours for two weeks. It never posted results, and the results submission was formally cancelled in 2016. Nobody knows what it found.

[[embed:source:w_rwwqkuud]]

The trial that could actually settle the tissue-repair question started recruiting in February 2026. It is randomised, double-blind, placebo-controlled, injected under the skin once a day for 14 days alongside a standard rehab programme, in 120 people aged 18–45 who have a grade II hamstring tear confirmed on a scan within 72 hours of doing it. The two things being measured are days until they can play sport again and the change in the size of the injury on the scan from day 0 to day 14. It is expected to finish in February 2027.

[[embed:source:s6]]

Until that reads out, there is nothing controlled in a human for any soft-tissue injury. Not weak data. None.

## Rats: what happened, in which tissue, at what dose

This is where nearly all the positive findings live. Read it as a picture of what the compound does in a living body when everything about the animal, the dose and the injury is controlled — and remember that the animals were young, healthy and injured on purpose, which is not your disc.

### A rat Achilles torn off the bone came back mechanically stronger

The join between tendon and bone is the hardest soft-tissue repair in the body and the one that most often fails. In rats whose Achilles tendon was surgically cut off the heel bone, BPC-157 raised the load the repair could take before failing, its stiffness and its springiness, all significantly above untreated animals. Under the microscope the collagen fibres were better lined up, there was more type I collagen — the strong, rope-like kind — and more blood vessels had grown in. Dose was 10 µg/kg, 10 ng/kg or 10 pg/kg into the belly cavity once a day, starting 30 minutes after surgery.

The same paper carries the finding most relevant to anyone who has already had a cortisone shot: the steroid 6α-methylprednisolone consistently made the healing worse, and BPC-157 substantially undid that damage.

[[embed:source:w_59xoi0m3]]

### Cut a ligament, crush a muscle, or sever the join between them — all three healed faster

The ligament model cut through the medial collateral ligament in rats and followed them 90 days. Treated animals came out ahead on four separate measures at once: how the leg worked, how strong the ligament was, how it looked to the eye, and how it looked under the microscope. Three different ways of giving it each worked — injection into the belly cavity at 10 µg/kg or 10 ng/kg daily, a cream at 1.0 µg per gram rubbed on, and plain drinking water at 0.16 µg/mL.

[[embed:source:w_ccsq5zep]]

The muscle model both cut through and crushed the rat calf muscle, and deliberately gave the animals a steroid to wreck the healing. The authors' finding is that BPC-157 completely reversed that steroid damage, given either by injection or as a cream, with the leg working normally again in treated animals.

[[embed:source:w_gttxaz57]]

The place where muscle turns into tendon — a classic site of grumbling strain that never settles — got its own study. In treated rats the injured leg's stiffening resolved completely, while untreated animals stayed disabled. The muscle wasting seen in untreated animals was prevented. By days 28 to 42 the new tissue ran in the right direction instead of being bridged by scar. Both the microgram and the nanogram doses worked.

[[embed:source:w_urj74cu2]]

The biggest recent study, from January 2025, pulled the quadriceps entirely off its bony anchors and then treated the rats only through their drinking water. The vastus muscles reattached as early as 21 days. Rectus femoris was back to normal anatomy at about 28 days. At three months the mature fibres ran parallel to the bone and sat right against it. Reattachment was tracked on ultrasound — the same imaging used on people.

[[embed:source:w_67ce14vu]]

The review that swept this whole literature screened 544 papers and kept 36. Thirty-five of the 36 were animal or lab work. Across muscle, tendon, ligament and bone the results point the same way: better function, better structure, better mechanical strength. The same authors put the counterweight in the same breath — harm is possible from unregulated manufacturing, contamination, and the fact that safety in people is unknown.

[[embed:source:w_bburqn2u]]

### A cut sciatic nerve regrew faster, which is the nearest thing to a nerve finding

Rats with a completely severed sciatic nerve got 10 µg/kg or 10 ng/kg into the belly cavity, into the stomach, locally at the repair site, or loaded straight into the tube bridging a removed segment. Self-mutilation of the dead-feeling limb — the standard sign that a rat's nerve pain is bad — did not happen in treated animals. Electrical testing showed stronger muscle signals. Weekly walking tests improved. Counting fibres under the microscope found more of them, thicker, with better insulation around them, at one to two months.

[[embed:source:w_032xvatb]]

Read what that is and is not. It is a nerve cut clean through and sewn back together. It is not a nerve being slowly squashed by a bulging disc or a tight tunnel in the wrist. No study of BPC-157 in a squashed or chronically compressed nerve has ever been published. The difference is not a technicality: a cut-and-repaired nerve has to regrow along a clear path, and a squashed nerve has to survive a mechanical problem that is still there. Different problems, different bottlenecks.

### Nobody has ever tested it on a disc

Two rat spinal-cord studies exist and both squash the cord itself, not a disc.

The 2019 study opened the spine at L2–L3 and compressed the tail end of the cord for 60 seconds, then gave a single injection into the belly cavity ten minutes later at 200 µg/kg or 2 µg/kg. Treated rats got progressively better tail movement, did not self-mutilate, and their spasticity had resolved by day 15, with less swelling and fewer dead motor nerve cells in the grey matter.

[[embed:source:s127]]

The 2022 follow-up is the more interesting one, because it waited before treating. After a one-minute squash by a 60–66 g weight that definitely paralysed the tail, one group got 2 µg/kg into the belly cavity at ten minutes. A second got a 10 ng/kg dose into the stomach on day 4. A third drank 10 µg/kg in water from day 4 to day 30. Recovery was described as fast and lasting out to a full year, with only patchy swelling, minimal bleeding and no loss of nerve insulation at day 30. Treatment started four days late still worked — which matters, because nobody turns up at a clinic ten minutes after their back goes.

[[embed:source:w_dmscp9sw]]

Neither of those is a disc. There is no published study of BPC-157 in a herniated or worn-out disc, in any species. And the doses used in the spinal work run up to a hundred times the doses used in the tendon work, so you cannot even carry a number across.

The argument people make for the disc goes like this: the disc has almost no blood supply, its healing is therefore limited by blood supply, and BPC-157's main proposed action is growing new blood vessels — so it should help. That argument is coherent. It also has no animal model behind it, let alone a human one. Nobody has put this compound in a degenerating disc and looked.

There is one more wrinkle worth stating, because it runs the other way. A worn disc is not supposed to have blood vessels in it. Part of what goes wrong in a painful disc is that vessels and pain nerves grow *into* the cracked ring, from the outside in, and that ingrowth is one of the better-supported explanations for why some worn discs hurt and others do not. A compound whose headline action is growing new vessels is being proposed for a tissue where new vessel growth is part of the pain. Nobody has tested which way that lands.

## How the compound is supposed to build tissue back

Strip the marketing and the proposed action is a short chain you can check link by link.

BPC-157 raises the signals that grow new blood vessels at an injury. New vessels bring oxygen and repair cells to tissue that had neither. Alongside that, it pushes collagen production and gets tissue-building cells to crawl into the gap.

The receptor step has been worked out in detail. In the cells that line blood vessels, BPC-157 makes the cell pull VEGFR2 — the main docking point for the body's chief vessel-growing signal — inside itself, and then switches on the VEGFR2–Akt–eNOS chain over time. Block the pulling-inside step with a chemical called dynasore and the whole effect disappears, which means the pulling-inside is required, not incidental. Vessel density went up both in a dish and in living animals, and blood flow came back faster in muscle that had been starved of it.

[[embed:source:w_fo79e9nk]]

The crawling step has its own named mechanism. In tissue-building cells taken from rat tendon, BPC-157 dose-dependently added phosphate groups to two proteins, FAK and paxillin, which are the machinery a cell uses to grip a surface and haul itself along. The total amount of those two proteins did not change; only the switched-on fraction rose. The same study found the cells were not making more of themselves, so the effect is cells moving and surviving, not cells multiplying in number.

[[embed:source:w_ud0jx8hb]]

A third mechanism sits underneath both. Tendon cells given BPC-157 at 0.5 µg/mL grew about seven times more growth hormone receptors by day three, measured both as the instruction and as the finished protein. The cell does not get more growth hormone. It gets better at hearing the growth hormone already going past.

[[embed:source:w_y4s15wvm]]

Nitric oxide — the gas that makes vessels widen — is pushed up in some situations and down in others, always paired with mopping up damaging free radicals. The Zagreb group reads that two-way behaviour as the whole point of the molecule: it pushes tissue toward normal rather than in one fixed direction. FDA reads the same observation as the reason no dose-response curve has ever been drawn for it. Both readings fit the data.

[[embed:source:s38]]

Now map that chain onto your disc, honestly. Link one, new vessels: real, shown in cells and in rats, never in a disc. Link two, vessels feeding a starved tissue: real in muscle, never shown in a disc, and a disc is starved through hardened bone plates rather than through missing vessels, which is a different blockage. Link three, cells making the water-holding molecules again: never studied for this compound, in any tissue. The chain has a hole in the middle of it exactly where your problem is.

## The painkiller you are probably already taking runs the opposite way to expected

Most people who arrive with back pain are already on an anti-inflammatory, and most compounds interact badly with those. This one was studied as an antidote to them.

Diclofenac at 12.5 mg/kg into the belly cavity once daily for three days produced severe stomach, gut and liver damage in rats, raised bilirubin, AST and ALT, made the liver heavier, and caused prolonged drowsiness that progressed to liver-driven brain failure with brain swelling and damaged nerve cells. BPC-157 blocked that entire cascade at both the microgram and the nanogram dose, given either by injection or in drinking water.

[[embed:source:w_odtbasyy]]

Read carefully, that is a gut-and-liver protection finding, not proof that combining the two heals a tendon better. What it does mean is that the medicine most likely to already be in the room is not, in rats, a documented problem.

The steroid interaction is the more useful one for a back. Two separate studies show BPC-157 undoing the damage a corticosteroid does to healing tendon and muscle. If you have had a cortisone injection into a joint or around a nerve root, the animal data says that shot measurably impaired the repair you went in for, and that this compound reversed that impairment in rats. That is the single most relevant animal finding on this page for a person with a degenerating spine, because so many people arrive having already had the shot.

## It is gone from your blood in about fifteen minutes

The only published measurements of what the body does to this compound come from rats and beagles.

Average time to clear half of it: 15.2 minutes. In dogs given it into a vein, 5.27 minutes. Peak level in the blood arrived three minutes after an injection into muscle. How much reaches the blood after an injection into muscle (bioavailability) was 14–19% in rats and 45–51% in dogs — wildly different between two species, and far from all of it. It leaves in urine and bile. Levels in kidney, liver, stomach wall, thymus and spleen went well above the level in blood.

[[embed:source:w_n7ahbrni]]

A compound cleared that fast cannot be working by keeping a steady level in your blood. Whatever it does, it does fast and locally, then sets off a slower tissue process that outlasts the exposure by weeks. Two practical things follow. First, that is the argument for splitting a daily dose rather than taking it all at once. Second, a once-a-week schedule has nothing behind it.

No measurement of any of this has ever been made in a person. Every number in this section is a rat or a dog, carried across species by assumption.

## Turning powder into a dose is arithmetic, not judgement

BPC-157 arrives as a freeze-dried white powder in a sealed glass vial, usually 5 mg or 10 mg. You add liquid to it. The liquid is bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is the thing that lets you put a needle into the same vial repeatedly over weeks. Plain sterile water dissolves the powder fine but has no preservative, so that vial is a one-time proposition.

The measuring device is a U-100 insulin syringe. U-100 means 100 units in a millilitre, so one unit on the barrel is 0.01 mL. Every conversion you will ever need comes from two lines:

- Micrograms per mL = total micrograms in the vial ÷ mL of water you added.
- Micrograms per syringe unit = that number ÷ 100.

Worked through: a 10 mg vial holds 10,000 mcg. You add 2 mL of bacteriostatic water. 10,000 ÷ 2 = 5,000 mcg per mL. 5,000 ÷ 100 = 50 mcg in one unit. A 250 mcg dose is therefore 250 ÷ 50 = 5 units on the barrel.

| Vial | Water added | Strength | Mcg per unit | Units for 250 mcg | Units for 500 mcg | Doses in the vial at 250 mcg |
|---|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 10 | 20 | 20 |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 20 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 5 | 10 | 40 |
| 10 mg (10,000 mcg) | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 40 |
| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 40 |

Adding more water does not add or remove peptide. The vial holds what it holds. More water only changes how many syringe units carry a given dose. More water gives you bigger, easier-to-read unit counts and a slightly bigger squirt going in. Less water gives you a smaller sting and finer lines to misread. Below about 5 units per dose, the error in reading a U-100 barrel starts to swamp the dose itself — which is the practical argument for putting 3 mL rather than 2 mL into a 10 mg vial.

Ruining the peptide by accident is easy. Let the vial come to room temperature first. Run the water slowly down the inside wall of the glass rather than blasting it onto the powder. Swirl until it dissolves. Never shake it — shaking tears at the surface where liquid meets air, which unfolds peptide chains and makes them clump together, and clumping is the exact thing FDA named as the trigger for the immune system reacting to it (immunogenicity).

## The clock starts the moment you add water

| State | Temperature | How long it actually lasts |
|---|---|---|
| Sealed, still a powder | 2–8 °C, out of the light | Months to years, to the maker's date; −20 °C for long holding |
| Mixed with bacteriostatic water | 2–8 °C | About four weeks — that limit is set by the preservative, not the peptide |
| Mixed, left on the counter | 20–25 °C | Hours to days; treat it as ruined |
| Mixed, then frozen | −20 °C | Do not. Freezing and thawing clumps the peptide |

Do the arithmetic against your own plan before you buy. A 10 mg vial at 250 mcg a day is 40 doses. Four weeks is 28 doses. You will throw away roughly a third of the vial, or you must buy a smaller one, or take more per day. There is no fourth option — refreezing it is the one thing that definitely damages it.

## Where the needle goes was never settled, because nobody asked the animals

Two placements compete and the animal work cannot referee between them, because rats were dosed into the belly cavity, into the stomach or rubbed on the skin, almost never at a specific human-style injection site.

- **Under the skin, near the sore part.** What most people do. The argument is a higher concentration where the repair is needed, which fits a 15-minute clearance and fits tissue levels running above blood levels.
- **Under the skin of the belly, anywhere.** Standard for gut, nerve and organ targets, and easier to do to yourself. The argument is that a compound reaching kidney, liver and stomach wall above blood level obviously travels, so the entry point may not matter.

The evidence tilts slightly toward the entry point not mattering. Several of the strongest structural results in the entire literature — the cut ligament, the muscle-tendon junction, the quadriceps reattachment, the sciatic nerve, the spinal cord — were produced in rats that simply drank the compound and still repaired a specific injury a long way from their gut. Nothing anywhere in the record shows a local injection beating a systemic one head to head.

Here are the doses that exist, all of them either from rats or scaled up from rats:

| Where the number comes from | The dose | How long |
|---|---|---|
| The standard rat tier | 10 µg/kg, 10 ng/kg or 10 pg/kg once a day | For as long as the study ran |
| The rat drinking-water equivalent | 0.16 µg/mL in water, about 12 mL per rat per day | For as long as the study ran |
| Scaling 10 µg/kg straight up to a 70 kg adult | about 0.7 mg per day | Not an established human dose. Just arithmetic |
| Given to humans into a joint, published | 2–4 mg per injection, 1–2 injections | One course |
| Given to humans by mouth, published (2015 Phase 1) | 1, 3 or 6 mg once; then 3 mg every 8 hours | Two weeks |

There is no validated human dose, no validated cycle length, no taper and no ceiling. USADA states it without softening: nobody knows whether a safe dose exists, or whether there is any way to use this compound safely for a named condition.

[[embed:source:w_af5ht9pr]]

Now notice what the table shows, because it is the single most overlooked fact about this compound. Every dose ever given to a human in a published study is measured in **milligrams**. Scaling the standard rat dose up to an adult lands at roughly 0.7 mg. The regimens circulating on forums and printed on vendor sites are measured in **micrograms** — a thousandth of a milligram — and land around 250 to 500 mcg. That is roughly a hundredth of anything ever formally given to a person. Nothing in the literature supports the microgram regimens. Nothing in the literature refutes them either. The dose question is not contested; it is simply open, and everyone taking it is guessing.

## The tablet and the vial are not the same product

Swallowed BPC-157 exists as capsules or tablets, commonly 500 mcg each, and the stomach-survival finding is what makes that format arguable at all. But surviving your stomach acid and getting into your bloodstream are two separate questions, and only the first has ever been shown in a person.

| | Tablet you swallow | Vial you mix and inject under the skin |
|---|---|---|
| What is actually proven about this route | Survives human stomach juice past 24 hours | In rats, 14–19% of an injection into muscle reaches the blood; in dogs, 45–51% |
| Animal evidence using this route | Substantial — the ligament, muscle-tendon junction, quadriceps reattachment, nerve and spinal cord studies all worked with the compound given by mouth or in water | Extensive, but nearly all of it into the belly cavity rather than under the skin |
| What has been given to humans this way | 1–6 mg by mouth in the 2015 Phase 1; 80 mg per enema in the colitis trial | 2–4 mg into a joint; 10–20 mg into a vein |
| Best-supported target | The gut, and any whole-body target where the rat drinking-water arm worked | Musculoskeletal — by convention, not by any head-to-head comparison |
| How much gets into a human's blood | Never measured | Never measured |
| What it costs you in practice | No needles, no mixing, no four-week clock | Needles, arithmetic, a fridge, and a four-week clock |

The evidence is friendlier to the swallowed route than the injection convention implies. Several of the strongest structural repair results in the whole corpus — ligament, muscle-tendon junction, muscle reattached to bone, delayed spinal cord recovery — came from rats drinking it in water. What nobody has is a measurement of how much of a swallowed dose gets into a human's blood, so choosing between the two forms rests on rat route data and on convenience, not on anything measured in a person.

## How long anything would take, if it worked

Timelines here are set by tissue biology, not by the compound. Collagen remodels at the speed collagen remodels. Nerves regrow at about a millimetre a day. Nothing changes that.

| Model | Time to the reported result |
|---|---|
| Squashed spinal cord, spasticity gone | 15 days |
| Quadriceps reattached to bone, vastus muscles | 21 days |
| Quadriceps reattached to bone, rectus femoris | ~28 days |
| Muscle-tendon junction, tissue running the right way | 28–42 days |
| Cut sciatic nerve, function and microscope findings | 1–2 months |
| Cut medial collateral ligament, full follow-up | 90 days |
| Hamstring tear Phase 2, injury size on scan | 14 days (the primary measure; reads out 2027) |

No human timeline has been established, because no controlled human trial has finished.

The one inference that is honest: these are collagen and nerve timescales — four to twelve weeks. Anything promising a result inside a fortnight is describing pain relief, not repair. That distinction has a consequence you can act on. Pain relief arrives before tissue has been rebuilt. If you feel better at day 10 and go back to loading your spine on that signal, you are loading a structure that has not changed.

## FDA's own toxicology is more specific than the safety talk around it

The Zagreb group's stated position is that BPC-157 is very safe, with no side effects in trials and a lethal dose never reached in toxicology work. FDA read the same body of work and described it differently.

In 28-day repeat-dose studies injecting into muscle, rats showed shortened clotting time and dogs showed lengthened clotting time on the same test — an unexplained effect on clotting that runs in opposite directions in two species. Blood ALT, glucose and triglycerides went up. No cancer-causing study of BPC-157 in either of its two chemical forms has ever been done. It did not damage DNA, and no birth-defect signal appeared when it was injected through gestation days 6–15.

FDA raised four objections. They are independent of each other, which means answering one leaves the other three standing.

| The objection | What it actually means |
|---|---|
| Not enough clinical safety information to describe the safety profile | The human safety file is too small to draw a picture from — not "reassuring so far", but too small to say anything |
| Real risk that the immune system reacts to it, made worse by clumping and by peptide impurities | Part of the risk comes from how it is made and handled, not from the molecule alone |
| No dose-response relationship established | The flat pattern where micrograms, nanograms and picograms all work reads to FDA as a weakness, not a feature |
| No molecular target identified | Despite the VEGFR2 and FAK work, no confirmed receptor has been pinned down |

[[embed:source:w_9qu2rfyq]]

## The cancer question has a real answer and a real hole in it

The worry is mechanically sensible. A tumour cannot grow past a millimetre or two without recruiting new blood vessels. A compound whose headline action is growing new blood vessels could, in principle, supply them. An independent 2025 review states the worry and lands on the practical version of it: a cancer nobody has found yet.

[[embed:source:w_uhm2s5ar]]

The Zagreb group published a formal rebuttal in the same journal. Their case is that BPC-157 strongly *blocked* vessel growth into the cornea, that it has shown anti-tumour activity both in living animals and in a dish, and that its nitric oxide effect is always paired with mopping up free radicals — that it pushes vessel growth toward the normal, self-limiting kind rather than driving it indiscriminately.

[[embed:source:s131]]

Where that leaves you: no published rodent study shows BPC-157 speeding up tumour growth. No cancer-causing study exists. There is zero human cancer safety data. An active or suspected cancer is the one situation the mechanism itself argues against, and the missing study means the argument cannot be closed either way. If you have had a cancer, this is the question to take to your oncologist rather than to a forum.

## FDA said no, and its own advisory committee said yes by two votes

The regulatory position moved twice during 2026, and most summaries you will find online are stale.

| Date | What happened |
|---|---|
| Sept 2023 | FDA puts BPC-157 in Category 2 of the 503A bulk-substances list — significant safety risk, which bars compounding pharmacies from making it |
| 14 May 2026 | The revised interim list carries only six substances in Category 2. BPC-157 is in none of Categories 1, 2 or 3 — the nominations were withdrawn |
| July 2026 | FDA's own briefing document recommends against adding BPC-157 to the 503A list |
| 23 July 2026 | The Pharmacy Compounding Advisory Committee votes 8–6, with one abstention, to recommend adding it — against FDA's own staff |

If a page you are reading still says BPC-157 is FDA Category 2, it has not been updated since 14 May 2026.

[[embed:source:w_ghpbaz64]]

One detail in the meeting agenda changes what that vote means. The only condition FDA evaluated was ulcerative colitis. Tendonitis was among the uses put forward, and FDA declined to evaluate it because there was not enough information. A favourable vote about a bowel condition is not a favourable vote about tendon or disc repair, and it is being quoted as though it were.

[[embed:source:w_38qd7eam]]

The committee itself was not persuaded of much. One panelist who voted yes described the thing being voted on as a black box. One who voted no pointed out that roughly 30% of people given a dummy treatment report improvement — sometimes even on objective measures — which is the entire difficulty with the uncontrolled reports the nomination rested on.

[[embed:source:w_oje4lc91]]

Reporting on the meeting noted that a majority of the panelists voting yes had ties to the peptide industry.

[[embed:source:w_lkfuwkh8]]

The vote creates no authority. It is advisory, FDA is not bound by it, and a formal rulemaking cycle realistically runs eight to twelve months.

[[embed:source:s129]]

## There are two legal ways to compound a peptide and BPC-157 is on neither list

503A covers traditional compounding pharmacies. 503B covers registered outsourcing facilities, and it is a separate list with a separate standard: an outsourcing facility may not compound with a bulk substance unless that substance is on the 503B list, or the finished medicine is on FDA's drug shortage list at the time. BPC-157 is not on the 503B list, and the July 2026 vote concerned 503A only.

[[embed:source:w_iff2eacs]]

That same page sets out what FDA expects of any lawfully compounded substance: a valid certificate of analysis, manufacture by an establishment registered under section 510 of the FD&C Act, and compliance with any applicable USP or National Formulary monograph. Grey-market BPC-157 meets none of the three.

## If you compete in anything, this is a strict-liability problem

BPC-157 is named explicitly on the WADA 2026 Prohibited List under S0, Non-Approved Substances, banned at all times — not just on competition day. S0 covers any substance with no current approval by any government health authority for human use anywhere, which is exactly what BPC-157 is.

[[embed:source:w_u19qrezt]]

Strict liability means you are responsible for what is in your body regardless of intent and regardless of who recommended it. That applies at college, professional and masters level, in sports most people do not think of as drug-tested.

The Department of Defense goes further. Its Operation Supplement Safety programme lists BPC-157 on the Prohibited Dietary Supplement Ingredients List and states the position flatly: BPC-157 is not a dietary ingredient, it is an unapproved drug. That applies to service members however it is taken.

[[embed:source:w_h2eu8h3c]]

## "Research use only" is a shipping label, not a legal category

Nearly all BPC-157 sold to the public is labelled a research chemical, not for human consumption. That phrase creates no lawful route to a person. It is a disclaimer attached to a product with no legal standing as a medicine, a food or a supplement in the United States. USADA names the tell directly: sites that print "research only" while also printing human dosing instructions are describing what they expect to happen.

The purity problem is the concrete risk, and it is bigger than the legal one. Independent testing of grey-market peptide samples finds mislabelling, wrong dosing or contamination in roughly 30%, and the contaminant classes are specific: bacterial toxins, incomplete chains that are missing pieces, leftover solvents, heavy metals, live microbes and breakdown products. Incomplete chains and clumping are the same two failure modes FDA named as the things that make an immune reaction more likely — which means the supply-chain risk and the drug risk are the same risk wearing two hats.

[[embed:source:w_macsi7l3]]

> 30% contained incorrect amino acid sequences and two-thirds of samples fell below the 95% purity threshold.

[[embed:source:s130]]

A certificate reading "99% by HPLC" does not clear a batch, and understanding why is worth two minutes. HPLC confirms the target peptide is there and measures how much of the total it is. It says nothing about what the other 1% consists of. An incomplete chain or a fever-causing bacterial toxin sits inside that remainder and never shows up. What you want is HPLC *and* mass spectrometry, done per batch, by a laboratory that is not the seller. A vendor's own certificate is not third-party testing, and a certificate photographed from a different batch is not a certificate at all.

## Which problems the evidence actually reaches

Every positive animal model in this literature is an acute surgical injury — a tendon cut through, a ligament severed, a muscle crushed, a tendon torn off bone, a nerve cut. There is no rat model of a fifteen-year grumbling tendon, and no reason to assume a repair signal helps tissue whose problem is failed remodelling rather than an unfilled hole.

| Your problem | What the animal data actually covers | How strong |
|---|---|---|
| Fresh tendon tear or rupture | Achilles cut through and torn off bone: strength to failure, stiffness, type I collagen all improved | Strongest animal case |
| Tendon pulling off bone | Achilles detachment and quadriceps reattachment, confirmed on ultrasound at 21–28 days | Strong in animals, nothing in humans |
| Ligament sprain | Medial collateral ligament cut through, 90-day follow-up, four measures | Strong in animals, nothing in humans |
| Fresh muscle strain | Calf muscle cut and crushed; the one Phase 2 trial targets a grade II hamstring | Animals plus one trial reading out 2027 |
| Pain where muscle becomes tendon | Its own rat model; stiffening resolved, wasting prevented | Strong in animals, nothing in humans |
| Healing spoiled by a cortisone shot you already had | Two studies show the steroid damage to tendon and muscle healing reversed | Animals, directly relevant, nothing in humans |
| You are on daily anti-inflammatories | Diclofenac damage to gut, liver and brain fully blocked | Animals; a protection finding, not a repair finding |
| Nerve cut and surgically repaired | Sciatic nerve: electrical signals, walking, insulation all improved | Moderate in animals, nothing in humans |
| Long-standing overuse tendon pain | No model exists. Every positive study is a fresh injury | Weak — the mechanism does not obviously apply |
| Carpal tunnel or other trapped nerve | No compression model exists | Absent |
| Herniated lumbar disc, sciatica | No disc model exists. Nearest thing is a squashed rat spinal cord at a 100× dose | Absent |
| Degenerative disc disease itself | Nothing. Not one study, in any species | Absent |

Three rows carry the weight and they are not the three people expect.

The cortisone-reversal row is the most useful finding in the entire animal literature, because a large share of people with a bad back arrive having already had a steroid injection that measurably worsened the healing they came in for. If any part of this compound's animal record applies to you, that is the part with the clearest logic behind it.

The long-standing-tendon-pain row is weak exactly where demand is highest.

And the two disc rows are empty. The problem people ask about most is the one with no animal model at all — and, as the next section shows, it is also one of the problems that generates the loudest success stories.

## Fifty people said what happened to them, and here is the count

Everything above this heading is evidence. Everything below it is testimony, and the difference is not a matter of degree.

This page holds 50 first-person accounts posted publicly between 2015 and 2026 — 40 on Reddit across r/Peptides, r/steroids, r/backpain, r/Sciatica, r/climbharder, r/PEDs, r/Biohackers, r/moreplatesmoredates, r/PeptideGuide, r/Peptidesource and r/Supplements, and 10 on X. Every one is self-reported by a person you cannot identify or question. Nobody assayed their vial, so the substance in the syringe is unknown in every single case. Nobody was randomly assigned. Almost nobody scanned the injury before and after. People who got better write posts more often than people who did not, so the set is filtered before you even read it.

It is here for one reason. No controlled trial in a human musculoskeletal injury has ever finished, so this is the entire record of people using it for the reasons you are considering it — and it is what you have already read by the time you got to this page.

### The count, with the denominator

Of the 50 accounts, 13 report no personal result at all — they are protocols, questions, general threads about the science, or one person's dosing accident. That leaves **37 accounts that state what happened to the person writing**. Here is the split:

| What they reported | Count | Share of the 37 |
|---|---|---|
| It helped — clear improvement they credit to it | 18 | 49% |
| Partly, or it faded, or they could not separate it from other things | 5 | 14% |
| Nothing happened | 10 | 27% |
| It made something worse | 4 | 11% |

Read that table twice. Half of the people who reported an outcome said it helped, and half did not. If you have seen this compound described online, you have almost certainly seen a version of that record where the 14 accounts reporting nothing or harm were left out. That version is a lie by selection, and it is the standard version.

Four more things the raw count hides.

The 10 "nothing happened" accounts are not shorter courses or smaller doses than the successes. Several ran six weeks or more at the same 500 mcg a day that the successes ran.

The 4 harm reports describe things the rat toxicology gives no reason to expect and the five human studies were far too small to catch: a joint that got worse and inflamed, vision going blurry over weeks, a finger swelling with fluid, and leg pain returning during treatment for a herniated disc.

One account reports a ten-fold dosing accident, which is a safety datapoint of its own and the reason the reconstitution arithmetic earlier on this page matters more than it looks.

And exactly one account in 50 reports an objective check by a clinician. One. Everybody else is reporting pain, movement and confidence — the three things most responsive to time, rest and expectation.

### The 18 who said it helped

[[embed:source:w_xmo3vo5n]]

[[embed:source:w_xypc4fgc]]

[[embed:source:w_ihoinuk1]]

[[embed:source:w_iquapnzf]]

[[embed:source:w_vhlzhg4n]]

[[embed:source:w_mez2amn7]]

[[embed:source:w_z8sd87d2]]

[[embed:source:w_5icolfqk]]

[[embed:source:w_8uy508st]]

[[embed:source:w_e1ub04di]]

[[embed:source:w_as6ue9dv]]

[[embed:source:w_e8sw6xul]]

[[embed:source:w_qqu8pdaq]]

[[embed:source:w_q512lyfs]]

[[embed:source:s82]]

[[embed:source:s83]]

[[embed:source:s93]]

[[embed:source:s101]]

Two of those deserve a note rather than applause. The account crediting a clinician with saying the tear was gone is the single best entry in the whole set, and even that was a re-examination, not a repeat scan. And the account that asks itself "is this placebo?" also added collagen and more protein in the same window, which the writer says outright — that honesty makes it more useful than the confident ones, not less.

### The 5 who got part of a result, or lost it

[[embed:source:w_sg898nqt]]

[[embed:source:w_vljlka3r]]

[[embed:source:w_q3b1i12c]]

[[embed:source:w_iqb7rlvn]]

[[embed:source:w_brwijbo1]]

The last one is a pattern with no counterpart anywhere in the published literature: the effect fading on a steady dose, then not returning when the dose was raised. Nothing in the rat work predicts that. Nothing in the pharmacology explains it.

### The 10 who said nothing happened

These are the entries marketing copy leaves out. They are the same doses, the same durations, and several of them are longer courses than the successes.

[[embed:source:w_jdqqio36]]

[[embed:source:w_fhil2can]]

[[embed:source:w_8dxl599w]]

[[embed:source:w_0t8zcb1s]]

[[embed:source:w_txuoas2j]]

[[embed:source:w_9l5g0ldo]]

[[embed:source:w_8kdirxz8]]

[[embed:source:w_18w5khoc]]

[[embed:source:w_hf6dcwyh]]

[[embed:source:w_mjx06qhj]]

The standard reply offered inside these threads to a negative report is that the person got a bad vial. That reply cannot be checked — nobody in this set tested their product — and it is the exact mechanism by which a grey-market compound builds a record that can never fail. Every success counts as evidence; every failure counts as a counterfeit.

### The 4 who got worse

[[embed:source:w_epyzmnva]]

[[embed:source:w_ucf38h39]]

[[embed:source:w_usaqx7am]]

[[embed:source:w_0d8jnd1s]]

The first of those is the one to read closely if you have a disc problem: leg pain returning and worsening during a course taken specifically to heal a herniated disc. That is the exact situation this page is about, and it is a harm report, not a success.

The second describes one joint improving while another got inflamed and worse in the same person, on the same dose, in the same course.

### The dosing accident, and where the numbers came from

[[embed:source:w_wnund5ki]]

That is ten times the intended dose, caused by misreading a syringe barrel. Nobody was hurt. It is on this page because the numbers everyone uses have nothing under them, and the people using them say so plainly:

[[embed:source:w_o9okgjxa]]

[[embed:source:w_mzg8md2j]]

[[embed:source:w_xk3kn65m]]

[[embed:source:w_1t3oc07y]]

Almost every account in the set describes 250 to 500 micrograms a day, under the skin, sometimes split into two or three shots, run for four to eight weeks. That band converged by copying, not by measurement. It is about a hundredth of the milligram doses used in every published human study.

### The 13 that report no outcome at all — including the six loudest posts here

Thirteen of the 50 accounts state no personal result. Seven are the protocols and dosing arguments already shown above. The other six are X posts, and they are worth looking at separately, because they are almost certainly the format in which most people first meet this compound.

[[embed:source:s88]]

[[embed:source:s89]]

[[embed:source:s99]]

[[embed:source:s100]]

[[embed:source:s95]]

[[embed:source:s96]]

Read what those six actually are. Four are summaries of the animal literature written in the voice of personal endorsement — "repaired 5 different tissues", "no compound heals as many tissue types" — with a dose attached at the end and no report of the writer's own outcome anywhere in them. One is a person asking for an alternative. One is a person saying they never took it but wish they had.

They are in this count because leaving them out would be dishonest, and they are separated out because counting them as successes would be worse. The most confident writing about this compound contains the least first-hand information in it, and that is the single most useful thing this section can tell you.

### Where the accounts contradict the animal work

The animal record is strongest for fresh injuries and weakest — or empty — for long-standing tendon pain and for discs.

The forum record inverts that exactly. Long-standing elbow, wrist and shoulder tendon pain of one to five years' standing is the most common thing people treat. Herniated discs and sciatica — the problem with no animal model whatsoever — generate some of the most emphatic success reports on this page.

The single most emphatic disc account on this page — the sciatica report above, in which pain eased over six to seven weeks of injections after everything else had failed — is also the one with the least behind it, because no animal has ever been given this compound for a disc.

Two readings fit that and the accounts cannot separate them. Either the compound reaches structures the animal work never tested, or long-standing pain that comes and goes was going to improve anyway and the compound arrived during a good month. The disc reports are the clearest case, because a herniated disc shrinks on its own in a large share of people over roughly six to twelve weeks — which is exactly the window these protocols run. Somebody who starts a course at their worst week and finishes it feeling better has described the natural history of the condition, and would have written the same post taking nothing.

The swallowed route contradicts the pharmacology the same way. Surviving stomach acid is proven; getting into a human's blood from the gut is not. People report the two forms doing different jobs, which is precisely what you would expect if the tablet works locally in the gut and never reaches a tendon at all.

[[embed:source:w_1bbc6bfn]]

### The stacking problem, which is the biggest hole in the whole set

Almost nobody takes this alone. TB-500 is combined with it so routinely that a large share of these accounts cannot attribute any outcome to either compound. Others add growth hormone, testosterone, surgery, physiotherapy, diet changes and rest inside the same weeks.

[[embed:source:w_ahk1cevh]]

The three most confident recovery stories on this page — the rotator cuff tear a clinician later called gone, the wrist rebuilt over seven vials, and the shoulder that felt 75% better in five days — were all run as BPC-157 plus TB-500, and two of them alongside structured rehab. Not one of them can tell you which part did the work.

That is not a small caveat. It means a good share of the 18 positive accounts are reports about a combination, run alongside the two interventions with the best evidence in all of musculoskeletal medicine — load management and time.

### What the counted record settles, and what it does not

It does not settle whether it works. Thirty-seven uncontrolled accounts filtered toward success are not weak evidence for a treatment effect; they are a different kind of object, and collecting three hundred more would change nothing about that. A 49% success rate in this set is not a 49% chance it works for you. It is a measurement of what people wrote down.

It does settle three things the published literature does not contain at all, and these are the reason it is worth counting rather than dismissing.

First, the real exposure. People are running 250–500 mcg a day under the skin for four to eight weeks, usually stacked with TB-500. No trial has ever studied that exposure. When somebody eventually does, this is the regimen they should test, and nobody would know it from the papers.

Second, harms at that exposure. Four of 37 accounts report getting worse — local swelling, a joint becoming more inflamed, blurred vision, and returning nerve pain. None of those appear in any published human safety dataset, because those datasets total about 130 people across five studies and would not detect a 1-in-10 problem if it existed.

Third, the mismatch. The two things people actually treat with it — long-standing tendon pain and lumbar disc disease — are the two the animal literature supports least and not at all, respectively.

The Phase 2 hamstring trial reading out in 2027 will answer the works-or-not question for one fresh injury in one muscle. Nothing currently running will answer it for a disc.

## What is settled about BPC-157, and what is not

| Status | Statement |
|---|---|
| Settled | It survives human stomach juice for more than 24 hours |
| Settled | It switches on the VEGFR2–Akt–eNOS chain and increases blood vessel density in a dish and in rodents |
| Settled | It improves mechanical strength and microscope appearance across many fresh rat injuries |
| Settled | It reverses the damage a corticosteroid does to tendon and muscle healing in rats |
| Settled | It blocks diclofenac-caused gut, liver and brain damage in rats |
| Settled | Half of it clears a rat's blood in about 15 minutes; 14–19% of an intramuscular dose reaches the blood in rats |
| Settled | It is on the WADA 2026 Prohibited List under S0, banned at all times, in and out of competition |
| Not shown | That it does anything for a musculoskeletal injury in a person — no controlled soft-tissue trial has finished |
| Not shown | That a swallowed dose reaches the bloodstream of a human |
| Not shown | That it feeds tumours — and equally not shown that it is safe if you have a cancer |
| Unknown | The right human dose. Every published human study used milligrams; everyone taking it uses micrograms |
| Unknown | Long-term safety, interactions with your other medicines, and why clotting time moves in opposite directions in rats and dogs |
| Unknown | Whether any of this reaches a spinal disc. Nobody has looked, in any species |

If you take one line from this page, take this one: the strongest argument for BPC-157 in a degenerating back is a chain of reasoning, and the strongest argument against it is that nobody has ever tested a single link of that chain in a disc. The animal work is real and it is good. It is also about tendons, ligaments, muscles and cut nerves in young rats injured on purpose, and your disc is none of those things.

*BPC-157 is not an approved medicine in any country. Everything sold to the public is grey-market and unverified. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:kpv]]

[[embed:wolverine-stack]]

[[embed:bpc-157-vs-nsaids]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:herniated-disc]]


## Sources

1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — https://pubmed.ncbi.nlm.nih.gov/30915550/
2. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — https://pubmed.ncbi.nlm.nih.gov/40131143/
3. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pubmed.ncbi.nlm.nih.gov/40789979/
4. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review — https://pubmed.ncbi.nlm.nih.gov/40005999/
5. BPC 157 for Acute Hamstring Muscle Strain Repair — https://clinicaltrials.gov/study/NCT07437547
6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine — https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
7. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity — https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/
8. Peptide BPC-157 - Does It Work? Breaking Down ... — https://www.youtube.com/watch?v=HIrI8STJPJo
9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
10. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT) — https://pubmed.ncbi.nlm.nih.gov/40759852/
11. SELFTEST graph fn ingest
12. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — https://pubmed.ncbi.nlm.nih.gov/41476424/
13. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
14. Multifunctionality and Possible Medical Application of the Stable Gastric Pentadecapeptide BPC 157 — https://www.mdpi.com/1424-8247/18/2/185
15. What Science ACTUALLY Says About BPC 157 Benefits — https://www.youtube.com/watch?v=gaQwrB8HW4o
16. The Role of BPC-157 in Tissue Repair and Pain Management — https://pubmed.ncbi.nlm.nih.gov/41898733/
17. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review — https://pubmed.ncbi.nlm.nih.gov/41754849/
18. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
19. BPC-157 – No Proof Required! — https://www.mcgill.ca/oss/article/medical-critical-thinking-health-and-nutrition-contributors/body-protection-compound-no-proof-required
20. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management — https://pmc.ncbi.nlm.nih.gov/articles/PMC13026520/
21. Pentadecapeptide BPC 157 and the central nervous system — https://pubmed.ncbi.nlm.nih.gov/34380875/
22. BPC-157: Miracle Healing Peptide or Hidden Danger? — https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
23. BPC-157 and the Difference Between an Evidence Gap and a Cover-Up — https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up
24. Stable Gastric Pentadecapeptide BPC 157 and Striated, ... — https://pubmed.ncbi.nlm.nih.gov/36551977/
25. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide — https://pubmed.ncbi.nlm.nih.gov/41155565/
26. S808 Oral Peptide BPC-157—An Emerging Adjunct to Gastrointestinal Therapies? — https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx
27. Peptides in Orthopedics: BPC-157 — What Patients Should Know About Safety, Efficacy, and Sourcing — https://www.mdorthospecialists.com/2026/04/28/peptides-in-orthopedics-bpc-157-what-patients-should-know-about-safety-efficacy-and-sourcing/
28. How does the Peptide BPC-157 Work? — https://www.youtube.com/watch?v=WjCtQM_rfBE
29. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... — https://pubmed.ncbi.nlm.nih.gov/40573323/
30. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... — https://pubmed.ncbi.nlm.nih.gov/41832718/
31. Stable Gastric Pentadecapeptide BPC 157 as Therapy ... — https://pubmed.ncbi.nlm.nih.gov/39861766/
32. Protective Effects of BPC 157 on Liver, Kidney, and Lung ... — https://pmc.ncbi.nlm.nih.gov/articles/PMC11857380/
33. Peptides and BPC-157 for Pain: What's the deal? — https://www.youtube.com/watch?v=-rIoG_UF6RI
34. Tracheocutaneous Fistula Resolved by Pentadecapeptide ... — https://pmc.ncbi.nlm.nih.gov/articles/PMC12844668/
35. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection — https://pubmed.ncbi.nlm.nih.gov/38980576/
36. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats — https://pubmed.ncbi.nlm.nih.gov/39861766/
37. Safety of Intravenous Infusion of BPC157 in Humans — https://pubmed.ncbi.nlm.nih.gov/40131143/
38. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — https://pubmed.ncbi.nlm.nih.gov/41476424/
39. The Role of BPC-157 in Tissue Repair and Pain Management — https://pubmed.ncbi.nlm.nih.gov/41898733/
40. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
41. Of all the peptides I've tried BPC-157 is my favorite. — https://x.com/mindpumpsal/status/1751417750806020447
42. BPC-157 post — https://x.com/Breedlove22/status/2071613094540030205
43. PEPTIDE MASTERCLASS: BPC-157 — https://x.com/KingOfVitamins/status/2071610257093145038
44. BPC-157 tendon healing details — https://x.com/KingOfVitamins/status/2071610274843332656
45. TB-500 with BPC-157 for tissue repair — https://x.com/Breedlove22/status/2071613106678337793
46. X post by @mariioo888 — https://x.com/mariioo888/status/2071633910514212931
47. X post by @TakeThiamine — https://x.com/TakeThiamine/status/2071621198287610002
48. X post by @BasedBiohacker — https://x.com/BasedBiohacker/status/2027900122026414320
49. X post by @HealthyAlfred — https://x.com/HealthyAlfred/status/2042931532688494967
50. X post by @WovenDissent — https://x.com/WovenDissent/status/2071612933382037588
51. BPC 157 promotes tendon healing via outgrowth, cell survival, and migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
52. BPC 157, in clinical trials for IBD (PL14736), heals colocutaneous fistulas in rats — https://pubmed.ncbi.nlm.nih.gov/18818478/
53. BPC 157 improves the healing course of spinal cord injury and leads to functional recovery in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
54. BPC-157 Legal Status 2026: FDA Category 2 Removal, PCAC Review — https://lotilabs.com/resources/bpc-157-legal-status-2026-fda-update/
55. An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition (TIME) — https://time.com/article/2026/07/23/fda-committee-peptides/
56. Gray-Market Peptides: The 'Research Use Only' Fiction — https://rethinkpeptides.com/articles/for-research-use-only-the-legal-fiction-of-gray-market-peptides
57. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide (review commentary) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/
58. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation — https://pubmed.ncbi.nlm.nih.gov/27847966/
59. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
60. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts — https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
61. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — https://pubmed.ncbi.nlm.nih.gov/20225319/
62. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — https://pubmed.ncbi.nlm.nih.gov/16583442/
63. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — https://pubmed.ncbi.nlm.nih.gov/20190676/
64. Stable gastric pentadecapeptide BPC 157 as a therapy for the disabled myotendinous junctions in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC8615275/
65. Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachments for muscle-to-bone reattachment in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/
66. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
67. Intra-articular injection of BPC 157 for multiple types of knee pain — https://pubmed.ncbi.nlm.nih.gov/34324435/
68. Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02 (BPC-157) — https://clinicaltrials.gov/study/NCT02637284
69. FDA briefing document, Pharmacy Compounding Advisory Committee: evaluation of BPC-157-related bulk drug substances for inclusion on the 503A bulk drug substances list — https://www.fda.gov/media/193343/download
70. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — https://www.fda.gov/media/94155/download
71. July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
72. World Anti-Doping Code International Standard: Prohibited List 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
73. BPC-157: experimental peptide creates risk for athletes — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
74. BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products — https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
75. FDA panel votes to loosen restrictions for four peptides — https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
76. FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
77. What's changing with peptide regulation in 2026 — https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
78. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review — https://pubmed.ncbi.nlm.nih.gov/40756949/
79. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
80. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury — https://pubmed.ncbi.nlm.nih.gov/19903499/
81. Novel therapeutic effects in rat spinal cord injuries: recovery of the definitive and early spinal cord injury by the administration of pentadecapeptide BPC 157 therapy — https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/
82. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
83. Bulk drug substances used in compounding under section 503B of the FD&C Act — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
84. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/
85. Does bpc157 increase recovery between workouts — https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/
86. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/
87. Chronic onesided thoracic pain — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/
88. Hlab27 sacroiliitis on mri vs disc obliteration — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
89. Compounds to help articular cartilage fissure in — https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/
90. Need help deciding between kpv low dose — https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/
91. Blend experience — https://www.reddit.com/r/Biohackers/comments/1u7ixcd/blend_experience/
92. Ligament injury repair with bpc157 and tb500 — https://www.reddit.com/r/moreplatesmoredates/comments/phepeu/ligament_injury_repair_with_bpc157_and_tb500/hsp96nl/
93. Bpc 157 and tb 500 for herniated disc — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
94. Bpc157 gone wrong — https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/
95. 1 month of bpc157 tb500 blend reviewblurry vision — https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/
96. Bpc157 for shoulder injury — https://www.reddit.com/r/Biohackers/comments/1tufuie/bpc157_for_shoulder_injury/
97. I know some will disagreebut new batch of bpc 157 — https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/
98. Bpc157 and tb4 has it not worked for you — https://www.reddit.com/r/Peptides/comments/1uute3b/bpc157_and_tb4_has_it_not_worked_for_you/
99. De quervains tendonitis recovery — https://www.reddit.com/r/PEDs/comments/1isdmz1/de_quervains_tendonitis_recovery/
100. Finally got around to trying the bpc157 capsules — https://www.reddit.com/r/Supplements/comments/1rcxvm9/finally_got_around_to_trying_the_bpc157_capsules/
101. Need guidance — https://www.reddit.com/r/PeptideGuide/comments/1s4vose/need_guidance/
102. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/
103. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dus0n8q/
104. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dutyok7/
105. And it begins bpc 157 and tb 500 — https://www.reddit.com/r/backpain/comments/1khc6p5/and_it_begins_bpc_157_and_tb_500/nokzab3/
106. Bpc 157 drinking reconstituted injectable vs — https://www.reddit.com/r/Peptides/comments/1u8m20w/bpc_157_drinking_reconstituted_injectable_vs/osdrkbj/
107. Experience with bpc157 and elbow tendinopathy — https://www.reddit.com/r/climbharder/comments/1j4fiij/experience_with_bpc157_and_elbow_tendinopathy/
108. My experience case study recovering from an a2 — https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
109. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi3v7kp/
110. Compounds healing compounds bpc157 tb500 — https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/
111. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/
112. Compounds bpc157 my experience — https://www.reddit.com/r/steroids/comments/tqsoik/compounds_bpc157_my_experience/
113. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/
114. Bpc 157 tb500 side effect for 65 yrs old — https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/
115. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/
116. Lifting 3 months after a broken wrist — https://www.reddit.com/r/moreplatesmoredates/comments/1l697k3/lifting_3_months_after_a_broken_wrist/
117. Accidentally took 30iu of bpc157 instead of 3iu — https://www.reddit.com/r/Peptides/comments/1teo1c6/accidentally_took_30iu_of_bpc157_instead_of_3iu/
118. Bpc157 and tb500 weekly update — https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/
119. Is oral bpc157 less effective than injecting it — https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/
120. Pinched sciatic nerve — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
121. Bpc157 for herniated disc l5 s1 — https://www.reddit.com/r/Sciatica/comments/uk0bhk/bpc157_for_herniated_disc_l5_s1/
122. Bpc157 saved my foot — https://www.reddit.com/r/Supplements/comments/1scedge/bpc157_saved_my_foot/
123. Bpc157peptides in general — https://www.reddit.com/r/climbharder/comments/lvmkqd/bpc157peptides_in_general/kcrhbqv/


---

# Thymosin Alpha-1 × Metformin

slug: thymosin-alpha-1-metformin · https://miscsubjects.com/a/thymosin-alpha-1-metformin · tags: peptide · updated 2026-07-17T02:43:07.503Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether thymosin-alpha-1 mechanisms address underlying repair deficits.

## What is known

Studied regenerative or supportive role in immune modulation — see peptide root ledger.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. thymosin-alpha-1 studied regenerative or supportive role in immune modulation — see peptide root ledger..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If thymosin-alpha-1 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is under investigation.

## Parent peptide claims relevant here

- Tα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets.
- In animal and cell studies, Tα1 restores immune function in thymectomized models and enhances T-cell responses.
- Multiple human trials and reviews document use in conditions involving immune compromise, with observations of restored cell-mediated immunity.
- Tα1 is described as supporting immune function rather than suppressing it.
- Commercial vendors and clinics market this compound (6 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Evidence status unclear — research ongoing.

## What we do not know

- Whether thymosin-alpha-1 reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# tb 500 nsaids

slug: tb-500-nsaids · https://miscsubjects.com/a/tb-500-nsaids · tags: peptide · updated 2026-07-17T02:42:16.987Z

## Regeneration vs degeneration — where this fits

nsaids represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.

## What is known

Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.

Target condition: nsaids.
Body system: Suppress inflammation signal; may slow structural repair cascade..

## Logic chain

1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..
2. nsaids involves suppress inflammation signal; may slow structural repair cascade. dysfunction.
3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.
- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.
- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.
- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.
- Tβ4 production declines approximately 60% by age 60.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether tb-500 reaches nsaids tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for nsaids
- Long-term safety profile in this population

## Safety note

All peptide use for nsaids is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# tb 500 metformin

slug: tb-500-metformin · https://miscsubjects.com/a/tb-500-metformin · tags: peptide · updated 2026-07-17T02:42:16.200Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.

## What is known

Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.
- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.
- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.
- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.
- Tβ4 production declines approximately 60% by age 60.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether tb-500 reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# tb 500 herniated disc

slug: tb-500-herniated-disc · https://miscsubjects.com/a/tb-500-herniated-disc · tags: peptide · updated 2026-07-17T02:42:15.620Z

## Regeneration vs degeneration — where this fits

herniated disc represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.

## What is known

Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.

Target condition: herniated disc.
Body system: spine / nerve root.

## Logic chain

1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..
2. herniated disc involves spine / nerve root dysfunction.
3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.
- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.
- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.
- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.
- Tβ4 production declines approximately 60% by age 60.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether tb-500 reaches herniated disc tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for herniated disc
- Long-term safety profile in this population

## Safety note

All peptide use for herniated disc is research-context only. Not medical advice. Consult a physician before any experimental compound.

## Sources

1. Herniated disc's L3/L4 - L4/L5 - L5/S1 With BPC 157 - TB 500 — https://www.reddit.com/r/backpain/comments/1tglmzp/herniated_discs_l3l4_l4l5_l5s1_with_bpc_157_tb_500/
2. Peptides for Lower Back Pain + Recovery? — https://www.reddit.com/r/backpain/comments/14iol96/peptides_for_lower_back_pain_recovery/
3. Back Pain Relief: Do TB-500 & BPC 157 Really Work? — https://www.youtube.com/watch?v=KJWUCe0w_FU
4. Back Pain Relief: Do TB-500 & BPC 157 Really Work? — https://www.youtube.com/watch?v=KJWUCe0w_FU
5. X post by @Applesa18888542 — https://x.com/Applesa18888542/status/2069580054569312257
6. Therapeutic Peptides in Orthopaedics — https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/
7. Thymosin Beta-4 Recombinant Adeno-associated Virus — https://pmc.ncbi.nlm.nih.gov/articles/PMC4733779/
8. Exogenous thymosin β4 prevents apoptosis in human — https://pmc.ncbi.nlm.nih.gov/articles/PMC2886502/
9. Peptide Therapy 101: Can BPC-157 & Thymosin Beta-4 Accelerate Ortho-Recovery? — https://ospinamedical.com/orthopedic-blog/peptide-therapy-101-can-bpc-157-thymosin-beta-4-accelerate-ortho-recovery
10. Disc Herniations Treatment in Philadelphia — https://www.meetingpointhealth.com/conditions/disc-herniations/
11. BPC 157 to aid herniated discs? — https://www.reddit.com/r/bpc_157/comments/1foo6q0/bpc_157_to_aid_herniated_discs/
12. Should I use BPC-157 and TB-500 with Predinisone Pack ... — https://www.reddit.com/r/backpain/comments/1q6mxeq/should_i_use_bpc157_and_tb500_with_predinisone/
13. TB-500 for L5/S1 disc bulge and lower back pain — https://www.reddit.com/r/Biohackers/comments/1tbsnp0/tb500_for_l5s1_disc_bulge_and_lower_back_pain_did/
14. Where to inject BPC 157 for low back pain — https://www.youtube.com/watch?v=U6sicxuFpKQ
15. What Science ACTUALLY Says About TB 500 Benefits — https://www.youtube.com/watch?v=C9FOnvFDlSo


---

# tb 500 glp1 agonists

slug: tb-500-glp1-agonists · https://miscsubjects.com/a/tb-500-glp1-agonists · tags: peptide · updated 2026-07-17T02:42:14.788Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.

## What is known

Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.
- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.
- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.
- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.
- Tβ4 production declines approximately 60% by age 60.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether tb-500 reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# TB-500 × Frozen shoulder

slug: tb-500-frozen-shoulder · https://miscsubjects.com/a/tb-500-frozen-shoulder · tags: peptide · updated 2026-07-17T02:42:14.173Z

## Regeneration vs degeneration — where this fits

frozen shoulder represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.

## What is known

Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.

Target condition: frozen shoulder.
Body system: joint capsule.

## Logic chain

1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..
2. frozen shoulder involves joint capsule dysfunction.
3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.
- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.
- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.
- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.
- Tβ4 production declines approximately 60% by age 60.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether tb-500 reaches frozen shoulder tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for frozen shoulder
- Long-term safety profile in this population

## Safety note

All peptide use for frozen shoulder is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# semax statins

slug: semax-statins · https://miscsubjects.com/a/semax-statins · tags: peptide · updated 2026-07-17T02:41:58.491Z

## Regeneration vs degeneration — where this fits

statins represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether semax mechanisms address underlying repair deficits.

## What is known

Studied for BDNF and neural support — building connections, not sedating symptoms.

Target condition: statins.
Body system: Lipid management; debated cognitive/muscle side effects in subset..

## Logic chain

1. semax studied for bdnf and neural support — building connections, not sedating symptoms..
2. statins involves lipid management; debated cognitive/muscle side effects in subset. dysfunction.
3. If semax reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In rat hippocampus, a single intranasal dose of Semax (50 μg/kg) produced a maximal 1.4-fold increase in BDNF protein levels, accompanied by increased trkB phosphorylation and mRNA expression.
- In a study of 110 patients after ischemic stroke, Semax increased plasma BDNF levels.
- Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2025 study showing Semax improves cognitive functions in transgenic Alzheimer's disease mouse model.
- 2025 study on Semax for spinal cord injury recovery in mice.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether semax reaches statins tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for statins
- Long-term safety profile in this population

## Safety note

All peptide use for statins is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# semax metformin

slug: semax-metformin · https://miscsubjects.com/a/semax-metformin · tags: peptide · updated 2026-07-17T02:41:55.304Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether semax mechanisms address underlying repair deficits.

## What is known

Studied for BDNF and neural support — building connections, not sedating symptoms.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. semax studied for bdnf and neural support — building connections, not sedating symptoms..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If semax reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In rat hippocampus, a single intranasal dose of Semax (50 μg/kg) produced a maximal 1.4-fold increase in BDNF protein levels, accompanied by increased trkB phosphorylation and mRNA expression.
- In a study of 110 patients after ischemic stroke, Semax increased plasma BDNF levels.
- Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2025 study showing Semax improves cognitive functions in transgenic Alzheimer's disease mouse model.
- 2025 study on Semax for spinal cord injury recovery in mice.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether semax reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# Semax × GLP-1 agonists (class)

slug: semax-glp1-agonists · https://miscsubjects.com/a/semax-glp1-agonists · tags: peptide · updated 2026-07-17T02:41:53.959Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether semax mechanisms address underlying repair deficits.

## What is known

Studied for BDNF and neural support — building connections, not sedating symptoms.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. semax studied for bdnf and neural support — building connections, not sedating symptoms..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If semax reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In rat hippocampus, a single intranasal dose of Semax (50 μg/kg) produced a maximal 1.4-fold increase in BDNF protein levels, accompanied by increased trkB phosphorylation and mRNA expression.
- In a study of 110 patients after ischemic stroke, Semax increased plasma BDNF levels.
- Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2025 study showing Semax improves cognitive functions in transgenic Alzheimer's disease mouse model.
- 2025 study on Semax for spinal cord injury recovery in mice.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether semax reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# semax benzo withdrawal

slug: semax-benzo-withdrawal · https://miscsubjects.com/a/semax-benzo-withdrawal · tags: peptide · updated 2026-07-17T02:41:51.226Z

## Regeneration vs degeneration — where this fits

benzo withdrawal represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether semax mechanisms address underlying repair deficits.

## What is known

Studied for BDNF and neural support — building connections, not sedating symptoms.

Target condition: benzo withdrawal.
Body system: GABA / CNS.

## Logic chain

1. semax studied for bdnf and neural support — building connections, not sedating symptoms..
2. benzo withdrawal involves gaba / cns dysfunction.
3. If semax reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In rat hippocampus, a single intranasal dose of Semax (50 μg/kg) produced a maximal 1.4-fold increase in BDNF protein levels, accompanied by increased trkB phosphorylation and mRNA expression.
- In a study of 110 patients after ischemic stroke, Semax increased plasma BDNF levels.
- Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2025 study showing Semax improves cognitive functions in transgenic Alzheimer's disease mouse model.
- 2025 study on Semax for spinal cord injury recovery in mice.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether semax reaches benzo withdrawal tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for benzo withdrawal
- Long-term safety profile in this population

## Safety note

All peptide use for benzo withdrawal is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# semax adderall amphetamine

slug: semax-adderall-amphetamine · https://miscsubjects.com/a/semax-adderall-amphetamine · tags: peptide · updated 2026-07-17T02:41:50.801Z

## Regeneration vs degeneration — where this fits

adderall amphetamine represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether semax mechanisms address underlying repair deficits.

## What is known

Studied for BDNF and neural support — building connections, not sedating symptoms.

Target condition: adderall amphetamine.
Body system: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve..

## Logic chain

1. semax studied for bdnf and neural support — building connections, not sedating symptoms..
2. adderall amphetamine involves forces neurotransmitter release; borrows focus at cost of sleep/gut reserve. dysfunction.
3. If semax reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In rat hippocampus, a single intranasal dose of Semax (50 μg/kg) produced a maximal 1.4-fold increase in BDNF protein levels, accompanied by increased trkB phosphorylation and mRNA expression.
- In a study of 110 patients after ischemic stroke, Semax increased plasma BDNF levels.
- Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2025 study showing Semax improves cognitive functions in transgenic Alzheimer's disease mouse model.
- 2025 study on Semax for spinal cord injury recovery in mice.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether semax reaches adderall amphetamine tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for adderall amphetamine
- Long-term safety profile in this population

## Safety note

All peptide use for adderall amphetamine is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# selank statin brain fog

slug: selank-statin-brain-fog · https://miscsubjects.com/a/selank-statin-brain-fog · tags: peptide · updated 2026-07-17T02:41:41.616Z

## Regeneration vs degeneration — where this fits

statin brain fog represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: statin brain fog.
Body system: CNS / metabolic.

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. statin brain fog involves cns / metabolic dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches statin brain fog tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for statin brain fog
- Long-term safety profile in this population

## Safety note

All peptide use for statin brain fog is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# selank metformin

slug: selank-metformin · https://miscsubjects.com/a/selank-metformin · tags: peptide · updated 2026-07-17T02:41:38.762Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# Selank × GLP-1 agonists (class)

slug: selank-glp1-agonists · https://miscsubjects.com/a/selank-glp1-agonists · tags: peptide · updated 2026-07-17T02:41:37.472Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# selank benzodiazepines

slug: selank-benzodiazepines · https://miscsubjects.com/a/selank-benzodiazepines · tags: peptide · updated 2026-07-17T02:41:35.052Z

## Regeneration vs degeneration — where this fits

benzodiazepines represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: benzodiazepines.
Body system: GABAergic suppression; does not rebuild neurochemistry..

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. benzodiazepines involves gabaergic suppression; does not rebuild neurochemistry. dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches benzodiazepines tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for benzodiazepines
- Long-term safety profile in this population

## Safety note

All peptide use for benzodiazepines is research-context only. Not medical advice. Consult a physician before any experimental compound.

## Sources

1. Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/с Mice — https://link.springer.com/article/10.1134/S1819712425700783


---

# selank benzo withdrawal

slug: selank-benzo-withdrawal · https://miscsubjects.com/a/selank-benzo-withdrawal · tags: peptide · updated 2026-07-17T02:41:34.837Z

## Regeneration vs degeneration — where this fits

benzo withdrawal represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: benzo withdrawal.
Body system: GABA / CNS.

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. benzo withdrawal involves gaba / cns dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches benzo withdrawal tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for benzo withdrawal
- Long-term safety profile in this population

## Safety note

All peptide use for benzo withdrawal is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# selank adderall amphetamine

slug: selank-adderall-amphetamine · https://miscsubjects.com/a/selank-adderall-amphetamine · tags: peptide · updated 2026-07-17T02:41:34.415Z

## Regeneration vs degeneration — where this fits

adderall amphetamine represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.

## What is known

Studied for anxiolytic pathways without classic benzodiazepine sedation.

Target condition: adderall amphetamine.
Body system: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve..

## Logic chain

1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..
2. adderall amphetamine involves forces neurotransmitter release; borrows focus at cost of sleep/gut reserve. dysfunction.
3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether selank reaches adderall amphetamine tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for adderall amphetamine
- Long-term safety profile in this population

## Safety note

All peptide use for adderall amphetamine is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# PT-141 × Metformin

slug: pt-141-metformin · https://miscsubjects.com/a/pt-141-metformin · tags: peptide · updated 2026-07-17T02:41:07.607Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether pt-141 mechanisms address underlying repair deficits.

## What is known

Studied regenerative or supportive role in sexual / CNS arousal — see peptide root ledger.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. pt-141 studied regenerative or supportive role in sexual / cns arousal — see peptide root ledger..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If pt-141 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is under investigation.

## Parent peptide claims relevant here

- PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that activates central nervous system pathways for sexual arousal signaling.
- In two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT), subcutaneous bremelanotide 1.75 mg as needed produced statistically significant increases in Female Sexual Function Index-desire domain scores and reductions in Female Sexual Distress Scale scores versus placebo in premenopausal women with hypoactive sexual desire disorder.
- Bremelanotide received FDA approval in 2019 as Vyleesi for acquired generalized hypoactive sexual desire disorder in premenopausal women.
- Animal studies indicate melanocortin receptor activation in hypothalamic regions linked to sexual behavior.
- Commercial vendors and clinics market this compound (10 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Evidence status unclear — research ongoing.

## What we do not know

- Whether pt-141 reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# KPV × Metformin

slug: kpv-metformin · https://miscsubjects.com/a/kpv-metformin · tags: peptide · updated 2026-07-17T02:40:02.515Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether kpv mechanisms address underlying repair deficits.

## What is known

Studied regenerative or supportive role in gut / localized anti-inflammatory — see peptide root ledger.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. kpv studied regenerative or supportive role in gut / localized anti-inflammatory — see peptide root ledger..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If kpv reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is under investigation.

## Parent peptide claims relevant here

- KPV is transported into intestinal epithelial and immune cells via the PepT1 transporter and inhibits NF-κB and MAP kinase pathways
- In DSS- and TNBS-induced murine colitis models, oral KPV reduced histologic inflammation, disease activity, and cytokine expression
- Commercial vendors and clinics market this compound (13 commercial/clinic sources catalogued) — marketing material, not evidence.
- Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
- 2017 study on transdermal delivery of KPV for potential skin inflammation treatment.

## Evidence tier

Evidence status unclear — research ongoing.

## What we do not know

- Whether kpv reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# kpv glp1 agonists

slug: kpv-glp1-agonists · https://miscsubjects.com/a/kpv-glp1-agonists · tags: peptide · updated 2026-07-17T02:40:01.296Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether kpv mechanisms address underlying repair deficits.

## What is known

Studied regenerative or supportive role in gut / localized anti-inflammatory — see peptide root ledger.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. kpv studied regenerative or supportive role in gut / localized anti-inflammatory — see peptide root ledger..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If kpv reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is under investigation.

## Parent peptide claims relevant here

- KPV is transported into intestinal epithelial and immune cells via the PepT1 transporter and inhibits NF-κB and MAP kinase pathways
- In DSS- and TNBS-induced murine colitis models, oral KPV reduced histologic inflammation, disease activity, and cytokine expression
- Commercial vendors and clinics market this compound (13 commercial/clinic sources catalogued) — marketing material, not evidence.
- Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
- 2017 study on transdermal delivery of KPV for potential skin inflammation treatment.

## Evidence tier

Evidence status unclear — research ongoing.

## What we do not know

- Whether kpv reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# GHK-Cu × Metformin

slug: ghk-cu-metformin · https://miscsubjects.com/a/ghk-cu-metformin · tags: peptide · updated 2026-07-17T02:39:23.068Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ghk-cu mechanisms address underlying repair deficits.

## What is known

Studied regenerative or supportive role in collagen / skin matrix — see peptide root ledger.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. ghk-cu studied regenerative or supportive role in collagen / skin matrix — see peptide root ledger..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If ghk-cu reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is under investigation.

## Parent peptide claims relevant here

- Plasma GHK levels measure approximately 200 ng/mL at age 20 and decline to approximately 80 ng/mL by age 60.
- In human dermal fibroblast cultures, GHK-Cu at nanomolar concentrations increases synthesis of collagen types I, III, and IV as well as elastin and glycosaminoglycans.
- Placebo-controlled topical application studies in women around age 50 reported improved skin quality parameters and increased collagen deposition in skin biopsies.
- A registered Phase 2 randomized double-blind trial (NCT07437586) is evaluating topical GHK-Cu gel versus vehicle for acute skin wound re-epithelialization in healthy adults.
- 2018 review on GHK-Cu regenerative actions based on gene data, covering wound healing, skin regeneration, anti-inflammatory effects.

## Evidence tier

Evidence status unclear — research ongoing.

## What we do not know

- Whether ghk-cu reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# dsip statin brain fog

slug: dsip-statin-brain-fog · https://miscsubjects.com/a/dsip-statin-brain-fog · tags: peptide · updated 2026-07-17T02:39:07.830Z

## Regeneration vs degeneration — where this fits

statin brain fog represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether dsip mechanisms address underlying repair deficits.

## What is known

Studied for sleep architecture and deep-sleep promotion.

Target condition: statin brain fog.
Body system: CNS / metabolic.

## Logic chain

1. dsip studied for sleep architecture and deep-sleep promotion..
2. statin brain fog involves cns / metabolic dysfunction.
3. If dsip reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Rat studies show DSIP antiserum blocks sleep-deprivation-induced increases in SWS and GH release.
- 1992 double-blind study (n=16 chronic insomniacs) reported higher objective sleep efficiency and shorter latency with DSIP vs placebo, but no subjective change.
- 1981 study (n=6 insomniacs) found longer sleep duration, fewer interruptions, and more REM with DSIP, without daytime sedation.
- DSIP promotes sleep in rabbits, rats, cats, and mice.
- Limited user reports note subjective deep sleep increases on tracking without hangover effects.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether dsip reaches statin brain fog tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for statin brain fog
- Long-term safety profile in this population

## Safety note

All peptide use for statin brain fog is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# dsip metformin

slug: dsip-metformin · https://miscsubjects.com/a/dsip-metformin · tags: peptide · updated 2026-07-17T02:39:05.391Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether dsip mechanisms address underlying repair deficits.

## What is known

Studied for sleep architecture and deep-sleep promotion.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. dsip studied for sleep architecture and deep-sleep promotion..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If dsip reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Rat studies show DSIP antiserum blocks sleep-deprivation-induced increases in SWS and GH release.
- 1992 double-blind study (n=16 chronic insomniacs) reported higher objective sleep efficiency and shorter latency with DSIP vs placebo, but no subjective change.
- 1981 study (n=6 insomniacs) found longer sleep duration, fewer interruptions, and more REM with DSIP, without daytime sedation.
- DSIP promotes sleep in rabbits, rats, cats, and mice.
- Limited user reports note subjective deep sleep increases on tracking without hangover effects.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether dsip reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# DSIP × GLP-1 agonists (class)

slug: dsip-glp1-agonists · https://miscsubjects.com/a/dsip-glp1-agonists · tags: peptide · updated 2026-07-17T02:39:04.145Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for sleep architecture and deep-sleep promotion.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. bpc-157 studied for sleep architecture and deep-sleep promotion..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Rat studies show DSIP antiserum blocks sleep-deprivation-induced increases in SWS and GH release.
- 1992 double-blind study (n=16 chronic insomniacs) reported higher objective sleep efficiency and shorter latency with DSIP vs placebo, but no subjective change.
- 1981 study (n=6 insomniacs) found longer sleep duration, fewer interruptions, and more REM with DSIP, without daytime sedation.
- DSIP promotes sleep in rabbits, rats, cats, and mice.
- Limited user reports note subjective deep sleep increases on tracking without hangover effects.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# dsip benzo withdrawal

slug: dsip-benzo-withdrawal · https://miscsubjects.com/a/dsip-benzo-withdrawal · tags: peptide · updated 2026-07-17T02:39:01.672Z

## Regeneration vs degeneration — where this fits

benzo withdrawal represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for sleep architecture and deep-sleep promotion.

Target condition: benzo withdrawal.
Body system: GABA / CNS.

## Logic chain

1. bpc-157 studied for sleep architecture and deep-sleep promotion..
2. benzo withdrawal involves gaba / cns dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Rat studies show DSIP antiserum blocks sleep-deprivation-induced increases in SWS and GH release.
- 1992 double-blind study (n=16 chronic insomniacs) reported higher objective sleep efficiency and shorter latency with DSIP vs placebo, but no subjective change.
- 1981 study (n=6 insomniacs) found longer sleep duration, fewer interruptions, and more REM with DSIP, without daytime sedation.
- DSIP promotes sleep in rabbits, rats, cats, and mice.
- Limited user reports note subjective deep sleep increases on tracking without hangover effects.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches benzo withdrawal tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for benzo withdrawal
- Long-term safety profile in this population

## Safety note

All peptide use for benzo withdrawal is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# dsip adderall amphetamine

slug: dsip-adderall-amphetamine · https://miscsubjects.com/a/dsip-adderall-amphetamine · tags: peptide · updated 2026-07-17T02:39:01.250Z

## Regeneration vs degeneration — where this fits

adderall amphetamine represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for sleep architecture and deep-sleep promotion.

Target condition: adderall amphetamine.
Body system: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve..

## Logic chain

1. bpc-157 studied for sleep architecture and deep-sleep promotion..
2. adderall amphetamine involves forces neurotransmitter release; borrows focus at cost of sleep/gut reserve. dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- Rat studies show DSIP antiserum blocks sleep-deprivation-induced increases in SWS and GH release.
- 1992 double-blind study (n=16 chronic insomniacs) reported higher objective sleep efficiency and shorter latency with DSIP vs placebo, but no subjective change.
- 1981 study (n=6 insomniacs) found longer sleep duration, fewer interruptions, and more REM with DSIP, without daytime sedation.
- DSIP promotes sleep in rabbits, rats, cats, and mice.
- Limited user reports note subjective deep sleep increases on tracking without hangover effects.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches adderall amphetamine tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for adderall amphetamine
- Long-term safety profile in this population

## Safety note

All peptide use for adderall amphetamine is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 statins

slug: bpc-157-statins · https://miscsubjects.com/a/bpc-157-statins · tags: peptide · updated 2026-07-17T02:38:40.041Z

## Regeneration vs degeneration — where this fits

statins represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: statins.
Body system: Lipid management; debated cognitive/muscle side effects in subset..

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. statins involves lipid management; debated cognitive/muscle side effects in subset. dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches statins tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for statins
- Long-term safety profile in this population

## Safety note

All peptide use for statins is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 plantar fasciitis

slug: bpc-157-plantar-fasciitis · https://miscsubjects.com/a/bpc-157-plantar-fasciitis · tags: peptide · updated 2026-07-17T02:38:38.376Z

## Regeneration vs degeneration — where this fits

plantar fasciitis represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: plantar fasciitis.
Body system: fascia / foot.

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. plantar fasciitis involves fascia / foot dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches plantar fasciitis tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for plantar fasciitis
- Long-term safety profile in this population

## Safety note

All peptide use for plantar fasciitis is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 ozempic face

slug: bpc-157-ozempic-face · https://miscsubjects.com/a/bpc-157-ozempic-face · tags: peptide · updated 2026-07-17T02:38:38.175Z

## Regeneration vs degeneration — where this fits

ozempic face represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: ozempic face.
Body system: skin / face.

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. ozempic face involves skin / face dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches ozempic face tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for ozempic face
- Long-term safety profile in this population

## Safety note

All peptide use for ozempic face is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 metformin

slug: bpc-157-metformin · https://miscsubjects.com/a/bpc-157-metformin · tags: peptide · updated 2026-07-17T02:38:37.202Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 glp1 muscle loss

slug: bpc-157-glp1-muscle-loss · https://miscsubjects.com/a/bpc-157-glp1-muscle-loss · tags: peptide · updated 2026-07-17T02:38:35.300Z

## Regeneration vs degeneration — where this fits

glp1 muscle loss represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: glp1 muscle loss.
Body system: muscle.

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. glp1 muscle loss involves muscle dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches glp1 muscle loss tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 muscle loss
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 muscle loss is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 glp1 agonists

slug: bpc-157-glp1-agonists · https://miscsubjects.com/a/bpc-157-glp1-agonists · tags: peptide · updated 2026-07-17T02:38:34.735Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 frozen shoulder

slug: bpc-157-frozen-shoulder · https://miscsubjects.com/a/bpc-157-frozen-shoulder · tags: peptide · updated 2026-07-17T02:38:34.162Z

## Regeneration vs degeneration — where this fits

frozen shoulder represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: frozen shoulder.
Body system: joint capsule.

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. frozen shoulder involves joint capsule dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches frozen shoulder tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for frozen shoulder
- Long-term safety profile in this population

## Safety note

All peptide use for frozen shoulder is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# bpc 157 degenerative disc

slug: bpc-157-degenerative-disc · https://miscsubjects.com/a/bpc-157-degenerative-disc · tags: peptide · updated 2026-07-17T02:38:33.720Z

## Regeneration vs degeneration — where this fits

degenerative disc represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether bpc-157 mechanisms address underlying repair deficits.

## What is known

Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.

Target condition: degenerative disc.
Body system: spine / disc.

## Logic chain

1. bpc-157 studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue..
2. degenerative disc involves spine / disc dysfunction.
3. If bpc-157 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.
- Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.
- A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.
- Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.
- One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether bpc-157 reaches degenerative disc tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for degenerative disc
- Long-term safety profile in this population

## Safety note

All peptide use for degenerative disc is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ara 290 trigeminal neuralgia

slug: ara-290-trigeminal-neuralgia · https://miscsubjects.com/a/ara-290-trigeminal-neuralgia · tags: peptide · updated 2026-07-17T02:38:18.186Z

## Regeneration vs degeneration — where this fits

trigeminal neuralgia represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: trigeminal neuralgia.
Body system: cranial nerve.

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. trigeminal neuralgia involves cranial nerve dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches trigeminal neuralgia tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for trigeminal neuralgia
- Long-term safety profile in this population

## Safety note

All peptide use for trigeminal neuralgia is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ara 290 statin brain fog

slug: ara-290-statin-brain-fog · https://miscsubjects.com/a/ara-290-statin-brain-fog · tags: peptide · updated 2026-07-17T02:38:17.044Z

## Regeneration vs degeneration — where this fits

statin brain fog represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: statin brain fog.
Body system: CNS / metabolic.

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. statin brain fog involves cns / metabolic dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches statin brain fog tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for statin brain fog
- Long-term safety profile in this population

## Safety note

All peptide use for statin brain fog is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ara 290 postherpetic neuralgia

slug: ara-290-postherpetic-neuralgia · https://miscsubjects.com/a/ara-290-postherpetic-neuralgia · tags: peptide · updated 2026-07-17T02:38:15.913Z

## Regeneration vs degeneration — where this fits

postherpetic neuralgia represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: postherpetic neuralgia.
Body system: peripheral nerve.

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. postherpetic neuralgia involves peripheral nerve dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches postherpetic neuralgia tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for postherpetic neuralgia
- Long-term safety profile in this population

## Safety note

All peptide use for postherpetic neuralgia is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ara 290 metformin

slug: ara-290-metformin · https://miscsubjects.com/a/ara-290-metformin · tags: peptide · updated 2026-07-17T02:38:13.721Z

## Regeneration vs degeneration — where this fits

metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: metformin.
Body system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches metformin tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for metformin
- Long-term safety profile in this population

## Safety note

All peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ARA-290 × GLP-1 agonists (class)

slug: ara-290-glp1-agonists · https://miscsubjects.com/a/ara-290-glp1-agonists · tags: peptide · updated 2026-07-17T02:38:12.395Z

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ara 290 chemo neuropathy

slug: ara-290-chemo-neuropathy · https://miscsubjects.com/a/ara-290-chemo-neuropathy · tags: peptide · updated 2026-07-17T02:38:09.721Z

## Regeneration vs degeneration — where this fits

chemo neuropathy represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: chemo neuropathy.
Body system: peripheral nerve.

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. chemo neuropathy involves peripheral nerve dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches chemo neuropathy tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for chemo neuropathy
- Long-term safety profile in this population

## Safety note

All peptide use for chemo neuropathy is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ara 290 benzo withdrawal

slug: ara-290-benzo-withdrawal · https://miscsubjects.com/a/ara-290-benzo-withdrawal · tags: peptide · updated 2026-07-17T02:38:08.603Z

## Regeneration vs degeneration — where this fits

benzo withdrawal represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: benzo withdrawal.
Body system: GABA / CNS.

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. benzo withdrawal involves gaba / cns dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches benzo withdrawal tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for benzo withdrawal
- Long-term safety profile in this population

## Safety note

All peptide use for benzo withdrawal is research-context only. Not medical advice. Consult a physician before any experimental compound.


---

# ARA-290 × Stimulant-driven insomnia

slug: ara-290-adderall-insomnia · https://miscsubjects.com/a/ara-290-adderall-insomnia · tags: peptide · updated 2026-07-17T02:38:08.385Z

## Regeneration vs degeneration — where this fits

adderall insomnia represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: adderall insomnia.
Body system: sleep / CNS.

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. adderall insomnia involves sleep / cns dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches adderall insomnia tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for adderall insomnia
- Long-term safety profile in this population

## Safety note

All peptide use for adderall insomnia is research-context only. Not medical advice. Consult a physician before any experimental compound.